0000950170-24-12404410-Q ORGANOVO HOLDINGS, INC. 20241108202411081604061604071604070 0000950170-24-124044 10-Q 65 20240930 20241108 20241108 ORGANOVO HOLDINGS, INC. 0001497253 2836 271488943 DE 0331 10-Q 34 001-35996 241440426 11555 SORRENTO VALLEY ROAD SUITE 100 SAN DIEGO CA 92121 858-224-1000 11555 SORRENTO VALLEY ROAD SUITE 100 SAN DIEGO CA 92121 REAL ESTATE RESTORATION & RENTAL, INC. 20100722 10-Q 1 onvo-20240930.htm 10-Q 10-Q --03-31false0001497253Q220252024-030001497253us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-09-300001497253us-gaap:RestrictedStockUnitsRSUMemberonvo:EquityIncentivePlanTwoThousandTwentyTwoMember2024-09-300001497253us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-09-300001497253onvo:ClemsonUniversityMember2023-07-012023-09-300001497253onvo:CommonWarrantsMember2024-03-310001497253us-gaap:RestrictedStockUnitsRSUMemberonvo:EquityIncentivePlanTwoThousandTwelveMember2024-09-300001497253us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-09-300001497253onvo:MosaicSegmentMember2024-03-310001497253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001497253onvo:CommonWarrantsMember2024-05-082024-05-080001497253us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-3000014972532024-04-012024-06-3000014972532024-11-010001497253us-gaap:PerformanceSharesMemberonvo:EquityIncentivePlanTwoThousandTwentyTwoMemberonvo:ExecutiveChairmanMember2024-08-052024-08-050001497253us-gaap:RetainedEarningsMember2023-06-300001497253onvo:ResearchDevelopmentSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:RoyaltyMember2023-07-012023-09-300001497253onvo:TwoThousandEighteenSalesAgreementMember2024-04-012024-09-300001497253onvo:CommonWarrantsMemberus-gaap:IPOMembersrt:MaximumMember2024-05-080001497253us-gaap:AdditionalPaidInCapitalMember2024-06-300001497253onvo:InsurancePremiumFinancingLiabilityMember2024-04-012024-09-300001497253us-gaap:TreasuryStockCommonMember2023-04-012023-06-300001497253onvo:AtTheMarketFacilityMember2024-09-300001497253us-gaap:TreasuryStockCommonMember2024-09-300001497253us-gaap:RetainedEarningsMember2024-03-310001497253onvo:AtTheMarketFacilityMember2024-07-012024-09-300001497253us-gaap:CommonStockMemberonvo:EquityIncentivePlanTwoThousandTwentyTwoMember2022-10-120001497253us-gaap:CommonStockMemberonvo:EquityIncentivePlanTwoThousandTwentyTwoMembersrt:MaximumMember2022-10-120001497253onvo:SanDiegoPermanentLeaseMember2020-11-232020-11-230001497253us-gaap:AdditionalPaidInCapitalMember2023-03-310001497253us-gaap:EmployeeStockOptionMemberonvo:EquityIncentivePlanTwoThousandTwelveMember2024-09-300001497253onvo:TwoThousandAndTwentyTwoInducementEquityPlanMember2022-10-120001497253us-gaap:ProductMember2024-07-012024-09-3000014972532023-04-012023-06-300001497253us-gaap:ProductMember2023-04-012023-09-300001497253us-gaap:TreasuryStockCommonMember2023-03-310001497253us-gaap:ProductMember2024-04-012024-09-300001497253onvo:UniversityOfMissouriMember2022-12-052022-12-050001497253onvo:SalesBasedRoyaltiesMemberonvo:BICOGroupABMember2024-04-012024-09-300001497253us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMember2022-07-25000149725 3us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001497253us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001497253us-gaap:OperatingSegmentsMember2024-04-012024-09-300001497253us-gaap:OperatingSegmentsMemberonvo:MosaicSegmentMember2023-07-012023-09-300001497253us-gaap:TreasuryStockCommonMember2023-09-300001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMember2024-04-012024-09-300001497253us-gaap:TreasuryStockCommonMember2024-04-012024-06-300001497253us-gaap:OperatingSegmentsMember2023-07-012023-09-300001497253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001497253us-gaap:OperatingSegmentsMemberonvo:MosaicSegmentMember2023-04-012023-09-300001497253onvo:ESPPSharesMember2023-04-012023-09-300001497253onvo:CommonWarrantsMember2024-05-080001497253srt:MaximumMember2024-04-012024-09-3000014972532024-09-300001497253us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001497253onvo:ClemsonUniversityMember2016-03-310001497253onvo:SanDiegoPermanentLeaseMember2021-11-172021-11-170001497253onvo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember2024-09-300001497253onvo:EquityIncentivePlanTwoThousandTwelveMember2024-09-300001497253onvo:ResearchDevelopmentSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:RoyaltyMember2024-04-012024-09-300001497253onvo:ResearchDevelopmentSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300001497253us-gaap:OperatingSegmentsMemberonvo:MosaicSegmentMemberus-gaap:ProductMember2023-04-012023-09-300001497253us-gaap:TreasuryStockCommonMember2024-03-310001497253us-gaap:RetainedEarningsMember2023-07-012023-09-300001497253onvo:ClemsonUniversityMemberonvo:SublicenseAgreementsMember2024-04-012024-09-300001497253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001497253us-gaap:TreasuryStockCommonMember2024-06-300001497253us-gaap:RetainedEarningsMember2024-04-012024-06-300001497253onvo:InsurancePremiumFinancingLiabilityMember2024-09-300001497253us-gaap:OperatingSegmentsMember2024-07-012024-09-300001497253us-gaap:RetainedEarningsMember2023-03-310001497253onvo:PreFundedWarrantMember2024-03-310001497253onvo:CommonWarrantsMember2024-09-300001497253onvo:TwoThousandAndTwentyFourShelfMember2024-09-300001497253onvo:ViscientBiosciencesMember2024-07-012024-09-300001497253onvo:ESPPSharesMember2024-04-012024-09-300001497253us-gaap:TreasuryStockCommonMember2023-06-300001497253us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001497253us-gaap:CommonStockMember2023-04-012023-06-300001497253onvo:CommonWarrantsMemberus-gaap:IPOMember2024-05-082024-05-080001497253onvo:ResearchDevelopmentSegmentMemberus-gaap:OperatingSegmentsMember2024-03-310001497253us-gaap:CommonStockMember2024-03-310001497253onvo:ClemsonUniversityMember2024-07-012024-09-300001497253onvo:ProspectusToTwoThousandAndTwentyFourShelfMemberonvo:AtTheMarketFacilityMembersrt:MaximumMember2024-01-260001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMember2024-09-300001497253us-gaap:OperatingSegmentsMember2023-04-012023-09-300001497253onvo:AtTheMarketFacilityMember2024-04-012024-09-300001497253onvo:EquityIncentivePlanTwoThousandTwelveMember2022-07-252022-10-120001497253onvo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember2024-04-012024-09-300001497253us-gaap:IPOMember2024-05-082024-05-080001497253onvo:ViscientBiosciencesMember2023-04-012023-09-300001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMemberonvo:ExecutiveChairmanMemberus-gaap:EmployeeStockOptionMember2024-08-052024-08-050001497253us-gaap:CommonStockMember2023-09-300001497253onvo:ESPPSharesMember2023-07-012023-09-300001497253onvo:PreFundedWarrantMember2024-04-012024-09-300001497253srt:MaximumMemberonvo:ViscientBiosciencesMember2023-07-012023-09-300001497253us-gaap:OperatingSegmentsMemberonvo:MosaicSegmentMember2024-03-310001497253onvo:ClemsonUniversityMember2022-04-012023-03-310001497253onvo:ClemsonUniversityMember2014-03-310001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMemberus-gaap:EmployeeStockOptionMember2024-09-300001497253onvo:TwoThousandAndTwentyFourShelfMember2024-01-260001497253us-gaap:AdditionalPaidInCapitalMember2024-03-3100014972532021-12-17001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMemberonvo:ExecutiveChairmanMember2024-05-082024-05-080001497253us-gaap:OperatingSegmentsMemberonvo:MosaicSegmentMember2024-04-012024-09-300001497253onvo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMemberus-gaap:EmployeeStockOptionMember2024-09-300001497253onvo:MetacrinesFxrProgramMember2024-04-012024-09-300001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMemberonvo:ExecutiveChairmanMemberonvo:VestingCriteriaBasedOnMarketConditionsMember2024-08-052024-08-050001497253us-gaap:CommonStockMember2024-09-300001497253onvo:UniversityOfMissouriMember2009-03-012009-03-310001497253onvo:InsurancePremiumFinancingLiabilityMember2024-09-012024-09-3000014972532023-03-310001497253us-gaap:RoyaltyMember2024-04-012024-09-300001497253onvo:ResearchDevelopmentSegmentMemberus-gaap:OperatingSegmentsMember2024-04-012024-09-300001497253us-gaap:OperatingSegmentsMemberonvo:MosaicSegmentMemberus-gaap:ProductMember2024-07-012024-09-300001497253onvo:CommonWarrantsMember2024-04-012024-09-300001497253onvo:ResearchDevelopmentSegmentMemberus-gaap:OperatingSegmentsMember2023-04-012023-09-300001497253onvo:ClemsonUniversityMemberus-gaap:LicensingAgreementsMember2011-05-012011-05-310001497253onvo:ProspectusToTwoThousandAndTwentyFourShelfMemberonvo:AtTheMarketFacilityMember2024-04-012024-09-300001497253onvo:JonestradingInstitutionalServicesLlcMemberus-gaap:IPOMember2024-05-082024-05-080001497253us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001497253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001497253onvo:AtTheMarketFacilityMemberonvo:TwoThousandAndTwentyFourShelfMember2024-04-012024-09-300001497253onvo:ClemsonUniversityMember2023-04-012023-09-300001497253us-gaap:IPOMember2024-09-300001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMemberonvo:ExecutiveChairmanMemberonvo:VestingCriteriaBasedOnAchievingCumulativeRevenueMember2024-08-052024-08-050001497253onvo:EquityIncentivePlanTwoThousandTwelveMember2022-10-120001497253onvo:ClemsonUniversityMember2024-04-012024-09-300001497253us-gaap:RoyaltyMember2024-07-012024-09-300001497253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001497253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001497253onvo:MosaicSegmentMember2024-09-300001497253us-gaap:RestrictedStockUnitsRSUMember2024-09-300001497253us-gaap:RoyaltyMember2023-04-012023-09-300001497253us-gaap:EmployeeStockOptionMemberonvo:IncentiveAwardPlanMember2024-09-300001497253onvo:ClemsonUniversityMember2015-03-3100014972532024-04-012024-09-300001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMemberonvo:ExecutiveChairmanMember2024-08-052024-08-0500014972532023-07-012023-09-300001497253us-gaap:RetainedEarningsMember2024-09-300001497253us-gaap:ProductMember2023-07-012023-09-300001497253onvo:ResearchDevelopmentSegmentMemberus-gaap:OperatingSegmentsMember2024-09-300001497253us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001497253us-gaap:CommonStockMember2023-07-012023-09-300001497253onvo:ResearchDevelopmentSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:RoyaltyMember2024-04-012023-09-300001497253us-gaap:CommonStockMember2023-06-300001497253us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-09-300001497253us-gaap:AdditionalPaidInCapitalMember2023-06-3000014972532023-09-300001497253onvo:ResearchDevelopmentSegmentMemberus-gaap:OperatingSegmentsMember2024-07-012024-09-300001497253us-gaap:OperatingSegmentsMember2024-03-310001497253us-gaap:RetainedEarningsMember2024-07-012024-09-300001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMemberonvo:ExecutiveChairmanMemberonvo:VestingCriteriaBasedOnDefinitiveAgreementMember2024-08-052024-08-050001497253onvo:ESPPSharesMember2024-07-012024-09-3000014972532023-04-012023-09-3000014972532024-07-012024-09-300001497253onvo:ResearchDevelopmentSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:RoyaltyMember2024-07-012024-09-300001497253us-gaap:OperatingSegmentsMemberonvo:MosaicSegmentMemberus-gaap:ProductMember2024-04-012024-09-300001497253onvo:SanDiegoPermanentLeaseMember2020-11-230001497253onvo:PreFundedWarrantMember2024-05-080001497253us-gaap:CommonStockMember2023-03-310001497253us-gaap:CommonStockMember2024-07-012024-09-300001497253us-gaap:AdditionalPaidInCapitalMember2023-09-300001497253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001497253us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001497253onvo:TwoThousandAndTwentyTwoInducementEquityPlanMember2024-09-300001497253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001497253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001497253onvo:ViscientBiosciencesMember2024-04-012024-09-3000014972532024-03-310001497253onvo:BICOGroupABMember2024-07-012024-09-300001497253srt:MaximumMemberonvo:ViscientBiosciencesMember2023-04-012023-09-300001497253onvo:SalesBasedRoyaltiesMemberonvo:BICOGroupABMember2024-07-012024-09-300001497253us-gaap:RetainedEarningsMember2024-06-300001497253onvo:ProspectusTo2021ShelfMemberonvo:AtTheMarketFacilityMembersrt:MaximumMember2021-01-290001497253us-gaap:IPOMember2024-05-132024-05-130001497253onvo:ClemsonUniversityMember2023-04-012024-03-310001497253onvo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember2023-10-310001497253onvo:PreFundedWarrantMember2024-09-300001497253us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001497253us-gaap:CommonStockMember2024-06-300001497253us-gaap:CommonStockMember2024-04-012024-06-300001497253us-gaap:EmployeeStockOptionMemberonvo:TwoThousandAndTwentyOneInducementEquityPlanMember2024-09-300001497253onvo:ViscientBiosciencesMember2023-07-012023-09-300001497253us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-09-300001497253us-gaap:EmployeeStockOptionMember2024-04-012024-09-300001497253us-gaap:RetainedEarningsMember2023-04-012023-06-300001497253us-gaap:OperatingSegmentsMember2024-09-300001497253us-gaap:OperatingSegmentsMemberonvo:MosaicSegmentMemberus-gaap:ProductMember2023-07-012023-09-300001497253us-gaap:AdditionalPaidInCapitalMember2024-09-300001497253us-gaap:OperatingSegmentsMemberonvo:MosaicSegmentMember2024-09-300001497253us-gaap:RetainedEarningsMember2023-09-300001497253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001497253us-gaap:RoyaltyMember2023-07-012023-09-300001497253us-gaap:RestrictedStockUnitsRSUMember2024-03-310001497253onvo:TwoThousandAndTwentyOneInducementEquityPlanMember2021-03-310001497253onvo:EquityIncentivePlanTwoThousandTwentyTwoMember2022-10-120001497253onvo:BICOGroupABMember2024-04-012024-09-300001497253us-gaap:OperatingSegmentsMemberonvo:MosaicSegmentMember2024-07-012024-09-300001497253onvo:ProspectusToTwoThousandAndTwentyFourShelfMemberonvo:AtTheMarketFacilityMember2024-09-300001497253us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2024-09-30xbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharesonvo:Compoundsiso4217:USD Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Â Form 10-Q Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35996 Â Organovo Holdings, Inc. (Exact name of registrant as specified in its charter) Â Â Delaware 27-1488943 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) Â Â Â 11555 Sorrento Valley Rd, Suite 100,San Diego, CA 92121 (858) 224-1000 (Address of principal executive offices and zip code) (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section

12(b) of the Act: Â Title of each class Trading symbol Name of Each Exchange on which registered Common Stock, $0.001 par value ONVO The NasdaqÂ Stock Market LLC Â Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Â Â Â Â Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of November 1, 2024, a total of 15,365,826 shares of the registrantâ€™s Common Stock, $0.001 par value, were outstanding. Â Â Â Â ORGANOVO HOLDINGS, INC. INDEX PART I. FINANCIAL INFORMATION Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and March 31, 2024 3 Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss for the Three and Six Months Ended September 30, 2024 and 2023 4 Unaudited Condensed Consolidated Statements of Stockholdersâ€™ Equity for the Three and Six Months Ended September 30, 2024 and 2023 5 Â Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended September 30, 2024 and 2023 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3. Quantitative and Qualitative Disclosures About Market Risk 30 Item 4. Controls and Procedures 30 PART II. OTHER INFORMATION Item 1. Legal Proceedings 31 Item 1A. Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 52 Item 3. Defaults Upon Senior Securities 52 Item 4. Mine Safety Disclosure 52 Item 5. Other Information 53 Item 6. Exhibits 54 Â Â Â Â 2 Â PART Iâ€”FINANCIAL INFORMATION Â ITEM 1. FINANCIAL STATEMENTS Organovo Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands except for share and per share data) Â Â Â September 30, 2024 Â Â March 31, 2024 Â Â Â (Unaudited) Â Â Â Â Assets Â Â Â Â Â Â Current Assets Â Â Â Â Â Â Cash and cash equivalents Â $ 3,174 Â Â $ 2,901 Â Accounts receivable Â Â 29 Â Â Â 33 Â Inventory Â Â 640 Â Â Â 297 Â Prepaid expenses and other current assets Â Â 940 Â Â Â 705 Â Total current assets Â Â Â 4,783 Â Â Â 3,936 Â Fixed assets, net Â Â 545 Â Â Â 669 Â Restricted cash Â Â 143 Â Â Â 143 Â Operating lease right-of-use assets Â Â 1,086 Â Â Â 1,299 Â Prepaid expenses and other assets, net Â Â 197 Â Â Â 302 Â Total assets Â $ 6,754 Â Â $ 6,349 Â Liabilities and Stockholdersâ€™ Equity Â Â Â Â Â Â Current Liabilities Â Â Â Â Â Â Accounts payable Â $ 419 Â Â $ 627 Â Accrued expenses Â Â 879 Â Â Â 727 Â Insurance premium financing liability Â Â 385 Â Â Â â€” Â Liability to be settled in equity Â Â 218 Â Â Â â€” Â Operating lease liability, current portion Â Â 513 Â Â Â 506 Â Total current liabilities Â Â 2,414 Â Â Â 1,860 Â Operating lease liability, net of current portion Â Â 660 Â Â Â 888 Â Total liabilities Â Â Â 3,074 Â Â Â 2,748 Â Commitments and Contingencies (Note 7) Â Â Â Â Â Â Stockholdersâ€™ Equity Â Â Â Â Â Â Common stock, $0.001Â par value; 200,000,000Â shares authorized, 15,365,825Â and 10,077,726Â shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively Â Â 15 Â Â Â 10 Â Additional paid-in capital Â Â 349,227 Â Â Â 343,261 Â Accumulated deficit Â Â (345,562) Â Â (339,669) Accumulated other comprehensive income Â Â 1 Â Â Â â€” Â Treasury stock, 46Â shares at cost Â Â (1) Â Â (1) Total stockholdersâ€™ equity Â Â 3,680 Â Â Â 3,601 Â Total Liabilities and Stockholdersâ€™ Equity Â $ 6,754 Â Â $ 6,349 Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 3 Â Organovo Holdings, Inc. Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss (in thousands except share and per share data) Â Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Revenues Â Â Â Â Â Â Â Â Â Â Â Â Royalty revenue Â $ 28 Â Â $ â€” Â Â $ 53 Â Â $ 75 Â Product revenue Â Â 2 Â Â Â Â â€” Â Â Â 16 Â Â Â Â â€” Â Total Revenues Â Â 30 Â Â Â Â â€” Â Â Â 69 Â Â Â 75 Â Cost of revenues Â Â 1 Â Â Â Â â€” Â Â Â 3 Â Â Â â€” Â Research and development expenses Â Â 984 Â Â Â 1,335 Â Â Â 2,386 Â Â Â 3,001 Â Selling, general and administrative expenses Â Â 1,653 Â Â Â 2,780 Â Â Â 3,674 Â Â Â 5,384 Â Total costs and expenses Â Â 2,638 Â Â Â 4,115 Â Â Â 6,063 Â Â Â 8,385 Â Loss from Operations Â Â (2,608) Â Â (4,115) Â Â (5,994) Â Â (8,310) Other Income Â Â Â Â Â Â Â Â Â Â Â Â Gain on investment in equity securities Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 12 Â Interest income Â Â 59 Â Â Â 121 Â Â Â 103 Â Â Â 278 Â Total Other Income Â Â 59 Â Â Â 121 Â Â Â 103 Â Â Â 290 Â Income Tax Expense Â Â Â€” Â Â Â Â€” Â Â Â (2) Â Â (2) Net Loss Â $ (2,549) Â $ (3,994) Â $ (5,893) Â $ (8,022) Other Comprehensive loss: Â Â Â Â Â Â Â Â Â Â Â Â Unrealized gain (loss) on available-for-sale debt securities Â $ 1 Â Â $ (1) Â $ 1 Â Â $ (1) Comprehensive Loss Â $ (2,548) Â $ (3,995) Â $ (5,892) Â $ (8,023) Net loss per common shareâ€”basic and diluted Â $ (0.14) Â $ (0.46) Â $ (0.36) Â $ (0.92) Weighted average shares used in computing Â Â Â net loss per common shareâ€”basic and Â Â Â diluted Â Â 17,994,538 Â Â Â 8,718,502 Â Â Â 16,338,216 Â Â $ 8,717,870 Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 4 Â Organovo Holdings, Inc. Unaudited Condensed Consolidated Statements of Stockholdersâ€™ Equity (in thousands) Â Â Â Three and Six Months Ended September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â

subsidiary, Organovo, Inc. Note 2. Summary of Significant Accounting PoliciesBasis of Presentation and Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2024 is derived from the Companyâ€™s audited consolidated balance sheet as filed with the SEC on May 31, 2024. The unaudited condensed consolidated financial statements include the accounts of Organovo and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Companyâ€™s financial position, results of operations, stockholdersâ€™ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Companyâ€™s Annual Report on Form 10-K for the year ended March 31, 2024, as filed with the Securities and Exchange Commission (â€œSECâ€). Operating results for any interim period are not necessarily indicative of the operating results for any other interim period or the Companyâ€™s full fiscal year ending March 31, 2025 (see â€œNote 1. Description of Businessâ€).Â Liquidity and Going ConcernThe accompanying consolidated financial statements have been prepared on the basis that we are a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of September 30, 2024, the Company had cash and cash equivalents of approximately $3.2 million, restricted cash of approximately $0.1 million and an accumulated deficit of approximately $345.6 million. The restricted cash was pledged as collateral for a letter of credit that the Company is required to maintain as a security deposit under the terms of the lease agreement for its facilities. The Company also had negative cash flows from operations of approximately $5.6 million during the six months ended September 30, 2024. Through September 30, 2024, the Company has financed its operations primarily through the sale of common stock through public and at-the-market (â€œATMâ€) offerings, the private placement of equity securities, from revenue derived from the licensing of intellectual property, products and research service-based services, grants, and collaborative research agreements, and from the sale of convertible notes. During the six months ended September 30, 2024, the Company issued 1,352,600 shares of its common stock through its ATM facility, for net proceeds of approximately $1.7 million. Additionally, on May 8, 2024, the Company priced a best efforts public offering (the â€œOfferingâ€) of: (i) 1,562,500 shares of its common stock and accompanying common warrants (â€œCommon Warrantsâ€) to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) pre-funded warrants (â€œPre-Funded Warrantsâ€) to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. The closing of the Offering occurred on May 13, 2024. The Company received net proceeds of approximately $4.5 million from the Offering, after deducting the estimated offering expenses payable by the Company, including the Placement Agent fees. On July 18, 2024, the Company received a written notice (the â€œNoticeâ€) from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (â€œNasdaqâ€) indicating that, based upon the closing bid price of the Companyâ€™s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (â€œRule 5550(a)(2)â€). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until January 14, 2025, to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of the Companyâ€™s common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. The Notice provides that the Nasdaq staff will provide written confirmation to the Company if the Company regains compliance with Rule 5550(a)(2). If the Company does not regain compliance with Rule 5550(a)(2) by January 14, 2025, the Company may be eligible for an additional compliance period of 180 calendar days. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice to Nasdaq of its intention to cure the bid price deficiency during the second compliance period. However, if it appears to the 8 Â Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities will be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq staffâ€™s determination to delist its securities, but there can be no assurance the Nasdaq staff would grant any request for continued listing.Based on the Company's current operating plan and available cash resources, it will need substantial additional funding to support future operating activities. The Company has concluded that the prevailing conditions and ongoing liquidity risks faced by it raise substantial doubt about its ability to continue as a going concern for at least one year following the date these financial statements are issued. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. As the Company continues its operations and is focusing its efforts on drug discovery and development, the Company will need to raise additional capital to implement this business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. The Company will seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Companyâ€™s business, operating results, and financial condition. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. On an ongoing basis, management reviews these estimates and assumptions. Investments Investments in debt securities consist of investments in U.S. Treasury bills. All investments that have original maturities of three months or less are classified as cash equivalents on the condensed consolidated balance sheets. As of September 30, 2024 and March 31, 2024, all investments are classified as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies. Available-for-sale debt securities are recorded at fair value. Any unrealized gains and losses are included in accumulated other comprehensive income as a component of stockholders' equity until realized. As U.S. Treasury bills have minimal risk, any declines in fair value are considered temporary. Fair value measurement Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: â€¢Level 1 â€” Quoted prices in active markets for identical assets or liabilities. â€¢Level 2 â€“ Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. â€¢Level 3 â€“ Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. InventoryInventories are stated at the lower of cost or net realizable value. Inventory as of September 30, 2024 and March 31, 2024 consisted of approximately $0.6 million, net of reserve, and $0.3 million in finished goods, respectively, which is related to Mosaic. An inventory reserve of approximately $0.2 million was established during the three months ended September 30, 2024 to write-down inventory to its new cost basis. Please refer to "Note 11. Business Segment Information" for further information regarding Mosaic's inventory. Insurance Premium Financing LiabilityIn September 2024, the Company entered into an insurance premium financing agreement for $0.4 million, with a term of nine months and an annual interest rate of 8.57%. The Company made a down payment of 10% and is required to make monthly principal and interest payments of $44,281 over the term of the agreement, which matures in June 2025. Related prepaid insurance at September 30, 9 Â 2024 of $0.4 million is included in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets. Net Loss Per Share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options, shares reserved for purchase under the Companyâ€™s 2023 Employee Stock Purchase Plan (â€œ2023 ESPPâ€), the assumed vesting of restricted stock units (â€œRSUsâ€), the exercise of warrants, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the six months ended September 30, 2024 and 2023 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive.Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 11.3 million at September 30, 2024 and 1.0 million at September 30, 2023. Revenue recognitionRoyalty revenue The Company has entered into an intellectual property license agreement with another company that includes royalties based on specified percentages of net product sales, if any. At the initiation of the agreement, the Company analyzed whether it results in a contract with a customer under Accounting Standards Codification ("ASC") Topic 606.Â The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the Company is a principal vs. agent, whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, sales-based royalty payments have been identified as variable consideration which must be evaluated to determine if it has been constrained and, therefore, excluded from the transaction price. Please refer to â€œNote 6. Collaborative Research, Development, and License Agreementsâ€ for further information.Product revenue, net The Companyâ€™s product-based division, Mosaic, produces high-quality cell-based products for use in Organovoâ€™s R&D and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Companyâ€™s product, typically upon delivery. Product revenues are recorded at the transaction price under Topic 606. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.In December 2023, the FASB issued Accounting Standards Update (â€œASUâ€) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Companyâ€™s Consolidated Financial Statements.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (â€œCODMâ€) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segmentâ€™s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods 10 Â within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this guidance. Note 3. Investments and Fair Value MeasurementÂ Investments in debt securitiesAs of September 30, 2024, the Company held $1.0 million of investments in debt securities (which are included in the $3.2 million of cash and cash equivalents). For the six months ended September 30, 2024, there was less than $0.1 million of interest income related to the investments in debt securities. As the investments in debt securities consist of U.S. Treasury bills from active markets, the fair value is measured using level 1 inputs. The following table summarizes the Company's investments in debt securities that are measured at fair value as of September 30, 2024 and March 31, 2024, respectively (in thousands):Â Â Â Amortized costs basis Â Â Gross unrealized gains Â Â Gross unrealized losses Â Â Fair value Â As of September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Investment in debt securities Â $ 994 Â Â $ 1 Â Â $ â€” Â Â $ 995 Â As of March 31, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Investment in debt securities Â $ 997 Â Â $ 1 Â Â $ â€” Â Â $ 998 Â Â Note 4. Accrued ExpensesAccrued expenses consisted of the following (in thousands):Â Â Â September 30,2024 Â Â March 31,2024 Â Accrued compensation Â $ 356 Â Â $ 536 Â Accrued legal and professional fees Â Â 462 Â Â Â Â 93 Â Other accrued expenses Â Â 61 Â Â Â Â 98 Â Â Â Â $ 879 Â Â $ 727 Â Â Note 5. Stockholdersâ€™ Equity Preferred Stock The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no current plans to issue shares of preferred stock. 11 Â Common StockIn March 2021, the Company's Board of Directors ("Board") approved the 2021 Inducement Equity Incentive Plan ("Inducement Plan"). The Inducement Plan authorized the issuance of up to 750,000 shares of common stock for awards of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, RSUs, performance units, performance shares, and other stock or cash awards. The only persons eligible to receive grants under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance. The Company also committed to reducing the aggregate number of shares of its common stock issuable pursuant to the Inducement Plan from 750,000 shares to 51,000 shares (which includes 50,000 shares of its common stock issuable pursuant to an outstanding option to purchase common stock with an exercise price of $2.75 per share, leaving only 1,000 shares available for future issuance under the Inducement Plan) and the share reserve was reduced accordingly effective October 12, 2022. As of September 30, 2024, there were 1,000 shares available for future grant under the Inducement Plan. On October 12, 2022, the Company's stockholders and the Board approved the 2022 Equity Incentive Plan ("2022 Plan"), and it became effective on that date. The 2022 Plan replaced the Amended and Restated 2012 Equity Incentive Plan ("2012 Plan") on the effective date. Upon the effective date, the Company ceased granting awards under the 2012 Plan and any shares remaining available for future issuance under the 2012 Plan were cancelled and are no longer available for future issuance. The 2012 Plan continues to govern awards previously granted under it. At the time the Board approved the 2022 Plan, an aggregate of 1,363,000 shares of the Companyâ€™s common stock was initially reserved for issuance under the

2022 Plan. The Company committed to reducing the 2022 Plan share reserve by the number of shares that were granted under the 2012 Plan and the Inducement Plan between July 25, 2022 and October 12, 2022. From July 25, 2022 to October 12, 2022, the Company issued 126,262 shares of its common stock under the 2012 Plan. As a result, the number of shares initially reserved for future issuance under the 2022 Plan was 1,236,738 shares of common stock. The Company previously had an effective shelf registration statement on Form S-3 (File No. 333-252224), declared effective by the SEC on January 29, 2021 (the â€œ2021 Shelfâ€), which registered $150.0 million of common stock, preferred stock, warrants and units, or any combination of the foregoing, that expired on January 29, 2024. On January 26, 2024, the Company filed a new shelf registration statement on Form S-3 (File No. 333-276722) to register $150.0 million of the Company's common stock, preferred stock, debt securities, warrants and units, or any combination of the foregoing (the "2024 Shelf"). The 2024 Shelf was declared effective by the SEC on February 8, 2024 and replaced the 2021 Shelf at that time.On March 16, 2018, the Company entered into a Sales Agreement (â€œSales Agreementâ€) with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC (each an â€œAgentâ€ and together, the â€œAgentsâ€). On January 29, 2021, the Company filed a prospectus supplement to the 2021 Shelf (the â€œ2021 ATM Prospectus Supplementâ€), pursuant to which the Company may offer and sell, from time to time through the Agents, shares of its common stock in ATM sales transactions having an aggregate offering price of up to $50.0 million. Any shares offered and sold were issued pursuant to the 2021 Shelf until it was replaced by the 2024 Shelf.On January 26, 2024, the Company filed a prospectus to the 2024 Shelf (the "2024 ATM Prospectus"), pursuant to which the Company may offer and sell, from time to time through the Agents, share of its common stock in ATM sales transactions having an aggregate offering price of up to $2,605,728. Any shares offered and sold in these ATM transactions will be issued pursuant to the 2024 Shelf.During the three and six months ended September 30, 2024, the Company issued zero and 1,352,600 shares of common stock in ATM offerings, respectively, for net proceeds of approximately $1.7 million, all of which were sold pursuant to the 2024 Shelf. As of September 30, 2024, the Company has sold an aggregate of 1,389,002 shares of common stock in ATM offerings under the 2024 ATM Prospectus, with gross proceeds of approximately $1.8 million and net proceeds of approximately $1.8 million. As of September 30, 2024, there was approximately $100.0 million available for future offerings under the 2024 Shelf, and approximately $0.8 million available for future offerings through the Companyâ€™s ATM program under the 2024 ATM Prospectus.May 2024 Best Efforts Public OfferingOn May 8, 2024, the Company priced a best efforts public offering (the â€œOfferingâ€) of: (i) 1,562,500 shares of its common stock and accompanying common warrants (â€œCommon Warrantsâ€) to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) pre-funded warrants (â€œPre-Funded Warrantsâ€) to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. In connection with the Offering, the Company entered into Securities Purchase Agreements with the purchasers of the securities in the Offering on May 8, 2024. 12 Â The per share exercise price for the Pre-Funded Warrants is $0.001, subject to adjustment as provided therein. The Pre-Funded Warrants were immediately exercisable, subject to certain beneficial ownership limitations, and will expire when exercised in full. The holders may exercise the Pre-Funded Warrants by means of a â€œcashless exercise.â€ The per share exercise price for the Common Warrants is $0.80, subject to adjustment as provided therein. The Common Warrants were immediately exercisable, subject to certain beneficial ownership limitations, and will expire on the date that is five years following the original issuance date. If a registration statement covering the issuance of the shares of common stock issuable upon exercise of the Common Warrants is not available for the issuance, then the holders may exercise the Common Warrants by means of a â€œcashless exercise.â€ In connection with the Offering, the Company paid JonesTrading Institutional Services LLC, which acted as the placement agent in connection with the Offering, a cash fee of 5.0% of the aggregate gross proceeds raised in the Offering. The closing of the Offering occurred on May 13, 2024. The Company received net proceeds of approximately $4.5 million from the Offering, after deducting the offering expenses payable by the Company, including the Placement Agent fees. Restricted Stock UnitsThe following table summarizes the Companyâ€™s RSUs activity for the six months ended September 30, 2024:Â Â Â Number ofShares Â Â WeightedAverage Price Â Unvested at March 31, 2024 Â Â 122,642 Â Â $ 1.75 Â Granted Â Â 117,642 Â Â $ 0.55 Â Vested Â Â (2,500) Â $ 10.27 Â Cancelled / forfeited Â Â â€” Â Â $ â€” Â Unvested at September 30, 2024 Â Â 237,784 Â Â $ 1.07 Â Â Stock Options During the six months ended September 30, 2024, under the 2022 Plan, 1,150,343 stock options were granted at various exercise prices.On August 5, 2024, the Company granted 1,006,116 stock options to its Executive Chairman under the 2022 Plan. Of the stock options granted, 574,923 will vest evenly on an annual basis over three years. 143,731 of the options granted have unique vesting criteria based on market conditions, more specifically the Company's stock price. As these market condition based stock options require significant estimates and assumptions to calculate their fair value, the Company engaged with valuation specialists to calculate the fair value and requisite service periods using Monte Carlo simulations. The stock options will be expensed over their determined requisite service periods. The remaining 287,462 options granted have unique vesting criteria based on specific Company performance conditions. The vesting criteria for 143,731 of these options includes the Company achieving cumulative revenue of $1.5 million. The vesting criteria for the remaining 143,731 options includes the Company entering into a definitive agreement that constitutes a major strategic partnership, at the discretion of the Board. The following table summarizes the Companyâ€™s stock option activity from March 31, 2024 to September 30, 2024: Â Â Â OptionsOutstanding Â Â WeightedAverageExercise Price Â Â AggregateIntrinsicValue Â Outstanding at March 31, 2024 Â Â 698,007 Â Â $ 4.26 Â Â $ â€” Â Options granted Â Â 1,150,343 Â Â $ 0.59 Â Â $ â€” Â Options cancelled / forfeited Â Â (6,912) Â $ 3.30 Â Â $ â€” Â Options expired Â Â (6,072) Â $ 5.14 Â Â $ â€” Â Outstanding at September 30, 2024 Â Â 1,835,366 Â Â $ 1.96 Â Â $ â€” Â Vested and Exercisable at September 30, 2024 Â Â 478,301 Â Â $ 5.08 Â Â $ â€” Â Â The weighted average remaining contractual term of stock options exercisable and outstanding at September 30, 2024 was approximately 8.93 years. 13 Â WarrantsIn connection with the Offering described above, the Company issued Common Warrants to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) Pre-Funded Warrants to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. The Company has determined that these warrants should be classified as equity instruments since they do not require the Company to repurchase the underlying common stock and do not require the Company to issue a variable amount of common stock. In addition, these warrants are indexed to common stock and do not have any antidilution rights. The following table summarizes the Companyâ€™s Common Warrant activity from March 31, 2024 to September 30, 2024: Â Â Number ofWarrants Â Â ExercisePrice Â Outstanding at March 31, 2024 Â Â â€” Â Â $ â€” Â Issued Â Â 6,562,500 Â Â $ 0.80 Â Exercised Â Â â€” Â Â $ 0.80 Â Outstanding at September 30, 2024 Â Â 6,562,500 Â Â $ 0.80 Â Â The following table summarizes the Companyâ€™s Pre-Funded Warrants activity from March 31, 2024 to September 30, 2024: Â Â Â Number ofWarrants Â Â ExercisePrice Â Outstanding at March 31, 2024 Â Â â€” Â Â $ â€” Â Issued Â Â 5,000,000 Â Â $ 0.001 Â Exercised Â Â (2,370,000) Â $ 0.001 Â Outstanding at September 30, 2024 Â Â 2,630,000 Â Â $ 0.001 Â Employee Stock Purchase PlanIn July 2023, the Board adopted, and on October 31, 2023, the Company's stockholders subsequently approved, the 2023 Employee Stock Purchase Plan (the "2023 ESPP"). The 2023 ESPP became effective on October 31, 2023. The Company reserved 45,000 shares of common stock for issuance thereunder. The 2023 ESPP permits employees to purchase common stock through payroll deductions, limited to 15 percent of each employeeâ€™s compensation up to $25,000 per employee per year or 500 shares per employee per six-month purchase period. Shares under the 2023 ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering under the 2023 ESPP commenced on March 1, 2024. During the six months ended September 30, 2024, 500 shares were issued under the 2023 ESPP. At September 30, 2024, there were 44,500 shares remaining available for purchase under the 2023 ESPP.Common Stock Reserved for Future Issuance Common stock reserved for future issuance consisted of the following at September 30, 2024: Â Common stock issuable pursuant to options outstanding and reserved under the 2012 Plan Â Â 423,488 Â Common stock reserved under the 2012 Plan Â Â â€” Â Common stock issuable pursuant to options outstanding and reserved under the 2022 Plan Â Â 1,361,878 Â Common stock reserved under the 2022 Plan Â Â 452,038 Â Common stock reserved under the 2023 ESPP Â Â 44,500 Â Common stock reserved under the 2021 Inducement Equity Plan Â Â 1,000 Â Common stock issuable pursuant to restricted stock units outstanding under the 2012 Plan Â Â 2,500 Â Common stock issuable pursuant to restricted stock units outstanding under the 2022 Plan Â Â 235,284 Â Common stock issuable pursuant to options outstanding and reserved under the Inducement Plan Â Â 50,000 Â Common stock issuable pursuant to outstanding pre-funded warrants Â Â 2,630,000 Â Common stock issuable pursuant to outstanding common warrants Â Â 6,562,500 Â Total at September 30, 2024 Â Â 11,763,188 Â Â 14 Â Stock-based Compensation Expense and Valuation InformationStock-based awards include stock options and RSUs under the 2022 Plan, 2012 Plan, Inducement Plan, and rights to purchase stock under the 2023 ESPP. The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense. Stock-based compensation expense for all stock-based awards consists of the following (in thousands):Â Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Research and development Â $ 25 Â Â $ (60) Â $ 51 Â Â $ 47 Â General and administrative Â Â 130 Â Â Â 735 Â Â Â 260 Â Â Â 1,103 Â Total Â $ 155 Â Â $ 675 Â Â $ 311 Â Â $ 1,150 Â Â The total unrecognized compensation cost related to unvested stock option grants as of September 30, 2024 was approximately $0.8 million and the weighted average period over which these grants are expected to vest is 2.74 years.The total unrecognized compensation cost related to unvested RSUs as of September 30, 2024 was $0.1 million, which will be recognized over a weighted average period of 0.6 years.Â The Company uses either the Black-Scholes or Monte Carlo option-pricing models to calculate the fair value of stock options, depending on the complexity of the equity grants. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The assumed dividend yield is based on the Companyâ€™s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption is based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. The measurement and classification of share-based payments to non-employees is consistent with the measurement and classification of share-based payments to employees. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:Â Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023* Â Â September 30, 2024 Â Â September 30, 2023 Â Dividend yield Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Volatility Â Â 99.00 % Â Â 0.00 % Â Â 99.37 % Â Â 98.51 % Risk-free interest rate Â Â 3.64 % Â Â 0.00 % Â Â 3.75 % Â Â 3.95 % Expected life of options Â 6Â years Â Â 0 Â Â 6Â years Â Â 6Â years Â Weighted average grantÂ Â Â date fair value Â $ 0.43 Â Â $ â€” Â Â $ 0.47 Â Â $ 1.45 Â *There were no stock options granted during the three months ended September 30, 2023.The fair value of each RSU is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant.The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the 2023 ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:Â Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023* Â Â September 30, 2024 Â Â September 30, 2023* Â Dividend yield Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Volatility Â Â 95.20 % Â Â 0.00 % Â Â 95.20 % Â Â 0.00 % Risk-free interest rate Â Â 5.27 % Â Â 0.00 % Â Â 5.27 % Â Â 0.00 % Expected term Â 6Â months Â Â Â â€” Â Â 6Â months Â Â Â â€” Â Grant date fair value Â $ 0.39 Â Â $ â€” Â Â $ 0.39 Â Â $ â€” Â *There were no participants in the ESPP for the purchase periods that commenced on March 1, 2023 September 1, 2023.The assumed dividend yield is based on the Companyâ€™s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption is based on U.S. Treasury rates. The expected life is the 6-month purchase period. Â 15 Â Note 6. Collaborative Research, Development, and License Agreements License AgreementsBICO Group ABFrom June 2021 to February 2022, certain patents owned or sublicensed by the Company became the subject of inter partes review proceedings filed by Cellink AB and its subsidiaries (collectively, â€œBICO Group ABâ€). The Company and BICO Group AB were also engaged in litigation regarding patent infringement during the same time period. On February 22, 2022, the Company and BICO Group AB signed a settlement and patent license agreement (â€œLicense Agreementâ€) to close all matters noted above. In addition to closing all legal matters and patent disputes noted above, as part of the agreement, the Company agreed to grant a non-exclusive license to BICO Group AB to use the Companyâ€™s aforementioned patents for its business operations of manufacturing and selling bioprinters as well as bioinks. The Company concluded that the nature of the license granted represents functional intellectual property. As part of the License Agreement, BICO Group AB agreed to pay the Company ongoing sales-based royalties (based on percentages of BICO Group ABâ€™s net sales) for the use of the granted license. The sales-based royalties became effective beginning on February 22, 2022, the effective date of the License Agreement, and continue until the expiration of the last surviving licensed patent. As the sales-based royalties are required to be paid 45 days after the end of every quarter, there is variable consideration that must be estimated to determine royalty revenue within a given reporting period. Once actual revenue earned is determined in the following fiscal quarter, an adjustment is made from the previously estimated amount. For the three and six months ended September 30, 2024, the Company recorded $29,000 and $60,000 of royalty revenue, respectively, based on sales-based royalties from the License Agreement. Royalty revenue presented on the statements of operations and other comprehensive loss is $28,000 and $53,000 for the three and six months ended September 30, 2024, respectively, due to adjustments related to prior quarters. Also as part of the License Agreement, certain patents involved in the agreement are sublicensed by the Company from the University of Missouri and Clemson University. See below for further information. University of MissouriIn March 2009, the Company entered into a license agreement with the Curators of the University of Missouri ("University of Missouri") to in-license certain technology and intellectual property relating to self-assembling cell aggregates and intermediate cellular units. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. The Company is required to pay the University of Missouri royalties ranging from 1% to 3% of net sales of covered tissue products, and of the fair market value of covered tissues transferred internally for use in the Companyâ€™s commercial service business, depending on the level of net sales achieved by the Company each year. On December 5, 2022, the Company amended the license agreement with the University of Missouri, whereby the Company agreed to pay a single, up-front payment of $50,000 to the University of Missouri in exchange for the aforementioned licensed intellectual property to be fully paid up by the Company. As a result, the Company will continue to

have rights to the licensed intellectual property until its expiration, but will no longer owe minimum annual royalty payments, royalty payments based on net sales, or any other payments (other than patent annuities and any prosecution costs) in the future.Clemson UniversityIn May 2011, the Company entered into a license agreement with Clemson University Research Foundation ("CURF") to in-license certain technology and intellectual property relating to ink-jet printing of viable cells. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. Under the agreement, the Company was required to pay CURF royalties ranging from 1.5% to 3% of net sales of covered tissue products and the fair market value of covered tissues transferred internally for use in the Companyâ€™s commercial service business, depending on the level of net sales reached each year. The license agreement was to terminate upon expiration of the patents licensed, which expired in May 2024, and was subject to certain conditions as defined in the license agreement. Minimum annual royalty payments of $20,000 were due for two years beginning in calendar 2014, and $40,000 per year beginning in calendar 2016. Royalty payments of $40,000 were made in each of the years ended March 31, 2024 and 2023. The annual minimum royalty was to be creditable against royalties owed during the same calendar year. As the licensed patents expired in May 2024, there will be no further royalty payments owed. Â In addition to the annual royalties noted above, CURF would have been owed 40% of all payments including but not limited to, upfront payments, license fees, issue fees, maintenance fees, and milestone payments received from third parties, including sublicensees, in consideration for sublicensing rights to licensed products. However, per the agreement, in the event that the Company defends the technology by litigation, it can offset any royalties due by legal expenses incurred. As of September 30, 2024, the Companyâ€™s legal expenses exceeded royalties owed from the upfront payment and sales-based royalties related to the license 16 Â agreement. Therefore, no royalty expense to CURF was recorded for the three and six months ended September 30, 2024 and 2023, respectively. No royalty expense related to sales-based royalties has been recorded to date. Â Note 7. Commitments and Contingencies Legal Matters In addition to commitments and obligations in the ordinary course of business, the Company may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of its business. On August 27, 2024, H.C. Wainwright & Co., LLC (â€œH.C. Wainwrightâ€) filed a complaint against the Company in the State of New York alleging that the Company breached a tail financing provision included in an engagement agreement the Company entered into with H.C. Wainwright in May 2023. In its complaint, H.C. Wainwright is seeking compensatory and consequential damages and attorneysâ€™ fees. On October 18, 2024, the Company filed an answer to the complaint. The Company is defending these claims vigorously, but there is no guarantee that it will be successful in these efforts.The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability.The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures and monitors each related legal issue and adjusts accruals as might be warranted based on new information and further developments. During the three months ended September 30, 2024, the Company recorded an accrual of $0.6 million (which was considered a financing fee related to the Offering discussed in Note 5. Stockholders' Equity) for the loss contingencies associated with the above described H.C. Wainwright complaint as it determined that an unfavorable outcome is probable or reasonably possible and believed that the amount or range of any possible loss was reasonably estimable. However, amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments, and the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. If one or more legal matters were resolved against the Company in a reporting period, the Companyâ€™s consolidated financial statements for that reporting period could be materially adversely affected. 17 Â Note 8. LeasesAfter the initial adoption of ASC Topic 842 (â€œASC 842â€), on an on-going basis, the Company evaluates all contracts upon inception and determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If a lease is identified, the Company will apply the guidance from ASC 842 to properly account for the lease.Operating LeasesOn November 23, 2020, the Company entered into a lease agreement, pursuant to which the Company permanently leased approximately 8,051 square feet of lab and office space (the â€œPermanent Leaseâ€) in San Diego once certain tenant improvements were completed by the landlord and the premises were ready for occupancy. Additionally, on November 17, 2021, the Permanent Lease was amended to add an additional 2,892 square feet of office space in the same building. The Permanent Lease commenced on December 17, 2021 and is intended to serve as the Companyâ€™s permanent premises for approximately sixty-two months. Monthly rental payments will be approximately $40,800 with 3% annual escalators. The Company determined that the Permanent Lease is considered an operating lease under ASC 842, and therefore upon the lease commencement date of December 17, 2021, recognized lease liabilities and corresponding right-of-use assets of $2.3 million. The Company records operating lease expense on a straight-line basis over the life of the lease (referred to as â€œoperating lease expenseâ€). Variable lease expenses associated with the Companyâ€™s leases, such as payments for additional monthly fees to cover the Companyâ€™s share of certain facility expenses (common area maintenance) are expensed as incurred. The table below summarizes the Companyâ€™s lease liabilities and corresponding right-of-use assets as of September 30, 2024 (in thousands except the year and percentage):Â Â Â September 30, 2024 Â ASSETS Â Â Â Operating lease right-of-use assets Â $ 1,086 Â Total lease right-of-use assets Â $ 1,086 Â Â Â Â Â LIABILITIES Â Â Â Current Â Â Â Operating lease liability Â $ 513 Â Noncurrent Â Â Â Operating lease liability, net of current portion Â $ 660 Â Total lease liabilities Â $ 1,173 Â Â Â Â Â Weighted average remaining lease term: Â 2.33Â years Â Weighted average discount rate: Â Â 6 % Â Variable lease expense was approximately $22,000 and $23,000 for the three and six months ended September 30, 2024, respectively, and approximately $39,000 and $75,000 for the three and six months ended September 30, 2023, respectively. Operating lease expense was approximately $126,000 and $252,000 for the three and six months ended September 30, 2024, respectively, and approximately $126,000 and $252,000 for the three and six months ended September 30, 2023, respectively.Cash flows associated with the Companyâ€™s operating lease for the three and six months ended September 30, 2024, were approximately $130,000 and $260,000, respectively, and approximately $126,000 and $252,000 for the three and six months ended September 30, 2023, respectively. Future lease payments relating to the Companyâ€™s operating lease liabilities as of September 30, 2024, are as follows (in thousands): 18 Â Â Fiscal year ending March 31, 2025 Â $ 263 Â Fiscal year ending March 31, 2026 Â Â 538 Â Fiscal year ending March 31, 2027 Â Â 460 Â Total future lease payments Â Â 1,261 Â Less: Imputed interest Â Â (88) Total lease obligations Â Â 1,173 Â Less: Current obligations Â Â (513) Noncurrent lease obligations Â $ 660 Â Â Note 9. Concentrations Credit risk and significant customersFinancial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. However, the Company only receives royalty revenue from one licensee and has not historically experienced any accounts receivable write-downs. Â Note 10. Related PartiesFrom time to time, the Company will enter into an agreement with a related party in the ordinary course of its business. These agreements are ratified by the Board or a committee thereof pursuant to its related party transaction policy. Viscient Biosciences (â€œViscientâ€) is an entity for which Keith Murphy, the Companyâ€™s Executive Chairman, serves as the Chief Executive Officer and President. On December 28, 2020, the Company entered into an intercompany agreement (the â€œIntercompany Agreementâ€) with Viscient and Organovo, Inc., the Companyâ€™s wholly-owned subsidiary, which included an asset purchase agreement for certain lab equipment. Pursuant to the Intercompany Agreement, the Company agreed to provide Viscient certain services related to 3D bioprinting technology, which include, but are not limited to, histology services, cell isolation, and proliferation of cells and Viscient agreed to provide the Company certain services related to 3D bioprinting technology, including bioprinter training, bioprinting services, and qPCR assays, in each case on payment terms specified in the Intercompany Agreement and as may be further determined by the parties. In addition, the Company and Viscient each agreed to share certain facilities and equipment and, subject to further agreement, to each make certain employees available for specified projects for the other party at prices to be determined in good faith by the parties. During the second quarter of fiscal 2025, the companies added a Statement of Work ("SOW") to the Intercompany Agreement, where Viscient agreed to provide the Company with certain testing services related to the Company's ongoing R&D. The Company evaluated the accounting for the Intercompany Agreement and concluded that any services provided by Viscient to the Company will be expensed as incurred, and any compensation for services provided by the Company to Viscient will be considered a reduction of personnel related expenses. Any services provided to Viscient do not fall under Topic 606 as the Intercompany Agreement is not a contract with a customer. For the three months and six months ended September 30, 2024, the Company incurred $70,000 of toxicity testing services from Viscient. The Company incurred zero expenses from Viscient for the three and six months ended September 30, 2023. Additionally, for the three months and six months ended September 30, 2024, the Company provided approximately $4,000 of histology services to Viscient, and approximately less than $1,000 and $10,000 of histology services to Viscient for the three and six months ended September 30, 2023, respectively. Note 11. Business Segment InformationOperating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing performance. The Company's operating segments were identified in fiscal 2024 and did not impact prior periods. The Company's operating segments are as follows: Research & DevelopmentThe research and development (â€œR&Dâ€) segment consists of the Company's drug development efforts. The Company's current clinical focus is in advancing FXR314 in IBD, including UC and CD. The Company plans to start a Phase 2a clinical trial in UC in the calendar year 2025. The Company released Phase 2 data for FXR314 for the treatment of MASH in April 2024 that are supportive of ongoing development, and believes FXR314 has a commercial opportunity in MASH, most likely in combination therapy. The 19 Â Company is exploring the potential for combination therapies using FXR314 and currently approved mechanisms in preclinical animal studies and its IBD disease models.The Company's second focus is building high fidelity, 3D tissues that recapitulate key aspects of human disease. The Company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. The Company believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas.As with the clinical development program, the Company is initially focusing on the intestine and has ongoing 3D tissue development efforts in human tissue models of UC and CD. The Company uses these models to identify new molecular targets responsible for driving the disease and to explore the mechanism of action of known drugs including FXR314 and related molecules. The Company intends to initiate drug discovery programs around these new validated targets to identify drug candidates for partnering and/or internal clinical development.Mosaic Cell SciencesThe Mosaic Cell Sciences segment, which began operations in February 2024, consists of our Mosaic Cell Sciences division (â€œMosaicâ€), which will serve as a key source of certain of the primary human cells that the Company utilizes in its research and development efforts. The Company believes Mosaic can help optimize its supply chain, reduce operating expenses related to cell sourcing and procurement, and ensure that the cellular raw materials it uses are of the highest quality and are derived from tissues that are ethically sourced in full compliance with state and federal guidelines. Mosaic provides the Company with qualified human cells for use in its clinical research and development programs. In addition to supplying the Company with primary human cells, Mosaic offers human cells for sale to life science customers, both directly and through distribution partners, which the Company expects to offset costs and over time become a profit center that offsets overall R&D spending by the Company.Business Segment InformationThe Company's R&D segment generates royalty revenue related to its IP. The Company's Mosaic segment generates product revenue as part of its core operations. Segment revenues consisted of the following (in thousands):Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Â R&D Â Â Â Â Â Â Â Â Â Â Â Â Royalty revenue $ 28 Â Â $ â€” Â Â $ 53 Â Â $ 75 Â Â Mosaic Â Â Â Â Â Â Â Â Â Â Â Â Product revenue Â 2 Â Â Â â€” Â Â Â 16 Â Â Â â€” Â Â Total segment revenue $ 30 Â Â $ â€” Â Â $ 69 Â Â $ 75 Â Â Total Company revenue $ 30 Â Â $ â€” Â Â $ 69 Â Â $ 75 Â Â Operating segment costs and expenses consisted of the following (in thousands):Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Â R&D Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development expenses $ 934 Â Â $ 1,335 Â Â $ 2,110 Â Â $ 3,001 Â Â Mosaic Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenues Â 1 Â Â Â â€” Â Â Â 3 Â Â Â â€” Â Â Â Â Â Â Research and development expenses Â 50 Â Â Â â€” Â Â Â 276 Â Â Â â€” Â Â Â Â Â Â Selling, general, and administrative expenses Â 68 Â Â Â â€” Â Â Â 135 Â Â Â â€” Â Â Total segment costs and expenses $ 1,053 Â Â $ 1,335 Â Â $ 2,524 Â Â $ 3,001 Â Â Other selling, general, and administrative expenses Â 1,585 Â Â Â 2,780 Â Â Â 3,539 Â Â Â 5,384 Â Â Total Company costs and expenses $ 2,638 Â Â $ 4,115 Â Â $ 6,063 Â Â $ 8,385 Â Â Â 20 Â The R&D segment's identifiable assets are its fixed assets. The Mosaic segment's identifiable assets are its fixed assets and inventory. Other Company assets are comprised of all other assets that are not distinctly identifiable to a segment. Operating segment assets consisted of the following (in thousands):Â Â September 30, 2024 Â Â March 31, 2024 Â R&D Â Â Â Â Â Fixed assets, net $ 343 Â Â $ 423 Â Mosaic Â Â Â Â Â Fixed assets, net Â 161 Â Â Â 183 Â Inventory Â 640 Â Â Â 297 Â Total segment assets $ 1,144 Â Â $ 903 Â Other Company assets Â 5,610 Â Â Â 5,446 Â Total Company assets $ 6,754 Â Â $ 6,349 Â Â Â 21 Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following managementâ€™s discussion and analysis of financial condition and results of operations should be read in conjunction with our historical consolidated financial statements and the related notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024. This managementâ€™s discussion and analysis contains forward-looking statements, such as statements related to our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words â€œbelieve,â€ â€œplan,â€ â€œintend,â€ â€œanticipate,â€ â€œtarget,â€ â€œestimate,â€ â€œexpectâ€ and the like, and/or future tense or conditional constructions such as â€œwill,â€ â€œmay,â€ â€œcould,â€ â€œshould,â€ or similar expressions, identify certain of these forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to risks and uncertainties, including those described in this Quarterly Report on Form 10-Q, as well as the risk factors disclosed in our Annual Report on the Form 10-K for the fiscal year ended March 31, 2024, filed with the Securities and Exchange Commission on May 31, 2024, and discussed in the section titled â€œRisk Factorsâ€ under Part II, Item 1A in this Quarterly

Report on Form 10-Q, that could cause our actual results or events to differ materially from those expressed or implied by such forward-looking statements. Unless the context otherwise requires, the terms â€œOrganovo,â€ the â€œCompanyâ€, â€œweâ€, â€œusâ€ and â€œourâ€ in this Quarterly Report on Form 10-Q refer to Organovo Holdings, Inc. and its wholly owned subsidiary, Organovo, Inc. Except to the limited extent required by applicable law, we do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report on Form 10-Q. Basis of Presentation The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the Securities and Exchange Commission (the â€œSECâ€) instructions to Quarterly Reports on Form 10-Q. Accordingly, the unaudited condensed consolidated financial statements presented elsewhere in this Form 10-Q and discussed below are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (â€œGAAPâ€) to be included in a full set of financial statements. The audited financial statements for the year ended March 31, 2024, filed with the SEC on Form 10-K on May 31, 2024, include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Overview We are a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (â€œIBDâ€), including ulcerative colitis (â€œUCâ€), based on demonstration of clinical promise in three-dimensional (â€œ3Dâ€) human tissues as well as strong preclinical data. FXR is a mediator of gastrointestinal and liver diseases. FXR agonism has been tested in a variety of preclinical models of IBD. FXR314 is the lead compound in our established FXR program containing two clinically tested compounds (including FXR314) and over 2,000 discovery or preclinical compounds. FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials. Further, FXR314 has FDA clinical trial authorization for a Phase 2 trial in UC. Our current clinical focus is in advancing FXR314 in IBD, including UC and Crohnâ€™s disease (â€œCDâ€). We plan to start a Phase 2a clinical trial in UC in the calendar year 2025. We released Phase 2 data for FXR314 for the treatment of metabolic function-associated steatohepatitis ("MASH") in April 2024 that are supportive of ongoing development, and we believe FXR314 has a commercial opportunity in MASH, most likely in combination therapy. We are exploring the potential for combination therapies using FXR314 and currently approved mechanisms in preclinical animal studies and our IBD disease models. Our second focus is building high fidelity, 3D tissues that recapitulate key aspects of human disease. We use our proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. We believe these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. As with the clinical development program, we are initially focusing on the intestine and have ongoing 3D tissue development efforts in human tissue models of UC and CD. We use these models to identify new molecular targets responsible for driving the disease and to explore the mechanism of action of known drugs including FXR314 and related molecules. We intend to initiate drug discovery programs around these new validated targets to identify drug candidates for partnering and/or internal clinical development. Our current understanding of intestinal tissue models and IBD disease models leads us to believe that we can create models that provide greater insight into the biology of these diseases than are generally currently available. We are creating high fidelity disease 22 Â models, leveraging our prior work including the work found in our peer-reviewed publication on bioprinted intestinal tissues (Madden et al. Bioprinted 3D Primary Human Intestinal Tissues Model Aspects of Native Physiology and ADME/Tox Functions. iScience. 2018 Apr 27;2:156-167. doi: 10.1016/j.isci.2018.03.015.) Our advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Using these disease models, we intend to identify and validate novel therapeutic targets. After finding therapeutic drug targets, we intend to focus on developing novel small molecule, antibody, or other therapeutic drug candidates to treat the disease, and advance these novel drug candidates towards an Investigational New Drug filing and potential future clinical trials. We expect to broaden our work into additional therapeutic areas over time and are currently exploring specific tissues for development. In our work to identify the areas of interest, we evaluate areas that might be better served with 3D disease models than currently available models as well as the potential commercial opportunity. In line with these plans, we are building upon both our external and in house scientific expertise, which will be essential to our drug development effort. Recent Developments Mosaic Cell Sciences Division In February 2024, we formed our Mosaic Cell Sciences division (â€œMosaicâ€) to serve as a key source of certain of the primary human cells we utilize in our research and development efforts. We believe Mosaic can help us optimize our supply chain, reduce operating expenses related to cell sourcing and procurement and ensure that the cellular raw materials we use are of the highest quality and are derived from tissues that are ethically sourced in full compliance with state and federal guidelines. Mosaic provides us with qualified human cells for use in its clinical research and development programs. In addition to supplying us with primary human cells, Mosaic offers human cells for sale to life science customers, both directly and through distribution partners, which we expect to offset costs and over time become a profit center that offsets our overall R&D spending. Nasdaq Minimum Bid Notice On July 18, 2024, we received a written notice (the â€œNoticeâ€) from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (â€œNasdaqâ€) indicating that, based upon the closing bid price of our common stock for the last 30 consecutive business days, we no longer meet the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (â€œRule 5550(a)(2)â€). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided with an initial period of 180 calendar days, or until January 14, 2025, to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. The Notice provides that the Nasdaq staff will provide written confirmation to us if we regain compliance with Rule 5550(a)(2). If we do not regain compliance with Rule 5550(a)(2) by January 14, 2025, we may be eligible for an additional compliance period of 180 calendar days. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice to Nasdaq of our intention to cure the bid price deficiency during the second compliance period. However, if it appears to the Nasdaq staff that we will not be able to cure the deficiency, or we are otherwise not eligible, Nasdaq would notify us that our securities will be subject to delisting. In the event of such a notification, we may appeal the Nasdaq staffâ€™s determination to delist our securities, but there can be no assurance the Nasdaq staff would grant any request for continued listing. The Notice had no immediate effect on the listing or trading of our common stock and our common stock will continue to trade on the Nasdaq Capital Market under the symbol â€œONVOâ€. We intend to monitor the closing bid price of our common stock and consider our available options if our common stock does not trade at a level likely to result in us regaining compliance with Rule 5550(a)(2) by January 14, 2025, including effecting a reverse stock split, which would be subject to the prior approval of our stockholders. At our 2024 annual meeting of our stockholders to be held on November 20, 2024, we are asking our stockholders to approve an amendment to our Certificate of Incorporation, as amended, to effect, in the sole discretion of our Board of Directors (our â€œBoardâ€) at any time on or before November 20, 2025, a reverse split of our common stock at a ratio to be determined by the Board within a range of 1-to-5 to 1-to-20 (or any number in between). Â There can be no assurance that we will be able to regain compliance with Nasdaqâ€™s minimum bid price requirement or that we will maintain our compliance with the other listing requirements necessary for us to maintain the listing of our common stock on the Nasdaq Capital Market. 23 Â Critical Accounting Policies, Estimates, and Judgments Our financial statements are prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments used in preparing our financial statements and related disclosures, none of which are considered critical. All estimates affect reported amounts of assets, liabilities, revenues and expenses, as well as disclosures of contingent assets and liabilities. These estimates and judgments are also based on historical experience and other factors that are believed to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. There have been no significant changes to our critical accounting policies since March 31, 2024. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our condensed consolidated financial statements, refer to Item 7. â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ and â€œNote 1. Description of Business and Summary of Significant Accounting Policiesâ€ in the Notes to Consolidated Financial Statements contained in our Annual Report on Form 10-K for the year ended March 31, 2024, filed with the SEC on May 31, 2024. Results of Operations Comparison of the three months ended September 30, 2024, and 2023 The following table summarizes our results of operations for the three months ended September 30, 2024 and 2023 (in thousands, except %): Â Â Â Three Months Ended Â Â Â Â Â Â Â Â Â September 30, Â Â Increase (decrease) Â Â 2024 Â Â 2023 Â Â $ Â Â % Â Royalty revenue Â $ 28 Â Â $ â€” Â Â $ 28 Â Â Â 100 % Product revenue Â $ 2 Â Â $ â€” Â Â $ 2 Â Â Â 100 % Cost of revenues Â $ 1 Â Â $ â€” Â Â $ 1 Â Â Â 100 % Research and development Â $ 984 Â Â $ 1,335 Â Â $ (351) Â Â (26 %) Selling, general and administrative Â $ 1,653 Â Â $ 2,780 Â Â $ (1,127) Â Â (41 %) Other income Â $ 59 Â Â $ 121 Â Â $ (62) Â Â (51 %) Revenues For the three months ended September 30, 2024 and 2023, total revenue was less than $0.1 million and zero, respectively. Royalty revenue is related to sales-based royalties from licensing intellectual property. The increase in the second fiscal quarter royalty revenue year over year relates to overestimating royalty revenue in the first fiscal quarter of 2023, resulting in an adjustment to actual sales. We expect quarterly sales of royalty bearing products by the licensee to remain consistent with the sales in the second quarter of fiscal 2025 going forward. Product revenue is related to the sale of human cells developed by Mosaic. The first two quarters of fiscal 2025 are the first two quarters of product sales since the inception of Mosaic. We expect product revenue to increase going forward. Cost of Revenues For the three months ended September 30, 2024 and 2023, total cost of revenues was less than $0.1 million and zero, respectively, and is related to the sale of finished goods inventory by Mosaic. Research and Development Expenses The following table summarizes our research and development expenses for the three months ended September 30, 2024 and 2023 (in thousands, except %): Â Â Â Three Months Ended Â Â Â Â Â Three Months Ended Â Â Â Â Â Increase (decrease) Â Â September 30, 2024 Â Â % of total Â Â September 30, 2023 Â Â % of total Â Â $ Â Â % Â Research and development Â $ 902 Â Â Â 91 % Â $ 1,338 Â Â Â 100 % Â $ (436) Â Â (33 %) Non-cash stock-based compensation Â Â 25 Â Â Â 3 % Â Â (60) Â Â (4 %) Â Â 85 Â Â Â (142 %) Depreciation and amortization Â Â 57 Â Â Â 6 % Â Â 57 Â Â Â 4 % Â Â â€” Â Â 0 % Total research and developmentÂ Â Â expenses Â $ 984 Â Â Â 100 % Â $ 1,335 Â Â Â 100 % Â $ (351) Â Â (26 %) Â 24 Â For the three months ended September 30, 2024, total research and development expenses were $1.0 million, a decrease of $0.4 million, or approximately 26%, from the prior year period. Our average full-time research and development staff decreased from an average of eighteen full-time employees for the three months ended September 30, 2023 to an average of fourteen full-time employees for the three months ended September 30, 2024. Our operations for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 resulted in a $0.1 million decrease in facilities costs, and a $0.4 million decrease in material related costs, offset by a $0.1 million increase in personnel related costs which includes stock-based compensation. Going forward, we intend to continue to advance the clinical drug development of FXR314 and expect an associated increase in expenses. Â Selling, General and Administrative Expenses The following table summarizes our selling, general and administrative expenses for the three months ended September 30, 2024 and 2023 (in thousands, except %): Â Â Â Three Months Ended Â Â Â Â Â Three Months Ended Â Â Â Â Â Increase (decrease) Â Â September 30, 2024 Â Â % of total Â Â September 30, 2023 Â Â % of total Â Â $ Â Â % Â Selling, general and administrative Â $ 1,511 Â Â Â 91 % Â $ 2,033 Â Â Â 74 % Â $ (522) Â Â (26 %) Non-cash stock-based compensation Â Â 130 Â Â Â 8 % Â Â 734 Â Â Â 26 % Â Â (604) Â Â (82 %) Depreciation and amortization Â Â 12 Â Â Â 1 % Â Â 13 Â Â Â 0 % Â Â (1) Â Â (8 %) Total selling, general andÂ Â Â administrative expenses Â $ 1,653 Â Â Â 100 % Â $ 2,780 Â Â Â 100 % Â $ (1,127) Â Â (41 %) Â For the three months ended September 30, 2024, total selling, general and administrative expenses were approximately $1.7 million, a decrease of $1.1 million, or approximately 41%, compared to the prior year period. Our average full-time general and administrative staff of five employees remained the same for each of the three months ended September 30, 2024 and 2023. However, in fiscal 2024 one of the employees was our former General Counsel who was an executive officer and was included in a reduction in force during the second quarter of fiscal 2024. Subsequently, a sales associate for Mosaic was hired in the fourth quarter of fiscal 2024. Our operations for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 resulted in a $0.8 million decrease in personnel related expenses which includes stock-based compensation, and a $0.3 million decrease in legal and other corporate costs, which includes a $0.1 million decrease in legal expenses, a $0.1 million decrease in audit and tax expense, and a $0.1 million decrease in investor relations expenses. Other Income Other income was less than $0.1 million and $0.1 million for the three months ended September 30, 2024 and 2023, respectively, which was related to interest income. Comparison of the six months ended September 30, 2024 and 2023 The following table summarizes our results of operations for the six months ended September 30, 2024 and 2023 (in thousands, except %): Â Â Six Months Ended Â Â Â Â Â Â Â Â Â September 30, Â Â Increase (decrease) Â Â 2024 Â Â 2023 Â Â $ Â Â % Â Royalty Revenue Â $ 53 Â Â $ 75 Â Â $ (22) Â Â (29 %) Product Revenue Â $ 16 Â Â $ â€” Â Â $ 16 Â Â Â 100 % Cost of Revenue Â $ 3 Â Â $ â€” Â Â $ 3 Â Â Â 100 % Research and development Â $ 2,386 Â Â $ 3,001 Â Â $ (615) Â Â (20 %) Selling, general and administrative Â $ 3,674 Â Â $ 5,384 Â Â $ (1,710) Â Â (32 %) Other income Â $ 103 Â Â $ 290 Â Â $ (187) Â Â (64 %) Revenues For each of the six months ended September 30, 2024 and 2023, total revenue was $0.1 million. Royalty revenue is related to sales-based royalties from licensing intellectual property. The decrease in royalty revenue year over year relates to a decrease in sales of royalty bearing products by the licensee in fiscal 2025. We expect quarterly sales of royalty bearing products by the licensee to remain consistent with the sales in the second quarter of fiscal 2025 going forward. Product revenue is related to the sale of human cells 25 Â developed by Mosaic. The first two quarters of fiscal 2025 are the first two quarters of product sales since the inception of Mosaic. We expect product revenue to increase going forward. Cost of Revenues For the six months ended September 30, 2024 and 2023, total cost of revenues was less than $0.1 million and zero, respectively, and is related to the sale of finished goods inventory by Mosaic. Research and Development Expenses The following table summarizes our research and development expenses for the six months ended September 30, 2024 and 2023 (in thousands, except %): Â Â Six Months Ended Â Â Â Â Â Six Months Ended Â Â Â Â Â Increase (decrease) Â Â September 30, 2024 Â Â % of total Â Â September 30, 2023 Â Â % of total Â Â $ Â Â % Â Research and development Â $ 2,220 Â Â Â 93 % Â $ 2,843 Â Â Â 94 % Â $ (623) Â Â (22 %) Non-cash stock-based compensation Â Â 51 Â Â Â 2 % Â Â 47 Â Â Â 2 % Â Â 4 Â Â Â 9 % Depreciation and amortization Â Â 115 Â Â Â 5 % Â Â 111 Â Â Â 4 % Â Â 4 Â Â Â 4 % Total research andÂ Â Â development expenses Â $ 2,386 Â Â Â 100 % Â $ 3,001 Â Â Â 100 % Â $ (615) Â Â (20 %) For the six months ended September 30, 2024, total research and development expenses were $2.4 million, a decrease of $0.6 million, or approximately 20% from the prior year period. Our average full-time research and development staff decreased from an average of eighteen full-time employees

for the six months ended September 30, 2023 to an average of fourteen full-time employees for the six months ended September 30, 2024. Our operations for the six months ended September 30, 2024 as compared to the six months ended September 30, 2023 resulted in a $0.1 million decrease in personnel related costs, a $0.4 million decrease in material related costs, and a $0.2 million decrease in facilities costs, offset by a $0.1 million increase in consulting expenses. Going forward, we intend to continue to advance the clinical drug development of FXR314 and expect an associated increase in expenses. Selling, General and Administrative Expenses The following table summarizes our selling, general and administrative expenses for the six months ended September 30, 2024 and 2023 (in thousands, except %): Â Â Six Months Ended Â Â Â Â Â Six Months Ended Â Â Â Â Â Increase (decrease) Â Â September 30, 2024 Â Â % of total Â Â September 30, 2023 Â Â % of total Â Â $ Â Â % Â Selling, general and administrative Â $ 3,391 Â Â Â 92 % Â $ 4,255 Â Â Â 79 % Â $ (864) Â Â (20 %) Non-cash stock-based compensation Â Â 260 Â Â Â 7 % Â Â 1,103 Â Â Â 20 % Â Â (843) Â Â (76 %) Depreciation and amortization Â Â 23 Â Â Â 1 % Â Â 26 Â Â Â 1 % Â Â (3) Â Â (12 %) Total selling, general andÂ Â Â administrative expenses Â $ 3,674 Â Â Â 100 % Â $ 5,384 Â Â Â 100 % Â $ (1,710) Â Â (32 %) For the six months ended September 30, 2024, total selling, general and administrative expenses were approximately $3.7 million, a decrease of $1.7 million, or approximately 32%, compared to the prior year period. Our average full-time general and administrative staff of five employees remained the same for each of the six months ended September 30, 2024 and 2023. However, in fiscal 2024 one of the employees was our former General Counsel who was an executive officer and was included in a reduction in force during the second quarter of fiscal 2024. Subsequently, a sales associate for Mosaic was hired in the fourth quarter of fiscal 2024. Our operations for the six months ended September 30, 2024 as compared to the six months ended September 30, 2023 resulted in a $1.0 million decrease in personnel related expenses which includes stock-based compensation, a $0.2 million decrease in consulting expenses, a $0.5 million decrease in legal and other corporate costs, which includes a $0.4 million decrease in legal expenses, and a $0.2 million decrease in audit and tax expense, offset by a $0.1 million increase in investor relations expenses. Other Income 26 Â Other income was $0.1 million and $0.3 million for the six months ended September 30, 2024 and 2023, respectively, which was related to interest income. Financial Condition, Liquidity and Capital Resources Going forward, we intend to focus on clinical drug development of FXR314, the lead compound in our established FXR program. Our current clinical focus is in advancing FXR314 in IBD, including UC and CD. We plan to start a Phase 2a clinical trial in UC in the calendar year 2025. We released Phase 2 data for FXR314 for the treatment of metabolic function-associated steatohepatitis (â€œMASHâ€) in April 2024 that is supportive of ongoing development, and we believe FXR314 has a commercial opportunity in MASH, most likely in combination therapy. Additionally, we plan to leverage our proprietary technology platform to develop therapeutic drugs, focusing on IBD, including CD and UC, with a goal of broadening our work into additional therapeutic areas over time. The accompanying consolidated financial statements have been prepared on the basis that we are a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At September 30, 2024, we had cash and cash equivalents of approximately $3.2 million, restricted cash of approximately $0.1 million and an accumulated deficit of approximately $345.6 million. The restricted cash was pledged as collateral for a letter of credit that we are required to maintain as a security deposit under the terms of the lease agreement for our facilities. We had negative cash flow from operations of approximately $5.6 million during the six months ended September 30, 2024. At March 31, 2024, we had cash and cash equivalents of approximately $2.9 million, restricted cash of approximately $0.1 million and an accumulated deficit of approximately $339.7 million. At September 30, 2024, we had total current assets of approximately $4.8 million and current liabilities of approximately $2.4 million, resulting in working capital of $2.4 million. At March 31, 2024, we had total current assets of approximately $3.9 million and current liabilities of approximately $1.9 million, resulting in working capital of $2.0 million. The following table summarizes the primary sources and uses of cash for the six months ended September 30, 2024 and 2023 (in thousands): Â Â Six Months Ended Â Â September 30, Â 2024 Â 2023 Â Net cash (used in) provided by: Â Â Â Â Operating activities $ (5,625) $ (8,460) Investing activities Â 20 Â Â 776 Â Financing activities Â 5,878 Â Â â€” Â Net increase (decrease) in cash, cash equivalents, and restricted cash $ 273 Â $ (7,684) Â Operating activities Net cash used in operating activities for the six months ended September 30, 2024, was approximately $5.6 million as compared to $8.5 million used in operating activities for the six months ended September 30, 2023. This $2.9 million decrease in operating cash usage can be attributed primarily to the $2.0 million cash payment in fiscal 2024 for acquired in-process research and development assets. Investing activities Net cash provided by investing activities was less than $0.1 million for the six months ended September 30, 2024, which consisted of interest income. Net cash provided by investing activities was $0.8 million for the six months ended September 30, 2023, which consisted of the purchases of investments of $7.9 million, the maturities of investments of $8.0 million, the liquidation of equity securities of $0.7 million, and fixed asset purchases of less than $0.1 million. Financing activities Net cash provided by financing activities was $5.9 million and zero for the six months ended September 30, 2024 and 2023, respectively. Financing activities consisted of the sale of common stock through at-the-market (â€œATMâ€) share offerings and a public offering of common stock and accompanying common warrants and pre-funded warrants. Refer to â€œOperations funding requirementsâ€ below for further information regarding financing activities. 27 Â Operations funding requirements Through September 30, 2024, we have financed our operations primarily through the sale of common stock through public and ATM offerings, the private placement of equity securities, from revenue derived from the licensing of intellectual property, products and research-based services, grants, and collaborative research agreements, and from the sale of convertible notes. Our ongoing cash requirements include research and development expenses, compensation for personnel, consulting fees, legal and accounting support, insurance premiums, facilities, maintenance of our intellectual property portfolio, license and collaboration agreements, listing on the Nasdaq Capital Market, and other miscellaneous fees to support our operations. We expect our total operating expense for the fiscal year ending March 31, 2025 to be between $13.0 million and $15.0 million. Based on our current operating plan and available cash resources, we will need substantial additional funding to support future operating activities. We have concluded that the prevailing conditions and ongoing liquidity risks faced by us raise substantial doubt about our ability to continue as a going concern for at least one year following the date these financial statements are issued. The accompanying consolidated financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. Â We previously had an effective shelf registration statement on Form S-3 (File No. 333-252224), declared effective by the SEC on January 29, 2021 (the â€œ2021 Shelfâ€), which registered $150.0 million of common stock, preferred stock, warrants and units, or any combination of the foregoing, that expired on January 29, 2024. On January 26, 2024, we filed a new shelf registration statement on Form S-3 (File No. 333-276722) to register $150.0 million of common stock, preferred stock, debt securities, warrants and units, or any combination of the foregoing (the â€œ2024 Shelfâ€). The 2024 Shelf was declared effective by the SEC on February 8, 2024 and replaced the 2021 Shelf at that time. Â On March 16, 2018, we entered into a Sales Agreement (â€œSales Agreementâ€) with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC (each an â€œAgentâ€ and together, the â€œAgentsâ€). On January 29, 2021, we filed a prospectus supplement to the 2021 Shelf (the â€œ2021 ATM Prospectus Supplementâ€), pursuant to which we could offer and sell, from time to time through the Agents, shares of our common stock in ATM sales transactions having an aggregate offering price of up to $50.0 million. Any shares offered and sold were issued pursuant to our 2021 Shelf until it was replaced by the 2024 Shelf. On January 26, 2024, we filed a prospectus to the 2024 Shelf (the â€œ2024 ATM Prospectusâ€), pursuant to which we may offer and sell, from time to time, through the Agents, shares of its common stock in ATM sales transactions having an aggregate offering price of up to $2,605,728. Any shares offered and sold in these ATM transactions are issued pursuant to the 2024 Shelf. During the six months ended September 30, 2024, we issued 1,352,600 shares of common stock in ATM offerings for net proceeds of approximately $1.7 million, all of which were sold pursuant to the 2024 Shelf. As of September 30, 2024, we have sold an aggregate of 1,389,002 shares of common stock in ATM offerings under the 2024 ATM Prospectus, with gross proceeds of approximately $1.8 million and net proceeds of approximately $1.8 million. As of September 30, 2024, there was approximately $100.0 million available for future offerings under the 2024 Shelf, and approximately $0.8 million available for future offerings through our ATM program under the 2024 ATM Prospectus. On May 8, 2024, we priced a best efforts public offering (the â€œOfferingâ€) of: (i) 1,562,500 shares of our common stock and accompanying common warrants (â€œCommon Warrantsâ€) to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) pre-funded warrants (â€œPre-Funded Warrantsâ€) to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. The closing of the Offering occurred on May 13, 2024. We received net proceeds of approximately $4.5 million from the Offering, after deducting the offering expenses payable by us including the placement agent fees. On October 25, 2024, we filed a registration statement on Form S-1 for a potential best efforts offering of shares of common stock and warrants to purchase shares of common stock. However, the specific number of shares of common stock and warrants to purchase shares of common stock to be offered, the price range for the offering and the closing date of the offering have yet to be determined, and there can be no assurances that the offering will be consummated. To the extent an offering under such registration statement is consummated, we expect to use the net proceeds for working capital and general corporate purposes, which could include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, legal expenditures, including intellectual property protection and maintenance expenditures, acquisitions of new technologies and investments, business combinations and the repurchase of capital stock. Such offering, if consummated at all, will depend on a variety of factors, including, among other things, the SEC declaring the registration statement effective, market conditions and the trading price of our common stock, and such offering would be dilutive to our existing stockholders. See the risk factor under the heading â€œWe may require substantial additional funding. Raising additional capital would cause dilution to our existing stockholders and may restrict our operations or require us to relinquish rights to our technologies or to a product candidate.â€ in the section titled â€œRisk Factorsâ€ under Part II, Item 1A in this Quarterly Report on Form 10-Q for additional considerations related to this potential offering. 28 Â Having insufficient funds may require us to relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. We cannot be sure that additional financing will be available if and when needed, or that, if available, we can obtain financing on terms favorable to our stockholders. Any failure to obtain financing when required will have a material adverse effect on our business, operating results, financial condition and ability to continue as a going concern. Off-Balance Sheet Arrangements We have no off-balance sheet arrangements, including unrecorded derivative instruments that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We have certain options outstanding but we do not expect to receive sufficient proceeds from the exercise of these instruments unless and until the underlying securities are registered, and/or all restrictions on trading, if any, are removed, and in either case the trading price of our common stock is significantly greater than the applicable exercise prices of the options and warrants. 29 Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and this is not required for smaller reporting companies under Item 305(e) of Regulation S-K. ITEM 4. CONTROLS AND PROCEDURES Disclosure Controls and Procedures We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure. Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of the end of the quarterly period covered by this report were designed and operating effectively. Changes in Internal Control over Financial Reporting There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitations on Effectiveness of Controls Our management, including our principal executive officer and our principal financial officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systemâ€™s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. 30 Â PART IIâ€”OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS See the information under "Legal Matters" of Note 7 of the Notes to the Unaudited Condensed Consolidated Financial Statements within this Form 10-Q for a discussion of our legal proceedings and contingencies. ITEM 1A. RISK FACTORS Investment in our common stock involves a substantial degree of risk and should be regarded as speculative. As a result, the purchase of our common stock should be considered only by persons who can reasonably afford to lose their entire investment. Before you elect to purchase our common stock, you should carefully consider the risk and uncertainties described below in addition to the other information incorporated herein by reference. Additional risks and uncertainties of which we are unaware or which we currently believe are immaterial could also materially adversely affect our business, financial condition or results of operations. If any of the risks or uncertainties discussed in this Quarterly Report on Form 10-Q occur, our business, prospects, liquidity, financial condition and results of operations could be materially and adversely affected, in which case the trading price of our common stock could decline, and you could lose all or part of your investment. Risk factors marked with an asterisk (*) below include a substantive change from or an update to the risk factors included in our Annual Report on Form 10-

K for the fiscal year ended March 31, 2024, filed with the SEC on May 31, 2024. Risk Factor Summary Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission before making investment decisions regarding our common stock. â€¢We will incur substantial additional operating losses over the next several years as our research and development activities increase. â€¢Using our platform technology to develop human tissues and disease models for drug discovery and development is new and unproven. â€¢As we pursue drug development through 3D tissues and disease models, we will require access to a constant, steady, reliable supply of human cells to support our development activities. â€¢We may require substantial additional funding. Raising additional capital would cause dilution to our existing stockholders and may restrict our operations or require us to relinquish rights to our technologies or to a product candidate. â€¢Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future results. â€¢The near and long-term viability of our drug discovery and development efforts will depend on our ability to successfully establish strategic relationships. â€¢Current and future legislation may increase the difficulty and cost of commercializing our drug candidates and may affect the prices we may obtain if our drug candidates are approved for commercialization. â€¢Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. â€¢Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to curtail or cease our operations. â€¢We have a history of operating losses and expect to incur significant additional operating losses. â€¢There is no assurance that an active market in our common stock will continue at present levels or increase in the future. â€¢The price of our common stock may continue to be volatile, which could lead to losses by investors and costly securities litigation. 31 Â â€¢Patents covering our products could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad. â€¢We may be involved in lawsuits or other proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. Â Risks Related to our Business Â *We are a clinical stage biotechnology company focusing on clinical drug development of the farnesoid X receptor (â€œFXRâ€) agonist FXR314, which involves a substantial degree of uncertainty, and on 3D bioprinting technology to develop human tissues and disease models for drug discovery and development, which is an unproven business strategy that may never achieve profitability. We are a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (â€œIBDâ€), including ulcerative colitis (â€œUCâ€), based on demonstration of clinical promise in three-dimensional human tissues as well as strong preclinical data. Our current clinical focus is in advancing FXR314 in IBD, including UC and Crohnâ€™s disease. Our secondary focus is building high fidelity, 3D tissues that recapitulate key aspects of human disease. Our success will depend upon our ability to advance the development of FXR314, our ability to determine the appropriate clinical focus for FXR314, our ability to identify additional drug candidates to pursue and the viability of our platform technology and any disease models we develop. Our success will also depend on our ability to select an appropriate development strategy for FXR314 and any other drug candidates we may identify, including internal development or partnering or licensing arrangements with pharmaceutical companies. We may not be able to partner or license our drug candidates. We may never achieve profitability, or even if we achieve profitability, we may not be able to maintain or increase our profitability. We will incur substantial additional operating losses over the next several years as our research and development activities increase. We will incur substantial additional operating losses over the next several years as our research and development activities increase. The amount of future losses and when, if ever, we will achieve profitability are uncertain. Our ability to generate revenue and achieve profitability will depend on, among other things: â€¢successfully developing human tissues and disease models for drug discovery and development that enable us to identify drug candidates; â€¢successfully outsourcing certain portions of our development efforts; â€¢entering into partnering or licensing arrangements with pharmaceutical companies to further develop and conduct clinical trials for any drug candidates we identify; â€¢obtaining any necessary regulatory approval for any drug candidates we identify; and â€¢raising sufficient funds to finance our activities and long-term business plan. We might not succeed at any of these undertakings. If we are unsuccessful at one or more of these undertakings, our business, prospects, and results of operations will be materially adversely affected. Using our platform technology to develop human tissues and disease models for drug discovery and development is new and unproven. Utilizing our 3D bioprinting platform technology to develop human tissues and disease models for drug discovery and development will involve new and unproven technologies, disease models and approaches, each of which is subject to the risk associated with new and evolving technologies. To date, we have not identified or developed any drug candidates utilizing our new business model. Our future success will depend on our ability to utilize our 3D bioprinting platform to develop human tissues and disease models that will enable us to identify and develop viable drug candidates. We may experience unforeseen technical complications, unrecognized defects and limitations in our technology or our ability to develop disease models or identify viable drug candidates. These complications could materially delay or substantially increase the anticipated costs and time to identify and develop viable drug candidates, which would have a material adverse effect on our business and financial condition and our ability to continue operations. We will face intense competition in our drug discovery efforts. The biotechnology and pharmaceutical industry is subject to intense competition and rapid and significant technological change. There are many potential competitors for the disease indications we may pursue, including major drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. Many of these competitors have significantly greater financial and technical resources, experience and expertise in the following areas than we have, including: 32 Â â€¢research and technology development; â€¢development of or access to disease models; â€¢identification and development of drug candidates; â€¢regulatory processes and approvals; and â€¢identifying and entering into agreements with potential collaborators. Principal competitive factors in our industry include: the quality, scientific and technical support, management and the execution of drug development and regulatory approval strategies; skill and experience of employees, including the ability to recruit and retain skilled, experienced employees; intellectual property portfolio; range of capabilities, including drug identification, development and regulatory approval; and the availability of substantial capital resources to fund these activities. In order to effectively compete, we may need to make substantial investments in our research and technology development, drug candidate identification and development, testing and regulatory approval and licensing and business development activities. There is no assurance that we will be successful in discovering effective drug candidates using our 3D bioprinted tissues or disease models. Our technologies and drug development plans also may be rendered obsolete or noncompetitive as a result of drugs, intellectual property, technologies, products and services introduced by competitors. Any of these risks may prevent us from building a successful drug discovery business or entering into a strategic partnership or collaboration related to, any drug candidates we identify on favorable terms, or at all. As we pursue drug development through 3D tissues and disease models, we will require access to a constant, steady, reliable supply of human cells to support our development activities. As we pursue drug development through 3D tissues and disease models, we will require access to a constant, steady, reliable supply of human cells to support our 3D tissue development activities. We purchase human cells from selected third-party suppliers based on quality assurance, cost effectiveness, and regulatory requirements. We need to continue to identify additional sources of qualified human cells and there can be no guarantee that we will be able to access the quantity and quality of raw materials needed at a cost-effective price. Any failure to obtain a reliable supply of sufficient human cells or a supply at cost effective prices would harm our business and our results of operations and could cause us to be unable to support our drug development efforts. We may not be successful in establishing our Mosaic Cell Sciences Division (â€œMosaic") as a profitable commercial business. We formed Mosaic to serve as a key source of certain of the primary human cells we utilize in our research and development efforts. In addition to supplying human cells for our business requirements, we believe there is an opportunity for Mosaic to operate as a commercial business by selling human cells to other pharmaceutical, biotech and research organizations. We intend for Mosaic to begin selling its human cell offerings to end users both directly and through distribution partners during fiscal 2025. Operating and developing Mosaicâ€™s business is subject to a number of risks and uncertainties, including: â€¢failing to source a sufficient supply of high-quality human organs or cells; â€¢failing to achieve market acceptance for its human cell offerings; â€¢failing to demonstrate the quality and reliability of its human cell offerings; â€¢failing to be both cost effective and competitive with the products offered by third parties; â€¢failing to obtain any necessary regulatory approvals; â€¢failing to be able to produce its human cell offerings on a large enough scale; â€¢failing to establish and maintain distribution relationships with reliable third parties; â€¢failing to hire and retain qualified personnel; and â€¢infringing the proprietary rights of third parties or failing to protect our own intellectual property. If any of these or any other risks and uncertainties occur, our efforts to establish Mosaic as a commercial business may be unsuccessful, which would harm our business and results of operations. Our inability to manage inventory levels for our cell-based products could have a material adverse effect on our business. 33 Â Our ability to manage inventory levels to meet demand for cell-based products is important for our Mosaic Cell Sciences division. If we overestimate demand for our cell-based products, we may not maintain appropriate inventory levels or we could have excess inventory that we may need to hold for a long period of time, write down, sell at prices lower than expected or discard, which could negatively impact our reputation, net sales, working capital or cash flows from working capital, or cause us to incur excess and obsolete inventory charges. Alternatively, if we underestimate demand for our cell-based products, we may experience inventory shortages, which could result in missed sales, lost revenues and/or delays in fulfilling our need for qualified human cells for use in our clinical research and development programs and other customer demands while we work to replenish inventory levels. Our business will be adversely impacted if we are unable to successfully attract, hire and integrate key additional employees or contractors. Our future success depends in part on our ability to successfully attract and then retain key additional executive officers and other key employees and contractors to support our drug discovery plans. Recruiting and retaining qualified scientific and clinical personnel are critical to our success. Competition to hire qualified personnel in our industry is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. If we are unable to attract and retain high quality personnel, our ability to pursue our drug discovery business will be limited, and our business, prospects, financial condition and results of operations may be adversely affected. *We may require substantial additional funding. Raising additional capital would cause dilution to our existing stockholders and may restrict our operations or require us to relinquish rights to our technologies or to a product candidate. We currently do not have any committed external source of funds and do not expect to generate any meaningful revenue in the foreseeable future. If our board of directors decides that we should pursue further research and development activities than already proposed, we will require substantial additional funding to operate our proposed business, including expanding our facilities and hiring additional qualified personnel, and we would expect to finance these cash needs through a combination of equity offerings, debt financings, government or other third-party funding and licensing or collaboration arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt, the ownership interests of our stockholders will be diluted. In addition, the terms of any equity or convertible debt we agree to issue may include liquidation or other preferences that adversely affect the rights of our stockholders. Convertible debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, and declaring dividends, and may impose limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Moreover, we have the ability to sell up to $0.8 million of additional shares of our common stock to the public through an â€œat the marketâ€ offering pursuant to a Sales Agreement that we entered into with H.C. Wainwright & Co., LLC and JonesTrading Institutional Services LLC on March 16, 2018 (the "Sales Agreement"). Any shares of common stock issued in the at-the-market ("ATM") offering will result in dilution to our existing stockholders. We currently have an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (the â€œSECâ€), which we may use to offer from time to time any combination of debt securities, common and preferred stock and warrants. On March 16, 2018, we entered into the Sales Agreement pursuant to which we have the ability to sell shares of our common stock to the public through an ATM offering. As of September 30, 2024, we have issued and sold pursuant to the Sales Agreement an aggregate of 6,724,018 shares of our common stock for gross proceeds of approximately $48.7 million. However, in the event that the aggregate market value of our common stock held by non-affiliates (â€œpublic floatâ€) is less than $75.0 million, the amount we can raise through primary public offerings of securities, including sales under the Sales Agreement, in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our public float. As of May 23, 2024, our public float was less than $75.0 million, and therefore we are limited to an aggregate of one-third of our public float in the amount we could raise through primary public offerings of securities in any twelve-month period using shelf registration statements, or $3,094,641. Although we would still maintain the ability to raise funds through other means, such as through the filing of a registration statement on Form S-1 or in private placements, the rules and regulations of the SEC or any other regulatory agencies may restrict our ability to conduct certain types of financing activities, or may affect the timing of and amounts we can raise by undertaking such activities. On October 25, 2024, we filed a registration statement on Form S-1 for a potential best efforts offering of shares of common stock and warrants to purchase shares of common stock. However, the specific number of shares of common stock and warrants to purchase shares of common stock to be offered, the price range for the offering and the closing date of the offering have yet to be determined, and there can be no assurances that the offering will be consummated. While such offering may not be consummated due to a variety of reasons, including the SEC not declaring the registration statement effective, poor market conditions or a decline in the trading price of our common stock, to the extent we issue such securities or securities this offering, our stockholders may experience substantial dilution and the trading price of our common stock could decline. 34 Â Further, additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to curtail or cease our operations. Raising additional funding through debt or equity financing is likely to be difficult or unavailable altogether given the early stage of our technology and any drug candidates we identify. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline further and existing stockholders may not agree with our financing plans or the terms of such financings. Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future results. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidates we identify, any such drug candidates must undergo extensive clinical trials to demonstrate the safety and efficacy of the drug candidates in humans. Human clinical testing is expensive and can take many years to complete, and we cannot be certain that any clinical trials will be conducted as planned or completed on schedule, if at all. We may elect to complete this testing, or some portion thereof, internally or enter into a partnering or development agreement with a pharmaceutical company to complete these trials. Our inability, or the inability of any third party with

whom we enter into a partnering or development agreement, to successfully complete preclinical and clinical development could result in additional costs to us and negatively impact our ability to generate revenues or receive development or milestone payments. Our future success is dependent on our ability, or the ability of any pharmaceutical company with whom we enter into a partnering or development agreement, to successfully develop, obtain regulatory approval for, and then successfully commercialize any drug candidates we identify. Any drug candidates we identify will require additional clinical development, management of clinical, preclinical and manufacturing activities, regulatory approval in applicable jurisdictions, achieving and maintaining commercial-scale supply, building of a commercial organization, substantial investment and significant marketing efforts. We are not permitted to market or promote any of our drug candidates before we receive regulatory approval from the U.S. Food and Drug Administration (â€œFDAâ€) or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our drug candidates. Â We, or any third party with whom we enter into a partnering or development agreement, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to earn development or milestone payments or for any drug candidates to obtain regulatory approval, including: â€¢delays in or failure to reach agreement on acceptable terms with prospective contract research organizations (â€œCROsâ€) and clinical sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; â€¢failure to obtain sufficient enrollment in clinical trials or participants may fail to complete clinical trials; â€¢clinical trials of our drug candidates that may produce negative or inconclusive results, and as a result we, or any pharmaceutical company with who we enter into a partnering or development agreement, may decide, or regulators may require, additional clinical trials; â€¢suspension or termination of clinical research, either by us, any third party with whom we enter into a partnering or development agreement, regulators or institutional review boards, for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; â€¢additional or unanticipated clinical trials required by regulators or institutional review boards to obtain approval or any drug candidates may be subject to additional post-marketing testing requirements to maintain regulatory approval; â€¢regulators may revise the requirements for approving any drug candidates, or such requirements may not be as anticipated; â€¢the cost of clinical trials for any drug candidates may be greater than anticipated; â€¢the supply or quality of any drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate or may be delayed; and â€¢regulatory authorities may suspend or withdraw their approval of a product or impose restrictions on its distribution; If we, or any third party with whom we enter into a partnering or development agreement, experience delays in the completion of, or termination of, any clinical trial of any drug candidates that we develop, or are unable to achieve clinical endpoints due to unforeseen events, the commercial prospects of our drug candidates will be harmed, and our ability to develop milestones, development fees or product revenues from any of these drug candidates will be delayed. 35 Â We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications among many potential options. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Currently, we are focused on developing FXR314 in IBD, including UC, based on demonstration of clinical promise in 3D human tissues as well as strong preclinical data. Our resource allocation decisions may cause us to fail to capitalize on viable commercial medicines or profitable market opportunities. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates. If any of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished and have an adverse material impact on our business. Additionally, the potentially addressable patient population for our product candidates may be limited, or may not be amenable to treatment with our product candidates. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Any such event could have a material adverse effect on our business, financial condition, results of operations and prospects. We will rely upon third-party contractors and service providers for the execution of critical aspects of any future development programs. Failure of these collaborators to provide services of a suitable quality and within acceptable timeframes may cause the delay or failure of any future development programs. We plan to outsource certain functions, tests and services to CROs, medical institutions and collaborators as well as outsource manufacturing to collaborators and/or contract manufacturers, and we will rely on third parties for quality assurance, clinical monitoring, clinical data management and regulatory expertise. We may elect, in the future, to engage a CRO to run all aspects of a clinical trial on our behalf. There is no assurance that such individuals or organizations will be able to provide the functions, tests, biologic supply or services as agreed upon or in a quality fashion and we could suffer significant delays in the development of our drug candidates or development programs. In some cases, there may be only one or few providers of such services, including clinical data management or manufacturing services. In addition, the cost of such services could be significantly increased over time. We may rely on third parties and collaborators to enroll qualified patients and conduct, supervise and monitor our clinical trials. Our reliance on these third parties and collaborators for clinical development activities reduces our control over these activities. Our reliance on these parties, however, does not relieve us of our regulatory responsibilities, including ensuring that our clinical trials are conducted in accordance with Good Clinical Practice (â€œGCPâ€) regulations and the investigational plan and protocols contained in the regulatory agency applications. In addition, these third parties may not complete activities on schedule or may not manufacture under Current Good Manufacturing Practice (â€œcGMPâ€) conditions. Preclinical or clinical studies may not be performed or completed in accordance with Good Laboratory Practices (â€œGLPâ€) regulatory requirements or our trial design. If these third parties or collaborators do not successfully carry out their contractual duties or meet expected deadlines, obtaining regulatory approval for manufacturing and commercialization of our drug candidates may be delayed or prevented. We may rely substantially on third-party data managers for our clinical trial data. There is no assurance that these third parties will not make errors in the design, management or retention of our data or data systems. There is no assurance these third parties will pass FDA or regulatory audits, which could delay or prohibit regulatory approval. In addition, we will exercise limited control over our third-party partners and vendors, which makes us vulnerable to any errors, interruptions or delays in their operations. If these third parties experience any service disruptions, financial distress or other business disruption, or difficulties meeting our requirements or standards, it could make it difficult for us to operate some aspects of our business. The near and long-term viability of our drug discovery and development efforts will depend on our ability to successfully establish strategic relationships. The near and long-term viability of our drug discovery and development efforts depend in part on our ability to successfully establish new strategic partnering, collaboration and licensing arrangements with biotechnology companies, pharmaceutical companies, universities, hospitals, insurance companies and or government agencies. Establishing strategic relationships is difficult and time-consuming. Potential partners and collaborators may not enter into relationships with us based upon their assessment of our technology or drug candidates or our financial, regulatory or intellectual property position. If we fail to establish a sufficient number of strategic relationships on acceptable terms, we may not be able to develop and obtain regulatory approval for our drug candidates or generate sufficient revenue to fund further research and development efforts. Even if we establish new strategic relationships, these 36 Â relationships may never result in the successful development or regulatory approval for any drug candidates we identify for a number of reasons both within and outside of our control. Investorsâ€™ expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks. There is an increasing focus from certain investors, employees, regulators and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance (â€œESGâ€) factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases, investors may choose not to invest in our company if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers and if we are perceived as lagging with respect to ESG initiatives, certain investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or take other actions, to hold us and our board of directors accountable. In addition, the criteria by which our corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate. We may face reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. We may face reputational damage in the event our corporate responsibility initiatives or objectives do not meet the standards set by our investors, stockholders, lawmakers, listing exchanges or other constituencies, or if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our common stock from consideration by certain investors who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, share price, financial condition, or results of operations, including the sustainability of our business over time. Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price. Our business, financial condition and share price could be adversely affected by general conditions in the global economy and in the global financial markets. As widely reported, in the past several years, global credit and financial markets have experienced volatility and disruptions, and especially in 2020, 2021 and 2022 due to the impacts of the COVID-19 pandemic, and, more recently, the ongoing conflict between Ukraine and Russia and the global impact of restrictions and sanctions imposed on Russia, including, for example, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. Moreover, the global impacts of the Israel-Hamas war are still unknown. There can be no assurances that further deterioration in credit and financial markets and confidence in economic conditions will not occur. For example, U.S. debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the United States. Although U.S. lawmakers passed legislation to raise the federal debt ceiling on multiple occasions, including a suspension of the federal debt ceiling in June 2023, ratings agencies have lowered or threatened to lower the long-term sovereign credit rating on the United States. The impact of this or any further downgrades to the U.S. governmentâ€™s sovereign credit rating or its perceived creditworthiness could adversely affect the U.S. and global financial markets and economic conditions. Absent further quantitative easing by the Federal Reserve, these developments could cause interest rates and borrowing costs to rise, which may negatively impact our results of operations or financial condition. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and share price and could require us to delay or abandon clinical development plans. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. *The impact of the Russian invasion of Ukraine and the Israel-Hamas War on the global economy, energy supplies and raw materials is uncertain, but may prove to negatively impact our business and operations. The short and long-term implications of Russiaâ€™s invasion of Ukraine and the Israel-Hamas war are difficult to predict at this time. We continue to monitor any adverse impact that the outbreak of war in Ukraine and the subsequent institution of sanctions against Russia by the United States and several European and Asian countries and the Israel-Hamas war may have on the global economy in general, on our business and operations and on the businesses and operations of our suppliers and other third parties with which we conduct business. For example, prolonged conflict in Ukraine or Israel has resulted and may result, respectively, in increased inflation, 37 Â escalating energy prices and constrained availability, and thus increasing costs, of raw materials. We will continue to monitor this fluid situation and develop contingency plans as necessary to address any disruptions to our business operations as they develop. To the extent the war in Ukraine or Israel may adversely affect our business as discussed above, it may also have the effect of heightening many of the other risks described herein. Such risks include, but are not limited to, adverse effects on macroeconomic conditions, including inflation; disruptions to our technology infrastructure, including through cyberattack, ransom attack, or cyber-intrusion; adverse changes in international trade policies and relations; disruptions in global supply chains; and constraints, volatility, or disruption in the capital markets, any of which could negatively affect our business and financial condition. Risks Related to Government Regulation In the past, we have used hazardous chemicals, biological materials and infectious agents in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly. Our product manufacturing, research and development, and testing activities have involved the controlled use of hazardous materials, including chemicals, biological materials and infectious disease agents. We cannot eliminate the risks of accidental contamination or the accidental spread or discharge of these materials, or any resulting injury from such an event. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed our insurance coverage and our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. We were also subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, and the experimental use of animals. Our operations may have required that environmental permits and approvals be issued by applicable government agencies. If we failed to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain compliance. If we fail to obtain and sustain an adequate level of reimbursement for our potential products by third-party payors, potential future sales would be materially adversely affected. There will be no viable commercial market for our drug candidates, if approved, without reimbursement from third-party payors. Reimbursement policies may be affected by future healthcare reform measures. We cannot be certain that reimbursement will be available for our current drug candidates or any other drug candidate we may develop. Additionally, even if there is a viable commercial market, if the level of reimbursement is

below our expectations, our anticipated revenue and gross margins will be adversely affected. Third-party payors, such as government or private healthcare insurers, carefully review and increasingly question and challenge the coverage of and the prices charged for drugs. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and other factors. Reimbursement rates may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. There is a current trend in the U.S. healthcare industry toward cost containment. Large public and private payors, managed care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third-party payors, including Medicare, may question the coverage of, and challenge the prices charged for, medical products and services, and many third-party payors limit coverage of or reimbursement for newly approved healthcare products. In particular, third-party payors may limit the covered indications. Cost-control initiatives could decrease the price we might establish for products, which could result in product revenues being lower than anticipated. We believe our drugs will be priced significantly higher than existing generic drugs and consistent with current branded drugs. If we are unable to show a significant benefit relative to existing generic drugs, Medicare, Medicaid and private payors may not be willing to provide reimbursement for our drugs, which would significantly reduce the likelihood of our products gaining market acceptance. We expect that private insurers will consider the efficacy, cost-effectiveness, safety and tolerability of our potential products in determining whether to approve reimbursement for such products and at what level. Obtaining these approvals can be a time consuming and expensive process. Our business, financial condition and results of operations would be materially adversely affected if we do not receive approval for reimbursement of our potential products from private insurers on a timely or satisfactory basis. Limitations on coverage could also be imposed at the local Medicare carrier level or by fiscal intermediaries. Medicare Part D, which provides a pharmacy benefit to Medicare patients as discussed below, does not require participating prescription drug plans to cover all drugs within a class of products. Our business, financial condition and results of operations could be materially adversely affected 38 Â if Part D prescription drug plans were to limit access to, or deny or limit reimbursement of, our drug candidates or other potential products. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. In many countries, the product cannot be commercially launched until reimbursement is approved. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. The negotiation process in some countries can exceed 12 months. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our products to other available therapies. If the prices for our potential products are reduced or if governmental and other third-party payors do not provide adequate coverage and reimbursement of our drugs, our future revenue, cash flows and prospects for profitability will suffer. Current and future legislation may increase the difficulty and cost of commercializing our drug candidates and may affect the prices we may obtain if our drug candidates are approved for commercialization. In the U.S. and some foreign jurisdictions, there have been a number of adopted and proposed legislative and regulatory changes regarding the healthcare system that could prevent or delay regulatory approval of our drug candidates, restrict or regulate post-marketing activities and affect our ability to profitably sell any of our drug candidates for which we obtain regulatory approval. In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (â€œMMAâ€) changed the way Medicare covers and pays for pharmaceutical products. Cost reduction initiatives and other provisions of this legislation could limit the coverage and reimbursement rate that we receive for any of our approved products. While the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors. In addition, on August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which, among other things, includes policies that are designed to have a direct impact on drug prices and reduce drug spending by the federal government, which shall take effect in 2023. Under the Inflation Reduction Act of 2022, Congress authorized Medicare beginning in 2026 to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars. This provision is limited in terms of the number of pharmaceuticals whose prices can be negotiated in any given year and it only applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition are categorically excluded from price negotiation. Further, the new legislation provides that if pharmaceutical companies raise prices in Medicare faster than the rate of inflation, they must pay rebates back to the government for the difference. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the â€œPPACAâ€), was enacted. The PPACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The PPACA increased manufacturersâ€™ rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate amount for both branded and generic drugs and revised the definition of â€œaverage manufacturer priceâ€, which may also increase the amount of Medicaid drug rebates manufacturers are required to pay to states. The legislation also expanded Medicaid drug rebates and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the rebates due on those drugs. The Centers for Medicare & Medicaid Services (â€œCMSâ€), which administers the Medicaid Drug Rebate Program, also has proposed to expand Medicaid rebates to the utilization that occurs in the territories of the U.S., such as Puerto Rico and the Virgin Islands. Further, beginning in 2011, the PPACA imposed a significant annual fee on companies that manufacture or import branded prescription drug products and required manufacturers to provide a 50% discount off the negotiated price of prescriptions filled by beneficiaries in the Medicare Part D coverage gap, referred to as the â€œdonut hole.â€ Legislative and regulatory proposals have been introduced at both the state and federal level to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. There have been public announcements by members of the U.S. Congress, regarding plans to repeal and replace the PPACA and Medicare. For example, on December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act of 2017, which, among other things, eliminated the individual mandate requiring most Americans (other than those who qualify for a hardship exemption) to carry a minimum level of health coverage, effective January 1, 2019. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the PPACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act of 2017, the remaining provisions of the 39 Â PPACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Courtâ€™s ruling with respect to the individual mandate but remanded the case to the District Court to consider whether other parts of the law can remain in effect. While the Texas District Court Judge has stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the PPACA will impact the law and our business. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDAâ€™s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing approval testing and other requirements. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. The U.S. Department of Health and Human Services has started soliciting feedback on some of these measures and, at the same time, is implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMSâ€™s policy change that was effective January 1, 2019. While any proposed measures will require authorization through additional legislation to become effective, Congress has indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our drug candidates, if approved for commercialization. In Europe, the United Kingdom formally withdrew from the European Union on January 31, 2020, and entered into a transition period that ended on December 31, 2020. A significant portion of the regulatory framework in the United Kingdom is derived from the regulations of the European Union. We cannot predict what consequences the recent withdrawal of the United Kingdom from the European Union will have on the regulatory frameworks of the United Kingdom or the European Union, or on our future operations, if any, in these jurisdictions, and the United Kingdom is in the process of negotiating trade deals with other countries. Additionally, the United Kingdomâ€™s withdrawal from the European Union may increase the possibility that other countries may decide to leave the European Union again. Risks Related to Our Capital Requirements, Finances and Operations *Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. Our financial statements as of September 30, 2024 have been prepared under the assumption that we will continue as a going concern for the next twelve months. Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity or debt financing, obtain government grants, reduce expenditures and generate significant revenue. Our financial statements as of September 30, 2024 do not include any adjustments that might result from the outcome of this uncertainty. The reaction of investors to the inclusion of a going concern statement by management and our auditors, and our potential inability to continue as a going concern, in future years could materially adversely affect our share price and our ability to raise new capital or enter into strategic alliances. *Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to curtail or cease our operations. There can be no assurance that we will be able to raise sufficient additional capital on acceptable terms or at all. Raising additional funding through debt or equity financing is likely to be difficult or unavailable altogether given the early stage of our therapeutic candidates. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, we may be required to delay, limit or eliminate the development of business opportunities and our ability to achieve our business objectives, our competitiveness, and our business, financial condition and results of operations will be materially adversely affected. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline further and existing stockholders may not agree with our financing plans or the terms of such financings. In addition, if we seek funds through arrangements with collaborative partners, these 40 Â arrangements may require us to relinquish rights to our technology or potential future product candidates or otherwise agree to terms unfavorable to us. *We have a history of operating losses and expect to incur significant additional operating losses. We have generated operating losses each year since we began operations, including $6.0 million and $8.3 million for the six months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of $345.6 million. We expect to incur substantial additional operating losses over the next several years as our research and development activities increase. The amount of future losses and when, if ever, we will achieve profitability are uncertain. Our ability to generate revenue and achieve profitability will depend on, among other things: â€¢successfully developing and advancing FXR314 and our FXR program generally; â€¢successfully developing human tissues and disease models for drug discovery and development that enable us to identify drug candidates; â€¢successfully outsourcing certain portions of our development efforts; â€¢entering into collaboration or licensing arrangements with pharmaceutical companies to further develop and conduct clinical trials for any drug candidates we identify; â€¢obtaining any necessary regulatory approvals for any drug candidates we identify; and â€¢raising sufficient funds to finance our activities and long-term business plan. We might not succeed at any of these undertakings. If we are unsuccessful at one or more of these undertakings, our business, prospects, and results of operations will be materially adversely affected. We may never generate significant revenue, and even if we do generate significant revenue, we may never achieve profitability. Our quarterly operating results may vary, which could negatively affect the market price of our common stock. Our results of operations in any quarter may vary from quarter to quarter and are influenced by such factors as expenses related to: â€¢evaluating and implementing strategic alternatives, technology licensing opportunities, potential collaborations, and other strategic transactions; â€¢litigation; â€¢research and development expenditures, including commencement of preclinical studies and clinical trials; â€¢the timing of the hiring of new employees, which may require payments of signing, retention or similar bonuses; and â€¢changes in costs related to the general global economy. We believe that operating results for any particular quarter are not necessarily a meaningful indication of future results. Nonetheless, fluctuations in our quarterly operating results could negatively affect the market price of our common stock. We may identify material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. Our management team is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. We cannot assure you that we will not have material weaknesses or significant deficiencies in our internal control over financial reporting. If we identify any material weaknesses or significant deficiencies that may exist, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely 41 Â filing of periodic reports in addition to applicable stock exchange listing requirements, and our stock price may decline materially as a result. Future strategic investments could negatively affect our business, financial condition and results of operations if we fail to achieve the desired returns on our investment. Our ability

to benefit from future external strategic investments depends on our ability to successfully conduct due diligence, evaluate prospective opportunities, and buy the equity of our target investments at acceptable market prices. Our failure in any of these tasks could result in unforeseen losses associated with the strategic investments. We may also discover deficiencies in internal controls, data adequacy and integrity, product quality, regulatory compliance, product liabilities or other undisclosed liabilities that we did not uncover prior to our investment, which could result in us becoming subject to asset impairments, including potential loss of our investment capital. In addition, if we do not achieve the anticipated benefits of an external investment as rapidly as expected, or at all, investors or analysts may downgrade our stock. We also expect to continue to carry out strategic investments that we believe are necessary to expand our business. There are no assurances that such initiatives will yield favorable results for us. Accordingly, if these initiatives are not successful, our business, financial condition and results of operations could be adversely affected. If these risks materialize, our stock price could be materially adversely affected. Any difficulties in such investments could have a material adverse effect on our business, financial condition and results of operations. Â *We may engage in strategic transactions, including acquisitions, investments, joint development agreements or divestitures that may have an adverse effect on our business. We may pursue transactions, including acquisitions of complementary businesses, technology licensing arrangements, strategic relationships, and joint development agreements to expand our product offerings and geographic presence as part of our business strategy, which could be material to our financial condition and results of operations. We may also consider divesting programs or other assets or out-licensing our technology. We may not complete transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the expected benefits of any acquisition, license arrangement, strategic relationship, joint development agreement or divestiture. Other companies may compete with us for these strategic opportunities. We also could experience negative effects on our results of operations and financial condition from charges related to acquisitions and investments, amortization of intangible assets and asset impairment charges, and other issues that could arise in connection with, or as a result of, acquisitions or divestitures, including issues related to internal control over financial reporting, regulatory or compliance issues and potential adverse short-term effects on results of operations through increased costs or otherwise. Acquisitions involve numerous risks, including the following: â€¢difficulties in finding suitable partners or acquisition candidates or purchasers for programs or assets that we may seek to divest; â€¢difficulties in obtaining financing on favorable terms, if at all; â€¢difficulties in completing transactions on favorable terms, if at all; â€¢the possibility that we will pay more than the value we derive from the acquisition, which could result in future non-cash impairment charges and/or a dilution of future earnings per share; â€¢the assumption of certain known and unknown liabilities of acquired companies; â€¢the incurrence of debt, contingent liabilities, or future write-offs of intangible assets or goodwill; â€¢difficulties in retaining key relationships with employees, customers, partners and suppliers following any transaction; and â€¢difficulties in operating in different business markets where we may not have historical experience. Any of these factors could have a negative impact on our business, results of operations or financial position. Further, past and potential acquisitions entail risks, uncertainties and potential disruptions to our business, especially where we have limited experience as company developing or marketing a particular product or technology. Following any acquisition, we must integrate the new business, which can be expensive, time-consuming and cause disruptions to our existing operations. Failure to timely and successfully integrate acquired businesses may result in non-compliance with regulatory or other requirements and may result in unexpected costs, including as a result of inadequate cost containment and failure to fully realize expected synergies. As a result of any of the foregoing, 42 Â we may not realize the expected benefit from any acquisition or investment. If we cannot integrate acquired businesses, products or technologies, our business, financial conditions and results of operations could be materially and adversely affected. Any divestitures may result in a dilutive impact to our future earnings, as well as significant write-offs, including those related to goodwill and other intangible assets, which could have a material adverse effect on our results of operations and financial condition. Divestitures could involve additional risks, including difficulties in the separation of operations, services, products and personnel, the diversion of managementâ€™s attention from other business concerns, the disruption of our business and the potential loss of key employees. We may not be successful in managing these or any other significant risks that we encounter in divesting a product or technology. Our business could be adversely impacted if we are unable to retain our executive officers and other key personnel. Our future success will depend to a significant degree upon the continued contributions of our key personnel, especially our executive officers. We do not currently have long-term employment agreements with our executive officers or our other key personnel, and there is no guarantee that our executive officers or key personnel will remain employed with us. Moreover, we have not obtained key man life insurance that would provide us with proceeds in the event of the death, disability or incapacity of any of our executive officers or other key personnel. Further, the process of attracting and retaining suitable replacements for any executive officers and other key personnel we lose in the future would result in transition costs and would divert the attention of other members of our senior management from our existing operations. Additionally, such a loss could be negatively perceived in the capital markets. Finally, our Executive Chairman also provides services to Viscient Biosciences, Inc. (â€œViscientâ€). Executives that provide services to us and Viscient do not dedicate all of their time to us, as disclosed in our filings, and we may therefore compete with Viscient for the time commitments of our Executive Chairman from time to time. We may be subject to security breaches or other cybersecurity incidents that could compromise our information and expose us to liability. We routinely collect and store sensitive data (such as intellectual property, proprietary business information and personally identifiable information) for ourselves, our employees and our suppliers and customers. We make significant efforts to maintain the security and integrity of our computer systems and networks and to protect this information. However, like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee error, malfeasance or other disruption. Any such breach could result in unauthorized access to (or disclosure of) sensitive, proprietary or confidential information of ours, our employees or our suppliers or customers, and/or loss or damage to our data. Any such unauthorized access, disclosure, or loss of information could cause competitive harm, result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and/or cause reputational harm. *Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition and results of operations. The regulatory framework for the collection, use, safeguarding, sharing, transfer, and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the EU General Data Protection Regulation (the â€œGDPRâ€), which took effect across all member states of the European Economic Area (the â€œEEAâ€) in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20 million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting 43 Â from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. Further, Brexit has led to, and could continue to lead to legislative and regulatory changes, which may increase our compliance costs. As of January 1, 2021 and the expiry of transitional arrangements agreed to between the United Kingdom and the European Union, data processing in the United Kingdom is governed by a United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which authorizes similar fines and other potentially divergent enforcement actions for certain violations. On June 28, 2021, the European Commission adopted an Adequacy Decision for the United Kingdom, allowing for the relatively free exchange of personal information between the European Union and the United Kingdom, however, the European Commission may suspend the Adequacy Decision if it considers that the United Kingdom no longer provides for an adequate level of data protection. A bill to amend the existing UK framework has been reintroduced (in a different form) by the new UK Government and was announced as a bill which will be introduced into Parliament at the Kingâ€™s Speech on July 17, 2024. At this time, there is no specific clarity on the provisions of the bill, or the extent to which it will amend the UK framework, beyond general descriptions on its intended purpose. Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules and regulations. Similar actions are either in place or under way in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels and several states have passed comprehensive privacy laws. For example, the California Consumer Privacy Act â€” which went into effect on January 1, 2020 â€” is creating similar risks and obligations as those created by the GDPR, though the California Consumer Privacy Act does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). As of January 1, 2023, the California Consumer Privacy Act (as amended and expanded by the California Privacy Rights Act) is in full effect, with enforcement by Californiaâ€™s dedicated privacy enforcement agency expected to start later in 2023. While California was first among the states in adopting comprehensive data privacy legislation similar to the GDPR, many other states are following suit. Similar laws passed in Virginia, Colorado, Connecticut, and Utah took effect in 2023. Additionally, Delaware, Florida, Indiana, Iowa, Montana, Oregon, Tennessee, Texas and others have adopted privacy laws, which take effect from July 1, 2024 through 2026. Some state laws also minimize what data can be collected from consumers and how businesses may use and disclose it. These state privacy laws also require businesses to make disclosures to consumers about data collection, use and sharing practices. In addition, some of these laws (including the California Privacy Rights Act), along with other standalone health privacy laws, subject health-related information to additional safeguards and disclosures and some specifically regulate consumer health data, such as the Washington My Health My Data Act, which became effective in 2023 and 2024. Additionally, a broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. This is particularly true with respect to data security incidents, and sensitive personal information, including health and biometric data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and business. Given the breadth and depth of changes in data protection obligations, preparing for and complying with these requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the European Union. The GDPR, new state privacy laws and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition and results of operations. We and our partners may be subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security, and changes in such laws, regulations, policies or how they are interpreted or changes in contractual obligations could adversely affect our business. There are numerous U.S. federal and state data privacy and protection laws and regulations that apply to the collection, transmission, processing, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues 44 Â with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. If we are unable to properly protect the privacy and security of health-related information or other sensitive or confidential information in our possession, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face significant administrative, civil and criminal penalties. Enforcement activity can also result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. *We may experience conflicts of interest with Viscient Biosciences, Inc. with respect to business opportunities and other matters. Keith Murphy, our Executive Chairman, is the Chief Executive Officer, Chairman and principal stockholder of Viscient, a private company that he founded in 2017 that is focused on drug discovery and development utilizing 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics). In addition, Adam Stern, Douglas Jay Cohen and David Gobel (through the Methuselah Foundation and the Methuselah Fund), members of our Board, have invested funds through a convertible promissory note in Viscient, but do not serve as an employee, officer or director of Viscient. Additional members of our Research and Development organization also work at Viscient, and we expect that additional employees or consultants of ours will also be employees of or consultants to Viscient. We use certain Viscient-owned facilities and equipment and allow Viscient to use certain of our facilities and equipment. During fiscal 2024, we provided

services to Viscient, and we expect to continue to provide services to Viscient and enter into additional agreements with Viscient in the future. No services were provided to Viscient during the six months ended September 30, 2024. In addition, we license, as well as cross-license, certain intellectual property to and from Viscient and expect to continue to do so in the future. In particular, pursuant to an Asset Purchase and Non-Exclusive Patent License Agreement with Viscient, dated November 6, 2019, as amended, we have provided a paid up, worldwide, irrevocable, perpetual, non-exclusive license to Viscient under certain of our patents and know-how to (a) make, have made, use, sell, offer to sell, import and otherwise exploit the inventions and subject matter covered by certain patents regarding certain bioprinter devices and bioprinting methods, engineered liver tissues, engineered renal tissues, engineered intestinal tissue and engineered tissue for in vitro research use, (b) to use and internally repair the bioprinters, and (c) to make additional bioprinters for internal use only in connection with drug discovery and development research, target identification and validation, compound screening, preclinical safety, absorption, distribution, metabolism, excretion and toxicology (ADMET) studies, and in vitro research to complement clinical development of a therapeutic compound. Although we have entered, and expect to enter, into agreements and arrangements that we believe appropriately govern the ownership of intellectual property created by joint employees or consultants of Viscient and/or using our or Viscientâ€™s facilities or equipment, it is possible that we may disagree with Viscient as to the ownership of intellectual property created by shared employees or consultants, or using shared equipment or facilities. On December 28, 2020, we entered into an intercompany agreement with Viscient and Organovo, Inc., our wholly-owned subsidiary (the â€œIntercompany Agreementâ€). Pursuant to the Intercompany Agreement and subsequent statements of work entered into pursuant thereto, we agreed to provide Viscient certain services related to 3D bioprinting technology, which includes, but is not limited to, histology services, cell isolation, and proliferation of cells, and Viscient agreed to provide us certain services related to 3D bioprinting technology, including bioprinter training, bioprinting services, and qPCR assays, in each case on payment terms specified in the Intercompany Agreement and as may be further determined by the parties. In addition, Viscient and we each agreed to share certain facilities and equipment and, subject to further agreement, to each make certain employees available for specified projects to the other party at prices to be determined in good faith by the parties. Under the Intercompany Agreement, each party will retain its own prior intellectual property and will obtain new intellectual property rights within their respectively defined fields of use. Due to the interrelated nature of Viscient with us, conflicts of interest may arise with respect to transactions involving business dealings between us and Viscient, potential acquisitions of businesses or products, the development and ownership of technologies and products, the sale of products, markets and other matters in which our best interests and the best interests of our stockholders may conflict with the best interests of the stockholders of Viscient. In addition, we and Viscient may disagree regarding the interpretation of certain terms of the arrangements we previously entered into with Viscient or may enter into in the future. We cannot guarantee that any conflict of interest will be resolved in our favor, or that, with respect to our transactions with Viscient, we will negotiate terms that are as favorable to us as if such transactions were with another third-party. In addition, executives that provide services to us and Viscient may not dedicate all of their time to us and we may therefore compete with Viscient for the time commitments of our executive officers from time to time. 45 Â Risks Related to Our Common Stock and Liquidity Risks *We could fail to maintain the listing of our common stock on the Nasdaq Capital Market, which could seriously harm the liquidity of our stock and our ability to raise capital or complete a strategic transaction. The Nasdaq Stock Market LLC (â€œNasdaqâ€) has established continued listing requirements, including a requirement to maintain a minimum closing bid price of at least $1 per share. If a company trades for 30 consecutive business days below such minimum closing bid price, it will receive a deficiency notice from Nasdaq. Assuming it is in compliance with the other continued listing requirements, Nasdaq would provide such company a period of 180 calendar days in which to regain compliance by maintaining a closing bid price at least $1 per share for a minimum of ten consecutive business days. There can be no assurance that we will continue to maintain compliance with the minimum bid price requirement or other listing requirements necessary for us to maintain the listing of our common stock on the Nasdaq Capital Market. Â On July 18, 2024, we received a written notice (the â€œNoticeâ€) from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (â€œNasdaqâ€) indicating that, based upon the closing bid price of our common stock for the last 30 consecutive business days, we no longer meet the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (â€œRule 5550(a)(2)â€). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided with an initial period of 180 calendar days, or until January 14, 2025, to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. The Notice provides that the Nasdaq staff will provide written confirmation to us if we regain compliance with Rule 5550(a)(2). If we do not regain compliance with Rule 5550(a)(2) by January 14, 2025, we may be eligible for an additional compliance period of 180 calendar days. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice to Nasdaq of our intention to cure the bid price deficiency during the second compliance period. However, if it appears to the Nasdaq staff that we will not be able to cure the deficiency, or we are otherwise not eligible, Nasdaq would notify us that our securities will be subject to delisting. In the event of such a notification, we may appeal the Nasdaq staffâ€™s determination to delist our securities, but there can be no assurance the Nasdaq staff would grant any request for continued listing. The Notice had no immediate effect on the listing or trading of our common stock and our common stock will continue to trade on the Nasdaq Capital Market under the symbol â€œONVOâ€. We intend to monitor the closing bid price of our common stock and consider our available options if our common stock does not trade at a level likely to result in us regaining compliance with Rule 5550(a)(2) by January 14, 2025, including effecting a reverse stock split, which would be subject to the prior approval of our stockholders. At our 2024 annual meeting of our stockholders to be held on November 20, 2024, we are asking our stockholders to approve an amendment to our Certificate of Incorporation, as amended, to effect, in the sole discretion of our Board of Directors (our â€œBoardâ€) at any time on or before November 20, 2025, a reverse split of our common stock at a ratio to be determined by the Board within a range of 1-to-5 to 1-to-20 (or any number in between). However, there can be no assurances that our stockholders will approve this proposal. Â There can be no assurance that we will be able to regain compliance with Nasdaqâ€™s minimum bid price requirement or that we will maintain our compliance with the other listing requirements necessary for us to maintain the listing of our common stock on the Nasdaq Capital Market. A delisting from the Nasdaq Capital Market and commencement of trading on the Over-the-Counter Bulletin Board would likely result in a reduction in some or all of the following, each of which could have a material adverse effect on stockholders: â€¢the liquidity of our common stock; â€¢the market price of our common stock (and the accompanying valuation of our Company); â€¢our ability to obtain financing or complete a strategic transaction; â€¢the number of institutional and other investors that will consider investing in shares of our common stock; â€¢the number of market markers or broker-dealers for our common stock; and â€¢the availability of information concerning the trading prices and volume of shares of our common stock. There is no assurance that an active market in our common stock will continue at present levels or increase in the future. Our common stock is currently traded on the Nasdaq Capital Market, but there is no assurance that an active market in our common stock will continue at present levels or increase in the future. As a result, an investor may find it difficult to dispose of our common stock on the timeline and at the volumes they desire. This factor limits the liquidity of our common stock and may have a material adverse effect on the market price of our common stock and on our ability to raise additional capital. 46 Â *The price of our common stock may continue to be volatile, which could lead to losses by investors and costly securities litigation. The trading price of our common stock is likely to be highly volatile and could fluctuate in response to factors such as: â€¢announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; â€¢our ability to execute on our new strategic plan; â€¢reduced government funding for research and development activities; â€¢actual or anticipated variations in our operating results; â€¢adoption of new accounting standards affecting our industry; â€¢additions or departures of key personnel; â€¢sales of our common stock or other securities in the open market; â€¢degree of coverage of securities analysts and reports and recommendations issued by securities analysts regarding our business; â€¢volume fluctuations in the trading of our common stock; and â€¢other events or factors, many of which are beyond our control. The stock market is subject to significant price and volume fluctuations. The trading price of our common stock is, and is likely to continue to be, volatile. For example, during the quarter ended September 30, 2024, our closing stock price ranged from $0.44 to $1.04 per share. In the past, following periods of volatility in the market price of a companyâ€™s securities, securities class action litigation has often been initiated against such a company. Litigation initiated against us, whether or not successful, could result in substantial costs and diversion of our managementâ€™s attention and resources, which could harm our business and financial condition. *Investors may experience dilution of their ownership interests because of the future issuance of additional shares of our capital stock. We are authorized to issue 200,000,000 shares of common stock and 25,000,000 shares of preferred stock. As of September 30, 2024, there were an aggregate of 15,365,826 shares of our common stock issued and outstanding and available for issuance on a fully diluted basis and no shares of preferred stock outstanding. That total for our common stock includes 2,475,188 shares of our common stock that may be issued upon the vesting of restricted stock units, the exercise of outstanding stock options, or is available for issuance under our equity incentive plans, 44,500 shares of common stock that may be issued through our 2023 Employee Stock Purchase Plan (â€œESPPâ€), and 9,192,500 shares of our common stock that may be issued upon the exercise of outstanding warrants. In the future, we may issue additional authorized but previously unissued equity securities to raise funds to support our continued operations and to implement our business plan. We may also issue additional shares of our capital stock or other securities that are convertible into or exercisable for our capital stock in connection with hiring or retaining employees, future acquisitions, or for other business purposes. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders may result. In addition, the future issuance of any such additional shares of capital stock may create downward pressure on the trading price of our common stock. There can be no assurance that we will not be required to issue additional shares, warrants or other convertible securities in the future in conjunction with any capital raising efforts, including at a price (or exercise prices) below the price at which shares of our common stock is currently traded on the Nasdaq Capital Market. Moreover, depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. We do not intend to pay dividends for the foreseeable future. We have paid no dividends on our common stock to date and it is not anticipated that any dividends will be paid to holders of our common stock in the foreseeable future. While our future dividend policy will be based on the operating results and capital needs of our business, it is currently anticipated that any earnings will be retained to finance our future expansion and for the implementation of our business plan. As an investor, you should take note of the fact that a lack of a dividend can further affect the market value of our stock and could significantly affect the value of any investment. 47 Â Anti-takeover provisions in our organizational documents and Delaware law may discourage or prevent a change of control, even if an acquisition would be beneficial to our stockholders, which could affect our stock price adversely and prevent attempts by our stockholders to replace or remove our current management. Our Certificate of Incorporation, as amended (â€œCertificate of Incorporationâ€), and Amended and Restated Bylaws, as amended (â€œBylawsâ€) contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions: â€¢authorize the issuance of preferred stock which can be created and issued by our board of directors without prior stockholder approval, with rights senior to those of the common stock; â€¢provide for a classified board of directors, with each director serving a staggered three-year term; â€¢provide that each director may be removed by the stockholders only for cause; â€¢prohibit our stockholders from filling board vacancies, calling special stockholder meetings, or taking action by written consent; and â€¢require advance written notice of stockholder proposals and director nominations. In addition, we are subject to the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our Certificate of Incorporation, Bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delaying or impeding a merger, tender offer, or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. Risks Related to Our Intellectual Property *If we are not able to adequately protect our proprietary rights, our business could be harmed. Our success will depend to a significant extent on our ability to obtain patents and maintain adequate protection for our technologies, intellectual property and products and service offerings in the United States and other countries. If we do not protect our intellectual property adequately, competitors may be able to use our technologies and gain a competitive advantage. To protect our products and technologies, we, and our collaborators and licensors, must prosecute and maintain existing patents, obtain new patents and pursue other intellectual property protection. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technologies or from developing competing products and technologies. Changes in either the patent laws or interpretations of patent laws in the United States and other countries may also affect the value of our licensed or owned intellectual property or create uncertainty. Moreover, the patent positions of many biotechnology and pharmaceutical companies are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, we cannot guarantee that: â€¢any patent applications filed by us will issue as patents; â€¢third parties will not challenge our proprietary rights, and if challenged that a court or an administrative board of a patent office will hold that our patents are valid and enforceable; â€¢third parties will not independently develop similar or alternative technologies or duplicate any of our technologies by inventing around our claims; â€¢any patents issued to us will cover our technology and products as ultimately developed; â€¢we will develop additional proprietary technologies that are patentable; â€¢the patents of others will not have an adverse effect on our business; or â€¢as issued patents expire, we will not lose some competitive advantage. As previously disclosed, we have recommenced certain historical operations and are now focusing our future efforts on developing highly customized 3D human tissues as living, dynamic models for healthy and diseased human biology for drug development. Previously, we focused our efforts on developing our in vivo liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there were limited treatment options other than organ transplant. We also explored the development of other potential pipeline in vivo tissue constructs. As we focus our business on developing highly customized 3D human tissues, we may sell, discontinue, adjust or abandon certain patents and patent applications relating to our historical operations. There can be no assurance that we will be successful at such efforts or sell or otherwise monetize such assets on acceptable terms, if at 48 Â all. There is also no guarantee that our remaining patents will be sufficiently broad to prevent others from using our technologies or from developing competing products and technologies. We may not be able to protect our intellectual property rights throughout the world. Certain foreign jurisdictions have an absolute requirement of novelty that renders any public disclosure of an invention immediately fatal to patentability in such jurisdictions. Therefore, there is a risk that we may not be able to protect some of our intellectual property in the United States or abroad due to disclosures, which we may not be aware of, by our

collaborators or licensors. Some foreign jurisdictions prohibit certain types of patent claims, such as â€œmethod-of-treatment/use-typeâ€ claims; thus, the scope of protection available to us in such jurisdictions is limited. Moreover, filing, prosecuting and defending patents on all of our potential products and technologies throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not sought or obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our future products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Patents covering our products could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office (the â€œUSPTOâ€), or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review (â€œIPRâ€), or interference proceedings or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications. Such challenges may result in loss of patent rights, in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology or products. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. For example, our U.S. Patent Nos. 9,855,369 and 9,149,952, which relate to our bioprinter technology, were the subject of IPR proceedings filed by Cellink AB and its subsidiaries (collectively, â€œBICO Group ABâ€), one of our competitors. Likewise, U.S. Patent Nos. 9,149,952, 9,855,369, 8,931,880, 9,227,339, 9,315,043 and 10,967,560 (all assigned to Organovo, Inc.) and U.S. Patent Nos. 7,051,654, 8,241,905, 8,852,932 and 9,752,116 (assigned to Clemson University and the University of Missouri, respectively) were implicated in a declaratory judgment complaint filed against Organovo, Inc., our wholly owned subsidiary, by BICO Group AB and certain of its subsidiaries in the United States District Court for the District of Delaware. All of these matters were eventually settled in February 2022. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations. We may become involved in lawsuits to protect or enforce our inventions, patents or other intellectual property or the patents of our licensors, which could be expensive and time consuming. In addition, if we initiate legal proceedings against a third party to enforce a patent covering our products, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several 49 Â statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise claims challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad, even outside the context of litigation, including through re-examination, post-grant review, IPR, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our products. Such a loss of patent protection would have a material adverse effect on our business, financial condition, and results of operations. We may be involved in lawsuits or other proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. Competitors may infringe our patents or the patents of our collaborators or licensors or our licensors may breach or otherwise prematurely terminate the provisions of our license agreements with them. To counter infringement or unauthorized use, we may be required to file infringement claims or lawsuits, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our collaborators or licensors is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our other patent applications at risk of not issuing. Additionally, our licensors may continue to retain certain rights to use technologies licensed by us for research purposes. Patent disputes can take years to resolve, can be very costly and can result in loss of rights, injunctions or substantial penalties. Moreover, patent disputes and related proceedings can distract managementâ€™s attention and interfere with running our business. Furthermore, because of the potential for substantial discovery in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments which could harm our business. As more companies file patents relating to bioprinters and bioprinted tissues, it is possible that patent claims relating to bioprinters or bioprinted human tissue may be asserted against us. In addition, the drug candidates we pursue may also be pursued by other companies, and it is possible that patent claims relating to such drug candidates may also be asserted against us. Any patent claims asserted against us could harm our business. Moreover, we may face claims from non-practicing entities, which have no relevant product revenue and against whom our own patent portfolio may have no deterrent effect. Any such claims, with or without merit, could be time-consuming to defend, result in costly litigation and diversion of resources, cause product shipment or delays or require us to enter into royalty or license agreements. These licenses may not be available on acceptable terms, or at all. Even if we are successful in defending such claims, infringement and other intellectual property litigation can be expensive and time-consuming to litigate and divert managementâ€™s attention from our core business. Any of these events could harm our business significantly. Our current and future research, development and commercialization activities also must satisfy the obligations under our license agreements. Any disputes arising under our license agreements could be costly and distract our management from the conduct of our business. Moreover, premature termination of a license agreement could have an adverse impact on our business. In addition to infringement claims against us, if third parties have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the United States Patent and Trademark Office (â€œPTOâ€) to determine the priority of invention and opposition proceedings outside of the United States. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Third parties may also attempt to initiate reexamination, post grant review or inter partes review of our patents or those of our collaborators or licensors in the PTO. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Â Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is costly, time-consuming and inherently uncertain. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act included a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and that may also affect patent litigation. In particular, under the 50 Â Leahy-Smith Act, the United States transitioned in March 2013 to a â€œfirst to fileâ€ system in which the first inventor to file a patent application is typically entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings, including opposition, derivation, reexamination, inter partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, in June 2023, a new unitary patent system was introduced, which will significantly impact European patents, including those granted before the introduction of the system. Under the unitary patent system, after a European patent is granted, the patent proprietor can request unitary effect, thereby getting a European patent with unitary Effect, or a Unitary Patent. Each Unitary Patent is subject to the jurisdiction of the Unitary Patent Court, or the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC may be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of the new unitary patent system. We depend on license agreements with University of Missouri and the Salk Institute for Biological Studies for rights to use certain patents, pending applications, and know how. Failure to comply with or maintain obligations under these agreements and any related or other termination of these agreements could materially harm our business and prevent us from developing or commercializing new product candidates. We are party to license agreements with University of Missouri and the Salk Institute for Biological Studies under which we were granted exclusive rights to patents and patent applications that are important to our business and to our ability to develop and commercialize our 3D tissue products fabricated using our NovoGen Bioprinters and our FXR314 agonist in gastrointestinal disease. Our rights to use these patents and patent applications and employ the inventions claimed in these licensed patents are subject to the continuation of and our compliance with the terms of our license agreements. If we were to breach the terms of these license agreements and the agreements were terminated as a result, our ability to continue to develop and commercialize our NovoGen Bioprinters, 3D tissue products and the FXR314 agonist and to operate our business could be adversely impacted. We may be unable to adequately prevent disclosure of trade secrets and other proprietary information. In order to protect our proprietary and licensed technology and processes, we rely in part on confidentiality agreements with our corporate partners, employees, consultants, manufacturers, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of our confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Failure to obtain or maintain trade secret protection could adversely affect our competitive business position. We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. We employ or engage individuals who were previously employed at other biopharmaceutical companies. Although we have no knowledge of any such claims against us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employeesâ€™ former employers or other third parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. To date, none of our employees have been subject to such claims. 51 Â Risks Related to Litigation *Claims, litigation, government investigations and other proceedings may adversely affect our business, operating results and financial condition. We are, from time to time, involved in various claims, litigation matters and regulatory proceedings that could have a material adverse effect on us. These matters may include intellectual property disputes, contract disputes, employment and tax matters and other proceedings and litigation, including class action lawsuits. It is not possible to predict the outcome of pending or future litigation and any such claims, with or without merit, could be time consuming and expensive, and may require us to incur substantial costs and divert the resources of management. For example, on August 27, 2024, H.C. Wainwright filed a complaint against us in the State of New York alleging that we breached a tail financing provision included in an engagement agreement we entered into with H.C. Wainwright in May 2023. In its complaint, H.C. Wainwright is seeking compensatory and consequential damages and attorneysâ€™ fees. On October 18, 2024, we filed an answer to the complaint. We are defending these claims vigorously, but there is no guarantee that we will be successful in these efforts. Determining legal reserves or possible losses from claims against us involves judgment and may not reflect the full range of uncertainties and unpredictable outcomes. Until the final resolution of such matters, we may be exposed to losses in excess of the amount recorded, and such excess amounts could have a material effect on our business, results of operations and financial condition. In addition, it is possible that a resolution of any claim, including as a result of a settlement, could require us to make substantial future payments or require us to change our business practices each of which could have a material adverse effect on our business, operating results and financial

condition. General Risk Factors Compliance with the reporting requirements of federal securities laws can be expensive. We are a public reporting company in the United States, and accordingly, subject to the information and reporting requirements of the Exchange Act and other federal securities laws, including the compliance obligations of the Sarbanes-Oxley Act of 2002 (â€œSarbanes-Oxley Actâ€). The costs of complying with the reporting requirements of the federal securities laws, including preparing and filing annual and quarterly reports and other information with the Securities and Exchange Commission (the â€œSECâ€) and furnishing audited reports to stockholders, can be substantial. If we fail to comply with the rules of Section 404 of the Sarbanes-Oxley Act related to accounting controls and procedures, or, if we discover material weaknesses and deficiencies in our internal control and accounting procedures, we may be subject to sanctions by regulatory authorities and our stock price could decline. Section 404 of the Sarbanes-Oxley Act (â€œSection 404â€) requires that we evaluate and determine the effectiveness of our internal control over financial reporting. We believe our system and process evaluation and testing comply with the management certification requirements of Section 404. We cannot be certain, however, that we will be able to satisfy the requirements in Section 404 in all future periods. If we are not able to continue to meet the requirements of Section 404 in a timely manner or with adequate compliance, we may be subject to sanctions or investigation by regulatory authorities, such as the SEC or Nasdaq. Any such action could adversely affect our financial results or investorsâ€™ confidence in us and could cause our stock price to fall. Moreover, if we are not able to comply with the requirements of Section 404 in a timely manner, or if we identify deficiencies in our internal controls that are deemed to be material weaknesses, we may be required to incur significant additional financial and management resources to achieve compliance. Â Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Â None. Â ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. Â Â ITEM 4. MINE SAFETY DISCLOSURE Not applicable. Â Â 52 Â ITEM 5. OTHER INFORMATION Â During the fiscal quarter ended September 30, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any â€œnon-Rule 10b5-1 trading arrangement,â€ as defined in Item 408(a) of Regulation S-K. 53 Â ITEM 6. EXHIBITS The following exhibit index shows those exhibits filed with this report and those incorporated herein by reference: Â ExhibitNo. Â Description Â Â Â Â Â Â Â 3.1 Â Certificate of Incorporation of Organovo Holdings, Inc. (Delaware) (incorporated by reference from Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K, as filed with the SEC on February 3, 2012). Â Â Â Â Â Â Â 3.2 Â Certificate of Amendment of Certificate of Incorporation of Organovo Holdings, Inc. (incorporated by reference from Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K, as filed with the SEC on July 27, 2018). Â Â Â Â Â Â 3.3 Â Certificate of Second Amendment of Certificate of Incorporation of Organovo Holdings, Inc. (incorporated by reference from Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K as filed with the SEC on August 17, 2020). Â Â Â Â Â Â Â 3.4 Â Amended and Restated Bylaws of Organovo Holdings, Inc., effective as of July 13, 2023 (incorporated by reference to Exhibit 3.4 the Companyâ€™s Annual Report on Form 10-K, as filed with the SEC on July 14, 2023). Â Â Â Â Â Â Â 4.1 Â Form of Common Warrant (incorporated by reference from Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K, as filed with the SEC on May 13, 2024). Â Â Â Â Â Â Â 4.2 Â Form of Pre-Funded Warrant (incorporated by reference from Exhibit 4.2 to the Companyâ€™s Current Report on Form 8-K, as filed with the SEC on May 13, 2024). Â Â Â Â Â Â 31.1 Â Certification of Keith Murphy, Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.* Â Â Â Â Â Â 31.2 Â Certification of Thomas Hess, Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.* Â Â Â Â Â Â 32.1 Â Certification of Keith Murphy, Executive Chairman, and Thomas Hess, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.** Â Â Â 101.INS Â Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).* 101.SCH Â Inline XBRL Taxonomy Extension Schema.* 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document.* 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document.* 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document.* 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document.* 104 Â Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).* Â * Filed herewith. ** Furnished herewith. Â 54 Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â Â ORGANOVO HOLDINGS, INC. Â Â Date: November 8, 2024 Â By: /s/ Keith Murphy Â Â Name: Keith Murphy Â Â Title: Executive Chairman(Principal Executive Officer)Â Â Â Â Â Â Date: November 8, 2024 Â By: /s/ Thomas Hess Â Â Name: Thomas Hess Â Â Title: Chief Financial Officer(Principal Financial Officer) Â 55 EX-31.1 2 onvo-ex31_1.htm EX-31.1 EX-31.1 Exhibit 31.1 CERTIFICATION I, Keith Murphy, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Organovo Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting Dated: November 8, 2024 Â /s/ Keith Murphy Â Â Keith Murphy Â Â Executive Chairman(Principal Executive Officer) Â EX-31.2 3 onvo-ex31_2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATION I, Thomas Hess, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Organovo Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting Dated: November 8, 2024 Â /s/ Thomas Hess Â Â Thomas Hess Â Â Chief Financial Officer (Principal Financial Officer) Â EX-32.1 4 onvo-ex32_1.htm EX-32.1 EX-32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Organovo Holdings, Inc. (the â€œCompanyâ€) for the period ended September 30, 2024, as filed with the Securities and Exchange Commission (the â€œReportâ€), I, Keith Murphy, Executive Chairman and I, Thomas Hess, Chief Financial Officer of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: â€¢The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and â€¢The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 8, 2024 Â /s/ Keith Murphy Keith Murphy Executive Chairman(Principal Executive Officer) Â /s/ Thomas Hess Thomas Hess Chief Financial Officer (Principal Financial Officer) Â A signed original of this written statement required by Section 906 has been provided to Organovo Holdings, Inc. and will be retained by Organovo Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission, and is not to be incorporated by reference into any filing of Organovo Holdings, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. EX-101.SCH 5 onvo-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Unaudited Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Investments and Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Collaborative Research, Development, and License Agreements link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Concentrations link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Business Segment Information link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Investments and Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Business Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Description of Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Investments and Fair Value Measurement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Investments and Fair Value Measurement - Summary of Investments in Debt Securities that are Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Stockholders' Equity - Preferred Stock - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Stockholders' Equity - Common Stock - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Stockholders' Equity - Summary of Company's RSUs Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Stockholders' Equity - Warrants - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Leases - Schedule of Future Lease Payments (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Stockholders' Equity -

Common Stock Reserved for Future Issuance (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Options (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Options (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Stockholders' Equity - Fair Value of ESPP Shares (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Collaborative Research, Development, and License Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Leases - Schedule of Lease Liabilities and Corresponding Right-of-use Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Leases - Schedule of Future Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Related Parties - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Business Segment Information - Summary of Segment Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Business Segment Information - Summary of Operating Segment Costs and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Business Segment Information - Summary of Operating Segment Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Subsequent Events - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Increase (Decrease) in Accounts Receivable Accounts receivable Accounts receivable Plan Name [Domain] Plan Name Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of Warrant Activity Entity Address, Postal Zip Code Entity Address, Postal Zip Code Operating lease right of use asset non current. Operating Lease Right Of Use Asset Non Current Operating lease right-of-use assets Pre-funded warrant. Pre-Funded Warrant [Member] Pre-Funded Warrants [Member] Inventory segment. Inventory Segment [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized stock-based compensation expense Stock issued during period value under employee and director stock option RSU and purchase plans. Stock Issued During Period Value Under Employee And Director Stock Option R S U And Purchase Plans Issuance of common stock under employee and director stock option, RSU, and purchase plans Warrant expiration period. Warrant expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested and Exercisable, Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Employee subscription rate Shares, Outstanding Ending balance, Shares Beginning balance, Shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] 2024 ATM Prospectus [Member] Prospectus To Two Thousand and Twenty Four Shelf [Member] Prospectus to 2024 shelf. Two thousand and twenty one inducement equity plan. Two Thousand And Twenty One Inducement Equity Plan [Member] 2021 Inducement Equity Plan [Member] Investments, Total Investments Investments in debt securities Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Fiscal year ending March 31, 2025 Lessee, Operating Leases [Text Block] Leases Stock, Class of Stock [Table] Schedule Of Stock By Class [Table] Product and Service [Axis] Equity sales agreement expiration date. Equity Sales Agreement Expiration Date Equity sales agreement expiration date Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class Depreciation, Depletion and Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Payments To Acquire Investment Purchases of investments Payments to acquire investment. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Title and Position [Axis] Title of Individual Class of Warrant or Right [Axis] Sale of Stock [Domain] Sale of Stock Inventory, Policy [Policy Text Block] Inventory Entity Central Index Key Entity Central Index Key Toxicity testing services to related parties Toxicity Testing Services to Related Parties Toxicity Testing Services to Related Parties Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP) Name ESPP shares. E S P P Shares [Member] ESPP Shares [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Cancelled / forfeited, Options Outstanding Voluntarily forfeited outstanding stock options Voluntarily forfeited outstanding stock options Increase (Decrease) in Operating Capital [Abstract] Increase (decrease) in cash resulting from changes in: Concentration Risk Disclosure [Text Block] Concentrations Common Stock, Shares, Issued Common stock, shares issued Issuance of common stock Other Company assets Other Assets, Total Other Assets Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Percentage of down payment Percentage Of Down Payment Percentage of down payment. Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Issuance of common stock under employee stock purchase plans Stock Issued During Period, Value, Employee Stock Purchase Plan Monthly rent payments. Monthly Rent Payments Monthly rental payments Class of Warrant or Right [Table] Sublicense agreements. Sublicense Agreements [Member] Sublicense Agreements [Member] BICO Group AB. B I C O Group A B [Member] BICO Group AB [Member] Increase to inventory reserve Increase to inventory reserve Increase to inventory reserve Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Vested and Exercisable, Aggregate Intrinsic Value Treasury Stock, Common, Shares Treasury stock, shares Cover Cover [Abstract] Subsequent Event [Line Items] Earnings Per Share, Basic Net loss per common share basic Earnings Per Share, Basic, Total Investment in debt securities, Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross unrealized gains Asset Acquisition [Axis] Number of discovery or preclinical compounds Number of discovery or preclinical compounds Number of discovery or preclinical compounds. Consolidation Items [Domain] Share-Based Payment Arrangement, Expense Stock-based compensation Total stock-based compensation expense Reconciliation of Assets from Segment to Consolidated [Table] Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Operating lease. Operating Lease [Line Items] Operating Lease [Line Items] Plan Name [Axis] Plan Name Segment Reporting [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options Outstanding, Ending balance Options Outstanding, Beginning balance Number of shares subject to outstanding Assets, Current [Abstract] Current Assets Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for future issuance Number of common stock shares approved under ESPP Investment Type [Axis] Investment Type Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Cash flow from operations Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Canceled / forfeited, Weighted Average Price Product and Service [Domain] Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Lessee, Operating Lease, Term of Contract Lease term Term Debt Instrument, Term Share-Based Compensation Arrangement by Share-Based Payment Award, Description Description of plan Property, Plant and Equipment, Net Fixed assets, net Property, Plant and Equipment, Net, Total Lessee, Operating Lease, Liability, to be Paid, Year Four Fiscal year ending March 31, 2029 Investment, Policy [Policy Text Block] Investments Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Cash fee percentage of aggregate gross proceeds raised in offering. Cash fee percentage of aggregate gross proceeds raised in offering Common Stock, Par or Stated Value Per Share Common stock, par value Unrealized gain (loss) on available-for-sale debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Two thousand and twenty two inducement equity plan. Two Thousand And Twenty Two Inducement Equity Plan [Member] 2022 Inducement Equity Plan [Member] Statement of Cash Flows [Abstract] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Issuance of warrants Selling, General and Administrative Expenses [Member] Equity Components [Axis] Equity Components Entity Address, Address Line One Entity Address, Address Line One Other Commitments [Axis] Other Commitments Employee-related Liabilities, Current, Total Employee-related Liabilities, Current Accrued compensation Related Party Transaction [Table] Schedule Of Related Party Transactions By Related Party [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted, Number of Shares Issued San Diego temporary lease. San Diego Temporary Lease [Member] San Diego Temporary Lease [Member] Subsequent Event Type [Axis] Nonoperating Income (Expense) Total Other Income Financing agreement amount Line of Credit Facility, Maximum Borrowing Capacity Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Stock issued during period shares under employee and director stock option RSU and purchase plans. Stock Issued During Period Shares Under Employee And Director Stock Option R S U And Purchase Plans Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Ending balance, Unvested, Number of Shares Beginning balance, Unvested, Number of Shares Initial Offering Period Initial offering date Amendment Amendment Flag Amendment Flag Operating Lease, Liability, Noncurrent Operating lease liability, net of current portion Noncurrent lease obligations Additional Paid in Capital, Common Stock Additional paid-in capital Chief scientific officer. Chief Scientific Officer [Member] Chief Scientific Officer [Member] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Summary of Operating Segment Costs and Expenses Net Loss Net Loss Net loss Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercised, Options Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Common stock shares issued Operating Costs and Expenses Total segment costs and expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Vested and Exercisable, Options Outstanding Research and Development Expense [Member] Research and development Liquidity and Going Concern Liquidity And Going Concern [Policy Text Block] Liquidity and going concern. Equity Component [Domain] Equity Component Statistical Measurement [Domain] Statistical Measurement Treasury Stock [Member] Treasury Stock, Common [Member] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Financing fees, shares Adjustments to Additional Paid in Capital, Financing Fees, Shares Adjustments to additional paid in capital, financing fees, shares. Operating Lease, Payments Operating cash flows from operating leases Lessee, Operating Lease, Discount Rate Base rent escalators Payables and Accruals [Abstract] Shares issued under ESPP Issuance of common stock under employee stock purchase plans, Shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Share based compensation arrangement by share based payment award initial offering period. Share Based Compensation Arrangement By Share Based Payment Award Initial Offering Period Initial offering period Consolidation Items [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Stock options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options cancelled / forfeited, Weighted-Average Exercise Price Restricted Cash, Noncurrent Restricted cash Restricted cash Restricted cash Viscient Biosciences. Viscient Biosciences [Member] Viscient [Member] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Collaborative Arrangement Disclosure [Text Block] Collaborative Research, Development, and License Agreements Comprehensive Loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name Fair Value Measurement, Policy [Policy Text Block] Fair value measurement Accretion On Investments Accretion on investments Accretion on investments Accretion on Investments. Other Commitments [Domain] Other Commitments Number of clinically tested compounds Number of clinically tested compounds Number of clinically tested compounds. Entity Interactive Data Current Entity Interactive Data Current Product [Member] Product [Member] Product Revenue [Member] Document Quarterly Report Document Quarterly Report Consolidated Entities [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested, Weighted Average Price Related Party Transaction [Domain] Related Party Transactions Disclosure [Text Block] Related Parties Statistical Measurement [Axis] Statistical Measurement Operating lease disclosure. Operating Lease [Table] Operating Lease [Table] Cost of Goods and Services Sold, Total Cost of Goods and Services Sold Cost of revenues Operating Lease, Expense Operating Lease, Cost Rent expense Histology services to related parties. Histology Services To Related Parties Histology services to related parties Related and Nonrelated Parties [Domain] Related Party Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Future Lease Payments Summary of Company's RSUs Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Shares remaining available for the purchase under the ESPP Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Shares available for purchase under ESPP Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted, Weighted Average Price Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total unrecognized compensation cost related, weighted average period Royalty fees percentage minimum. Royalty Fees Percentage Minimum Royalty fees percentage minimum Statement of Income Location, Balance [Axis] Income Statement Location University of Missouri. University Of Missouri [Member] University of Missouri [Member] Assets Total assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected life of options Expected term Issuance of common stock from exercise of pre-funded warrants Stock Issued During Period Value Exercise Of Prefunded Warrant Stock issued during period value exercise of prefunded warrant. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested, Number of Shares New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Entity Address, City or Town Entity Address, City or Town AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income [Member] Equity [Abstract] Prepaid Expense and Other Assets, Noncurrent Prepaid expenses and other assets, net Segments [Axis] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Shareholders' Equity and Share-Based Payments [Text Block] Stockholders' Equity Unrealized gain (loss) on available-for-sale debt securities, Shares Unrealized gain (loss) on shares available-for-sale securities Unrealized Gain (Loss) on Shares Available-for-Sale

Securities Licensing Agreements [Member] Licensing Agreements [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Common shares authorized to be issued Financed insurance premium exchanged for prepaid insurance Financed Insurance Premium Exchanged for Prepaid Insurance Financed insurance premium exchanged for prepaid insurance. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Expired, Options Outstanding Expired, Options Outstanding Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate: Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Canceled / forfeited, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations, Total Vesting criteria options achieving cumulative revenue Stock Issued During Period, Value, New Issues Value of shares sold under equity distribution agreement Vesting Criteria Based on Definitive Agreement [Member] Vesting criteria based on definitive agreement [member] Vesting criteria based on definitive agreement. San Diego permanent lease. San Diego Permanent Lease [Member] San Diego Permanent Lease [Member] Liabilities, Current [Abstract] Current Liabilities Investments. Investments [Table] Investments [Table] Document Type Document Type Equity incentive plan two thousand twelve. Equity Incentive Plan Two Thousand Twelve [Member] Equity Incentive Plan 2012 [Member] Title of 12(b) Security Title of 12(b) Security Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Fair market value at discount Lease, Cost [Table Text Block] Schedule of Lease Liabilities and Corresponding Right-of-use Assets Statement of Stockholders' Equity [Abstract] Inventory reserve Inventory Valuation Reserves Document Fiscal Period Focus Document Fiscal Period Focus Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Options Exercised, Aggregate Intrinsic Value Research and Development Expense Research and development expenses Research and Development Expense, Total Total segment operating expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Granted, Options Outstanding Stock option, granted Disaggregation of Revenue [Abstract] Revenues Minimum annual royalty payment. Minimum Annual Royalty Payment Minimum annual royalty paid Subsequent Event Type [Domain] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair Value of Employee Stock Options Operating Segments [Member] Operating Segments [Member] Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercise price per share Exercise Price, Outstanding, Beginning Balance Exercise Price, Outstanding, Ending Balance 2024 Shelf [Member] Two Thousand and Twenty Four Shelf [Member] 2024 shelf. Class of Warrant or Right [Line Items] Sale of Stock [Axis] Sale of Stock Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investments [Domain] Investments Financing fees Adjustments to Additional Paid in Capital, Financing Fees Adjustments to additional paid in capital, financing fees. Segment Reporting, Asset Reconciling Item [Line Items] Revenue from Contract with Customer, Excluding Assessed Tax Total Revenues Total Revenues Stock issued during period shares public offering. Stock Issued During Period Shares Public Offering Issuance of common stock from public offering, Shares Class of warrant or rights exercised. Class Of Warrant Or Rights Exercised Number of Warrants, Exercised Consolidated Entities [Domain] Warrants and Rights Note Disclosure [Abstract] Selling, general, and administrative expenses Selling, general and administrative expenses Selling, General and Administrative Expense Selling, General and Administrative Expense, Total Credit Facility [Domain] Basis of presentation and principles of consolidation. Basis Of Presentation And Principles Of Consolidation Policy [Text Block] Basis of Presentation and Principles of Consolidation Vesting criteria probability of achievement percentage. Vesting Criteria Probability Of Achievement Percentage Vesting criteria probability of achievement percentage Insurance premium financing agreement description Line of Credit Facility, Description License agreement expiration month. License Agreement Expiration Month Expired year of license agreement Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Entity Address, Address Line Two Entity Address, Address Line Two Segment assets. Segment assets Total segment assets Segment assets, Total Liabilities and Equity [Abstract] Liabilities and Stockholdersâ€™ Equity Period End Date Document Period End Date Document Period End Date Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Liabilities, Noncurrent [Abstract] Noncurrent Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common stock equivalents excluded from computing diluted net loss per share APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Class of warrant or rights isued. Class of Warrant or Rights Isued Number of Warrants, Issued Accrued Liabilities, Current Accrued expenses Accrued expenses R&D Segment. Research & Development Segment [Member] R&D [Member] Income Tax Expense (Benefit) Income Tax Expense Income Tax Expense (Benefit), Total Trading Symbol Trading Symbol Equity, Attributable to Parent Total stockholdersâ€™ equity Stockholders' Equity Attributable to Parent, Beginning Balance Stockholders' Equity Attributable to Parent, Ending Balance Employee Stock Purchase Plan. Employee Stock Purchase Plan [Member] 2016 Employee Stock Purchase Plan [Member] Accrual for loss contingencies Loss Contingency Accrual Loss Contingency Accrual, Ending Balance Loss Contingency Accrual, Beginning Balance Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Class of Warrant or Right, Outstanding Number of Warrants, Outstanding, Beginning Balance Number of Warrants, Outstanding, Ending Balance Restricted Stock Units (RSUs) [Member] Restricted stock units (RSUs) [Member] Related Party Transactions [Abstract] Metacrine's FXR program member. Metacrine's FXR Program [Member] Metacrine's FXR Program [Member] Variable Lease, Cost Variable lease expense Gain on investment in equity securities Equity Securities, FV-NI, Gain (Loss) Equity Securities, FV-NI, Gain (Loss), Total (Loss) gain on investment in equity securities Gain on investment in equity securities Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Stock-based Compensation Expense Nature of Operations [Text Block] Description of Business Incentive award plan. Incentive Award Plan [Member] Incentive Award Plan [Member] Investment in debt securities, Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross unrealized losses Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total unrecognized compensation cost related to unvested stock option grants Leases [Abstract] Use of Estimates, Policy [Policy Text Block] Use of Estimates Subsegments [Axis] Percentage of royalty revenue from sublicensee. Percentage Of Royalty Revenue From Sublicensee Percentage of royalty revenue from sublicensee Schedule of summary of significant accounting policy. Schedule Of Summary Of Significant Accounting Policy [Table] Schedule Of Summary Of Significant Accounting Policy [Table] Class of Stock [Line Items] Class Of Stock [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Security Exchange Name Security Exchange Name Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Investments, All Other Investments [Abstract] Lessee, Operating Lease, Liability, to be Paid, Year Three Fiscal year ending March 31, 2028 Grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type Subsequent Event [Member] Subsequent Event [Member] Investments. Investments [Line Items] Investments [Line Items] Maximum [Member] Maximum [Member] Liabilities and Equity Total Liabilities and Stockholdersâ€™ Equity Number of participants enrolled in employee stock purchase plan. Number Of Participants Enrolled In Employee Stock Purchase Plan Participants enrolled into the employee stock purchase plan Interest income on investments in debt securities Interest Income On Investments in debt securities Interest income on investments in debt securities. Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Total lease right-of-use assets Supplemental Cash Flow Information [Abstract] Supplemental Disclosure of Cash Flow Information: Investments and Fair Value Measurement Investment [Text Block] Earnings Per Share, Diluted Net loss per common share diluted Earnings Per Share, Diluted, Total Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Summary of Segment Revenues Liabilities Total liabilities Assets, Current Total current assets Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Sales based royalties member. Sales Based Royalties [Member] Sales Based Royalties [Member] Segment Reconciliation [Abstract] Common stock, shares issued Issuance of common stock from stock options exercises, net, Shares Issuance of common stock Vesting Criteria Based on Achieving Cumulative Revenue of $1.5 Million [Member] Vesting Criteria Based on Achieving Cumulative Revenue [Member] Vesting criteria based on achieving cumulative revenue Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Entity Filer Category Entity Filer Category Segment Reporting, Revenue Reconciling Item [Line Items] Asset Acquisition [Domain] Equity, Including Portion Attributable to Noncontrolling Interest Ending balance Beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total Stock issued during period value public offering. Stock Issued During Period Value Public Offering Issuance of common stock from public offering, net Nonoperating Income (Expense) [Abstract] Other Income Description of business and summary of significant accounting policies. Description Of Business And Summary Of Significant Accounting Policies [Table] Description Of Business And Summary Of Significant Accounting Policies [Table] Current Fiscal Year End Date Current Fiscal Year End Date Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Imputed interest Related Party Transaction [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Options Ending balance Aggregate Intrinsic Value, Options Beginning balance Related and Nonrelated Parties [Axis] Related Party Entity Registrant Name Entity Registrant Name Insurance Premium Financing Liability [Member] Insurance Premium Financing Liability [Member] Insurance premium financing liability member. Cost of Revenue, Total Cost of Revenue Cost of revenues Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Entity Emerging Growth Company Entity Emerging Growth Company Other Liabilities, Current Other accrued expenses Weighted Average Number of Shares Outstanding, Basic Weighted average shares used in computing net loss per common share basic Weighted Average Number of Shares Outstanding, Basic, Total Class of warrant or right, exercise price of warrants or rights, issued. Class of Warrant or Right, Exercise Price of Warrants or Rights, Issued Exercise Price, Issued Fixed assets segment. Fixed Assets Segment [Member] Liquidation of equity securities. Liquidation of Equity Securities Liquidation of equity securities Stock-based compensation expense, Shares Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Share Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Share Common Stock, Shares Authorized Common stock, shares authorized Royalty [Member] Royalty [Member] Royalty Revenue [Member] Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted, Weighted-Average Exercise Price Class of warrant or right, exercise price of warrants or rights, exercised. Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised Exercise Price, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-average remaining contractual term of stock options outstanding Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share General and Administrative Expense [Member] General and administrative Share-Based Payment Arrangement [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Subsegments [Domain] Equity Securities, FV-NI, Current Fair value of investment in equity securities Treasury Stock, Common, Value Treasury stock, 46 shares at cost Investment in debt securities, Fair value Investment in debt securities, Fair value Debt Securities, Available-for-Sale Fair value Accounting Policies [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity Equity, Attributable to Parent [Abstract] Stockholdersâ€™ Equity Statement [Table] Statement [Table] Common stock capital value reserved for future issuance. Common Stock Capital Value Reserved For Future Issuance Common stock value reserved for future issuance Subsequent Event [Table] Combination of securities authorized for offer and sale. Combination Of Securities Authorized For Offer And Sale Securities authorized for offer and sale, amount Preferred Stock, Shares Authorized Preferred stock, shares authorized Securities Act File Number Entity File Number Segment Reporting Disclosure [Text Block] Business Segment Information Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Liquidation of equity securities Liquidation of Equity Securities FVNi Liquidation of equity securities fvni. Statement of Financial Position [Abstract] IPO [Member] IPO [Member] Public Offering [Member] Operating Income (Loss) Loss from Operations Shares Issued, Price Per Share Excercise price per share Stock offering price per share Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility Fair Value of ESPP Shares Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Entity Shell Company Entity Shell Company Accrued Professional Fees, Current Accrued legal and professional fees Common warrants. Common Warrants [Member] Common Warrants [Member] Entity Tax Identification Number Entity Tax Identification Number Assets [Abstract] Assets Class of Warrant or Right [Domain] 2023 Employee Stock Purchase Plan. Two Thousand Twenty Three Employee Stock Purchase Plan [Member] 2023 Employee Stock Purchase Plan [Member] Entity Current Reporting Status Entity Current Reporting Status Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted-average remaining contractual term of stock options exercisable Prospectus to the 2021 Shelf. Prospectus To2021 Shelf [Member] ATM Prospectus Supplement [Member] Annual interest rate Line of Credit Facility, Interest Rate During Period Subsequent Events [Abstract] Revenue from Contract with Customer [Policy Text Block] Revenue recognition Document Fiscal Year Focus Document Fiscal Year Focus Increase decrease in operating lease right-of-use assets and liabilities, net. Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net Operating lease right-of-use assets and liabilities, net Other Selling, General and Administrative Expense Other selling, general, and administrative expenses Stock issued during period value new issues net. Stock Issued During Period Value New Issues Net Value of shares sold under equity distribution agreement, net Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, cash equivalents, and restricted cash at end of period Cash, cash equivalents, and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Two thousand and twenty one shelf. Two Thousand And Twenty One Shelf [Member] 2021 Shelf [Member] Proceeds from Issuance Initial Public Offering Net proceeds from issuance of offerings City Area Code City Area Code 2018 sales agreement. Two Thousand Eighteen Sales Agreement [Member] 2018 Sales Agreement [Member] Liabilities, Current Total current liabilities Equity Incentive Plan Two Thousand Twenty Two [Member] Equity Incentive Plan Two Thousand Twenty Two [Member] Equity Incentive Plan 2022 [Member] Inventory, net Inventory, Net, Total Inventory, Net Inventory Inventory finished goods, net of reserve Inventory, Finished Goods, Gross Royalty payments under license agreement due year two. Royalty Payments Under License Agreement Due Year Two Minimum annual royalty payment due Description of business and summary of significant accounting policies. Description Of Business And Summary Of Significant Accounting Policies [Line Items] Description Of Business And Summary Of Significant Accounting Policies [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Local

Phone Number Local Phone Number Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Reconciliation of Assets from Segment to Consolidated [Table Text Block] Summary of Operating Segment Assets Share based compensation arrangement by share based payment award maximum amount per employee. Share Based Compensation Arrangement By Share Based Payment Award Maximum Amount Per Employee Compensation amount per employee Commitments and Contingencies Disclosure [Abstract] Dilutive Securities, Effect on Basic Earnings Per Share Dilutive effect Dilutive Securities, Effect on Basic Earnings Per Share, Total Upfront fee payment. Upfront Fee Payment Upfront payment Executive chairman. Executive Chairman [Member] Executive Chairman [Member] Investment in debt securities, Amortized costs basis Debt Securities, Available-for-Sale, Amortized Cost, Total Debt Securities, Available-for-Sale, Amortized Cost Amortized costs basis Operating Lease, Liability, Current Operating lease liability, current portion Less: Current obligations Two thousand twelve plan. Two Thousand Twelve Plan [Member] 2012 Plan [Member] Retained Earnings [Member] Accumulated Deficit [Member] Payments to Acquire Property, Plant, and Equipment Purchases of fixed assets Payments to Acquire Property, Plant, and Equipment, Total At-the-market facility. At The Market Facility [Member] At-The-Market Facility [Member] Document Transition Report Document Transition Report Lessee, Operating Lease, Liability, to be Paid, Year Two Fiscal year ending March 31, 2027 Prospectus To 2021 and 2024 ATM prospectus Shelf. Prospectus To 2021 and 2024 A T M Prospectus Shelf [Member] Liability to be settled in equity Liability to be Settled in the Equity Liability to be settled in the equity. Lab and office space area under lease agreement. Lab And Office Space Area Under Lease Agreement Lab and Office space under lease agreement Minimum [Member] Minimum [Member] Common Stock [Member] Common Stock [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Ending balance, Unvested, Weighted Average Price Beginning balance, Unvested, Weighted Average Price Royalty fees percentage maximum. Royalty Fees Percentage Maximum Royalty fees percentage maximum Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Operating leases monthly rent expense. Operating Leases Monthly Rent Expense Monthly rental payments Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Other Comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Statement of Income Location, Balance [Domain] Income Statement Location Employee Stock Ownership Plan (ESOP), Plan [Domain] Employee Stock Ownership Plan (ESOP), Plan Lessee, Operating Lease, Liability, to be Paid, Year One Fiscal year ending March 31, 2026 Segments [Domain] Vesting Criteria Based on Performance Conditions [Member] Performance Shares [Member] Unrealized gain (loss) on available-for-sale debt securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Unvested, cancelled shares Unvested, cancelled shares Clemson University. Clemson University [Member] Clemson University [Member] Debt Securities, Unrealized Gain (Loss), Total Debt Securities, Unrealized Gain (Loss) Unrealized gains on investments in debt securities Title and Position [Domain] Title of Individual Insurance Premium Financing Liability Insurance Premium Financing Liability [Policy Text Block] Insurance premium financing liability policy text block. Common stock, $0.001 par value; 200,000,000 shares authorized, 15,365,825 and 10,077,726 shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively Common Stock, Value, Issued Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Stock issued during period shares exercise of prefunded warrants. Stock Issued During Period Shares Exercise Of Prefunded Warrants Issuance of common stock from exercise of pre-funded warrants, Shares Investment Income, Interest Interest income Prepaid insurance included in prepaid expenses and other current assets Prepaid Insurance Vesting Criteria Based on Market Conditions [Member] Vesting criteria based on market conditions [Member] Vesting criteria based on market conditions. Share-Based Payment Arrangement, Accelerated Cost Expense recorded Operating Lease, Liability Operating lease, liability Total lease liabilities Liability to be settled in equity Liability to be Settled in Equity Liability to be settled in equity. Debt Securities, Available-for-Sale [Table Text Block] Summary of Investments in Debt Securities that are Measured at Fair Value Schedule of Accrued Liabilities [Table Text Block] Summary of Accrued Expenses Commitments and Contingencies Commitments and Contingencies (Note 7) Income taxes paid Income Taxes Paid Income taxes paid JonesTrading Institutional Services LLC. JonesTrading Institutional Services LLC [Member] JonesTrading Institutional Services LLC [Member] Weighted Average Number of Shares Outstanding, Diluted Weighted average shares used in computing net loss per common share diluted Weighted Average Number of Shares Outstanding, Diluted, Total Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Lessee, Operating Lease, Liability, to be Paid Total future lease payments Increase (Decrease) in Inventories, Total Increase (Decrease) in Inventories Inventory Inventory Minimum percentage of income tax payment net of refunds received. Minimum Percentage Of Income Tax Payment Net Of Refunds Received Minimum percentage of income tax payment net of refunds received Insurance premium financing liability Insurance Premium Financing Liability Insurance premium financing liability. Common stock capital shares reserved for future issuance. Common Stock Capital Shares Reserved For Future Issuance Table [Text Block] Common Stock Reserved for Future Issuance Proceeds from maturities prepayments and calls of investments. Proceeds From Maturities Prepayments And Calls Of Investments Maturities of investments Entity Small Business Entity Small Business Number of lease agreement. Number Of Lease Agreement Number of lease agreement Mosaic segment. Mosaic Segment [Member] Mosaic Mosaic [Member] Credit Facility [Axis] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Options expired, Weighted-Average Exercise Price Share based compensation arrangement by share based payment award purchase period. Share Based Compensation Arrangement By Share Based Payment Award Purchase Period Purchase period Reconciliation of Revenue from Segments to Consolidated [Table] Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price, Options Ending balance Weighted-Average Exercise Price, Options Beginning balance Monthly principal and interest payments Line of Credit Facility, Periodic Payment Commitments Disclosure [Text Block] Commitments and Contingencies Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Number of shares per employee Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term: Subsequent Events Subsequent Events [Text Block] Metacrine, Inc. member. Metacrine, Inc. [Member] Metacrine, Inc. [Member] Summary of significant accounting policies. Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Costs and Expenses Total costs and expenses Risks and Uncertainties [Abstract] Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Accrued Liabilities, Total Short-Term Lease, Cost Short term lease cost XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 6 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2025 Â Document Fiscal Period Focus Q2 Â Trading Symbol ONVO Â Entity Registrant Name Organovo Holdings, Inc. Â Entity Central Index Key 0001497253 Â Current Fiscal Year End Date --03-31 Â Entity Filer Category Non-accelerated Filer Â Entity Shell Company false Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Common Stock, Shares Outstanding Â 15,365,826 Entity File Number 001-35996 Â Entity Current Reporting Status Yes Â Entity Tax Identification Number 27-1488943 Â Entity Address, Address Line One 11555 Sorrento Valley Rd Â Entity Address, Address Line Two Suite 100 Â Entity Address, City or Town San Diego Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 92121 Â City Area Code 858 Â Local Phone Number 224-1000 Â Entity Interactive Data Current Yes Â Title of 12(b) Security Common Stock, $0.001 par value Â Security Exchange Name NASDAQ Â Entity Incorporation, State or Country Code DE Â Document Quarterly Report true Â Document Transition Report false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type:

duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Mar. 31, 2024 Current Assets Â Â Cash and cash equivalents $ 3,174 $ 2,901 Accounts receivable 29 33 Inventory 640 297 Prepaid expenses and other current assets 940 705 Total current assets 4,783 3,936 Fixed assets, net 545 669 Restricted cash 143 143 Operating lease right-of-use assets 1,086 1,299 Prepaid expenses and other assets, net 197 302 Total assets 6,754 6,349 Current Liabilities Â Â Accounts payable 419 627 Accrued expenses 879 727 Insurance premium financing liability 385 0 Liability to be settled in equity 218 0 Operating lease liability, current portion 513 506 Total current liabilities 2,414 1,860 Operating lease liability, net of current portion 660 888 Total liabilities 3,074 2,748 Commitments and Contingencies (Note 7) Stockholdersâ€™ Equity Â Â Common stock, $0.001 par value; 200,000,000 shares authorized, 15,365,825 and 10,077,726 shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively 15 10 Additional paid-in capital 349,227 343,261 Accumulated deficit (345,562) (339,669) Accumulated other comprehensive income 1 0 Treasury stock, 46 shares at cost (1) (1) Total stockholdersâ€™ equity 3,680 3,601 Total Liabilities and Stockholdersâ€™ Equity $ 6,754 $ 6,349 X - DefinitionInsurance premium financing liability. + ReferencesNo definition available. + Details Name: onvo_InsurancePremiumFinancingLiability Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLiability to be settled in equity. + ReferencesNo definition available. + Details Name: onvo_LiabilityToBeSettledInEquity Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-

10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards

Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 9 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Mar. 31, 2024 Statement of Financial Position [Abstract] Â Â Common stock, par value $ 0.001 $ 0.001 Common stock, shares authorized 200,000,000 200,000,000 Common stock, shares issued 15,365,825 10,077,726 Common stock, shares outstanding 15,365,825 10,077,726 Treasury stock, shares 46 46 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues Â Â Â Â Total Revenues $ 30 $ 0 $ 69 $ 75 Cost of revenues 1 0 3 0 Research and development expenses 984 1,335 2,386 3,001 Selling, general and administrative expenses 1,653 2,780 3,674 5,384 Total costs and expenses 2,638 4,115 6,063 8,385 Loss from Operations (2,608) (4,115) (5,994) (8,310) Other Income Â Â Â Â Gain on investment in equity securities 0 0 0 12 Interest income 59 121 103 278 Total Other Income 59 121 103 290 Income Tax Expense 0 0 (2) (2) Net Loss (2,549) (3,994) (5,893) (8,022) Other Comprehensive loss: Â Â Â Â Unrealized gain (loss) on available-for-sale debt securities 1 (1) 1 (1) Comprehensive Loss $ (2,548) $ (3,995) $ (5,892) $ (8,023) Net loss per common share basic $ (0.14) $ (0.46) $ (0.36) $ (0.92) Net loss per common share diluted $ (0.14) $ (0.46) $ (0.36) $ (0.92) Weighted average shares used in computing net loss per common share basic 17,994,538 8,718,502 16,338,216 8,717,870 Weighted average shares used in computing net loss per common share diluted 17,994,538 8,718,502 16,338,216 8,717,870 Royalty Revenue [Member] Â Â Â Â Revenues Â Â Â Â Total Revenues $ 28 $ 0 $ 53 $ 75 Product Revenue [Member] Â Â Â Â Revenues Â Â Â Â Total Revenues $ 2 $ 0 $ 16 $ 0 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisaggregationOfRevenueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands Total Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stock [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Income [Member] Beginning balance at Mar. 31, 2023 $ 15,329 $ 9 $ 340,317 $ (1) $ (324,998) $ 2 Beginning balance, Shares at Mar. 31, 2023 Â 8,717 Â 0 Â Â Issuance of common stock under employee and director stock option, RSU, and purchase plans 0 $ 0 0 $ 0 0 0 Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares Â 1 Â 0 Â Â Stock-based compensation expense 475 $ 0 475 $ 0 0 0 Stock-based compensation expense, Shares Â 0 Â 0 Â Â Net loss (4,028) $ 0 0 $ 0 (4,028) 0 Ending balance at Jun. 30, 2023 11,776 $ 9 340,792 $ (1) (329,026) 2 Ending balance, Shares at Jun. 30, 2023 Â 8,718 Â 0 Â Â Beginning balance at Mar. 31, 2023 15,329 $ 9 340,317 $ (1) (324,998) 2 Beginning balance, Shares at Mar. 31, 2023 Â 8,717 Â 0 Â Â Net loss (8,022) Â Â Â Â Â Ending balance at Sep. 30, 2023 8,456 $ 9 341,467 $ (1) (333,020) 1 Ending balance, Shares at Sep. 30, 2023 Â 8,719 Â 0 Â Â Beginning balance at Jun. 30, 2023 11,776 $ 9 340,792 $ (1) (329,026) 2 Beginning balance, Shares at Jun. 30, 2023 Â 8,718 Â 0 Â Â Issuance of common stock under employee and director stock option, RSU, and purchase plans 0 $ 0 0 $ 0 0 0 Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares Â 2 Â 0 Â Â Stock-based compensation expense 675 $ 0 675 $ 0 0 0 Stock-based compensation expense, Shares Â 0 Â 0 Â Â Net loss (3,994) $ 0 0 $ 0 (3,994) 0 Unrealized gain (loss) on available-for-sale debt securities (1) $ 0 0 $ 0 0 (1) Unrealized gain (loss) on available-for-sale debt securities, Shares Â 0 Â 0 Â Â Ending balance at Sep. 30, 2023 8,456 $ 9 341,467 $ (1) (333,020) 1 Ending balance, Shares at Sep. 30, 2023 Â 8,719 Â 0 Â Â Beginning balance at Mar. 31, 2024 3,601 $ 10 343,261 $ (1) (339,669) 0 Beginning balance, Shares at Mar. 31, 2024 Â 10,078 Â 0 Â Â Issuance of common stock under employee and director stock option, RSU, and purchase plans 0 $ 0 0 $ 0 0 0 Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares Â 1 Â 0 Â Â Issuance of common stock from exercise of pre-funded warrants 1 $ 1 0 $ 0 0 0 Issuance of common stock from exercise of pre-funded warrants, Shares Â 1,379 Â 0 Â Â Issuance of common stock from public offering, net 6,248 $ 3 6,245 $ 0 0 0 Issuance of common stock from public offering, Shares Â 2,915 Â 0 Â Â Stock-based compensation expense 156 $ 0 156 $ 0 0 0 Stock-based compensation expense, Shares Â 0 Â 0 Â Â Net loss (3,344) $ 0 0 $ 0 (3,344) 0 Ending balance at Jun. 30, 2024 6,662 $ 14 349,662 $ (1) (343,013) 0 Ending balance, Shares at Jun. 30, 2024 Â 14,373 Â 0 Â Â Beginning balance at Mar. 31, 2024 3,601 $ 10 343,261 $ (1) (339,669) 0 Beginning balance, Shares at Mar. 31, 2024 Â 10,078 Â 0 Â Â Net loss (5,893) Â Â Â Â Â Ending balance at Sep. 30, 2024 3,680 $ 15 349,227 $ (1) (345,562) 1 Ending balance, Shares at Sep. 30, 2024 Â 15,366 Â 0 Â Â Beginning balance at Jun. 30, 2024 6,662 $ 14 349,662 $ (1) (343,013) 0 Beginning balance, Shares at Jun. 30, 2024 Â 14,373 Â 0 Â Â Issuance of common stock under employee and director stock option, RSU, and purchase plans 0 $ 0 0 $ 0 0 0 Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares Â 1 Â 0 Â Â Issuance of common stock from exercise of pre-funded warrants 1 $ 1 0 $ 0 0 0 Issuance of common stock from exercise of pre-funded warrants, Shares Â 991 Â 0 Â Â Stock-based compensation expense 155 $ 0 155 $ 0 0 0 Stock-based compensation expense, Shares Â 0 Â 0 Â Â Financing fees (590) $ 0 (590) $ 0 0 0 Financing fees, shares Â 0 Â 0 Â Â Net loss (2,549) $ 0 0 $ 0 (2,549) 0 Unrealized gain (loss) on available-for-sale debt securities 1 $ 0 0 $ 0 0 1 Unrealized gain (loss) on available-for-sale debt securities, Shares Â 0 Â 0 Â Â Ending balance at Sep. 30, 2024 $ 3,680 $ 15 $ 349,227 $ (1) $ (345,562) $ 1 Ending balance, Shares at Sep. 30, 2024 Â 15,366 Â 0 Â Â X - DefinitionAdjustments to additional paid in capital, financing fees. + ReferencesNo definition available. + Details Name: onvo_AdjustmentsToAdditionalPaidInCapitalFinancingFees Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAdjustments to additional paid in capital, financing fees, shares. + ReferencesNo definition available. + Details Name: onvo_AdjustmentsToAdditionalPaidInCapitalFinancingFeesShares Namespace Prefix: onvo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Share + ReferencesNo definition available. + Details Name: onvo_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShare Namespace Prefix: onvo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares exercise of prefunded warrants. + ReferencesNo definition available. + Details Name: onvo_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrants Namespace Prefix: onvo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares public offering. + ReferencesNo definition available. + Details Name: onvo_StockIssuedDuringPeriodSharesPublicOffering Namespace Prefix: onvo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares under employee and director stock option RSU and purchase plans. + ReferencesNo definition available. + Details Name: onvo_StockIssuedDuringPeriodSharesUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans Namespace Prefix: onvo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period value exercise of prefunded warrant. + ReferencesNo definition available. + Details Name: onvo_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value public offering. + ReferencesNo definition available. + Details Name: onvo_StockIssuedDuringPeriodValuePublicOffering Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value under employee and director stock option RSU and purchase plans. + ReferencesNo definition available. + Details Name: onvo_StockIssuedDuringPeriodValueUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUnrealized gain (loss) on shares available-for-sale securities + ReferencesNo definition available. + Details Name: onvo_UnrealizedGainLossOnSharesAvailableForSaleSecurities Namespace Prefix: onvo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X -

DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification

-Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 12 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Cash Flows from Operating Activities Â Â Â Â Net loss $ (2,549) $ (3,994) $ (5,893) $ (8,022) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Gain on investment in equity securities 0 0 0 (12) Accretion on investments Â Â (33) (103) Depreciation and amortization Â Â 138 138 Stock-based compensation 155 675 311 1,150 Increase (decrease) in cash resulting from changes in: Â Â Â Â Accounts receivable Â Â 4 97 Inventory Â Â (503) 0 Prepaid expenses and other assets Â Â 255 371 Accounts payable Â Â (208) 104 Accrued expenses Â Â 152 (2,182) Operating lease right-of-use assets and liabilities, net Â Â (8) (1) Net cash used in operating activities Â Â (5,625) (8,460) Cash Flows from Investing Activities Â Â Â Â Purchases of fixed assets Â Â (13) (42) Purchases of investments Â Â (2,467) (7,900) Maturities of investments Â Â 2,500 8,000 Liquidation of equity securities Â Â 0 718 Net cash provided by investing activities Â Â 20 776 Cash Flows from Financing Activities Â Â Â Â Proceeds from issuance of common stock, net Â Â 5,878 0 Net cash provided by financing activities Â Â 5,878 0 Net increase (decrease) in cash, cash equivalents, and restricted cash Â Â 273 (7,684) Cash, cash equivalents, and restricted cash at beginning of period Â Â 3,044 15,444 Cash, cash equivalents, and restricted cash at end of period 3,317 7,760 3,317 7,760 Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets Â Â Â Â Cash and cash equivalents 3,174 7,617 3,174 7,617 Restricted cash 143 143 143 143 Cash, cash equivalents, and restricted cash at end of period $ 3,317 $ 7,760 3,317 7,760 Supplemental Disclosure of Cash Flow Information: Â Â Â Â Income taxes paid Â Â 2 2 Liability to be settled in equity Â Â 218 0 Financed insurance premium exchanged for prepaid insurance Â Â $ 385 $ 0 X - DefinitionAccretion on Investments. + ReferencesNo definition available. + Details Name: onvo_AccretionOnInvestments Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFinanced insurance premium exchanged for prepaid insurance. + ReferencesNo definition available. + Details Name: onvo_FinancedInsurancePremiumExchangedForPrepaidInsurance Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in operating lease right-of-use assets and liabilities, net. + ReferencesNo definition available. + Details Name: onvo_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLiability to be settled in the equity. + ReferencesNo definition available. + Details Name: onvo_LiabilityToBeSettledInTheEquity Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLiquidation of equity securities. + ReferencesNo definition available. + Details Name: onvo_LiquidationOfEquitySecurities Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayments to acquire investment. + ReferencesNo definition available. + Details Name: onvo_PaymentsToAcquireInvestment Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from maturities prepayments and calls of investments. + ReferencesNo definition available. + Details Name: onvo_ProceedsFromMaturitiesPrepaymentsAndCallsOfInvestments Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -

Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (2,549) $ (3,994) $ (5,893) $ (8,022) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of

income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 14 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business 6 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Description of Business Note 1. Description of Business Nature of OperationsOrganovo Holdings, Inc. (â€œOrganovo Holdings,â€ â€œOrganovo,â€ and the â€œCompanyâ€) is a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease ("IBD"), including ulcerative colitis ("UC"), based on demonstration of clinical promise in three-dimensional ("3D") human tissues as well as strong preclinical data. FXR is a mediator of gastrointestinal and liver diseases. FXR agonism has been tested in a variety of preclinical models of IBD. FXR314 is the lead compound in the Company's established FXR program containing two clinically tested compounds (including FXR314) and over 2,000 discovery or preclinical compounds. FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials. Further, FXR314 has FDA clinical trial authorization for a Phase 2 trial in UC.Â The Company's current clinical focus is in advancing FXR314 in IBD, including UC and Crohnâ€™s disease (â€œCDâ€). The Company plans to start a Phase 2a clinical trial in UC in the calendar year 2025. The Company released Phase 2 data for FXR314 for the treatment of metabolic function-associated steatohepatitis (â€œMASHâ€) in April 2024 that is supportive of ongoing development, and the Company believes FXR314 has a commercial opportunity in MASH, most likely in combination therapy. The Company is exploring the potential for combination therapies using FXR314 and currently approved mechanisms in preclinical animal studies and the Company's IBD disease models. The Company's second focus is building high fidelity, 3D tissues that recapitulate key aspects of human disease. The Company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. The Company believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas.As with the clinical development program, the Company is initially focusing on the intestine and has ongoing 3D tissue development efforts in human tissue models of UC and CD. The Company uses these models to identify new molecular targets responsible for driving these diseases and to explore the mechanism of action of known drugs including FXR314 and related molecules. The Company intends to initiate drug discovery programs around these new validated targets to identify drug candidates for partnering and/or internal clinical development. The Companyâ€™s current understanding of intestinal tissue models and IBD disease models leads it to believe that it can create models that provide greater insight into the biology of these diseases than are generally currently available. The Company is creating high fidelity disease models, leveraging its prior work including the work found in its peer-reviewed publication on bioprinted intestinal tissues (Madden et al. Bioprinted 3D Primary Human Intestinal Tissues Model Aspects of Native Physiology and ADME/Tox Functions. iScience. 2018 Apr 27;2:156-167. doi: 10.1016/j.isci.2018.03.015.) Organovoâ€™s advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures.Using these disease models, the Company intends to identify and validate novel therapeutic targets. After finding therapeutic drug targets, the Company intends to focus on developing novel small molecule, antibody, or other therapeutic drug candidates to treat the disease, and advance these novel drug candidates towards an Investigational New Drug (â€œINDâ€) filing and potential future clinical trials. The Company expects to broaden its work into additional therapeutic areas over time and is currently exploring specific tissues for development. In the Companyâ€™s work to identify the areas of interest, it evaluates areas that might be better served with 3D disease models than currently available models as well as the potential commercial opportunity. In line with these plans, the Company is building upon both its external and in house scientific expertise, which will be essential to its drug development effort.Â In February 2024, the Company formed its Mosaic Cell Sciences division (â€œMosaicâ€) to serve as a key source of certain primary human cells that the Company utilizes in its research and development efforts. The Company believes Mosaic can help optimize its supply chain, reduce operating expenses related to cell sourcing and procurement and ensure that the cellular raw materials the Company uses are of the highest quality and are derived from tissues that are ethically sourced in full compliance with state and federal guidelines. Mosaic provides the Company with qualified human cells for use in its clinical research and development programs. In addition to supplying the Company with primary human cells, Mosaic offers human cells for sale to life science customers, both directly and through distribution partners, which the Company expects to offset costs and over time become a profit center that offsets overall research and development ("R&D") spending by the Company.Except where specifically noted or the context otherwise requires, references to â€œOrganovo Holdingsâ€, â€œthe Companyâ€, and â€œOrganovoâ€ in these notes to the unaudited condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiary, Organovo, Inc. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 6 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies Note 2. Summary of Significant Accounting PoliciesBasis of Presentation and Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not necessarily include all information and

notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2024 is derived from the Companyâ€™s audited consolidated balance sheet as filed with the SEC on May 31, 2024. The unaudited condensed consolidated financial statements include the accounts of Organovo and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Companyâ€™s financial position, results of operations, stockholdersâ€™ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Companyâ€™s Annual Report on Form 10-K for the year ended March 31, 2024, as filed with the Securities and Exchange Commission (â€œSECâ€). Operating results for any interim period are not necessarily indicative of the operating results for any other interim period or the Companyâ€™s full fiscal year ending March 31, 2025 (see â€œNote 1. Description of Businessâ€).Â Liquidity and Going ConcernThe accompanying consolidated financial statements have been prepared on the basis that we are a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of September 30, 2024, the Company had cash and cash equivalents of approximately $3.2 million, restricted cash of approximately $0.1 million and an accumulated deficit of approximately $345.6 million. The restricted cash was pledged as collateral for a letter of credit that the Company is required to maintain as a security deposit under the terms of the lease agreement for its facilities. The Company also had negative cash flows from operations of approximately $5.6 million during the six months ended September 30, 2024. Through September 30, 2024, the Company has financed its operations primarily through the sale of common stock through public and at-the-market (â€œATMâ€) offerings, the private placement of equity securities, from revenue derived from the licensing of intellectual property, products and research service-based services, grants, and collaborative research agreements, and from the sale of convertible notes. During the six months ended September 30, 2024, the Company issued 1,352,600 shares of its common stock through its ATM facility, for net proceeds of approximately $1.7 million. Additionally, on May 8, 2024, the Company priced a best efforts public offering (the â€œOfferingâ€) of: (i) 1,562,500 shares of its common stock and accompanying common warrants (â€œCommon Warrantsâ€) to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) pre-funded warrants (â€œPre-Funded Warrantsâ€) to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. The closing of the Offering occurred on May 13, 2024. The Company received net proceeds of approximately $4.5 million from the Offering, after deducting the estimated offering expenses payable by the Company, including the Placement Agent fees. On July 18, 2024, the Company received a written notice (the â€œNoticeâ€) from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (â€œNasdaqâ€) indicating that, based upon the closing bid price of the Companyâ€™s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (â€œRule 5550(a)(2)â€). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until January 14, 2025, to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of the Companyâ€™s common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. The Notice provides that the Nasdaq staff will provide written confirmation to the Company if the Company regains compliance with Rule 5550(a)(2). If the Company does not regain compliance with Rule 5550(a)(2) by January 14, 2025, the Company may be eligible for an additional compliance period of 180 calendar days. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice to Nasdaq of its intention to cure the bid price deficiency during the second compliance period. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities will be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq staffâ€™s determination to delist its securities, but there can be no assurance the Nasdaq staff would grant any request for continued listing.Based on the Company's current operating plan and available cash resources, it will need substantial additional funding to support future operating activities. The Company has concluded that the prevailing conditions and ongoing liquidity risks faced by it raise substantial doubt about its ability to continue as a going concern for at least one year following the date these financial statements are issued. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. As the Company continues its operations and is focusing its efforts on drug discovery and development, the Company will need to raise additional capital to implement this business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. The Company will seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Companyâ€™s business, operating results, and financial condition. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. On an ongoing basis, management reviews these estimates and assumptions. Investments Investments in debt securities consist of investments in U.S. Treasury bills. All investments that have original maturities of three months or less are classified as cash equivalents on the condensed consolidated balance sheets. As of September 30, 2024 and March 31, 2024, all investments are classified as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies. Available-for-sale debt securities are recorded at fair value. Any unrealized gains and losses are included in accumulated other comprehensive income as a component of stockholders' equity until realized. As U.S. Treasury bills have minimal risk, any declines in fair value are considered temporary. Fair value measurement Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: â€¢Level 1 â€“ Quoted prices in active markets for identical assets or liabilities. â€¢Level 2 â€“ Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. â€¢Level 3 â€“ Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. InventoryInventories are stated at the lower of cost or net realizable value. Inventory as of September 30, 2024 and March 31, 2024 consisted of approximately $0.6 million, net of reserve, and $0.3 million in finished goods, respectively, which is related to Mosaic. An inventory reserve of approximately $0.2 million was established during the three months ended September 30, 2024 to write-down inventory to its new cost basis. Please refer to "Note 11. Business Segment Information" for further information regarding Mosaic's inventory. Insurance Premium Financing LiabilityIn September 2024, the Company entered into an insurance premium financing agreement for $0.4 million, with a term of nine months and an annual interest rate of 8.57%. The Company made a down payment of 10% and is required to make monthly principal and interest payments of $44,281 over the term of the agreement, which matures in June 2025. Related prepaid insurance at September 30, 2024 of $0.4 million is included in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets. Net Loss Per Share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options, shares reserved for purchase under the Companyâ€™s 2023 Employee Stock Purchase Plan (â€œ2023 ESPPâ€), the assumed vesting of restricted stock units (â€œRSUsâ€), the exercise of warrants, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the six months ended September 30, 2024 and 2023 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive.Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 11.3 million at September 30, 2024 and 1.0 million at September 30, 2023. Revenue recognitionRoyalty revenue The Company has entered into an intellectual property license agreement with another company that includes royalties based on specified percentages of net product sales, if any. At the initiation of the agreement, the Company analyzed whether it results in a contract with a customer under Accounting Standards Codification ("ASC") Topic 606.Â The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the Company is a principal vs. agent, whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, sales-based royalty payments have been identified as variable consideration which must be evaluated to determine if it has been constrained and, therefore, excluded from the transaction price. Please refer to â€œNote 6. Collaborative Research, Development, and License Agreementsâ€ for further information.Product revenue, net The Companyâ€™s product-based division, Mosaic, produces high-quality cell-based products for use in Organovoâ€™s R&D and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Companyâ€™s product, typically upon delivery. Product revenues are recorded at the transaction price under Topic 606. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.In December 2023, the FASB issued Accounting Standards Update (â€œASUâ€) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Companyâ€™s Consolidated Financial Statements.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (â€œCODMâ€) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segmentâ€™s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this guidance. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 17 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Measurement 6 Months Ended Sep. 30, 2024 Investments, All Other Investments [Abstract] Â Investments and Fair Value Measurement Note 3. Investments and Fair Value MeasurementÂ Investments in debt securitiesAs of September 30, 2024, the Company held $1.0 million of investments in debt securities (which are included in the $3.2 million of cash and cash equivalents). For the six months ended September 30, 2024, there was less than $0.1 million of interest income related to the investments in debt securities. As the investments in debt securities consist of U.S. Treasury bills from active markets, the fair value is measured using level 1 inputs. The following table summarizes the Company's investments in debt securities that are measured at fair value as of September 30, 2024 and March 31, 2024, respectively (in thousands):Â Â Â Amortized costs basis Â Â Gross unrealized gains Â Â Gross unrealized losses Â Â Fair value Â As of September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Investment in debt securities Â $ 994 Â Â $ 1 Â Â $ â€” Â Â $ 995 Â As of March 31, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Investment in debt securities Â $ 997 Â Â $ 1 Â Â $ â€” Â Â $ 998 Â X - DefinitionThe entire disclosure for investment. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 321 -Publisher FASB -URI https://asc.fasb.org/321/tableOfContentReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 325 -Publisher FASB -URI https://asc.fasb.org/325/tableOfContent + Details Name: us-gaap_InvestmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsAllOtherInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses 6 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Accrued Expenses Note 4. Accrued ExpensesAccrued expenses consisted of the following (in thousands):Â Â Â September 30,2024 Â Â March 31,2024 Â Accrued compensation Â $ 356 Â Â $ 536 Â Accrued legal and professional fees Â Â 462 Â Â Â 93 Â Other accrued expenses Â Â 61 Â Â Â 98 Â Â Â $ 879 Â Â $ 727 Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 6 Months Ended Sep. 30, 2024 Equity [Abstract] Â Stockholders' Equity Note 5. Stockholdersâ€™ Equity Preferred Stock The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no current plans to issue shares of preferred stock. Common StockIn March 2021, the Company's Board of Directors ("Board") approved the 2021 Inducement Equity Incentive Plan ("Inducement Plan"). The Inducement Plan authorized the issuance of up to 750,000 shares of common stock for awards of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, RSUs, performance units, performance shares, and other stock or cash awards. The only persons eligible to receive grants under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance. The Company also committed to reducing the aggregate number of shares of its common stock issuable pursuant to the Inducement Plan from 750,000 shares to 51,000 shares (which includes 50,000 shares of its common stock issuable pursuant to an outstanding option to purchase common stock with an exercise price of $2.75 per share, leaving only 1,000 shares available for future issuance under the Inducement Plan) and the share reserve was reduced accordingly effective October 12, 2022. As of September 30, 2024, there were 1,000 shares available for future grant under the Inducement Plan. On October 12, 2022, the Company's stockholders and the Board approved the 2022 Equity Incentive Plan ("2022 Plan"), and it became effective on that date. The 2022 Plan replaced the Amended and Restated 2012 Equity Incentive Plan ("2012 Plan") on the effective date. Upon the effective date, the Company ceased granting awards under the 2012 Plan and any shares remaining available for future issuance under the 2012 Plan were cancelled and are no longer available for future issuance. The 2012 Plan continues to govern awards previously granted under it. At the time the Board approved the 2022 Plan, an aggregate of 1,363,000 shares of the Companyâ€™s common stock was initially reserved for issuance under the 2022 Plan. The Company committed to reducing the 2022 Plan share reserve by the number of shares that were granted under the 2012 Plan and the Inducement Plan between July 25, 2022 and October 12, 2022. From July 25, 2022 to October 12, 2022, the Company issued 126,262 shares of its common stock under the 2012 Plan. As a result, the number of shares initially reserved for future issuance under the 2022 Plan was 1,236,738 shares of common stock. The Company previously had an effective shelf registration statement on Form S-3 (File No. 333-252224), declared effective by the SEC on January 29, 2021 (the â€œ2021 Shelfâ€), which registered $150.0 million of common stock, preferred stock, warrants and units, or any combination of the foregoing, that expired on January 29, 2024. On January 26, 2024, the Company filed a new shelf registration statement on Form S-3 (File No. 333-276722) to register $150.0 million of the Company's common stock, preferred stock, debt securities, warrants and units, or any combination of the foregoing (the "2024 Shelf"). The 2024 Shelf was declared effective by the SEC on February 8, 2024 and replaced the 2021 Shelf at that time.On March 16, 2018, the Company entered into a Sales Agreement (â€œSales Agreementâ€) with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC (each an â€œAgentâ€ and together, the â€œAgentsâ€). On January 29, 2021, the Company filed a prospectus supplement to the 2021 Shelf (the â€œ2021 ATM Prospectus Supplementâ€), pursuant to which the Company may offer and sell, from time to time through the Agents, shares of its common stock in ATM sales transactions having an aggregate offering price of up to $50.0 million. Any shares offered and sold were issued pursuant to the 2021 Shelf until it was replaced by the 2024 Shelf.On January 26, 2024, the Company filed a prospectus to the 2024 Shelf (the "2024 ATM Prospectus"), pursuant to which the Company may offer and sell, from time to time through the Agents, share of its common stock in ATM sales transactions having an aggregate offering price of up to $2,605,728. Any shares offered and sold in these ATM transactions will be issued pursuant to the 2024 Shelf.During the three and six months ended September 30, 2024, the Company issued zero and 1,352,600 shares of common stock in ATM offerings, respectively, for net proceeds of approximately $1.7 million, all of which were sold pursuant to the 2024 Shelf. As of September 30, 2024, the Company has sold an aggregate of 1,389,002 shares of common stock in ATM offerings under the 2024 ATM Prospectus, with gross proceeds of approximately $1.8 million and net proceeds of approximately $1.8 million. As of September 30, 2024, there was approximately $100.0 million available for future offerings under the 2024 Shelf, and approximately $0.8 million available for future offerings through the Companyâ€™s ATM program under the 2024 ATM Prospectus.May 2024 Best Efforts Public OfferingOn May 8, 2024, the Company priced a best efforts public offering (the â€œOfferingâ€) of: (i) 1,562,500 shares of its common stock and accompanying common warrants (â€œCommon Warrantsâ€) to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) pre-funded warrants (â€œPre-Funded Warrantsâ€) to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. In connection with the Offering, the Company entered into Securities Purchase Agreements with the purchasers of the securities in the Offering on May 8, 2024.The per share exercise price for the Pre-Funded Warrants is $0.001, subject to adjustment as provided therein. The Pre-Funded Warrants were immediately exercisable, subject to certain beneficial ownership limitations, and will expire when exercised in full. The holders may exercise the Pre-Funded Warrants by means of a â€œcashless exercise.â€ The per share exercise price for the Common Warrants is $0.80, subject to adjustment as provided therein. The Common Warrants were immediately exercisable, subject to certain beneficial ownership limitations, and will expire on the date that is five years following the original issuance date. If a registration statement covering the issuance of the shares of common stock issuable upon exercise of the Common Warrants is not available for the issuance, then the holders may exercise the Common Warrants by means of a â€œcashless exercise.â€ In connection with the Offering, the Company paid JonesTrading Institutional Services LLC, which acted as the placement agent in connection with the Offering, a cash fee of 5.0% of the aggregate gross proceeds raised in the Offering. The closing of the Offering occurred on May 13, 2024. The Company received net proceeds of approximately $4.5 million from the Offering, after deducting the offering expenses payable by the Company, including the Placement Agent fees. Restricted Stock UnitsThe following table summarizes the Companyâ€™s RSUs activity for the six months ended September 30, 2024:Â Â Â Number ofShares Â Â WeightedAverage Price Â Unvested at March 31, 2024 Â Â 122,642 Â Â $ 1.75 Â Granted Â Â 117,642 Â Â $ 0.55 Â Vested Â Â (2,500) Â $ 10.27 Â Cancelled / forfeited Â Â â€” Â Â $ â€” Â Unvested at September 30, 2024 Â Â 237,784 Â Â $ 1.07 Â Â Stock Options During the six months ended September 30, 2024, under the 2022 Plan, 1,150,343 stock options were granted at various exercise prices.On August 5, 2024, the Company granted 1,006,116 stock options to its Executive Chairman under the 2022 Plan. Of the stock options granted, 574,923 will vest evenly on an annual basis over three years. 143,731 of the options granted have unique vesting criteria based on market conditions, more specifically the Company's stock price. As these market condition based stock options require significant estimates and assumptions to calculate their fair value, the Company engaged with valuation specialists to calculate the fair value and requisite service periods using Monte Carlo simulations. The stock options will be expensed over their determined requisite service periods. The remaining 287,462 options granted have unique vesting criteria based on specific Company performance conditions. The vesting criteria for 143,731 of these options includes the Company achieving cumulative revenue of $1.5 million. The vesting criteria for the remaining 143,731 options includes the Company entering into a definitive agreement that constitutes a major strategic partnership, at the discretion of the Board. The following table summarizes the Companyâ€™s stock option activity from March 31, 2024 to September 30, 2024:Â Â Â OptionsOutstanding Â Â WeightedAverageExercise Price Â Â AggregateIntrinsicValue Â Outstanding at March 31, 2024 Â Â 698,007 Â Â $ 4.26 Â Â $ â€” Â Options granted Â Â 1,150,343 Â Â $ 0.59 Â Â $ â€” Â Options cancelled / forfeited Â Â (6,912) Â $ 3.30 Â Â $ â€” Â Options expired Â Â (6,072) Â $ 5.14 Â Â $ â€” Â Outstanding at September 30, 2024 Â Â 1,835,366 Â Â $ 1.96 Â Â $ â€” Â Vested and Exercisable at September 30, 2024 Â Â 478,301 Â Â $ 5.08 Â Â $ â€” Â Â The weighted average remaining contractual term of stock options exercisable and outstanding at September 30, 2024 was approximately 8.93 years. WarrantsIn connection with the Offering described above, the Company issued Common Warrants to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) Pre-Funded Warrants to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. The Company has determined that these warrants should be classified as equity instruments since they do not require the Company to repurchase the underlying common stock and do not require the Company to issue a variable amount of common stock. In addition, these warrants are indexed to common stock and do not have any antidilution rights. The following table summarizes the Companyâ€™s Common Warrant activity from March 31, 2024 to September 30, 2024:Â Â Number ofWarrants Â Â ExercisePrice Â Outstanding at March 31, 2024 Â Â â€” Â Â $ â€” Â Issued Â Â 6,562,500 Â Â $ 0.80 Â Exercised Â Â â€” Â Â $ 0.80 Â Outstanding at September 30, 2024 Â Â 6,562,500 Â Â $ 0.80 Â Â The following table summarizes the Companyâ€™s Pre-Funded Warrants activity from March 31, 2024 to September 30, 2024:Â Â Â Number ofWarrants Â Â ExercisePrice Â Outstanding at March 31, 2024 Â Â â€” Â Â $ â€” Â Issued Â Â 5,000,000 Â Â $ 0.001 Â Exercised Â Â (2,370,000) Â $ 0.001 Â Outstanding at September 30, 2024 Â Â 2,630,000 Â Â $ 0.001 Â Employee Stock Purchase PlanIn July 2023, the Board adopted, and on October 31, 2023, the Company's stockholders subsequently approved, the 2023 Employee Stock Purchase Plan (the "2023 ESPP"). The 2023 ESPP became effective on October 31, 2023. The Company reserved 45,000 shares of common stock for issuance thereunder. The 2023 ESPP permits employees to purchase common stock through payroll deductions, limited to 15 percent of each employeeâ€™s compensation up to $25,000 per employee per year or 500 shares per employee per six-month purchase period. Shares under the 2023 ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering under the 2023 ESPP commenced on March 1, 2024. During the six months ended September 30, 2024, 500 shares were issued under the 2023 ESPP. At September 30, 2024, there were 44,500 shares remaining available for purchase under the 2023 ESPP.Common Stock Reserved for Future Issuance Common stock reserved for future issuance consisted of the following at September 30, 2024: Â Common stock issuable pursuant to options outstanding and reserved under the 2012 Plan Â Â 423,488 Â Common stock reserved under the 2012 Plan Â Â â€” Â Common stock issuable pursuant to options outstanding and reserved under the 2022 Plan Â Â 1,361,878 Â Common stock reserved under the 2022 Plan Â Â 452,038 Â Common stock reserved under the 2023 ESPP Â Â 44,500 Â Common stock reserved under the 2021 Inducement Equity Plan Â Â 1,000 Â Common stock issuable pursuant to restricted stock units outstanding under the 2012 Plan Â Â 2,500 Â Common stock issuable pursuant to restricted stock units outstanding under the 2022 Plan Â Â 235,284 Â Common stock issuable pursuant to options outstanding and reserved under the Inducement Plan Â Â 50,000 Â Common stock issuable pursuant to outstanding pre-funded warrants Â Â 2,630,000 Â Common stock issuable pursuant to outstanding common warrants Â Â 6,562,500 Â Total at September 30, 2024 Â Â 11,763,188 Â Â Stock-based Compensation Expense and Valuation InformationStock-based awards include stock options and RSUs under the 2022 Plan, 2012 Plan, Inducement Plan, and rights to purchase stock under the 2023 ESPP. The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense. Stock-based compensation expense for all stock-based awards consists of the following (in thousands):Â Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Research and development Â $ 25 Â Â $ (60) Â $ 51 Â Â $ 47 Â General and administrative Â Â 130 Â Â Â 735 Â Â Â 260 Â Â Â 1,103 Â Total Â $ 155 Â Â $ 675 Â Â $ 311 Â Â $ 1,150 Â Â The total unrecognized compensation cost related to unvested stock option grants as of September 30, 2024 was approximately $0.8 million and the weighted average period over which these grants are expected to vest is 2.74 years.The total unrecognized compensation cost related to unvested RSUs as of September 30, 2024 was $0.1 million, which will be recognized over a weighted average period of 0.6 years.Â The Company uses either the Black-Scholes or Monte Carlo option-pricing models to calculate the fair value of stock options, depending on the complexity of the equity grants. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The assumed dividend yield is based on the Companyâ€™s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption is based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. The measurement and classification of share-based payments to non-employees is consistent with the measurement and classification of share-based payments to employees. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:Â Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023* Â Â September 30, 2024 Â Â September 30, 2023 Â Dividend yield Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Volatility Â Â 99.00 % Â Â 0.00 % Â Â 99.37 % Â Â 98.51 % Risk-free interest rate Â Â 3.64 % Â Â 0.00 % Â Â 3.75 % Â Â 3.95 % Expected life of options Â 6Â years Â Â 0 Â Â 6Â years Â Â 6Â years Â Weighted average grantÂ Â Â date fair value Â $ 0.43 Â Â $ â€” Â Â $ 0.47 Â Â $ 1.45 Â *There were no stock options granted during the three months ended September 30, 2023.The fair value of each RSU is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant.The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the 2023 ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:Â Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023* Â Â September 30, 2024 Â Â September 30, 2023* Â Dividend yield Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Volatility Â Â 95.20 % Â Â 0.00 % Â Â 95.20 % Â Â 0.00 % Risk-free interest rate Â Â 5.27 % Â Â 0.00 % Â Â 5.27 % Â Â 0.00 % Expected term Â 6Â months Â Â Â â€” Â Â 6Â months Â Â Â â€” Â Grant date fair value Â $ 0.39 Â Â $ â€” Â Â $ 0.39 Â Â $ â€” Â *There were no participants in the ESPP for the purchase periods that commenced on March 1, 2023 September 1, 2023.The assumed dividend yield is based on the Companyâ€™s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption is based on U.S. Treasury rates. The expected life is the 6-month purchase period. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix:

us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Collaborative Research, Development, and License Agreements 6 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Collaborative Research, Development, and License Agreements Note 6. Collaborative Research, Development, and License Agreements License AgreementsBICO Group ABFrom June 2021 to February 2022, certain patents owned or sublicensed by the Company became the subject of inter partes review proceedings filed by Cellink AB and its subsidiaries (collectively, â€œBICO Group ABâ€). The Company and BICO Group AB were also engaged in litigation regarding patent infringement during the same time period. On February 22, 2022, the Company and BICO Group AB signed a settlement and patent license agreement (â€œLicense Agreementâ€) to close all matters noted above. In addition to closing all legal matters and patent disputes noted above, as part of the agreement, the Company agreed to grant a non-exclusive license to BICO Group AB to use the Companyâ€™s aforementioned patents for its business operations of manufacturing and selling bioprinters as well as bioinks. The Company concluded that the nature of the license granted represents functional intellectual property. As part of the License Agreement, BICO Group AB agreed to pay the Company ongoing sales-based royalties (based on percentages of BICO Group ABâ€™s net sales) for the use of the granted license. The sales-based royalties became effective beginning on February 22, 2022, the effective date of the License Agreement, and continue until the expiration of the last surviving licensed patent. As the sales-based royalties are required to be paid 45 days after the end of every quarter, there is variable consideration that must be estimated to determine royalty revenue within a given reporting period. Once actual revenue earned is determined in the following fiscal quarter, an adjustment is made from the previously estimated amount. For the three and six months ended September 30, 2024, the Company recorded $29,000 and $60,000 of royalty revenue, respectively, based on sales-based royalties from the License Agreement. Royalty revenue presented on the statements of operations and other comprehensive loss is $28,000 and $53,000 for the three and six months ended September 30, 2024, respectively, due to adjustments related to prior quarters. Also as part of the License Agreement, certain patents involved in the agreement are sublicensed by the Company from the University of Missouri and Clemson University. See below for further information. University of MissouriIn March 2009, the Company entered into a license agreement with the Curators of the University of Missouri ("University of Missouri") to in-license certain technology and intellectual property relating to self-assembling cell aggregates and intermediate cellular units. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. The Company is required to pay the University of Missouri royalties ranging from 1% to 3% of net sales of covered tissue products, and of the fair market value of covered tissues transferred internally for use in the Companyâ€™s commercial service business, depending on the level of net sales achieved by the Company each year. On December 5, 2022, the Company amended the license agreement with the University of Missouri, whereby the Company agreed to pay a single, up-front payment of $50,000 to the University of Missouri in exchange for the aforementioned licensed intellectual property to be fully paid up by the Company. As a result, the Company will continue to have rights to the licensed intellectual property until its expiration, but will no longer owe minimum annual royalty payments, royalty payments based on net sales, or any other payments (other than patent annuities and any prosecution costs) in the future.Clemson UniversityIn May 2011, the Company entered into a license agreement with Clemson University Research Foundation ("CURF") to in-license certain technology and intellectual property relating to ink-jet printing of viable cells. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. Under the agreement, the Company was required to pay CURF royalties ranging from 1.5% to 3% of net sales of covered tissue products and the fair market value of covered tissues transferred internally for use in the Companyâ€™s commercial service business, depending on the level of net sales reached each year. The license agreement was to terminate upon expiration of the patents licensed, which expired in May 2024, and was subject to certain conditions as defined in the license agreement. Minimum annual royalty payments of $20,000 were due for two years beginning in calendar 2014, and $40,000 per year beginning in calendar 2016. Royalty payments of $40,000 were made in each of the years ended March 31, 2024 and 2023. The annual minimum royalty was to be creditable against royalties owed during the same calendar year. As the licensed patents expired in May 2024, there will be no further royalty payments owed. Â In addition to the annual royalties noted above, CURF would have been owed 40% of all payments including but not limited to, upfront payments, license fees, issue fees, maintenance fees, and milestone payments received from third parties, including sublicensees, in consideration for sublicensing rights to licensed products. However, per the agreement, in the event that the Company defends the technology by litigation, it can offset any royalties due by legal expenses incurred. As of September 30, 2024, the Companyâ€™s legal expenses exceeded royalties owed from the upfront payment and sales-based royalties related to the license agreement. Therefore, no royalty expense to CURF was recorded for the three and six months ended September 30, 2024 and 2023, respectively. No royalty expense related to sales-based royalties has been recorded to date. X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 6 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Note 7. Commitments and Contingencies Legal Matters In addition to commitments and obligations in the ordinary course of business, the Company may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of its business. On August 27, 2024, H.C. Wainwright & Co., LLC (â€œH.C. Wainwrightâ€) filed a complaint against the Company in the State of New York alleging that the Company breached a tail financing provision included in an engagement agreement the Company entered into with H.C. Wainwright in May 2023. In its complaint, H.C. Wainwright is seeking compensatory and consequential damages and attorneysâ€™ fees. On October 18, 2024, the Company filed an answer to the complaint. The Company is defending these claims vigorously, but there is no guarantee that it will be successful in these efforts.The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability.The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures and monitors each related legal issue and adjusts accruals as might be warranted based on new information and further developments. During the three months ended September 30, 2024, the Company recorded an accrual of $0.6 million (which was considered a financing fee related to the Offering discussed in Note 5. Stockholders' Equity) for the loss contingencies associated with the above described H.C. Wainwright complaint as it determined that an unfavorable outcome is probable or reasonably possible and believed that the amount or range of any possible loss was reasonably estimable. However, amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments, and the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. If one or more legal matters were resolved against the Company in a reporting period, the Companyâ€™s consolidated financial statements for that reporting period could be materially adversely affected. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 6 Months Ended Sep. 30, 2024 Leases [Abstract] Â Leases Note 8. LeasesAfter the initial adoption of ASC Topic 842 (â€œASC 842â€), on an on-going basis, the Company evaluates all contracts upon inception and determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If a lease is identified, the Company will apply the guidance from ASC 842 to properly account for the lease.Operating LeasesOn November 23, 2020, the Company entered into a lease agreement, pursuant to which the Company permanently leased approximately 8,051 square feet of lab and office space (the â€œPermanent Leaseâ€) in San Diego once certain tenant improvements were completed by the landlord and the premises were ready for occupancy. Additionally, on November 17, 2021, the Permanent Lease was amended to add an additional 2,892 square feet of office space in the same building. The Permanent Lease commenced on December 17, 2021 and is intended to serve as the Companyâ€™s permanent premises for approximately sixty-two months. Monthly rental payments will be approximately $40,800 with 3% annual escalators. The Company determined that the Permanent Lease is considered an operating lease under ASC 842, and therefore upon the lease commencement date of December 17, 2021, recognized lease liabilities and corresponding right-of-use assets of $2.3 million. The Company records operating lease expense on a straight-line basis over the life of the lease (referred to as â€œoperating lease expenseâ€). Variable lease expenses associated with the Companyâ€™s leases, such as payments for additional monthly fees to cover the Companyâ€™s share of certain facility expenses (common area maintenance) are expensed as incurred. The table below summarizes the Companyâ€™s lease liabilities and corresponding right-of-use assets as of September 30, 2024 (in thousands except the year and percentage):Â Â Â September 30, 2024 Â ASSETS Â Â Â Operating lease right-of-use assets Â $ 1,086 Â Total lease right-of-use assets Â $ 1,086 Â Â Â Â Â Â LIABILITIES Â Â Â Current Â Â Â Operating lease liability Â $ 513 Â Noncurrent Â Â Â Operating lease liability, net of current portion Â $ 660 Â Total lease liabilities Â $ 1,173 Â Â Â Â Â Â Weighted average remaining lease term: Â 2.33Â years Â Weighted average discount rate: Â Â 6 % Â Variable lease expense was approximately $22,000 and $23,000 for the three and six months ended September 30, 2024, respectively, and approximately $39,000 and $75,000 for the three and six months ended September 30, 2023, respectively. Operating lease expense was approximately $126,000 and $252,000 for the three and six months ended September 30, 2024, respectively, and approximately $126,000 and $252,000 for the three and six months ended September 30, 2023, respectively.Cash flows associated with the Companyâ€™s operating lease for the three and six months ended September 30, 2024, were approximately $130,000 and $260,000, respectively, and approximately $126,000 and $252,000 for the three and six months ended September 30, 2023, respectively. Future lease payments relating to the Companyâ€™s operating lease liabilities as of September 30, 2024, are as follows (in thousands):Â Fiscal year ending March 31, 2025 Â $ 263 Â Fiscal year ending March 31, 2026 Â Â 538 Â Fiscal year ending March 31, 2027 Â Â 460 Â Total future lease payments Â Â 1,261 Â Less: Imputed interest Â Â (88) Total lease obligations Â Â 1,173 Â Less: Current obligations Â Â (513) Noncurrent lease obligations Â $ 660 Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Concentrations 6 Months Ended Sep. 30, 2024 Risks and Uncertainties [Abstract] Â Concentrations Note 9. Concentrations Credit risk and significant customersFinancial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. However, the Company only receives royalty revenue from one licensee and has not historically experienced any accounts receivable write-downs. X - DefinitionThe entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details Name: us-gaap_ConcentrationRiskDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RisksAndUncertaintiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Related Parties 6 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Related Parties Note 10. Related PartiesFrom time to time, the Company will enter into an agreement with a related party in the ordinary course of its business. These agreements are ratified by the Board or a committee thereof pursuant to its

related party transaction policy. Viscient Biosciences (â€œViscientâ€) is an entity for which Keith Murphy, the Companyâ€™s Executive Chairman, serves as the Chief Executive Officer and President. On December 28, 2020, the Company entered into an intercompany agreement (the â€œIntercompany Agreementâ€) with Viscient and Organovo, Inc., the Companyâ€™s wholly-owned subsidiary, which included an asset purchase agreement for certain lab equipment. Pursuant to the Intercompany Agreement, the Company agreed to provide Viscient certain services related to 3D bioprinting technology, which include, but are not limited to, histology services, cell isolation, and proliferation of cells and Viscient agreed to provide the Company certain services related to 3D bioprinting technology, including bioprinter training, bioprinting services, and qPCR assays, in each case on payment terms specified in the Intercompany Agreement and as may be further determined by the parties. In addition, the Company and Viscient each agreed to share certain facilities and equipment and, subject to further agreement, to each make certain employees available for specified projects for the other party at prices to be determined in good faith by the parties. During the second quarter of fiscal 2025, the companies added a Statement of Work ("SOW") to the Intercompany Agreement, where Viscient agreed to provide the Company with certain testing services related to the Company's ongoing R&D. The Company evaluated the accounting for the Intercompany Agreement and concluded that any services provided by Viscient to the Company will be expensed as incurred, and any compensation for services provided by the Company to Viscient will be considered a reduction of personnel related expenses. Any services provided to Viscient do not fall under Topic 606 as the Intercompany Agreement is not a contract with a customer. For the three months and six months ended September 30, 2024, the Company incurred $70,000 of toxicity testing services from Viscient. The Company incurred zero expenses from Viscient for the three and six months ended September 30, 2023. Additionally, for the three months and six months ended September 30, 2024, the Company provided approximately $4,000 of histology services to Viscient, and approximately less than $1,000 and $10,000 of histology services to Viscient for the three and six months ended September 30, 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Business Segment Information 6 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Business Segment Information Note 11. Business Segment InformationOperating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing performance. The Company's operating segments were identified in fiscal 2024 and did not impact prior periods. The Company's operating segments are as follows: Research & DevelopmentThe research and development (â€œR&Dâ€) segment consists of the Company's drug development efforts. The Company's current clinical focus is in advancing FXR314 in IBD, including UC and CD. The Company plans to start a Phase 2a clinical trial in UC in the calendar year 2025. The Company released Phase 2 data for FXR314 for the treatment of MASH in April 2024 that are supportive of ongoing development, and believes FXR314 has a commercial opportunity in MASH, most likely in combination therapy. The Company is exploring the potential for combination therapies using FXR314 and currently approved mechanisms in preclinical animal studies and its IBD disease models.The Company's second focus is building high fidelity, 3D tissues that recapitulate key aspects of human disease. The Company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. The Company believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas.As with the clinical development program, the Company is initially focusing on the intestine and has ongoing 3D tissue development efforts in human tissue models of UC and CD. The Company uses these models to identify new molecular targets responsible for driving the disease and to explore the mechanism of action of known drugs including FXR314 and related molecules. The Company intends to initiate drug discovery programs around these new validated targets to identify drug candidates for partnering and/or internal clinical development.Mosaic Cell SciencesThe Mosaic Cell Sciences segment, which began operations in February 2024, consists of our Mosaic Cell Sciences division (â€œMosaicâ€), which will serve as a key source of certain of the primary human cells that the Company utilizes in its research and development efforts. The Company believes Mosaic can help optimize its supply chain, reduce operating expenses related to cell sourcing and procurement, and ensure that the cellular raw materials it uses are of the highest quality and are derived from tissues that are ethically sourced in full compliance with state and federal guidelines. Mosaic provides the Company with qualified human cells for use in its clinical research and development programs. In addition to supplying the Company with primary human cells, Mosaic offers human cells for sale to life science customers, both directly and through distribution partners, which the Company expects to offset costs and over time become a profit center that offsets overall R&D spending by the Company.Business Segment InformationThe Company's R&D segment generates royalty revenue related to its IP. The Company's Mosaic segment generates product revenue as part of its core operations. Segment revenues consisted of the following (in thousands):Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Â R&D Â Â Â Â Â Â Â Â Â Â Â Â Royalty revenue $ 28 Â Â $ â€” Â Â $ 53 Â Â $ 75 Â Â Mosaic Â Â Â Â Â Â Â Â Â Â Â Â Product revenue Â 2 Â Â Â â€” Â Â Â 16 Â Â Â â€” Â Â Total segment revenue $ 30 Â Â $ â€” Â Â $ 69 Â Â $ 75 Â Â Total Company revenue $ 30 Â Â $ â€” Â Â $ 69 Â Â $ 75 Â Â Operating segment costs and expenses consisted of the following (in thousands):Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Â R&D Â Research and development expenses $ 934 Â Â $ 1,335 Â Â $ 2,110 Â Â $ 3,001 Â Â Mosaic Â Cost of revenues Â 1 Â Â Â â€” Â Â Â 3 Â Â Â â€” Â Â Â Â Â Â Research and development expenses Â 50 Â Â Â â€” Â Â Â 276 Â Â Â Â â€” Â Â Â Â Â Â Â Selling, general, and administrative expenses Â 68 Â Â Â â€” Â Â Â 135 Â Â Â â€” Â Â Total segment costs and expenses $ 1,053 Â Â $ 1,335 Â Â $ 2,524 Â Â $ 3,001 Â Â Other selling, general, and administrative expenses Â 1,585 Â Â Â 2,780 Â Â Â 3,539 Â Â Â 5,384 Â Â Total Company costs and expenses $ 2,638 Â Â $ 4,115 Â Â $ 6,063 Â Â $ 8,385 Â Â Â The R&D segment's identifiable assets are its fixed assets. The Mosaic segment's identifiable assets are its fixed assets and inventory. Other Company assets are comprised of all other assets that are not distinctly identifiable to a segment. Operating segment assets consisted of the following (in thousands):Â Â September 30, 2024 Â Â March 31, 2024 Â Â R&D Â Â Â Â Â Fixed assets, net $ 343 Â Â $ 423 Â Mosaic Â Â Â Â Â Fixed assets, net Â 161 Â Â Â 183 Â Inventory Â 640 Â Â Â 297 Â Total segment assets $ 1,144 Â Â $ 903 Â Other Company assets Â 5,610 Â Â Â 5,446 Â Total Company assets $ 6,754 Â Â $ 6,349 Â X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 6 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation and Principles of Consolidation Basis of Presentation and Principles of ConsolidationThe accompanying

unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2024 is derived from the Companyâ€™s audited consolidated balance sheet as filed with the SEC on May 31, 2024. The unaudited condensed consolidated financial statements include the accounts of Organovo and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Companyâ€™s financial position, results of operations, stockholdersâ€™ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Companyâ€™s Annual Report on Form 10-K for the year ended March 31, 2024, as filed with the Securities and Exchange Commission (â€œSECâ€). Operating results for any interim period are not necessarily indicative of the operating results for any other interim period or the Companyâ€™s full fiscal year ending March 31, 2025 (see â€œNote 1. Description of Businessâ€). Liquidity and Going Concern Liquidity and Going ConcernThe accompanying consolidated financial statements have been prepared on the basis that we are a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of September 30, 2024, the Company had cash and cash equivalents of approximately $3.2 million, restricted cash of approximately $0.1 million and an accumulated deficit of approximately $345.6 million. The restricted cash was pledged as collateral for a letter of credit that the Company is required to maintain as a security deposit under the terms of the lease agreement for its facilities. The Company also had negative cash flows from operations of approximately $5.6 million during the six months ended September 30, 2024. Through September 30, 2024, the Company has financed its operations primarily through the sale of common stock through public and at-the-market (â€œATMâ€) offerings, the private placement of equity securities, from revenue derived from the licensing of intellectual property, products and research service-based services, grants, and collaborative research agreements, and from the sale of convertible notes. During the six months ended September 30, 2024, the Company issued 1,352,600 shares of its common stock through its ATM facility, for net proceeds of approximately $1.7 million. Additionally, on May 8, 2024, the Company priced a best efforts public offering (the â€œOfferingâ€) of: (i) 1,562,500 shares of its common stock and accompanying common warrants (â€œCommon Warrantsâ€) to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) pre-funded warrants (â€œPre-Funded Warrantsâ€) to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. The closing of the Offering occurred on May 13, 2024. The Company received net proceeds of approximately $4.5 million from the Offering, after deducting the estimated offering expenses payable by the Company, including the Placement Agent fees. On July 18, 2024, the Company received a written notice (the â€œNoticeâ€) from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (â€œNasdaqâ€) indicating that, based upon the closing bid price of the Companyâ€™s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (â€œRule 5550(a)(2)â€). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until January 14, 2025, to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of the Companyâ€™s common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. The Notice provides that the Nasdaq staff will provide written confirmation to the Company if the Company regains compliance with Rule 5550(a)(2). If the Company does not regain compliance with Rule 5550(a)(2) by January 14, 2025, the Company may be eligible for an additional compliance period of 180 calendar days. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice to Nasdaq of its intention to cure the bid price deficiency during the second compliance period. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities will be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq staffâ€™s determination to delist its securities, but there can be no assurance the Nasdaq staff would grant any request for continued listing.Based on the Company's current operating plan and available cash resources, it will need substantial additional funding to support future operating activities. The Company has concluded that the prevailing conditions and ongoing liquidity risks faced by it raise substantial doubt about its ability to continue as a going concern for at least one year following the date these financial statements are issued. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. As the Company continues its operations and is focusing its efforts on drug discovery and development, the Company will need to raise additional capital to implement this business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. The Company will seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Companyâ€™s business, operating results, and financial condition. Use of Estimates Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. On an ongoing basis, management reviews these estimates and assumptions. Investments Investments Investments in debt securities consist of investments in U.S. Treasury bills. All investments that have original maturities of three months or less are classified as cash equivalents on the condensed consolidated balance sheets. As of September 30, 2024 and March 31, 2024, all investments are classified as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies. Available-for-sale debt securities are recorded at fair value. Any unrealized gains and losses are included in accumulated other comprehensive income as a component of stockholders' equity until realized. As U.S. Treasury bills have minimal risk, any declines in fair value are considered temporary. Fair value measurement Fair value measurement Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: â€¢Level 1 â€” Quoted prices in active markets for identical assets or liabilities. â€¢Level 2 â€” Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. â€¢Level 3 â€” Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Inventory InventoryInventories are stated at the lower of cost or net realizable value. Inventory as of September 30, 2024 and March 31, 2024 consisted of approximately $0.6 million, net of reserve, and $0.3 million in finished goods, respectively, which is related to Mosaic. An inventory reserve of approximately $0.2 million was established during the three months ended September 30, 2024 to write-down inventory to its new cost basis. Please refer to "Note 11. Business Segment Information" for further information regarding Mosaic's inventory. Insurance Premium Financing Liability Insurance Premium Financing LiabilityIn September 2024, the Company entered into an insurance premium financing agreement for $0.4 million, with a term of nine months and an annual interest rate of 8.57%. The Company made a down payment of 10% and is required to make monthly principal and interest payments of $44,281 over the term of the agreement, which matures in June 2025. Related prepaid insurance at September 30, 2024 of $0.4 million is included in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets. Net Loss Per Share Net Loss Per Share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options, shares reserved for purchase under the Companyâ€™s 2023 Employee Stock Purchase Plan (â€œ2023 ESPPâ€), the assumed vesting of restricted stock units (â€œRSUsâ€), the exercise of warrants, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the six months ended September 30, 2024 and 2023 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive.Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 11.3 million at September 30, 2024 and 1.0 million at September 30, 2023. Revenue recognition Revenue recognitionRoyalty revenue The Company has entered into an intellectual property license agreement with another company that includes royalties based on specified percentages of net product sales, if any. At the initiation of the agreement, the Company analyzed whether it results in a contract with a customer under Accounting Standards Codification ("ASC") Topic 606.Â The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the Company is a principal vs. agent, whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, sales-based royalty payments have been identified as variable consideration which must be evaluated to determine if it has been constrained and, therefore, excluded from the transaction price. Please refer to â€œNote 6. Collaborative Research, Development, and License Agreementsâ€ for further information.Product revenue, net The Companyâ€™s product-based division, Mosaic, produces high-quality cell-based products for use in Organovoâ€™s R&D and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Companyâ€™s product, typically upon delivery. Product revenues are recorded at the transaction price under Topic 606. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. Recent Accounting Pronouncements Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.In December 2023, the FASB issued Accounting Standards Update (â€œASUâ€) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Companyâ€™s Consolidated Financial Statements.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (â€œCODMâ€) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segmentâ€™s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this guidance. X - DefinitionBasis of presentation and principles of consolidation. + ReferencesNo definition available. + Details Name: onvo_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock Namespace Prefix: onvo_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionInsurance premium financing liability policy text block. + ReferencesNo definition available. + Details Name: onvo_InsurancePremiumFinancingLiabilityPolicyTextBlock Namespace Prefix: onvo_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLiquidity and going concern. + ReferencesNo definition available. + Details Name: onvo_LiquidityAndGoingConcernPolicyTextBlock Namespace Prefix: onvo_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Measurement (Tables) 6 Months Ended Sep. 30, 2024 Investments, All Other Investments [Abstract] Â Summary of Investments in Debt Securities that are Measured at Fair Value The following table summarizes the Company's investments in debt securities that are measured at fair value as of September 30, 2024 and March 31, 2024, respectively (in thousands):Â Â Â Amortized costs basis Â Â Gross unrealized gains Â Â Gross unrealized losses Â Â Fair value Â As of September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Investment in debt securities Â $ 994 Â Â $ 1 Â Â $ â€” Â Â $ 995 Â As of March 31, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Investment in debt securities Â $ 997 Â Â $ 1 Â Â $ â€” Â Â $ 998 Â X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsAllOtherInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Tables) 6 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Summary of Accrued Expenses Accrued expenses consisted of the following (in thousands):Â Â Â September 30,2024 Â Â March 31,2024 Â Accrued compensation Â $ 356 Â Â $ 536 Â Accrued legal and professional fees Â Â 462 Â Â Â 93 Â Other accrued expenses Â Â 61 Â Â Â 98 Â Â Â $ 879 Â Â $ 727 Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Tables) 6 Months Ended Sep. 30, 2024 Class Of Stock [Line Items] Â Summary of Stock Option Activity The following table summarizes the Companyâ€™s stock option activity from March 31, 2024 to September 30, 2024: Â Â Â OptionsOutstanding Â Â WeightedAverageExercise Price Â Â AggregateIntrinsicValue Â Outstanding at March 31, 2024 Â Â 698,007 Â Â $ 4.26 Â Â $ â€” Â Options granted Â Â 1,150,343 Â Â $ 0.59 Â Â $ â€” Â Options cancelled / forfeited Â Â (6,912) Â $ 3.30 Â Â $ â€” Â Options expired Â Â (6,072) Â $ 5.14 Â Â $ â€” Â Outstanding at September 30, 2024 Â Â 1,835,366 Â Â $ 1.96 Â Â $ â€” Â Vested and Exercisable at September 30, 2024 Â Â 478,301 Â Â $ 5.08 Â Â $ â€” Â Common Stock Reserved for Future Issuance Common stock reserved for future issuance consisted of the following at September 30, 2024: Â Common stock issuable pursuant to options outstanding and reserved under the 2012 Plan Â Â 423,488 Â Common stock reserved under the 2012 Plan Â Â â€” Â Common stock issuable pursuant to options outstanding and reserved under the 2022 Plan Â Â 1,361,878 Â Common stock reserved under the 2022 Plan Â Â 452,038 Â Common stock reserved under the 2023 ESPP Â Â 44,500 Â Common stock reserved under the 2021 Inducement Equity Plan Â Â 1,000 Â Common stock issuable pursuant to restricted stock units outstanding under the 2012 Plan Â Â 2,500 Â Common stock issuable pursuant to restricted stock units outstanding under the 2022 Plan Â Â 235,284 Â Common stock issuable pursuant to options outstanding and reserved under the Inducement Plan Â Â 50,000 Â Common stock issuable pursuant to outstanding pre-funded warrants Â Â 2,630,000 Â Common stock issuable pursuant to outstanding common warrants Â Â 6,562,500 Â Total at September 30, 2024 Â Â 11,763,188 Â Schedule of Stock-based Compensation Expense Stock-based compensation expense for all stock-based awards consists of the following (in thousands):Â Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Research and development Â $ 25 Â Â $ (60) Â $ 51 Â Â $ 47 Â General and administrative Â Â 130 Â Â Â 735 Â Â Â 260 Â Â Â 1,103 Â Total Â $ 155 Â Â $ 675 Â Â $ 311 Â Â $ 1,150 Â Fair Value of Employee Stock Options The fair value of stock options was estimated at the grant date using the following weighted average assumptions: Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023* Â Â September 30, 2024 Â Â September 30, 2023 Â Dividend yield Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Volatility Â Â 99.00 % Â Â 0.00 % Â Â 99.37 % Â Â 98.51 % Risk-free interest rate Â Â 3.64 % Â Â 0.00 % Â Â 3.75 % Â Â 3.95 % Expected life of options Â 6Â years Â Â 0 Â Â 6Â years Â Â 6Â years Â Weighted average grantÂ Â Â date fair value Â $ 0.43 Â Â $ â€” Â Â $ 0.47 Â Â $ 1.45 Â *There were no stock options granted during the three months ended September 30, 2023. Summary of Warrant Activity The following table summarizes the Companyâ€™s Common Warrant activity from March 31, 2024 to September 30, 2024: Â Â Number ofWarrants Â Â ExercisePrice Â Outstanding at March 31, 2024 Â Â â€” Â Â $ â€” Â Issued Â Â 6,562,500 Â Â $ 0.80 Â Exercised Â Â â€” Â Â $ 0.80 Â Outstanding at September 30, 2024 Â Â 6,562,500 Â Â $ 0.80 Â Â The following table summarizes the Companyâ€™s Pre-Funded Warrants activity from March 31, 2024 to September 30, 2024: Â Â Â Number ofWarrants Â Â ExercisePrice Â Outstanding at March 31, 2024 Â Â â€” Â Â $ â€” Â Issued Â Â 5,000,000 Â Â $ 0.001 Â Exercised Â Â (2,370,000) Â $ 0.001 Â Outstanding at September 30, 2024 Â Â 2,630,000 Â Â $ 0.001 Â Restricted stock units (RSUs) [Member] Â Class Of Stock [Line Items] Â Summary of Company's RSUs Activity The following table summarizes the Companyâ€™s RSUs activity for the six months ended September 30, 2024:Â Â Â Number ofShares Â Â WeightedAverage Price Â Unvested at March 31, 2024 Â Â 122,642 Â Â $ 1.75 Â Granted Â Â 117,642 Â Â $ 0.55 Â Vested Â Â (2,500) Â $ 10.27 Â Cancelled / forfeited Â Â â€” Â Â $ â€” Â Unvested at September 30, 2024 Â Â 237,784 Â Â $ 1.07 Â ESPP Shares [Member] Â Class Of Stock [Line Items] Â Fair Value of Employee Stock Options The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:Â Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023* Â Â September 30, 2024 Â Â September 30, 2023* Â Dividend yield Â Â â€” Â Â Â Â â€” Â Â Â

â€” Â Â Â â€” Â Volatility Â Â 95.20 % Â Â 0.00 % Â Â 95.20 % Â Â 0.00 % Risk-free interest rate Â Â 5.27 % Â Â 0.00 % Â Â 5.27 % Â Â 0.00 % Expected term Â 6Â months Â Â Â â€” Â Â 6Â months Â Â Â â€” Â Grant date fair value Â $ 0.39 Â Â $ â€” Â Â $ 0.39 Â Â $ â€” Â *There were no participants in the ESPP for the purchase periods that commenced on March 1, 2023 September 1, 2023. X - DefinitionCommon stock capital shares reserved for future issuance. + ReferencesNo definition available. + Details Name: onvo_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock Namespace Prefix: onvo_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=onvo_ESPPSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 30 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 6 Months Ended Sep. 30, 2024 Leases [Abstract] Â Schedule of Lease Liabilities and Corresponding Right-of-use Assets The table below summarizes the Companyâ€™s lease liabilities and corresponding right-of-use assets as of September 30, 2024 (in thousands except the year and percentage):Â Â Â September 30, 2024 Â ASSETS Â Â Â Operating lease right-of-use assets Â $ 1,086 Â Total lease right-of-use assets Â $ 1,086 Â Â Â Â Â LIABILITIES Â Â Â Current Â Â Â Operating lease liability Â $ 513 Â Noncurrent Â Â Â Operating lease liability, net of current portion Â $ 660 Â Total lease liabilities Â $ 1,173 Â Â Â Â Â Weighted average remaining lease term: Â 2.33Â years Â Weighted average discount rate: Â Â 6 % Schedule of Future Lease Payments Future lease payments relating to the Companyâ€™s operating lease liabilities as of September 30, 2024, are as follows (in thousands):Â Fiscal year ending March 31, 2025 Â $ 263 Â Fiscal year ending March 31, 2026 Â Â 538 Â Fiscal year ending March 31, 2027 Â Â 460 Â Total future lease payments Â Â 1,261 Â Less: Imputed interest Â Â (88) Total lease obligations Â Â 1,173 Â Less: Current obligations Â Â (513) Noncurrent lease obligations Â $ 660 Â X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Business Segment Information (Tables) 6 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Summary of Segment Revenues Segment revenues consisted of the following (in thousands):Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Â R&D Â Â Â Â Â Â Â Â Â Â Â Â Â Â Royalty revenue $ 28 Â Â $ â€” Â Â $ 53 Â Â $ 75 Â Â Mosaic Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenue Â 2 Â Â Â â€” Â Â Â 16 Â Â Â â€” Â Â Total segment revenue $ 30 Â Â $ â€” Â Â $ 69 Â Â $ 75 Â Â Total Company revenue $ 30 Â Â $ â€” Â Â $ 69 Â Â $ 75 Â Â Summary of Operating Segment Costs and Expenses Operating segment costs and expenses consisted of the following (in thousands):Â Â Three Months Ended Â Â Three Months Ended Â Â Six Months Ended Â Â Six Months Ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Â R&D Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development expenses $ 934 Â Â $ 1,335 Â Â $ 2,110 Â Â $ 3,001 Â Â Mosaic Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenues Â 1 Â Â Â â€” Â Â Â 3 Â Â Â â€” Â Â Â Â Â Â Research and development expenses Â 50 Â Â Â â€” Â Â Â 276 Â Â Â â€” Â Â Â Â Â Â Selling, general, and administrative expenses Â 68 Â Â Â â€” Â Â Â 135 Â Â Â â€” Â Â Total segment costs and expenses $ 1,053 Â Â $ 1,335 Â Â $ 2,524 Â Â $ 3,001 Â Â Other selling, general, and administrative expenses Â 1,585 Â Â Â 2,780 Â Â Â 3,539 Â Â Â 5,384 Â Â Total Company costs and expenses $ 2,638 Â Â $ 4,115 Â Â $ 6,063 Â Â $ 8,385 Â Â Â Summary of Operating Segment Assets Operating segment assets consisted of the following (in thousands):Â Â September 30, 2024 Â Â March 31, 2024 Â R&D Â Â Â Â Â Fixed assets, net $ 343 Â Â $ 423 Â Mosaic Â Â Â Â Â Fixed assets, net Â 161 Â Â Â 183 Â Inventory Â 640 Â Â Â 297 Â Total segment assets $ 1,144 Â Â $ 903 Â Other Company assets Â 5,610 Â Â Â 5,446 Â Total Company assets $ 6,754 Â Â $ 6,349 Â X - DefinitionTabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business - Additional Information (Details) - Metacrine's FXR Program [Member] 6 Months Ended Sep. 30, 2024 Compounds Description Of Business And Summary Of Significant Accounting Policies [Line Items] Â Number of clinically tested compounds 2 Number of discovery or preclinical compounds 2,000 X - DefinitionDescription of business and summary of significant accounting policies. + ReferencesNo definition available. + Details Name:

onvo_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: onvo_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of clinically tested compounds. + ReferencesNo definition available. + Details Name: onvo_NumberOfClinicallyTestedCompounds Namespace Prefix: onvo_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of discovery or preclinical compounds. + ReferencesNo definition available. + Details Name: onvo_NumberOfDiscoveryOrPreclinicalCompounds Namespace Prefix: onvo_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=onvo_MetacrinesFxrProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended May 13, 2024 May 08, 2024 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Cash and cash equivalents Â Â $ 3,174,000 $ 3,174,000 $ 3,174,000 $ 7,617,000 $ 2,901,000 Restricted cash Â Â 143,000 143,000 143,000 143,000 143,000 Accumulated deficit Â Â $ (345,562,000) $ (345,562,000) (345,562,000) Â $ (339,669,000) Cash flow from operations Â Â Â Â $ 5,625,000 8,460,000 Â Issuance of common stock Â Â 15,365,825 15,365,825 15,365,825 Â 10,077,726 Inventory reserve Â Â $ 200,000 $ 200,000 $ 200,000 Â Â Dilutive effect Â Â Â Â $ 0 $ 0 Â Common stock equivalents excluded from computing diluted net loss per share Â Â Â Â 11,300,000 1,000,000 Â Minimum percentage of income tax payment net of refunds received Â Â Â Â 5.00% Â Â Insurance Premium Financing Liability [Member] Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Insurance premium financing agreement description Â Â Â Â In September 2024, the Company entered into an insurance premium financing agreement for $0.4 million, with a term of nine months and an annual interest rate of 8.57%. The Company made a down payment of 10% and is required to make monthly principal and interest payments of $44,281 over the term of the agreement, which matures in June 2025. Â Â Financing agreement amount Â Â $ 400,000 400,000 $ 400,000 Â Â Term Â Â 9 months Â Â Â Â Annual interest rate Â Â 8.57% Â Â Â Â Percentage of down payment Â Â 10.00% Â Â Â Â Monthly principal and interest payments Â Â $ 44,281 Â Â Â Â Prepaid insurance included in prepaid expenses and other current assets Â Â 400,000 400,000 400,000 Â Â Mosaic Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Inventory finished goods, net of reserve Â Â $ 600,000 $ 600,000 $ 600,000 Â $ 300,000 Common Warrants [Member] Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Issuance of common stock Â 5,000,000 Â Â Â Â Â Issuance of warrants Â 1,562,500 Â Â Â Â Â Stock offering price per share Â $ 0.8 Â Â Â Â Â Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Stock offering price per share Â $ 0.799 Â Â Â Â Â At-The-Market Facility [Member] Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Issuance of common stock Â Â 1,352,600 1,352,600 1,352,600 Â Â Issuance of common stock Â Â Â 0 1,352,600 Â Â Net proceeds from issuance of offerings Â Â Â Â $ 1,700,000 Â Â Public Offering [Member] Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Initial offering date Â May 8, 2024 Â Â Â Â Â Issuance of common stock Â 1,562,500 Â Â Â Â Â Net proceeds from issuance of offerings $ 4,500,000 Â Â Â Â Â Â Public Offering [Member] | Common Warrants [Member] Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Issuance of common stock Â 5,000,000 Â Â Â Â Â Public Offering [Member] | Common Warrants [Member] | Maximum [Member] Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Issuance of warrants Â 5,000,000 Â Â Â Â Â X - DefinitionMinimum percentage of income tax payment net of refunds received. + ReferencesNo definition available. + Details Name: onvo_MinimumPercentageOfIncomeTaxPaymentNetOfRefundsReceived Namespace Prefix: onvo_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of down payment. + ReferencesNo definition available. + Details Name: onvo_PercentageOfDownPayment Namespace Prefix: onvo_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionSummary of significant accounting policies. + ReferencesNo definition available. + Details Name: onvo_SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: onvo_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_DilutiveSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA description of the time period when the company made its initial offering of a class of securities. + ReferencesNo definition available. + Details Name: us-gaap_InitialOfferingPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of valuation reserve for inventory. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryValuationReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the required periodic payments of both interest and principal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance

Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CreditFacilityAxis=onvo_InsurancePremiumFinancingLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=onvo_MosaicSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=onvo_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=onvo_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=onvo_AtTheMarketFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Measurement - Additional Information (Details) - USD ($) 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Investments [Line Items] Â Â Â Â Â Investments in debt securities $ 1,000,000 Â $ 1,000,000 Â Â Cash and cash equivalents 3,174,000 $ 7,617,000 3,174,000 $ 7,617,000 $ 2,901,000 (Loss) gain on investment in equity securities $ 0 $ 0 0 $ 12,000 Â Maximum [Member] Â Â Â Â Â Investments [Line Items] Â Â Â Â Â Interest income on investments in debt securities Â Â $ 100,000 Â Â X - DefinitionInterest income on investments in debt securities. + ReferencesNo definition available. + Details Name: onvo_InterestIncomeOnInvestmentsInDebtSecurities Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionInvestments. + ReferencesNo definition available. + Details Name: onvo_InvestmentsLineItems Namespace Prefix: onvo_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Measurement - Summary of Investments in Debt Securities that are Measured at Fair Value (Details) - USD ($) $ in Thousands Sep. 30, 2024 Mar. 31, 2024 Investments, All Other Investments [Abstract] Â Â Investment in debt securities, Amortized costs basis $ 994 $ 997 Investment in debt securities, Gross unrealized gains 1 1 Investment in debt securities, Gross unrealized losses 0 0 Investment in debt securities, Fair value $ 995 $ 998 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsAllOtherInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Mar. 31, 2024 Payables and Accruals [Abstract] Â Â Accrued compensation $ 356 $ 536 Accrued legal and professional fees 462 93 Other accrued expenses 61 98 Accrued expenses $ 879 $ 727 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.

+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Preferred Stock - Additional Information (Detail) Sep. 30, 2024 shares Equity [Abstract] Â Preferred stock, shares authorized 25,000,000 Preferred stock, shares outstanding 0 X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 38 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Common Stock - Additional Information (Detail) - USD ($) 3 Months Ended 6 Months Ended May 13, 2024 May 08, 2024 Sep. 30, 2024 Oct. 12, 2022 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Jan. 26, 2024 Jul. 25, 2022 Mar. 31, 2021 Jan. 29, 2021 Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of common stock, net Â Â Â Â $ 5,878,000 $ 0 Â Â Â Â Â Number of shares subject to outstanding Â Â 1,835,366 Â 1,835,366 Â 698,007 Â Â Â Â Common Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock from stock options exercises, net, Shares Â 5,000,000 Â Â Â Â Â Â Â Â Â Issuance of warrants Â 1,562,500 Â Â Â Â Â Â Â Â Â Excercise price per share Â $ 0.8 Â Â Â Â Â Â Â Â Â Warrants exercise price per share Â $ 0.8 $ 0.8 Â $ 0.8 Â $ 0 Â Â Â Â Warrant expiration period Â 5 years Â Â Â Â Â Â Â Â Â Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Excercise price per share Â $ 0.799 Â Â Â Â Â Â Â Â Â Warrants exercise price per share Â $ 0.001 $ 0.001 Â $ 0.001 Â $ 0 Â Â Â Â 2021 Inducement Equity Plan [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Common shares authorized to be issued Â Â Â Â Â Â Â Â Â 750,000 Â Equity Incentive Plan 2022 [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Common shares authorized to be issued Â Â Â 1,363,000 Â Â Â Â 750,000 Â Excercise price per share Â Â Â $ 2.75 Â Â Â Â Â Â Â Equity Incentive Plan 2022 [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Common shares authorized to be issued Â Â Â 50,000 Â Â Â Â Â Â Â Â Â Equity Incentive Plan 2012 [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Common shares authorized to be issued Â Â Â 1,236,738 Â Â Â Â Â Â Â Common stock shares issued Â Â Â 126,262 Â Â Â Â Â Â Â 2022 Inducement Equity Plan [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Common shares authorized to be issued Â Â 1,000 1,000 1,000 Â Â Â Â Â Â Â Maximum [Member] | Equity Incentive Plan 2022 [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Common shares authorized to be issued Â Â Â 51,000 Â Â Â Â Â Â Â 2018 Sales Agreement [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Equity sales agreement expiration date Â Â Â Â Jan. 29, 2024 Â Â Â Â Â Â 2024 Shelf [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Securities authorized for offer and sale, amount Â Â Â Â Â Â $ 150,000,000 Â Â Â Common stock value reserved for future issuance Â Â $ 100,000,000 Â $ 100,000,000 Â Â Â Â Â Â IPO [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Securities authorized for offer and sale, amount Â Â $ 150,000,000 Â $ 150,000,000 Â Â Â Â Â Â Issuance of common stock from stock options exercises, net, Shares Â 1,562,500 Â Â Â Â Â Â Â Â Â Initial offering date Â May 8, 2024 Â Â Â Â Â Â Â Â Net proceeds from issuance of offerings $ 4,500,000 Â Â Â Â Â Â Â Â Â IPO [Member] | JonesTrading Institutional Services LLC [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Cash fee percentage of aggregate gross proceeds raised in offering Â 5.00% Â Â Â Â Â Â Â Â IPO [Member] | Common Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Issuance of common stock from stock options exercises, net, Shares Â 5,000,000 Â Â Â Â Â Â Â Â IPO [Member] | Maximum [Member] | Common Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Issuance of warrants Â 5,000,000 Â Â Â Â Â Â Â Â Â At-The-Market Facility [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Issuance of common stock from stock options exercises, net, Shares Â Â 0 Â 1,352,600 Â Â Â Â Â Net proceeds from issuance of offerings Â Â Â $ 1,700,000 Â Â Â Â Â At-The-Market Facility [Member] | ATM Prospectus Supplement [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Common stock value reserved for future issuance Â Â Â Â Â Â Â Â Â $ 50,000,000 At-The-Market Facility [Member] | 2024 ATM Prospectus [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Common stock value reserved for future issuance Â Â $ 800,000 Â $ 800,000 Â Â Â Â Â Â Issuance of common stock from stock options exercises, net, Shares Â Â Â 1,389,002 Â Â Â Â Â Value of shares sold under equity distribution agreement Â Â Â $ 1,800,000 Â Â Â Â Â Value of shares sold under equity distribution agreement, net Â Â Â 1,800,000 Â Â Â Â Â At-The-Market Facility [Member] | 2024 ATM Prospectus [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Common stock value reserved for future issuance Â Â Â Â Â Â $ 2,605,728 Â Â Â At-The-Market Facility [Member] | 2024 Shelf [Member] Â Â Â Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Â Â Proceeds from issuance of common stock, net Â Â Â Â $ 1,700,000 Â Â Â Â Â X - DefinitionCash fee percentage of aggregate gross proceeds raised in offering. + ReferencesNo definition available. + Details Name: onvo_CashFeePercentageOfAggregateGrossProceedsRaisedInOfferingNamespace Prefix: onvo_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionCombination of securities authorized for offer and sale. + ReferencesNo definition available. + Details Name: onvo_CombinationOfSecuritiesAuthorizedForOfferAndSale Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCommon stock capital value reserved for future issuance. + ReferencesNo definition available. + Details Name: onvo_CommonStockCapitalValueReservedForFutureIssuance Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEquity sales agreement expiration date. + ReferencesNo definition available. + Details Name: onvo_EquitySalesAgreementExpirationDate Namespace Prefix: onvo_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period value new issues net. + ReferencesNo definition available. + Details Name: onvo_StockIssuedDuringPeriodValueNewIssuesNet Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWarrant expiration period. + ReferencesNo definition available. + Details Name: onvo_WarrantExpirationPeriod Namespace Prefix: onvo_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA description of the time period when the company made its initial offering of a class of securities. + ReferencesNo definition available. + Details Name: us-gaap_InitialOfferingPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=onvo_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=onvo_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=onvo_TwoThousandAndTwentyOneInducementEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=onvo_EquityIncentivePlanTwoThousandTwentyTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=onvo_EquityIncentivePlanTwoThousandTwelveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=onvo_TwoThousandAndTwentyTwoInducementEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=onvo_TwoThousandEighteenSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=onvo_TwoThousandAndTwentyFourShelfMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=onvo_JonestradingInstitutionalServicesLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=onvo_AtTheMarketFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=onvo_ProspectusTo2021ShelfMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=onvo_ProspectusToTwoThousandAndTwentyFourShelfMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Summary of Company's RSUs Activity (Detail) - Restricted stock units (RSUs) [Member] 6 Months Ended Sep. 30, 2024 $ / shares shares Class Of Stock [Line Items] Â Beginning balance, Unvested, Number of Shares | shares 122,642 Granted, Number of Shares | shares 117,642 Vested, Number of Shares | shares (2,500) Canceled / forfeited, Number of Shares | shares 0 Ending balance, Unvested, Number of Shares | shares 237,784 Beginning balance, Unvested, Weighted Average Price | $ / shares $ 1.75 Granted, Weighted Average Price | $ / shares 0.55 Vested, Weighted Average Price | $ / shares 10.27 Canceled / forfeited, Weighted Average Price | $ / shares 0 Ending balance, Unvested, Weighted Average Price | $ / shares $ 1.07 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit)

options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares under non-option equity instrument agreements that were either cancelled or expired. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) - USD ($) 3 Months Ended 6 Months Ended Aug. 05, 2024 May 08, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Oct. 31, 2023 Class Of Stock [Line Items] Â Â Â Â Â Â Â Stock options granted Â Â Â 0 Â Â Â Voluntarily forfeited outstanding stock options Â Â Â Â 6,912 Â Â Expired, Options Outstanding Â Â Â Â 6,072 Â Â Stock-based compensation Â Â $ 155,000 $ 675,000 $ 311,000 $ 1,150,000 Â Weighted-average remaining contractual term of stock options exercisable Â Â Â Â 8 years 11 months 4 days Â Â Number of common stock shares approved under ESPP Â Â 11,763,188 Â 11,763,188 Â Â Expected term Â Â 6 years 0 years [1] 6 years 6 years Â 2023 Employee Stock Purchase Plan [Member] Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Number of common stock shares approved under ESPP Â Â Â Â Â Â 45,000 Employee subscription rate Â Â 15.00% Â 15.00% Â Â Compensation amount per employee Â Â Â Â $ 25,000 Â Â Number of shares per employee Â Â Â Â 500 Â Â Fair market value at discount Â Â Â Â 85.00% Â Â Purchase period Â Â Â Â 6 months Â Â Initial offering period Â Â Â Â 2024-03 Â Â Description of plan Â Â Â Â Shares under the 2023 ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. Â Â Shares issued under ESPP Â Â Â Â 500 Â Â Shares remaining available for the purchase under the ESPP Â Â 44,500 Â 44,500 Â Â 2023 Employee Stock Purchase Plan [Member] | Employee Stock Option Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Number of common stock shares approved under ESPP Â Â 44,500 Â 44,500 Â Â Equity Incentive Plan 2022 [Member] Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Stock options granted Â Â Â Â 1,150,343 Â Â Number of common stock shares approved under ESPP Â Â 452,038 Â 452,038 Â Â Equity Incentive Plan 2022 [Member] | Employee Stock Option Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Number of common stock shares approved under ESPP Â Â 1,361,878 Â 1,361,878 Â Â Equity Incentive Plan 2022 [Member] | Executive Chairman [Member] Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Stock options granted 1,006,116 Â Â Â Â Â Â Vesting period Â 3 years Â Â Â Â Â Equity Incentive Plan 2022 [Member] | Executive Chairman [Member] | Employee Stock Option Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Stock options granted 574,923 Â Â Â Â Â Â Equity Incentive Plan 2022 [Member] | Executive Chairman [Member] | Vesting Criteria Based on Market Conditions [Member] Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Stock options granted 143,731 Â Â Â Â Â Â Equity Incentive Plan 2022 [Member] | Executive Chairman [Member] | Vesting Criteria Based on Performance Conditions [Member] Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Stock options granted 287,462 Â Â Â Â Â Â Equity Incentive Plan 2022 [Member] | Executive Chairman [Member] | Vesting Criteria Based on Achieving Cumulative Revenue of $1.5 Million [Member] Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Stock options granted 143,731 Â Â Â Â Â Â Vesting criteria options achieving cumulative revenue $ 1,500,000 Â Â Â Â Â Â Equity Incentive Plan 2022 [Member] | Executive Chairman [Member] | Vesting Criteria Based on Definitive Agreement [Member] Â Â Â Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Â Â Â Stock options granted 143,731 Â Â Â Â Â Â [1] There were no stock options granted during the three months ended September 30, 2023. X - DefinitionShare based compensation arrangement by share based payment award initial offering period. + ReferencesNo definition available. + Details Name: onvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialOfferingPeriod Namespace Prefix: onvo_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award maximum amount per employee. + ReferencesNo definition available. + Details Name: onvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award purchase period. + ReferencesNo definition available. + Details Name: onvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod Namespace Prefix: onvo_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDiscount rate from fair value on purchase date that participants pay for shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe highest percentage of annual salary that an employee is permitted to utilize with respect to the plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe highest quantity of shares an employee can purchase under the plan per period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)

(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_PlanNameAxis=onvo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=onvo_EquityIncentivePlanTwoThousandTwentyTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=onvo_ExecutiveChairmanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=onvo_VestingCriteriaBasedOnMarketConditionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=onvo_VestingCriteriaBasedOnAchievingCumulativeRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=onvo_VestingCriteriaBasedOnDefinitiveAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Summary of Stock Option Activity (Detail) 6 Months Ended Sep. 30, 2024 USD ($) $ / shares shares Share-Based Payment Arrangement [Abstract] Â Options Outstanding, Beginning balance | shares 698,007 Granted, Options Outstanding | shares 1,150,343 Cancelled / forfeited, Options Outstanding | shares (6,912) Expired, Options Outstanding | shares (6,072) Options Outstanding, Ending balance | shares 1,835,366 Vested and Exercisable, Options Outstanding | shares 478,301 Weighted-Average Exercise Price, Options Beginning balance | $ / shares $ 4.26 Options granted, Weighted-Average Exercise Price | $ / shares 0.59 Options cancelled / forfeited, Weighted-Average Exercise Price | $ / shares 3.3 Options expired, Weighted-Average Exercise Price | $ / shares 5.14 Weighted-Average Exercise Price, Options Ending balance | $ / shares 1.96 Vested and Exercisable, Weighted-Average Exercise Price | $ / shares $ 5.08 Aggregate Intrinsic Value, Options Beginning balance | $ $ 0 Options Exercised, Aggregate Intrinsic Value | $ 0 Aggregate Intrinsic Value, Options Ending balance | $ 0 Vested and Exercisable, Aggregate Intrinsic Value | $ $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Warrants - Additional Information (Detail) May 08, 2024 $ / shares shares Common Warrants [Member] Â Class of Stock [Line Items] Â Issuance of warrants 1,562,500 Excercise price per share | $ / shares $ 0.8 Issuance of common stock

from stock options exercises, net, Shares 5,000,000 Pre-Funded Warrants [Member] Â Class of Stock [Line Items] Â Excercise price per share | $ / shares $ 0.799 IPO [Member] Â Class of Stock [Line Items] Â Issuance of common stock from stock options exercises, net, Shares 1,562,500 IPO [Member] | Common Warrants [Member] Â Class of Stock [Line Items] Â Issuance of common stock from stock options exercises, net, Shares 5,000,000 IPO [Member] | Maximum [Member] | Common Warrants [Member] Â Class of Stock [Line Items] Â Issuance of warrants 5,000,000 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=onvo_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=onvo_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Summary of Warrant Activity (Detail) 6 Months Ended Sep. 30, 2024 $ / shares shares Common Warrants [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding, Beginning Balance | shares 0 Number of Warrants, Issued | shares 6,562,500 Number of Warrants, Exercised | shares 0 Number of Warrants, Outstanding, Ending Balance | shares 6,562,500 Exercise Price, Outstanding, Beginning Balance | $ / shares $ 0 Exercise Price, Issued | $ / shares 0.8 Exercise Price, Exercised | $ / shares 0.8 Exercise Price, Outstanding, Ending Balance | $ / shares $ 0.8 Pre-Funded Warrants [Member] Â Class of Warrant or Right [Line Items] Â Number of Warrants, Outstanding, Beginning Balance | shares 0 Number of Warrants, Issued | shares 5,000,000 Number of Warrants, Exercised | shares (2,370,000) Number of Warrants, Outstanding, Ending Balance | shares 2,630,000 Exercise Price, Outstanding, Beginning Balance | $ / shares $ 0 Exercise Price, Issued | $ / shares 0.001 Exercise Price, Exercised | $ / shares 0.001 Exercise Price, Outstanding, Ending Balance | $ / shares $ 0.001 X - DefinitionClass of warrant or right, exercise price of warrants or rights, exercised. + ReferencesNo definition available. + Details Name: onvo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised Namespace Prefix: onvo_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionClass of warrant or right, exercise price of warrants or rights, issued. + ReferencesNo definition available. + Details Name: onvo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued Namespace Prefix: onvo_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionClass of warrant or rights exercised. + ReferencesNo definition available. + Details Name: onvo_ClassOfWarrantOrRightsExercised Namespace Prefix: onvo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionClass of warrant or rights isued. + ReferencesNo definition available. + Details Name: onvo_ClassOfWarrantOrRightsIsued Namespace Prefix: onvo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=onvo_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=onvo_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) - shares Sep. 30, 2024 Oct. 31, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 11,763,188 Â Pre-Funded Warrants [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 2,630,000 Â Common Warrants [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 6,562,500 Â Equity Incentive Plan 2012 [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 0 Â Equity Incentive Plan 2022 [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 452,038 Â 2023 Employee Stock Purchase Plan [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance Â 45,000 Employee Stock Option | Equity Incentive Plan 2012 [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 423,488 Â Employee Stock Option | Equity Incentive Plan 2022 [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 1,361,878 Â Employee Stock Option | 2023 Employee Stock Purchase Plan [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 44,500 Â Employee Stock Option | 2021 Inducement Equity Plan [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 1,000 Â Employee Stock Option | Incentive Award Plan [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 50,000 Â Restricted stock units (RSUs) [Member] | Equity Incentive Plan 2012 [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 2,500 Â Restricted stock units (RSUs) [Member] | Equity Incentive Plan 2022 [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Common stock reserved for future issuance 235,284 Â X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards

Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=onvo_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=onvo_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=onvo_EquityIncentivePlanTwoThousandTwelveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=onvo_EquityIncentivePlanTwoThousandTwentyTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=onvo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=onvo_TwoThousandAndTwentyOneInducementEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=onvo_IncentiveAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Class Of Stock [Line Items] Â Â Â Â Â Total unrecognized compensation cost related to unvested stock option grants $ 0.8 Â $ 0.8 Â Stock options granted Â 0 Â Â Expected term 6 years 0 years [1] 6 years 6 years Employee Stock Option Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Total unrecognized compensation cost related, weighted average period Â Â 2 years 8 months 26 days Â Restricted stock units (RSUs) [Member] Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Total unrecognized compensation cost related, weighted average period Â Â 7 months 6 days Â Restricted stock units (RSUs) [Member] | Maximum [Member] Â Â Â Â Class Of Stock [Line Items] Â Â Â Â Unrecognized stock-based compensation expense $ 0.1 Â $ 0.1 Â [1] There were no stock options granted during the three months ended September 30, 2023. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Total stock-based compensation expense $ 155 $ 675 $ 311 $ 1,150 Research and development Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Total stock-based compensation expense 25 (60) 51 47 General and administrative Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Total stock-based compensation expense $ 130 $ 735 $ 260 $ 1,103 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Fair Value of Employee Stock Options (Detail) - $ / shares 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 [1] Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement [Abstract] Â Â Â Â Dividend yield 0.00% 0.00% 0.00% 0.00% Volatility 99.00% 0.00% 99.37% 98.51% Risk-free interest rate 3.64% 0.00% 3.75% 3.95% Expected life of options 6 years 0 years 6 years 6 years Weighted average grant date fair value $ 0.43 $ 0 $ 0.47 $ 1.45 [1] There were no stock options granted during the three months ended September 30, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 48 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Fair Value of Employee Stock Options (Parenthetical) (Details) 3 Months Ended Sep. 30, 2023 shares Share-Based Payment Arrangement [Abstract] Â Stock options granted 0 X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 49 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Fair Value of ESPP Shares (Detail) - $ / shares 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Dividend yield 0.00% 0.00% [1] 0.00% 0.00% Volatility 99.00% 0.00% [1] 99.37% 98.51% Risk-free interest rate 3.64% 0.00% [1] 3.75% 3.95% Expected term 6 years 0 years [1] 6 years 6 years Grant date fair value $ 0.43 $ 0 [1] $ 0.47 $ 1.45 ESPP Shares [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Dividend yield 0.00% 0.00% [2] 0.00% 0.00% [2] Volatility 95.20% 0.00% [2] 95.20% 0.00% [2] Risk-free interest rate 5.27% 0.00% [2] 5.27% 0.00% [2] Expected term 6 months Â 6 months Â Grant date fair value $ 0.39 $ 0 [2] $ 0.39 $ 0 [2] [1] There were no stock options granted during the three months ended September 30, 2023. [2] There were no participants in the ESPP for the purchase periods that commenced on March 1, 2023 September 1, 2023. X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=onvo_ESPPSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Collaborative Research, Development, and License Agreements - Additional Information (Details) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended Dec. 05, 2022 May 31, 2011 Mar. 31, 2009 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Mar. 31, 2023 Mar. 31, 2016 Mar. 31, 2015 Mar. 31, 2014 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â

Â Â $ 40,000 $ 40,000 Â Â Â Upfront payment Â Â Â $ 0 $ 0 $ 0 $ 0 Â Â Â Â Â Minimum annual royalty payment due Â Â Â Â Â Â Â Â Â $ 40,000 $ 20,000 $ 20,000 Clemson University [Member] | Sublicense Agreements [Member] Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Percentage of royalty revenue from sublicensee Â Â Â Â Â 40.00% Â Â Â Â Â Â Clemson University [Member] | Licensing Agreements [Member] Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Royalty fees percentage minimum Â 1.50% Â Â Â Â Â Â Â Â Â Â Royalty fees percentage maximum Â 3.00% Â Â Â Â Â Â Â Â Â Â Expired year of license agreement Â 2024-05 Â Â Â Â Â Â Â Â Â Â X - DefinitionLicense agreement expiration month. + ReferencesNo definition available. + Details Name: onvo_LicenseAgreementExpirationMonth Namespace Prefix: onvo_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionMinimum annual royalty payment. + ReferencesNo definition available. + Details Name: onvo_MinimumAnnualRoyaltyPayment Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of royalty revenue from sublicensee. + ReferencesNo definition available. + Details Name: onvo_PercentageOfRoyaltyRevenueFromSublicensee Namespace Prefix: onvo_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty fees percentage maximum. + ReferencesNo definition available. + Details Name: onvo_RoyaltyFeesPercentageMaximum Namespace Prefix: onvo_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty fees percentage minimum. + ReferencesNo definition available. + Details Name: onvo_RoyaltyFeesPercentageMinimum Namespace Prefix: onvo_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty payments under license agreement due year two. + ReferencesNo definition available. + Details Name: onvo_RoyaltyPaymentsUnderLicenseAgreementDueYearTwo Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUpfront fee payment. + ReferencesNo definition available. + Details Name: onvo_UpfrontFeePayment Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=onvo_BICOGroupABMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=onvo_SalesBasedRoyaltiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=onvo_UniversityOfMissouriMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=onvo_ClemsonUniversityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onvo_SublicenseAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Details) $ in Millions Sep. 30, 2024 USD ($) Commitments and Contingencies Disclosure [Abstract] Â Accrual for loss contingencies $ 0.6 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details Name: us-gaap_LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 52 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Additional Information (Details) 3 Months Ended 6 Months Ended Nov. 17, 2021 ftÂ² Nov. 23, 2020 USD ($) ftÂ² Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Mar. 31, 2024 USD ($) Dec. 17, 2021 USD ($) Operating Lease [Line Items] Â Â Â Â Â Â Â Â Operating lease, liability Â Â $ 1,173,000 Â $ 1,173,000 Â Â $ 2,300,000 Operating lease right-of-use assets Â Â 1,086,000 Â 1,086,000 Â $ 1,299,000 $ 2,300,000 Variable lease expense Â Â 22,000 $ 9,000 23,000 $ 75,000 Â Â Rent expense Â Â 126,000 126,000 252,000 252,000 Â Â Operating cash flows from operating leases Â Â $ 130,000 $ 126,000 $ 260,000 $ 252,000 Â Â San Diego Permanent Lease [Member] Â Â Â Â Â Â Â Â Operating Lease [Line Items] Â Â Â Â Â Â Â Â Lab and Office space under lease agreement | ftÂ² 2,892 8,051 Â Â Â Â Â Â Lease term Â 62 months Â Â Â Â Â Â Monthly rental payments Â $ 40,800 Â Â Â Â Â Â Base rent escalators Â 3.00% Â Â Â Â Â Â X - DefinitionLab and office space area under lease agreement. + ReferencesNo definition available. + Details Name: onvo_LabAndOfficeSpaceAreaUnderLeaseAgreement Namespace Prefix: onvo_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: duration X - DefinitionOperating lease. + ReferencesNo definition available. + Details Name: onvo_OperatingLeaseLineItems Namespace Prefix: onvo_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOperating leases monthly rent expense. + ReferencesNo definition available. + Details Name: onvo_OperatingLeasesMonthlyRentExpense Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=onvo_SanDiegoPermanentLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Lease Liabilities and Corresponding Right-of-use Assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Mar. 31, 2024 Dec. 17, 2021 Assets Â Â Â Operating lease right-of-use assets $ 1,086 Â Â Total lease right-of-use assets 1,086 $ 1,299 $ 2,300 Current Liabilities Â Â Â Operating lease liability, current portion 513 506 Â Noncurrent Â Â Â Operating lease liability, net of current portion 660 $ 888 Â Total lease liabilities $ 1,173 Â $ 2,300 Weighted average remaining lease term: 2 years 3 months 29 days Â Â Weighted average discount rate: 6.00% Â Â X - DefinitionOperating lease right of use asset non current. + ReferencesNo definition available. + Details Name: onvo_OperatingLeaseRightOfUseAssetNonCurrent Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 54 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Mar. 31, 2024 Dec. 17, 2021 Leases [Abstract] Â Â Â Fiscal year ending March 31, 2025 $ 263 Â Â Fiscal year ending March 31, 2026 538 Â Â Fiscal year ending March 31, 2027 460 Â Â Total future lease payments 1,261 Â Â Less: Imputed interest (88) Â Â Total lease liabilities 1,173 Â $ 2,300 Less: Current obligations (513) $ (506) Â Noncurrent lease obligations $ 660 $ 888 Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 55 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Related Parties - Additional Information (Details) - Viscient [Member] - USD ($) 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Related Party Transaction [Line Items] Â Â Â Â Toxicity testing services to related parties $ 70,000 $ 0 $ 70,000 $ 0 Histology services to related parties $ 4,000 Â $ 4,000 Â Maximum [Member] Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Histology services to related parties Â $ 1,000 Â $ 10,000 X - DefinitionHistology services to related parties. + ReferencesNo definition available. + Details Name: onvo_HistologyServicesToRelatedParties Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionToxicity Testing Services to Related Parties + ReferencesNo definition available. + Details Name: onvo_ToxicityTestingServicesToRelatedParties Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onvo_ViscientBiosciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Business Segment Information - Summary of Segment Revenues (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Segment Reporting, Revenue Reconciling Item [Line Items] Â Â Â Â Total Revenues $ 30 $ 0 $ 69 $ 75 Royalty [Member] Â Â Â Â Segment Reporting, Revenue Reconciling Item [Line Items] Â Â Â Â Total Revenues 28 0 53 75 Product [Member] Â Â Â Â Segment Reporting, Revenue Reconciling Item [Line Items] Â Â Â Â Total Revenues 2 0 16 0 Operating Segments [Member] Â Â Â Â Segment Reporting, Revenue Reconciling Item [Line Items] Â Â Â Â Total Revenues 30 0 69 75 Operating Segments [Member] | R&D [Member] | Royalty [Member] Â Â Â Â Segment Reporting, Revenue Reconciling Item [Line Items] Â Â Â Â Total Revenues 28 0 53 75 Operating Segments [Member] | Mosaic [Member] | Product [Member] Â Â Â Â Segment Reporting, Revenue Reconciling Item [Line Items] Â Â Â Â Total Revenues $ 2 $ 0 $ 16 $ 0 X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingRevenueReconcilingItemLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=onvo_ResearchDevelopmentSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=onvo_MosaicSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Business Segment Information - Summary of Operating Segment Costs and Expenses (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Research and development expenses $ 984 $ 1,335 $ 2,386 $ 3,001 Selling, general, and administrative expenses 1,653 2,780 3,674 5,384 Total costs and expenses 2,638 4,115 6,063 8,385 Operating Segments [Member] Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Total segment costs and expenses 1,053 1,335 2,524 3,001 Other selling, general, and administrative expenses 1,585 2,780 3,539 5,384 Total costs and expenses 2,638 4,115 6,063 8,385 Operating Segments [Member] | R&D [Member] Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Research and development expenses 934 1,335 2,110 3,001 Operating Segments [Member] | Mosaic [Member] Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Research and development expenses 50 0 276 0 Cost of revenues 1 0 3 0 Selling, general, and administrative expenses $ 68 $ 0 $ 135 $ 0 X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingCostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of selling, general and administrative expense classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherSellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=onvo_ResearchDevelopmentSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=onvo_MosaicSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Business Segment Information - Summary of Operating Segment Assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Mar. 31, 2024 Segment Reporting, Asset Reconciling Item [Line Items] Â Â Fixed assets, net $ 545 $ 669 Inventory 640 297 Total assets 6,754 6,349 Operating Segments [Member] Â Â Segment Reporting, Asset Reconciling Item [Line Items] Â Â Segment assets, Total 1,144 903 Other Company assets 5,610 5,446 Total assets 6,754 6,349 Operating Segments [Member] | R&D [Member] Â Â Segment Reporting, Asset Reconciling Item [Line Items] Â Â Fixed assets, net 343 423 Operating Segments [Member] | Mosaic Segment [Member] Â Â Segment Reporting, Asset Reconciling Item [Line Items] Â Â Fixed assets, net 161 183 Inventory $ 640 $ 297 X - DefinitionSegment assets. + ReferencesNo definition available. + Details Name: onvo_SegmentAssets Namespace Prefix: onvo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in the statement that are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAssetReconcilingItemLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: us-gaap_ Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=onvo_ResearchDevelopmentSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=onvo_MosaicSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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|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}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}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

8O#B/Y=+'QR@}-_G(A0-.'[> "JOC[Z6F3H?U:3+;=3HXM5O M\Y/9Z2_<.^[<._Z5]/\GD;\6]-4&)>83\8) \56&QBEZ]'NM'(?+"PZNW5CQ MQ9:Y-FL_%K^O;55+\Y3>OA':
M"RDRV*XS9,@'$(A8:IB>%<:6=OTDLK@#0F2@Y2N+J%+GV"A4O7H]NKVY&;\98DY4-V2^:,F/G-PJ* M2AV@X/7HQS4M(I)(:BK$)K@.4IV]M;,59)/:4#BEWG9$AY>O1T=0)HJFDGBM
MO6\4G/4"%I7T%Q(M+ "&.GF L9R0+S$NEER66I05\[Z$9.UDQ5VH @A'RZ&K>UB5CZU!K4B$?%= M/J+J-^R=)>
<6X]EL1BYF]!66NX'EG9"^U5+DKEF#@4,AO%R1PPQ#6R+72XTT MX\$J4.BD+DDFQ=YZ,@#^W1<$EGED$_Z\$,&!04A)X^"^&[?:*,J?;RYWD."% M0C:AL"ZQ%"#K8--
%.GY<3T1WP>QS!KGP$\[:0QV$_()"_H(PD*F$4"L3/!L%(%>HQ$ZO&<-]_*[VW MH'%"#N"#LBA4C?!RQ2;/[BX?ONR8Q8C+VNF2^T["KZI:^NXWJ$&]6JQ+@(8*!B]JD*
)FD'@GMFO85'C>W @NQ. H%/6*,0-@E6! M2B4Q H.H7SMX6C'I CQ$34._4>@JT-/I(A]P'J%,L]W,%TVFON"#!%B97& M'D1E+(YN.@;D3, *>!":$OD4/Q7,]37F.Z:@2)A)[S!
(('ZHP3+X5A.38?X4 MO5X!\+(%'6K@'EO/*9@-J'0%<.UI-K$1])='@O$Z3AO2986&/NJSOH(*Z(H0PHH&4#_D/9&*$,B!,:'*2W7%:J1V 'HZC.T"80'[>7@6@^;5\J MP8T03B?
\]DE6K5:*)V7F0F0W*8T25TY9*O1V#4E@6HL=WJ3J@]BVJZ: M6D>J3@[3/&$#'!4-,^E M?V!KUUW:E@5CE$/G,.PS@M$;59)I$ <,@N/&53<7,2Q;A)K1[AGU!^&54 ,
M!P_%FE^1^9X.;Z3:9Y@MM((+AUK>[@^_C1JIVK>*E2[JU3&YQ:D(TMQ=:=$%Q)W/D6R@T[W(BKG:K46SW3M-I77SALKK=;?^>MM^1[>" MC@V_1C:\+YY\"B-
E[O+F[M/TNWW$)!39#QC6#YE6)D.X%K/Y!VJ[8O'^=/%Q M_N[D[?SD_02SE?XHYK/)?#8_F?XQ 9KUA)9.9D>3V?S=Y$UW\.AP%:<=U182 M&(G&YO!4J[=DHEZ!M_AHX'AH0-
#1VC8TC(0(XXX_ V/BC];<78./5R&I=M$. M@";I(T5@UFZ8Y>=#W] "EVBPPO5VY8=J6H+4\ _1+A/O*E20;T\C:ZT::'1 M+>'"3>M>U!?
[[_!$%+5Y=/BRXQOR>BES=&2Z5A!B@ZU]6B"ZH@@SXJ3\S& M*3\M ;&RP]U;Z7*J> !N0X!;R]25OX*Q;FAY.[O=?NW&4L2A3*34GX(:/]\. M9]$] @5',WJ)0IR55
Q45*GR\!0%HI,%!PTPGC<"3G"L6?L>(^Q&LPY\;=EQ MY^BSY.W@A-0!FHWH8X,6)<61+8$VC)^@.\)QPQ&,[]/$0C!&TU^J0&##ABX<\ M=NRC S9E?
GN&T3H2WIU#A\/F\W,M>T4W#-V$ %5\8#@8!KH1L*F)LH QSH%Z M3*U%1K(K+%JV\$0<@>-)N<-&3OC:%CHKH GVP5_E?;*-H@=1L24>3 ULXV>U M= WQ'$W]0]NHW(DY
W&=EU!)EX@B<1>=DS::[RB[XP2OZE!))R.*N>#YGT9' M;QO0#-\(P'3)XW5DV3B\$ 6E[/4- >1*_1=3&UM#ET@T6<8Y\G :>F&F3$Y0 M;RQ462-=P"[DLDPZYU!/*V#5&!KRA@R-
%SW(#07;4!]L)Q(XQP3++G7%Y\ K MCJ_,^#NV-$[M'.HHUDG,5]2"J22'OOJ(XM2"N6\"YN+/1L9C.%&)HR$0PQ?L
M6#E;#2=U>JM"D<;;&')&T*HIT\RLF8GB<9_N^%CJ2N74V,6ZX2YMB,I3R-+< M,+24M[-9*PT%_0Q2B3?QFH=BVU'0BXEKIS2&9,LY#"!.2]O^!ZJ?@<9%49XC!89#K9^=S_#?
+G$,9!HDQQ?T;RFB,YB_N*VR*[4BUX,VNO1MU>R MJD_IT@PL0AUOA\JEOSD1\>LQ4'6 HV++C8D:&L83C=)E ET]@G-CAMG1%Y]2? M#2+AJ1@0S%CR\.JEB\U4]N-
VP1ZE\ROR8&] _>^T9;T>X,[9]% (:(S'\Q?P%Z [3"D9Q3,$K;)U- MWK\;"1=_58E?@JWYEPS@$U#ECP6F?^5H =ZO+(*6OI""[J>MB[\!4$L#!!0 M ((" :%EQ^2V>\1< &!$ 9
>&PO=V]R:W-H965T=B.7U7CL;WKK)U,//;NK;IU/T D)#&F M")D@1U9^_3W=#8"@1$U\D_LAL23BT>CGZ6YPGFUL_=DMC6G4UU59N>='RZ99
M/SD]==G2K+0;V[6I\&1NZY5N\+5>G+IU;73.DU;EZ=ED\O!TI8QJZ,4S_NVF M?O',MDU95.:F5JY=K72]?6E*NWE^-#T*/WPH%LN&?CA]\6RM%^;6-) 6-S6^ MG<95\F)E*E?
82M5F_OSH:OKDY06-YP'_+LS&)9\5G61F[6?Z\C9_?C0A@DQI MLH96T/CGSER;LJ2%0,87O^91W)(FII_#ZF_X[#C+3#MS;W%^I++6-7;E)X."55')O_JKYT,RX?'D MP(0S/^&,Z9:-
F,I7NM$OGM5VHVH:C=7H Q^59X.XHB*AW#8UGA:8U[RX%6$H M.U>WQ:(JYD6FJT9=99EMJZ:H%NK&ED56&/?LM,%^-.LT\VN_E+7/#JS]4+VW M5;-TZG65F[P__Q1T1F+/
K$OS^Y=\-LQ^I\,E)GD[.+>}8[CX<_Y_7.#ZPW M<$KUWU3I/=+> M1&HO[EO]+XKJ_K5_MHU19V/U[7NHE]H5C@;>T%&K1HN553E^**JL6)>&'U_;
MRF%.+L_+@TL,;.KM:ZVM%Y;Z38O&I.KS$)-*B>?_!1\F1>5QG*Z5 Y[&#B$ MQJFEOC-J9DREP.BUKC&NJ'CA.L=H RMJENK3^':L%J8RM2[++37V:UI2=\=9 M=[0>?_^WQV=GDZ?
_N+JZX8_3IP\4W!Y6;DQ=K!)*BDK<83AQ@U,5%?2F95_C M5&,5.0TUG9S\RB.NZJ;(2J,>TL^F5;RNS;D_\:,WOK'.24VQ&MM56Y595M M5&4RXYRN"U /.LLV! ?* ?
TQ%@>HS9>V(%;,MHH.P<03JTL#Z0[Q<ZSI;JO.IV)^"]'/PY8YD5-L5,^%:!$OLFSYZZE0BVX,+.Y!6 MXF<6&2UR^_I:X6#0]39N)H3^.5T)C&N\ZK7T(Z3P2[W0E;VSS,$"OVV6EM3$
M;BHLY=J9*_("Q@#Y@.7@-@[+LL<'K\#=>JP%M:Z<]AK0::@I"SANI@\ZFJ7F M,%9O*Z;+KHN*A FR5KI"-"3261>20P_K'PE9}$^T=(W_V]RIM9@EYB'.41!T
MK#HZ_PU1A3DSPHD+2!3F W[CY!4M6O)9:I.U-6QC,8I*N.6MM)KKHN[X2R0/ M2;XC=FU=092.L*A#L&3F U743#^H0)#+/H/WT";GYRM2Y6;+I&3:+=4N& MU#GX@W]B6V-
KI6AV+AC6J,AHR"!@(]&B'C]-5OJ:L'[K@K'&"DX,-A/\%]C M]8LP&JXN<)^E6&UW%(:U8- GY @ A)N"F.W!Y2P>U[N+^I/N*4<+39P7+@.' M
A=HS1X;+M6Q,T;Y0W&$FH[5*^.RNE@WWEI>M@ZAS+GNP.*J$X>E.LMH;'-]!VO;(8(MQJ MEACNQ,ZAE&7QNPX'I\X9KW ./[JY.!9Z5!9Z5I2B"U[[O.7"&=6.937S?('S M8GN[I+(
N]T:;RWU.MU;,\6Y :A&']7Y^,SX-&R M#(;=U$7&%DES!\9/QM,PGO?0'*[;%05"3 .0!JQH!G>ZN!P_#',E$.SNMX&] M(,KE"PKN#FPH:55$?>^R$ #QE1;/($!LPU)+SU\DX1/!F]*91A.D@
B4$]M# M6#;LS." D3(;5M%\MOT(S@S(V$R80F MH*>5>(K&K\;;0VN8UW!-((S=>QRP;F< D*("S0F&GV"%S\ !P7M=?7P?T9>= MSTW=F0BVN\/9(6I@[!!\?*1PT3^.A'6UN3-
5:_8Q"K:GI)*,<,[^]J3H2,X: MW,79&H P?,K;S-L?!5)V3(3H,?F$TL \?,-^"P1^"]=L.Z1[,UN+/.4J!1^ M6*2F8U9UA[V+66DDPL#5_9\D.MK19]=BV'1T?GDV>CB9(/K!0[$6D0P'14,/
MP/V@KF #*7 %V8 =F3'YH".8CA]UQGF5YQSK"6^/%$ LH[C'C'V280T2:4T MO*MKE)EC,Q#@]2-(7AW3%*\:O_@?$_UXHHZ+!SCFY<.ST>7]QV25ZSM_?KK1 M-3R83^
M.WC6^VEV_S[XS6_G7^/?OR1&;A_GO\?;OI6!J@T[HS\RJHOQ973LT56$S>!!YA3.<$3*-[V+@!'Q_+SCC_FZ)G , MH]);38YEMDTM<.1!;%CA)KK5JP6'+T-
>Z)=*_=2"J.GC(3\33Z35!NZW 4Z" M]R*Q!(;[_ _4)=7A1.*Q_3_"N_+M08)*[>-GL\#BW_6+M=?\!OIPWN)%>_ > M74?]E>=Q[0!9^4P:.90XZW;M45L0X*$(_ T9PJ@]/0R0O=1P5>
<3QHT(..SC M]12N=ZZ/G7DY.=8/CL\>1![M_-Z!Y;?[19/!)1]/\)?9@^/S!\=7 M#_;A@8?']J[((0\H">(?3-)S_^51@#A4"YPA2YH#\PBWPE2HQI?I)(U]"CCF] M$/ _(N;4P$6)GP?_05-6"%
[IAP2GHG@7M,3 MD(>;87-:SU2'E:7#;("?8,X)?O3L$K\A=A-8ZSK8ZH7DV% V9T#*R8(K'!^L-66Q M8!PDJ:72$52D6]RC5F">55_8IVS[.VRZ$D "]JD,U4@A##I/N*GTVI\:*U^C
ML2KRHI;512(2O./28%T?Q#C<0"0A(Q8S"$M"9D1H[J)3\<*\UNNBP4#Q<:-. ME\U7JEOZY(\SSV&EIGWE@)61D^TJA7?->.+W]#B)4' 5- 6!S.QL(]F9J;)M M+\TP5'[9E\E8_=-N@+
[K$6D:TB5$-Z!@%]2PI[QF1AK,VD5&1EI04I21PB[MCAU%IGHT\7Q3.*EE!$T:A3T]>\"&>2\4"AG$BBZ/$$I A6MGOR%#($)RX\48 M*W>497 >XEJ"^;*VCV3[VLV<*/>X$%U-
;BBAI&JA%X9LN$,9@EK+3*LI8ZR(M1D0:#^'!T);5AD"W%(AWE'Y,I?VNS.') \$I1CATV%@#0B+F ML_D[790L+<[X=B7-0F(%XBR5=C9">Q3,1C+M*4L4Y4%^XS)^E2.@?%M28-
2JG- M;3L#[V:V%6%(!6;+RND9*+6"7@5(/%B(% 0MN=HU1XYH-\&,J/A$']QPC9XK M2Y+.C?], #GLK[;J+XGVWX?V>R"^- M&]ZWXEE!_1!!7Q1V8T
F7>ZK%DR+.+>FDE'6B# &^0BM-5OOF:&65-%KR2S@ MS:G2OX@E4:_$87.F:D=]F6QGS.?[R?89>FYFO(^O>7AY+FQ6VCDZ@2YI*DG-\[O)%CU?@8%9KW[QD
MR0MSO+YC)7++E.>MNH87F29 -$3A=IJ86@IJH4>0L2_)"TI,0_9G74(#IYFD M%MXY4[$YQ;^AF'8/-) CPY3XJN7 ?LC>3.\<<: M;KN%XX&O+YVT =-QS"=6+EL#9Y"1@*:P. NZ-
B;4[6 /)?D9XTW$2GQ(CO.)-(A)<56%-D,J*BY)?VF&[3B#82= M;Z);2?I':;^(5O03=A@8NE7HR0#TO'J$BE? K)&NU+RK[6 M!<=B[HJ3W>M(R%8=8Z3Y6C2RY(/@O;R+ _F4:UE' >@."
S:8EL7LJ^0-\6M MNG4+\2)4(*"F1->0!ZG-ALH4?@WX8Z1"V"JQMY219&ICJ6\PQD-QDRVK@E"S M:EU(&6WEX*B\N#JST5\" WP6&MQ/[(RZ!1(KJW7K!<-ZL#.RK?;&"F+H0&/A
M0A=>=ET6* 8P\ZVO=?%QR/.4!):D&,X+C>BC2%EB4 URFXW=U;,$@G"[A0M? M*6TCCQS%\@_SY(G4 !\^5>^(&C7E[].SI^K7UC;&9YA.#))+)"(A28]!$.PJ MZ_0YD3;
[C/[B9W'QM\+ET&:%4H3M);I1;I&[DPHJGBX2 5!+CGX4YH=:@9, _0"I-,:G?/""M>5. MD^0MR2"OY%!B+51VF4PIR)4[\ 2X B#Y)OZ>1_Y^VE?3CER?Q E96*D1NBL; M"//)W-
:K5YB6W#CSI8)$R^>GDR)]U5CXV? I>#O&5^SK6(^!?*413-[%M[=\ MZYV.XF-)MYS^]N@:\ 27X <:X ^[ACGMBC'^DJ#@21IR'JO^ FH+!'F$,FMS HWPK4%^(9K&/ LO?
6Z2*C4,CA64[@-QFF*3;QN8>.@ XNR*9)H:>' M8P[U'VE_JC.9D]QNTOT]C*_,1IC.V&ZL;J1;7INY%'./E%SQF([CI0[LLF!O M_+:
[[W3$"CUO:V\HW44HJD+6AL[X=**^"REV_W+#9[];N4U"+H\, MV_EEG'37+BY&9X^GBM+P>.LA&F0X9U!)QGSB[7YJ<2ZJ\X[5!Z^EG L5><(Z M6.: -OFNWD5G$/T[5V&=V./BVH[
.%^G"JY"HOMNV>1;H/7/U&L">E0W6/:6 M*_QT[37SV4_9-KZ71Q S:0/$I@AMR8.DOD%T;/BBN,E/@ 1K !M5M7QR I;# M35 +YTI%8UHALMP
M=T]6]SY&4Y(W79':3:XCX7+U&0F"W\"S2V[L)TVZHJAA:5S+R]B9>R1V% M,,"D40[B^[')I2 ALJV*I,_JX?:3ZZ^1'BNTQ<45^U,EA5]H6R OH&))D",0
MIO!ZPER%@X;]6!6^Q*&J2&M:W2V3.)% MO./GT5R/]NZ&V\X1KE,E3/-3KR3^%HMH%"OG88O(6^-C>E'W]XG$4#6['Z 0 M"[] ..PFZ$33\>3>4>>*W(_
MP&UL8UW;/'8\U/'1U>WUT0/UT:[A)A].'NZ45+LD0P-K :0U_+(!W6ZTM2_2 M2 LDN#E6"40IBG^':U;1U9 DNE*GZ[![./).PT@G$? .+E\O?"CK1ILRJ<3G MW"0!AR EQAX4+RQ TR)
<9TZFUI+"QZX.(4QVY2>ZI&Z Y 6C4#SE:427URG9 M<>ZO*$M6[+:K&;V"T>>KN>-,%3/8\H=IDWZ2D&)\\[G$G+%E"M BA>H/D&MX*R+N\N%[MO5H_?
24E;S^.TJHYU(9[L2:Z";=WW4GT*-(:E8G+]![%#*D]+#/J9)+KA.Y> M3PNY5AH7>N 5XN0II4F2E;_MS4T"3+B(/]D_JFZ;)?)=?W=\]UVA.Z=F:X MCM85+0?CRTN+?R*,>W-U^[*
[_QD*)N%2!=V.XNDS!"6J"WRJN.C>70N0P46U0Z7.^, M'5F*#=(Z\(TFZ!:_/1"28]\E0AZM9RU5X6I9D?K0R.?%'B3SFD$#>L"*[VIS MHIAM0U-
KI&:U_0Q+X"X_H;X.E&74II"J4MH([G;C]K6A!J9WZLE:4/2*LV+> M]C?D<(Y:RLG5+/.UD98TM<5D';)_QDD=$52(<=1YD)M[OCDK71WF5MV93W+:B,X5SZKEWGG>CLWBX/
M];&O4X?2N=K;Y"50Z-+/9+;W^(JXSZ-1K,K)NVU\25^F=-T<:)]\E_^R6I5)%4D\>6#)6CJ+3KOF] MW+J,@3J/-R>7A9DG[])!U@RVU'O]&4R+;P[\\JI[>47J:1YKDB; 6_B\W"?M
MH5M"E=E U@^,3>:%-+:LYEQ1[&%N M/ARH#F5',*745;2*I=UT0UIAEMD[@.N=(,58R3DXP615YEN07@@I_)/[/5G! MA2[>V;)A9^+5_94R,1MBQU\UT/-15_-
,7ISUHDI>3_P&6Q^KUWH5+]PA2R_B M3;HR)FXAV4UQ!\8MVH)O9H^'_GS :?)7'P '%_RW+?BN1=7('X"(O\8_GW$E M?S6B&RY_>^.]KA>$)$LSQ]3)^-'ED>#3*6Q:_X;$@BCP)[\
<6DT0@(-N^2: M/!(C_X4VB']4Y,7_ E!+ P04 " " @&A9JB(,[7<# "-" &0 'AL M+W=ORAZH*6Q180450YE)_OK=TC]J@/83H$]V.9CYIMO'ISQ>&WL
M/96(#AZTJF@2E<[5%TE">8E:4&QJK/AF8:P6CK=VF5!M411!2:LD2].S1 M9 M1=-Q.+NUT[%IG)(5WEJ@1FMA'R]1F?4D&D2;@\]R63I_D$S'M5CB';JO]:WE
M7=*C%%)C1=)48'$QB6:#B\N1EP\"WR2N:6L-WI.Y,?=^\ZF81*DGA ISYQ$$ M_ZSP"I7R0$SC9X<9]2:]XO9Z@WX=?&=?YH+PRJA_9.'*270>08$+T2CWV:S_ MQ,Z?
4X^7&T7A&]:M[.@L@KPA9W2GS RTK-I?\=#%84OA/-VCD'4*6>#=&@HL M/P@GIF-KUF"]-*/Y17 U:#,Y6?FDW#G+MY+UW/13M4)R'&5'(*H"KH6T\$VH
M!N$&!346_=TX<6S+:R1YAWO9XF9[<,_@QE2N)A8%5@\U4^88T\TVQ"]S X" MWF$=PS]@2S-1@?PAKWCPX W?-[Q$Y@I!7^[$BULQ^/[;$[._?
T@75(L=)Q(^%T*XPFKY\,3A+WQ\@/^K)CPZA_X^L'<3=S?HOXQ"&,?R> MT2=BLN(7,G= F#=6.HD$,P*S ,ZF0SWG@&]2>@(ES$L0%ODV5PT7GA?SN,?L0+8-
E0LJ@Q=A@3\;N1+* [^) M@9][4"+Y +JM8O15O(\UVUL+ H5$O!456TOCP5/BCJ7(>5Y&(W]B%S^_J MY%$2Z#:5!30DJR4[M4(% [97-]S]X8M7,(I[N;U82JZP:^CR7Z3M'+ZBYPAS
MK%S(5F^3]UMLQ)Y2"7F[$99S/1QL\L#AK3%XIQ[A=4B:@EZZUSVSNHXU%?/2K^'G'>!3GWX#[.T.L'/8U6'2K1&AT2[#(/0UTU2NG1;]:3]B VM9V(^27>#FIFN?
1Q4KA@U31^>QJ!;8=?NW&F#@-G;AR/K[L^?\"6B_]PO# M':7;> /]/Y#I?U!+ P04 " " @&A9{)7_0'P" "%!0 &0 'AL+W=O M,G"Q38J M6[UT1IL)ULI[^WF<[;T BL(.:;&$A@]'O :.;<@
MDO&[8WK]*VWA\?I_ ^AZIUZV3..UY#^JS)1+;?K]Y^PZV=B>:GD MVOW"OLV-(@_2G3:R[HI)0V5V]LD>N^]P5# +7B@(NX+0Z6Y?Y%2^9X8E"R7W
MH&PVT>S"M>JJ25PE[%#NC*+3BNI,LDI3M<,,/CS2F#7JA6^(:L_\M".L6T+X M B&&&RE,J>&#R##[M]XG-;VD\"!I'9X%WF$SA"BXA# (QV=X4=]BY'C1"[P-
M>V);CAJ8R,#UR[B&GZNM-HK^%+].M=P2QZ>)UBASW; 4EQXY0:-Z0"]Y_6H4 M!^_.Z!WW>L?GZ/UDK.$T_J^2(,P'L)S?!_ 0R"5Y#EM*"1S,"5"+CF9MQ(% MO*D$1>1.T[?
4;^<#FI7!>HO*#>R&J;2$:'0Y.#!365LHG;C9&- M,]I6&K*M6Y9T3Z*R"72>2QI!M[$OZ&_>Y]02P,$% @ @(!H64Z(!KGS M$P ^$< !D !X;"]W;W)K&UL[3QK<]O&M=_U M*W;4-
)4S$$4"?,FO&5N16V6:6&/9\8<[]\,*6)(;@P"-!20KO[[GL0LL0)"4 MW;2]=Z8SB24"NV?/^[G4_N\^&162I7BRSK-S(OC55ENGIZ=F7BEUM(,\HW*
MX,TB+]:RA(_%\LQL"B43VK1.S\+A<'JVECH[?OF7JLTOW]Q/#IV#][IY:K$!VB4(M M7AR_&CU]/<;UM.!7K>Z-][M 2F[S_!-^N$I>' \1(96]N$0($G[?UKE::(*\Q=Q^;G2Y)_7MV:L@!-^-
\^&AG$N!\$6L=3LY&Q>G$,ZF]4 M<:>.7W[_I]%T^&P/@N,.P?$^Z(^6PWXHO^2E$I.!*%]_Z=Y.)H]LS#%-6B] M*@J5\"+Q?J7$1;[>R.Q!:"-D5:[R0O\.[\L<'IA*B7 2#
(=#_%^8E03:1;X0 MFQJ.03@#!%0H :]%EN]>!SH-'[(R?1#@(DPILT1GRT# 3U%ZJ*RD03AVM=BD M,C,-1GO0 !KL'8F[BH3/LB7J$:C0+_@+\8\3J718(P?M0%^(B\,.+DF!X>
M/Q%RLRGR.\5(X6Z E52Q6B,VEI5760R?P*F(:T /-GM+\,GQ$^**Z#QN\1A> M(TD20^$JU0:]G$VZW(Z9*F8AN&(A[P%/>J5K+/AMOD%W9P)@7W8*#"XK(.VA M^Y(_(I4JUI(<9($.#%
[!D66AX]+Q-!#O;C[\XT]* @@JE6FR\XC1I8EF0-= MA3NR$+$T*XLQB9 M!MVYTTDE4R/N5Z!T0(=9/-!ZTBQB$7)+-[M;D'^1)I&?Q;+2"=(P:%D#@,V) M\;HLV1Q
S:H8U)5.D,MEH982#"ZKUK< #&31" S8TQ8:21FIW%0%RKM$@'V4 M+8I\W=4 6#H9^0].[E<:U!IDGU8)?-Y2F,>=#\=Y5FBU U_ HAA,4+5AW.MR MA7O4%U7$&MYN0$](;[\3X6
V09$R#H%(E;PCF"CJ%N[R3NJ44$'1+*JR*CPC MV"GR)[6/(#C"^F!Q#YZ"! ,RDG&<%TQ#*G*D6"T4A7[P%XT8!C4**)^% O"(> M09 I%8G.113IR$0#
['O\YC#3ITFZ,!^)MMG5XUPL9SU77%+)KZOJ@<*?CH9?L M!A8WO4*Z @06X"H'<*70A\"(>C M?>>/W/E\C'\NG_=AT_NBQ0X1*]"YA/F*RF.]7,/A^B!"#K=8^10*,U#:\TCU M:D"1M&-
\G::6;!O&TCQ;PO*](!TK';0X1]PKMMHER*_(!W@;.]T7AG03B(1 M#F-\= DZ61):):2\>W4 #T$A>PX(='D41-.HXP,\SMHDH.,3T'2 ::66*:!D M#2IAC]G','MZVTWN]I"-
>K4M]I9=]);;).TD8;2YLRWX/K]Y]\I[I3+Q4P6T M0,K"Q^/J;?M_@SZVO1"0WVNJG'DD\'(:A--PGZOMP9IPP4J#B5F)(U(*W(;RXO$,!/,JN@ A3A M><'YU0F\1!T-A_HP0VB0]&SP
B1SO&2"'D[\1H,AP,H2)*4\2O0VO0S0L! MA"PX\J-&V/0%\RC6X%N=,:'6;(#Q:IE39DI:J;YL- +;1GXLR,W73Z=>)*FY MO=#D6$0&5>JW@0-EOI]8Y>L\=QK(F<_?!A<#\1'"S#VERN)
[N=X\@Q,& M@?C[WR\(UY_R#/:_+R3E4U>9*37DW\ SF4*Z4=Q!NF1H\8F2,>52]N!7R^8X M=G'Y4F$RPF3XJXS#JJUXUI;Z%0^"B-D RRM(.*K-)F6J;0;J\73+$%^]_QE*
MQGKS3;VY,4X_H61#]3%82ZCT0-P%464@Q :Y)KCQKZXV.[:@CK^5\OE7RJ6,)@. M)\$LG(O]0M&444(=@]>VSKL'F4)&L$=BM21^KJ7L "U2C%X_46LN:7%N?". M6J&;'?RNBIP
0#XV03)V%O&65XX)7'=OV"NF#P&% DR5*/]8*2[U*1G\HM? M/8C;X/T',Z>]D!$"Q;"&)4WJ2CS:1_K>,JC5BB%0/3GG_!QRSO"Q-+9SEZ[. M!NQEE_# '"![7H<\Y/5A-LT]
(S]4^@&U6P"&?I3MK09VTDBLYJ*L"W;HT[$? MJ&^'W90>N0B (6=>[V?P "+D []X#66=N%S 66##U]5MJF/QUMDCA=(Z!K>5 M@6P5_=(M0E 6PH8AU!;MAQ$'MHZE^>*I.-
%/0'TFTS"8[&];$-^@JJ?3$;1] M6V/>&W^VEN*]SNY^_:3[V\.\PS,?S;W9^ M3@S/X>8 6\!0D6=V"$0>!I73:>6>+/&F3HS!0NQ!=69H&E .BZ(NNIN4 MVH:HQK;REFT)3I,;%>ITUM
7X/8><6.S'CDX'(X$Q.3J]C<@D7IZR6^5*2F_ MD^1'[W3"R7.AM*W=^^!QAK->JT2S@[*XH%-J'1"KHH0D&#Q IA8ZAI)5Y/<9
MD+_2&Y]JM2ZE;3*C"'"D2<_D$L4DUS4,*WXLJ31DEUP+#O*3FPB[:(:%.*YP(MH+=WC@:[S)!XF'K[P.73C^)Q5_$M?\'"OYJ]75#_!M;:YAJVU+@J O076&] M*%E@$SQ-
\WN7Y^10OV@L2>JF O?HKA;4H^BM3&/L9-D__LBB[LCVQ'_7,T~^25%ATO M%=/@+7'N:A2QOVKWD.RPYG "-AY,ZD2':XPV50ML9B38.BQK%76H@'ZKS 3 M-_*!M,(64Q:)P,Y W+
[KFJ54KB"K(.]YUXRT>##X 7L;1(QG&02>;R?HWY7I M3;9P%,97'; 1[C3T$>7"TZ-?ZH;?1[HKH)*C#]D=8(8*4=KN132RD6$40ODP M#CG+GQS]U79$1Z.9?3P<3"9'O_+V$\$)S1-*5@?
A[.BB;F>?(98+I7$=D1$^ M@U7VMQ8&VTB+,)H%L_F8L!C.+//>\A#1KYP>52_U="X#R,9&DV$0C:/VA++= M!P;D[D H>64ZWMM0)?VJ6H)/%I.^A-6!P&G.-!B-
IIUS<*8,JG#Y!6(V=:0N M5E+C2+.__W6.KP6#'M&("S<7 >1NR9[RA#OE,X *-*!?Z#BC_%6R3@Z]"? MVHJ3??1 C,91,(M&SAP[X+&(ILGKYTH1<$J'(<\ 0Y%T-87L%;3WDT)_G27:
M!HMUCM4@% $:@@IUF'MF4,Q0*I"XJ.X"LD>T22_4YPKCC]'+C*"$2%J:/O< M1I3@O=<-L^'\N$HY3"D-I0YP&X2;5JJ;BBW!*2;L!?&]#4A(A4PA0FU#\V#9 MQB'@9H _PK GQB1
YSA0(J^'=U;@0%FD.>"_1CB()3NYCC;:?H+U1HF3'E*0 M*)# FG+=G2?L^I98L'-0[[CJ:,'%?;QFT">'1'.2>XP MXKGN+24\0#<'7]0[4-[?*Z?D<7-N,PFPX]5S[MVXYN-9Z6@L=YS]*X-VJ
6<\FP<1E$6(PG#>0"&ŸWCO^@J45X&$\ MA<3)+5X.0Q^-)DVSN98;4/[9>,_E($W;[:3YX#QBCS]HTM0#>2>H/:BJOD6T M;\'U]/8>#U?N_U\Z'WTEWW^[&KM&N2N:K-4QB&=BY-
3KMI%9Y56:8 "+4XC' M$#NX"%%\GT.#YRPJ;FL8O$^&^Q]$DE-!YD*\KW(TA:P1Q3>4+:5^BZX1Q7Y M%!#2O5$T%+-H(D+8,@I&P\BJ,]X_15C3&?X;C1 2=9E([B6MJ;)"Q?DRHZ\[
MM400YP9KPE3:G*QRHXA6+\U^7T?NN+;3>U]GV+D@5/;U?5PF@XW<^GJ[;"?:.X](D+LI7 "< MJ8^SL\@*YVI*8_["A4@JP0AN8J@J,%DO6AURELG^'GRW?887
MCH$QB;T'0;DC8)*J+QCDK)79E@1+X1$&K,T6*TJO_VQYP U_]AF%1#Z=XGM\)*A:1KO?44N*TE],1J[#%!\4-IK =6W0/#" MM%&*\T#*T'KDX9UQ6C?Z5V",>8'#&W&78P,^129A<]O-

DO'+<+&$1530.,5M M%ML)A#:?3A?HFC1==4'=9"!N2-.B]V@!O852I[]X..L!FWI6GUBJA V6K%O]5YWVJV3K.O0>I,RQFU-Z-JY.D!Q+:^XEA&EYU:I0%;<
M^"IS^L9D4V/J.@0@I+HG^^W@:]"VT[3;4CIJ?GP^&>/MAR# _@8S3#G_,!Q+, _'[W;H>?18#IN M=D7XG47\<0X_CBYWJ;#UG6)8_V9 'GWLLIQ%A(Z;QBQ^UVT\H['&>")^L-^5
MIHH1ORS=-TP62?=>\OY2-NI3*FIL0*#I>$EI#]9.VY[4MS?*D+8.['I*UQCP MQLNM>TH6&!&\PQ&V(U(S!J;HXW@>YGYVNX/^\Y? _PSYC^9!#ZIM_ZN-/R8=6LV=3ZU%@^Z?
C469K# MH?N +^-LE2YHY-%YQ^I;#[J&CT-IR*8V?/V-+8,TP@W+.](W;M*]H__EUP:M MMNQ_4YO'IS;M3$8S"M,=377]SL'>R.Y9%LW#WF1N'!P[N<['Y97
M&^N^^)5203P6N?'7HU4(Y8O34Y^L5"']Q);*X)O,ND(&/+KEJ2^=DBD?*O+3 MV71Z>5I(;48W5[SVSMUFTE9+J0AFOK1%.9=>CV[,7=W/:SQO^KM7&]SX+\F1A[1=Z
M>)U>CZ9DD,I5$DB"Q+^UNE=Y3H)@QM=:YJA520?[GQOI#^P[?%E(K^YM_@^= MAM7UZ/E(I"J351[>V\TOJO;G@N0E-O?\5VSJO=.12"H?;%$?A@6%-O&_?*SC M\-
\>25=LAJ+5VJ-A)4(?Q@+:5+Q-YT@%4K<+IU2M.RO3@,,(#&G2:WL M+BJ;'5!V*=Y8$U9> -FD*MT^?PK#6^MGC?5WLZ,"/ZAR(LZG8S&;SN9'Y)VW MT3AG>>
<'Y+UU2VGT;Y(*9BSNK?$VUZF,]8,@O',(D EQP6;B01M!$BUS\0&+ M,2SBG[<+'QS*[5]#$8H&S(<-H!9\X4N9J.M12;K<6HUN?OCN['+ZHA[\]:]
M^3'IOW>RCRH;=N57&Y2XG(C_PY*AI;O7]V_%7YRM2G%[)QZ<+<1?*Z.H+,Y$ ML.)!+5P%S*&%V5@DR@7@E2B1,SIN-T:EPA)6+?(H/16+)Q%6"I86I31/8J$2 M62A>PJ[/ !4J
&V")UJZ33./D,C,U+!_Z>Q^.&[Y[/9].667[QV]O+'B?C8LXND;;N_44X)F7LK ME%D"6*'-B%P'O8QUZ]12.C*O]A]?9PZ/'$N15O0Y^LD. X)%J9RVZ42\-;U0
MSL9U,.-1<[Q>4G2E\"]"JA7;7R.MY"-MD4SVKG]_+T?X<{G>G>I:DVI<5Y;$G"47H.;V4;/*S M-7/';5I.2=7227(00LR)>DSRRE.%-UYBPW9TL%V!YU9=%7I[]]!*F8>2R*CBA
MTK98L%I(FZW8[J7Z/%.D+KHEG*[*ZU96O+-RUSY$QK/,,4^R3QP4\4V)4P3< M2\5!VNLK#K@\!V)!/W*020_EIK:R\;3V/,9K6&^-%2K+8D=C8:F-(4/MP0[J
M=F/@J".QH9PB/T&;"@;B?Q[//Y;:M9.)&@#Q*Y M=NIKI5V,_ (H('4JYA>P[XFJDY"/%<,>: 1RPZ>O%6&A8Y<@07NQ!L#)1:[(M9N!=7:NQK@H0')*L/&!&AJ@I51 JJ-
J:YX(6!4YN]%A!2R38HDP$9"5U@4& MLA:?$D5$C\JM.83)0NT#2UK!C(AD>@;0M1N2D&F?X%!KOB0 ^0SS&))PN) I M]M-DH8,E8;VM?[4LUT6MJ*X/M3%$U;
(66Q! _2B*2'T441\!X@*ZL$ $&_:R MC2=.)=;1QN_%[.?Q=#IE,=^+RRD_(-P[L1GC@R^[=)6_G!V6T?VZFLBWN}$ MO6[L*(X+IN,Z,*0'/V2CI<0CUP6.K8B\$_I9P!1B"&>>]YRY..>'[-
O"M>UO M6C&X=CFC<9PW)07<@Y(ZN8"Z6YJ.\C^BT"Y/T&9M\W57/MW,HFXY0A[:<'\R ML-=YC?!"[1OMO050L]/WF(T>$>ZV3. W80=*E(.458Z#BWG-%Q+$?')((@;@ M&Z)4"-
;TY^W:HEPZ=H("-C" J!=A)ZTH;82:S8C&[3%/ ; MKF[M(T]"7??\H3P1R\BTRE,.7-7,BD:_]EO VHRT \'M>A;S9\E01<5T)OY$ MA_Q#[O;R44/"7+RX:
(JK,Z#HXZDYG4#I#FON#@6N:5VC\(MZ#19\K5Q:(< M1GH>7:2Y6#?!+FWI8B:()"/U+55!FZH2'5T/0IY11/BW79#)2JOU?A,I?"&> M .?,0U\ABXP(%X,TM(C
T:)@SBK*"X]G,)IMNWG,2T++ M*M\AK1N-0FV9!$2MY+I?_;W@'=(?Z0?1T8Y^8/A4(0HW%M@/[QRN6(I>7^BB M*E"'A@=T/6?]N*$Z=E>Z*=96QYBN:L1DO_P M^R$F*/W)9P2-
&3_W6R;6-0_#T3\ )'Y"@[IC=ZJ-W =*"M)!2)Q<_,^@R-'\ MHP.B(^2#RAX ?AS&-1G[EEDNC<&JM&;@8M#PF::Y"? T9//.2&]BR<_F(HX- MDMR\]J BJ,L2X!$OV7RC3%76)]=[]DV ?
$<1($+G+$(GO\8@6L?(N+'LN>]= MI4@_XH,.=49NO2SA]M8+D C+%DH7/8 MC?DT-B4!0:M%\TL&?C>!B0%)*/0D;/38-V;JVB6IJ(R18,@=G+\3+_P'%) M][^X0HDH--
HG8(YV*ENDJRFY=BG? C1+;.WIN'Q+4:S3YB'8DG\86M@0;,$?5PIPYV@#OL\L>KM^ M(7M+X4W_P902P,$% @ @(!H66N68E@5!P 5Q !D !X;"]W;W)K
M&ULG5AIC]LV$/TKA%ND+6#87N_F0/8 LIL6"9 T M0=,V*(I^H*21S(0B%1YV._[AJ2UN6?G DF[2HU\OU:O5HV4ME9E<7 MZ=E;=W5A8]#*T%LG?.Q[Z?;7I.WN#[.@=A=^&MPYW
MR]%+HWHR7EDC'+67LVS)S/14"NC#K_8 MW0LJ]3QD?[75/OTO=MGVX7HFZNB#[&-+U*I:3624X:;\BXXO%58%ZYN;-^K)2#%)(TXL:: MH$Q'IE;D+Y8!
(=AP61=WU]G=^BON'HG7<+#QXD?34'.\?HG4QOS6A_RNU_I*=^D#5=SC IGMR69E_GR0#A!VGVX/9>5 21J#Y@<.>B=;87 3K @?AWSA=;Z92-7M1:JCX'
MA4PA1)>O41.R1\8ZY2WKG Q6>;::!.G$&'-?P;&ND99I8IZ<*51QR6X@W1CR+ M'091K!]G%L[%B\7-0KR'XNT<#[UX(/OA'!4LYN+5JQOQ_8-OGJS7J_,OS-+3 MD_,?1*LT-4(R; /R-T'(#C\
(,06B /I- (9B?;!='!VJY*0*E/KB-ED_](,AVTEUN'!SEJZE(W)-+YH!] MI\+F'!7#T6LT#="<+I@9C-]8VC_!4EYXHH^<%5M!WV6P(_;W#5WPJ"F6WC6R
M1VZYNR">=8;VGE$\>7PN6J+#1M')K7;]'X%D=\[QAV#7DH*ZCFY<:&=F)Y^-ZF1MY M\+%5Y[) !P67XD-LNJ(P%8]O&P/+-&USTN\W!#)OI8XR9&I-_-ZI,-&D= %Q M&HX&\41/TF
5]XL\Q(9'KXG)2 H3>^89(&ZA)];!,1ZF0A;V4U,37<$3\E0T MID^RR:B#VY[KGI<%((2I4]L2(^DSA!*4VM)!N6!F72H!:"SQ,HFIZ2P';;!=
MP;8,3P,LM!W2!+.,F7QD2_WK!W!.\FC;249^,57R>1DX(7L;&>A$_:P4DXX= MM HT'Y'T<> U,P%?99=1P[(-5Q+-(YTNF&@#]1$ U%QJ0KX'90)U9CL.T M"PJC6+,^^(,R3Z1=%?X?
CY*C+FKI-%]M^1#W;S,E&W!,UOM#A#(DOO O9]^, M)X/\O=+&I;18<4>KW#/E?CSN8OXW"5P:L(X,UL/1Z?C$7!48T,NPE@T M =5_*U:+1TA0:P[^_6ZC4-
M.)@0])L2EK>5V5X$&BTE[.<*;MB5WX&;T/M,G MG3$>+K"9V?KCQFJX\M^)'S':8?]#TBA>FP3KN%G0# N!X@!I[TG]JL!YP.%K
MIRJ\^'*#F6RKGEDZ=KO)^HR:IWI5N,C:DS65GSG4);UEB=C?TI;;49%6Z$1S MN_OF<4EK#AK,&!_K,*,X<9G5!6\7XH7=P1_K8QF[U! $8%@RH8XQL2TF@&46
M'Q[Y>'1']E(U8Y&4.0^1<[3G02K8 RC7%&22N+UV77992MLL=S".\]#X][7/.J M,ZJ%-@#YVT(@!2];))XZV%O4F\,5N1,[WK33!L4=_,JI2*"U2R=FX"G;8Z& MIQQ
\E!8K9I4\UU;:2%VPO788=D8JR3$>((C'32\ 0T\=T!BB&IX7=SUM;"< M?.SUY+KT29NV6A/R=]_X=/QJ?I8_%F_-\R?W:^EPD/0 J<72U>+QPYEP^3,V MWP0[I$_'RN+XU:=+L
/3RP9XWUH,=KGA ./?$[^!E!+ P04 " " @&A9 M4K4"9MD& !^$@ &0 'AL+W=OE>CL^MC MEO<"ORBYLAN_B3.9:_T'/JRF%[V(Y*Y3!Q;$/AW+V]DGK,AA/%G8[/7N63% MS=^M]?
<^=^0R%U;>Z/Q7E;KE16_:HU1FHL[=3WKU@VSR.6%[BD6&I6&-?_A4 MO3:*4R479>8,=A7TW.4'B93L^=#!%]\,DT;O.NC%S^A-Z$==NJ6E=V4JTVW] M(6+H HG;0*
[C%PW.9#6@<=2G.(J/7[W[A(;>WOC%Q.CWZ[FUAG4_O=].083 MQ_M-\#RY7??C";1FQ<"/.X"/'[)^@O(OZBW/ZJ/VDF: M#JC)^BISTI!;2E*EF4EDZ
ME2F9>D'GW3QG^UZNK5\T/*7D=-C%N/%B#7_ Q>.U:U65)!^2I2@7DL"!K&5KO[RH52H &F5&%]24 M@T.M##C80$HDB:Y+Y^-@#>]A0)\]'PYP:LK_J:2/B*R8([AX[$W"()(LW17D^
MS]8>5YTD-9),U@.Z2E/%549SK_TX=*".3CVHHP#J3MRT$FA0! -B9/Q$RE[Y M7V.-XO[T^W@7GBU8.#=8MC!#\UKE*:H[H+L]SI I7"5PA0#?RF0[0)\NMR#J
MW<;C*0/=O5E2QGIT^L8^EO81($9EN[Q6/;CU:[?25(1#8!!. VP9]"+#2JR; M>G'/S^6.@4,ZCOK3*,*V6]*8OD6<90T]:1.1"Z>-#=FV'=?1!Q=/N+VP(\UV M.*5'7'=S$?
J[!@*F':Q^VPFX!6B4P7-6-U0=K)P%I8B:2_0$WC[R3?2B5' ! M8U#,E9BK')5F5H2'1!NP-(QS"0/JO-;9:Z8<3S"6#1]2/!CC>,]S-,AVYNS MI/9),O(!]S+F+706\1'G+?-A$9@Z4)-/2&4=O07=
(^0LC6G:T[;S]XR+=@X' M](LPR"Z7V_N6$]&)$CQNOJ#[&LNKX/RP-<@$/KL.\>WU.!M%TT@8"QMXNLUC MUZ)=\O@@L98-,I$P\NO'P(ZXC(P0YIOXBNH)(Y&O>*458Z;GTZIF1
+XSFB'C/:RF,-XXR)3QF M"_GJ[."IA8.KV>S=W>S@TTXYJT5Q2X*-^-)TVB_+?;B)NBOI]<'MW^VV M<,. E>Z)GQ8+'O.3T?C@HP[8OB3:IS*P8"-)E3;^@VDR23:"F\3:@YK=#H^ M^-5?
OKF2:!;@@JGA:C\Z8O8XXR$;>QCM4XU4V7"X(D!Y1A-PTOYV#_2^0V=Q MW() 9UR=0SYR^:$]I=T2QZK? F^VC!G8^&GQF%%L)?V["I\ZK+;C;$S?;S@[M/?EJ9^-
M9YL7B2]G/(HGFRF?Q/JISO^BNR=9WPB[I RC_L^(;)" M[-XKOA\$)I2!6W\4!@?*>.0MG'C4QE^4F]#)>/I%J5,Z[K@GVPO"]!]/1@XQ MXNF1]KV-#C>^"132+/R7#[XA@>/"YX%NM?
NXN&0:!^&PO=V]R:W-H965TD7':\.6SM06AZ&*TUTJ35 MPYB_3TL#!+8PNQ<82?U>OR>I6]/.TU.H$!F>:^O"+*N8FZL\#[K"6H6!;]#) M2NF15BQ#6N6A(51%
M4V'PV'EWFMC,OFTS1W1_.I;]D:AW<$H:UK19L%6M_ MLHML-W%O5A7'B7P^;=0*'Y ?FSN24;YG*4R-+ACO@+"<9=<75XM)C$\!?QKL MPL$W1"=+
[Y_BX',QRX91$%K4'!F4_*WQ!JV-1"+CQY8SVZ>,P,/O'?MM\BY> MEBK@C;??3<'5+'N?08&E:BW?^^X3;OV\C7S:VY!^H>MCQV\ST&U@7V_!HJ V MKO]7S]M]. "\'[X &&T!HZ2[3Y14?
E2LYE/R'5","K;XD:PFM(@S+A[* Y.L M&L'Q_8[C8Y)Q3T*TYR%,Z[D>HM?]/C1'-A+^.(=5P'^< 46Q_A]@7 &/XI18[BD;#/#7]3*(M;M?%Y?#W\\HGNP53\ZQ_X\C.8L_ MK>ZK9X0/
S@FAQO"PC"0;%+:HV!6SI1&*\?;VX<4X-8XY;11%HR336NE*#D M5XJ&5[94&7M1@I[^8\4FRR@Y*D;Y3; 'O1Q2E^"/L@JJ\$$(2(C*9I$)"&, M=>-)V@1H%2K)N\; *>\
OAWPQ[X3SS3T<4ME1:DJ3?<]CJL MUXJQD'KCRK@D^M&9.// LB!YKK7V;72JDJ> QP2*$ +J5LS W M_;^V6EP*H;32-;H6^Z)0.X^$&LU:+2T.X)/O)(;>')VD=Y*KCQ(L^8VRO-F1
M04F^EA 4U:(@(";V2@5PGJ&2$_8DURKJQ><&R: HE?1"?$("="0G\5OA.R<; M<*JF\H.6)W=TE1J[7(+(U'>__>S^[;CN6^:O\[A^:)H%2^0Q5*@P\$[:=74 M-_-^P+Y)#73I60HB?
5;R_B'% %DOO9S&=A 3[%_4^4)02P,$% @ @(!H M69V;Z&ULK5=M M;]LV$/XK!V_H6L"S%2=-@^8%R,N*%4.7(.G:#\,^T-+)XBJ1*DG%\7[]GJ,L
M66[=+"CVQ1;)NX=WS[V0/%E:]\D7S($>JM+XTU$10OUZ.O5IP97R$UNSP4IN M7:4"AFXQ];5CE46EJIS.DN1P6BEM1F[&G9W8)I3:\(TCWU256T..\]/1^=[KBP.1CP(? M-
"_]X)O$D[FUGV3P-CL=)6(0EYP&05#XN^=++DL!@AF?UYBC?DM1''YWZ&^B M[_!EKCQ?VO*CSD)Q.CH:4<:Y:LIP:Y>_\MJ?EX*7VM+'7UJVLOL03AL?;+56 MA@65-NV_>ECS,%
X2KZA,%LKS*+=[4;1RBL5U-F)LTMR(@TT^8BN1FT8IXT$ MY2XXK&KHA;-;+E7@C&Z4"YK]R30 5):FZ1K&H@68?0/@D-Y9$PI/OYB,LVW]
M*8SI+9IU%EW,'@6\XWI"^\F89LGLX!&_=[# 8BW_P0/5_3>*>-5S A/?Y[/ M?7 8_;7+[Q;V8#>L%,MK7ZN43T>H!L_NGD=GSW[8.TR.'S'ZH#?ZX#'TIX3E M<8#?;6#:2R;T!1*]
<;:B@+JB8./_F$+!=&FK6ID5L]\LB4U@1]I 0J%P%HX9 M=1BP& I2J,46LHZ,:A,!K,NT05E3:AOG,ZQ0<*X/((''UT MAFTG=&WHBE.NYEB:'<422+;C$T,#G[O@:!FGZ\5-
I)Z+SMK/MT.1\TZD]SH& MM2=*#+IV"V7LO1W36Y-.=KN\+&QOKGZV2P-C?#.'!QK1'Z\YTR8M&_2#F# _> MXW!!\-)"#3,@4@P2 HX.*M6<^'.CZRH2<3,
(M6R_VX=M:B)P)AJUL_=@=.-5 MMXL$14L.=*D#X?TKFFM;.S"IS8("IX6QI5U\Z;Z00'5T MY2K5I8[M3Y3Z/)/16++W;]P11*TS1PTRS+;8E?JT >2J+NV*!>]>:>1NR3&; M-
R0@>@+JXW3LCQ&X;54*Y>!B_(.%@;> WQA;0:3I2R_Y.*J<3&VF/.<6HE0 M@S4 (YMR<*%*Z1DO6Z):\J/76:Q%N@O(EN@YY# _BND3/1W?7'T*;6P(GG[3%7U\54\,39]
[UZ53:N'697BE&D3 MMN/WD70#4>MN% HE4YM"[>R/:=>[MVU:>R8B3/R J[#GF+\HJ<:A$;=U$FL3
MTEANBSLFPZX]AKC8IM^RVP.VRF'@8KCPVZ1=LZC9>6L,ESV#:WN0%^<[71KB

[*]U"-J>L! M :G-/66=_!IP8HALL55B#U)&DBD8JW^!,3ZR,MFR*B@(4JT+60 >GLH3YWI6 M^@M0W1\25;7B1.V,[DV@3[5N_<6PG&Z-;*N=L0(NQB@<*'Q0W9=%O"@,$,;
MG[KDXY!E+ G[2FV#%QK11[EE<=PUR&WN[;8>)!2$ABK.8Z:TC7P@()9I/T\> M2TKW\HEZ1]2H*7^?GCY1O[:V,3YAX,1@<,9+;DBR'2 (>I]U\IS<-MNT_N*G MR42@PP66 MB-&R7NR-:&HXN$B%82@Y>!/:'9(3'U Z32&!_!PTK7E@N'$H8F@[R00XBU M4-D%IJ4$(MST0?@YH+AOXN]9Y.^G73'MR/4QN9"%E1JAN[*!,!^;;[QXA6E) M6ZO/_"12?IC. _;ZQVBO?
PJ5*H:6V^&3/0W3E7A4["U#(G9TK(6(8R2K@*R M;>Y6ZOLXB)'>TW;+Z6'0%M<3UGH)OBLNN^H%TQQCL3"4YHR%DL(4F$5 " MP=%;FSMNV5@;%E32B.@K:B,>'A?VWCI=9
04&+S("?PFPS3%CA!NR #< 1=D MTR1KV$-Y^XK9M#\E+<+#A^^"Z^U#^-VQ&*&38SB_CI+9\?CXZO9HJ2D+%GI]H MO\(Y@PXQA!?G\%.++7B>+O($];!E
R(OZ]IGW<:W.^*#.O$"B]G M-@65^RQML*P"AK:3AM\2*1T2\^0UA^E!,?^9RK6(*-0-:+NE LF@3!]<9%BF M=U>FQ+7O+),E'8M,]OTQB\A/$'35@JJI:OA@* M8X8[%"Q<)55T:
(7$RJ55O*\O&O"6IRA2OT4YD#M)@),D+J46#(F J;-"T*8G M:1V:?V5USS'!]%T'1NQAV\Y\00+/U&N$GW8#2RV%]YLP[892_J&N+"-O;V)/ M_R@X=2:-(E[?+)%T[
F1;54D32@?;C^Y_AKIL4+/BK@V?ZJD*@-E".2%&$=R M1#&L(;!TPER%POP#.:CP)0[ES$*9^0@W!"7?'C%1#$G=#_MW66F.C&D=8W. MEHG_C4W"!VION:._:3[>.\#
(5PC0;XH7$MYB)1+%P[M>(O#4>H15U?Y](#)6: M^@X?OK4#&,-6C$XT'4\.CCI3APW-:6=H3@\:F@^^WX_R'8NJV/?BS>%5ABW- MP-
+J@]WHDHI'_MEV36K760XT&OI>Q+1GU'=/=!F6KCI9>>VO>6N"I#%)%F2 ME!36S0R'V&RK?*,1-0IQ/LI)/KZB-R\$Q$I].LT)SXM%6==Z7)#J:+[I1&\
MU,0T*O>04)F'WMH*_E#>HC.U-S7)FUZWL0;^TN:Q7*J.CZYO7QX]4!_M&F;\ M5HRFDF^CJ)*Z+ M%,.1MZK-.@$0=_"8>N&10#?:E$D90+^<**SB$6V*L2>[6 B0OPOL:R=1:$EJQ
M)$P1!;N:$UU2*5&BT%&HO/ THLO+E.PX]^]@2 [&;58S>LFNSU=SQWD1S&#+ M-$R;%*.%%./K^CYRE?YTSH?*VRVD)']{PBFH!S?RK2VT@)-#Q8I#2(%4^ *" M-
FM*#'!X3G+JFVQKKV81D74&49()(0]+\B %:"\E0K4'9;YI)YPT'SI-@@OH M=3,M.;,J'\EE@">46>A95T:#25:*KV0W&DE?L[@DTYVV"'_P+<(C]2JM;1(K
MWWGKV8&NOZY[0$&AQ^''#RWBAX-N>(WQUC$.TQ?[$+K +BX8([XRJ$&U4(BR,K?<\0U^TT MV8)[L2>[1]5ML[1U>/%D^V7#B(-D'VZLHF#!ZT2BC95-KHG&?B6 Z-X/GAY\ MH1?.-
S-;+T;7ML)GZ54=K(/]Q275&V8#BX?E?T><<>B5/'L3NAZ-T&/;I>X' M_=X+BW\B_'US??NB:VH/:?#]15$KG4M$PSU7KT!VR$^^$4@\S^M.8>F_B&R>VGR&Q:Y63RXPA+
M<_GJH_Y"KRN+"CXZGSQXK-ZN2/,"+VPR4KU*R\RDJZWL%*O;.O2LQS83\EE2 MX/,U:L@6OQ(50@![@XQ=0./[/-J$> M/E*SVGZ&AG+K$]'1#BQF5$R4[&;:W=+MQCTYAKHRO+-
)UH*@5YSLX&U_0^SK MJ$\FZ3E'=EWG$CME;G553*[+$Y@7B@[M-GQOE!-)\J'45^:ZDA;FZ,6",GL^ESTWA!/*D>C/P])F],7[*@3MTMN&@;W# M^:9#W_4C?D4:O"[4=ZQ=MN'<52
L@I>]I-&+,[;7X@D9)0;PBV 4,A814$(8 M8^3(>M,D/P#OE@%-!S2/K7,.+7PRK-->]?&QU(4WFV=F450,G^4=@ZANTXM0 M$V=) 62A'H]]9J05-.$%K4T$ I&([PL+R^147;*N?
0EY\XZT=F]7NYKSGF9 M&I3.U-XF;]]#EGXFM3U@*^(^CT8Q.RPO%?.;1V(${3J^&C(,8\ 99B;&0!$; MP&K:04R"\]D 0?%^1M>EDC;R.I(X^2YQ>[R),TJ:%E'>M"5+LEYR#
U\696[M]I>0PE)I6LP*3A#R MSI85.Q.K[OMD16V('7]50<]&72H[^8L%_JJ2]* 0=?'ZG5?S0NW3].+V!Y< MQH R!.$I[L"X15OPZR:#992'R5_4 4Q=\-\-XC:MJI$_KA-_C7^;Z%K^(D\W
M7/ZPT7M=+PCAEF:.J9/QHXLCP&PO=V]R M:W-H965TA*32RU#OE(HRCZ"S,&9?!>.AU#WH\ M5*457.*#!E/F.=.O5RC4:A1T@K7BD2\RZQ3A>%BP!4[1?BL>-$EA@Y+R'*7A
M2H+&^2B8= 97/6?O#;YS7)F--;A,9DH].^$N'061(X0"$^L0&'V6>(U"."B M\;O&#)J0SG%SO4:_];E3+C-F\%J)'SRUV2CH!Y#BG)7"/JK5%ZSS.75XB1+& MOV%5V9[W
DA*8U5>.Q.#G,OJRU[J.FPX]*-W'.+:(?:\]T">Y0VS;#S4:@7: M61.:6_A4O3>1X](=RM1JVN7D9\=W0[ZW"WT\K>X2J/D682[A!F<6IIB4
MFEN.!FS&+##='&L*)+^~==EMB.T.W) _:4(]/9ES:U X6\QF=V+HG?!_?,YUDT.U4JF.: M'Z9 /P'$*QQ2-)NITI"E.1KL37*E+1%,(5&&R- UYP8^:V4,E))FG?";"YIQ
M+6I!,M&];9CM3=YAMO=V1FT)?X"+BQZ]._0<[/?C3GSI=>DH7*4TE;#I-$VHWA23: W\VJ.$\N%JY/ .;E&)^>G >AJ M-E:"586?1S-E:;KY94:_$]3.@/;G2MFUX (T/ZCQ7U!+ P04 " "
@&A9 MN)2_ H$" " !0 &0 'AL+W=O"$6J)!T[?]\A9:EN MX'ACD:.9PSL:7\YV4CWI M' ON)"S[W"F'KJ^SHIL&+Z1M8HZ$TF5<4,;57N MZUHA2UU1Q?
TP"$9^Q4KAQ3,76ZEX)K>&EP)7"O2VJIAZ62*7N[G7]K 8YD7 MQ@;\>%:S'-=HOM\0XYMR"2\>?]+HC;>'QNJ5_92[SWCH9VAYB>3:_<*NR8TB#Y*M-K(Z%).*JA3-D^T/W^&H
M8!*\41 >"D*GNSG(J?S(#(MG2NY V6RBV85KU563N%+8H:R-HK%>I)C^7^^3K$Y; MV&I;AF>!:ZQO(JN(0S"P1E>U/4:.5[T!F_%7EQOP$0*KG'&-?Q:,+11]. X
M?:KEAC@X3;2.F>J:)3CWR!(:U3-Z\?MW_5'PX8S>0:=W<(X>KQNC@,S@]9A. M23T+.RVUQ6([_422W;2A$!UJ"H1,5& M],!44D#4O^ZUS$16%LJ<^2X@&H[H=QB-N@2..>-
N%K62&6KKMRUNA6D,TD6[ZV71 MN.I?>G,W47=Y*31)SJ@TN!D//5"-WYN-D;7SV$8:T!WZ<9_ 5!+ P04 " " @&A9$6)UV4L' #*&@ &0 'AL+W=OR@_]':.[)
<):!G7,;T3C1^([65:\9NU,V7Z*"/E48T MH:%4$ 0NM_28)HE" CU^EJ#]>DTEV/Q=H9_JS<-FKHF@QRRYBB.Y.A-@'?131 M&2D2><[N?J7EACR%%[)$Z/_HSLQUO3X*"R%96@J#!FFS
4W]T%O5TJ!(M.OE9Q/(![5R0ZX2*W?V1A"74Q%%8PAT9./L1N#'ZRC*Y$.@DVBT*C\" MU6K[$J_([L3<$KS(7+P -G8=COPG']_CL9S'L$[3H@0Z-L,Z8VC'[_!<_1% MTE3\T;9;
^:V@ZF,V1,Y">E!'U)"4'Y+ ^X>_O++&^$.'JFZMJNM%?C@UB8)8 MI>RW7 ?R1Q7(X*8V?3L1V_6]6% T8PFD9YS-D52>+W,T_I,*).'Q,4MSDCW\ M\BJP+?
^#0$*KP_)E7JFHF7&6HJ^$APOD6,9A2#($'@3S7E->NW&O9W8BT)5. M&AJAC_,YIW,B:>];(84D6:24(7(=;SP)!ACZ#5RA_88+EHG^T.-..\C 6VBGM.*X?
M#!QL:15PL$1!'1HU1'H=48@^#T%#YOH.S5Z* 0_Q-I*D!UR)8);376\'6.,JF><$5HE2!RDKW MLJ;OP >U(@74-*Y7LS%$R%E",N3:SL -@EZ[ZFT2E9>WK)!=PEL04Q!;_G-4
MJF1GL=:BX3-I>A9AE=DDB2&#.6$PE8 M*1)591*;A6DGSF"$%0*,*W;W>A<+3ND*7T(M0]/XOGN@U^*!C2&GS4^;LWJJ MR.N.JR(THK?
VG,=CZ^1[<$_:'G8]#O5<5R_]YEFE*M(@/DD H(*>^=$,6UD M0?/T'0_9(+M&#MET$"_\Q36V%?_'4LAZ7;=%2U^'2U^9[2#.Q-E63$E=VE^TDGFF75,X8HP>
(88%P_:N\]J[636Y3CH!-O:X:#L,)5"+SD>_%[H 97 AO\^=2Q8.JZ*/<5,P>YUP](<#"7"O HQ6 MG T/GF;LZUCH!<8Y@^9\:IKS5=54_UL+>8H6J#^]*XRMAHEV@#XOGFZ6S]_
MVE(UW:ADNBK[I [V26>PG[<3M9WSZ7>QBWY\U3JT'N([<5]XB+?P\@4+WN8; MAQ)MR]HV7@=9SRTI9>R^%4B9N+.R=(-NK;1H/9;IP@QK%M#SNHOM2L)43:#W
M/;LM#]H;V6+9$,*NK3N [_4^5R\5++\RGI?)VDW5J[PGCO5;."0>Y< ''$913'C-]>@'Z7IXI M'Z6B_WOF^>[O4$]O:#>IY\KMH\P39OE+H96[)?,$@13(95E*AW6!TSY,-9O
MN%,5$6>RQCI7!M:)9TZXC,,XUZQ!'R:IB8BJ$JYY7Q51BJ\B($M,P4.FOC M4&AUL-)1X_-"2OE;KSRP_#P&UIS0&8AB M**Y]Q,V'$W,C6:X_5EPS*5FJ?
RXHB2A7$^#YC#%9W:@%ZL]7AW\!4$L#!!0 M ((" :%F$9S+TG0, <) 9 >&PO=V]R:W-H965T,TEZU*]$-))!%%) V]4AT=ZJ<->'TSV89 "KB9W: MSK+#'92?==;1 -/62KTT-
L:D_=]7\=;S)B^ MD3D*6EE+E3%#0[7Q=:Z0)8^,HW6V,G_-$@9QMY4ZYK)C&J4R_\<1LAU[/@P37K$C-5[G[ZM\',%8IMH]85?:1F0<%]K(MK'(F!AD7Y9L]574X 8C@LQ1FJ^%.))B<
M^OM$IF84'A-@HN "\QO(&PU(6@%G0MX89UAZ/#"RQG^,UYIHT@$_Y[+L83H MG(>P!Z.O"3,=:H]'G4KH<=+E%,';/864/9G4H
M^7\4T=#25&8Y$_L/[WI!^_:3AM3Q2O_'*S[AI8YY,<>+7C8KVE*#V0I5O:]P MQ04%DH4F' WX%).)B[Q'IAQXCBI&8>AFN.XW7B(TQHO%W7+1^)/LF+'Q2X[G
M6+R'=K/5BQI+:5CZ"W;SV7@RF\^6L[M%8UI0CL*\B'.HQ9ZNNVP\46*^"W3 M)@BZ9JD@E27D4KF[Z3U$4>N$WG&I+:WV;=CXYJX83( ]4H -Y8#VVGT.9%!E M?
0ANPM"54;_T2+B.94&1B2#V(8+?+@BX6PNX"\L"OB],H;#2\0/;T_U]7IX7 M(<^?N J[S#6OL*D(:5EL(\]*5[ZR&T[$\BS"4Q95]/J%CJU/-9GB]!N!E&[,4>M^S#+
M\L+N.1>D!]0&KJ#7@^L3>_B)0439M;B4--4[WN:4_%536@-;74IK#P :H_WU&/P%02P,$% @ @(!H65[$ MU&ULW59+;]LX M$+[[5Q!J$;2 $+UE.[$-Q&F+S2%H8*?
=PV(/M#2VA4JDEJ1CY]_OD)+H/!2W MW>->#)*:^>;UC323/1<_Y!9 D4-5,CEUMDK5%YXGLRU45)[S&AB^67-1485' ML?%D+8#F1JDJO=#W4Z^B!7-F$W-W)V83OE-
EP>!.$+FK*BH>YU#R_=0)G.YB M46RV2E]XLTE--[$]:V^$WCR+$I>5,!DP1D1LX2S\%/-7R1N![7OY9$]T M)"O.?^C#33YU?.T0E] IC4#Q\0#74)8:"-WXI\5TK$FM^'3?
H7\QL6,L*RKA MFI=_%KG:3IV10W)8TVUI%GS_![3Q)!HOXZ4T*]DWLC$*9SNI>-4JHP=5P9HG M/;1Y>*(P\M]0"%N%T/C=&#)>?J**SB:"[XG0THBF-R94HXW.%4P79:D$OBU0
M3\WF.XDW4I(E;##7BMRPIM(Z91_NZ:H$^7'B*32E%;RLA9TWL.$;L"FYY4QM M)?G,B\\0F\R,8=&;SH3;PFW 747*B" M;U@10M+,HYM)Q7DVJC: EGS$OM7Y^E#P?"& M[R1EN?
QX,;C?"H!GY28]5\OBZ2")=A,KCEDA;9X$[P?)?9/)#0B@9IMQW< M58TI+7)F0;Z'LR MCF)< S>*$LT[-PATP2/7]X..;KH6.A&V[0)+B,C2[>>V$M^JA<,C3Y?XJ\/$
MNF0##$M3N@:!YO@7*?273O\.CR#IZ,AU]+B?[#T5U2'ZIHV.H29A;$/]BE7& M(>"W? G<9)0@SG#D(TH2C4GB1J/X12OU.A.Z::1;/,9\:V=2UT^U8".:WKFB5!K-DQ]J.6&UT]
M6Y'$3;%3$C>.TQ<%MQBI.TQB\XSB<6]1O2<3405B8^8^G;D=4\UP9&_M:'G5 M3%1\68NQ7QM"B9)"6M4]<^'^&T4S:S7'!2OS7RUX@JG-;/=XG@,0@O@^S7G MJCMH
W;@GOT+4$L#!!0 ((" :%E@I_MCA0(+$% 9 >&PO=V]R M:W-H965T^*LNA>SNT[:OV=V[9@ :=27>"]SSIPSFYELJ\V=72,ZN)="V7&T M=JX^CV-
;K%$R>Z)K5'2STD8R1UM3Q;8VR,H DB).D^0LEHRK*,_"V=SDF6Z< MX KG!FPC)3,/4Q1Z.XY.HJW!#:_6SA_$>5:S"A?HOM9S0[NX9RFY1&6Y5F!P M-8XFI^?3D8\/
=\X;NW>&KR3I=9W?G-=CJ/$"T*!A?,,C#X;O$ A/!")^-5Q M1GU*#]Q?[]BO@G?RLF06+[3XSDNW'D?O(BAQQ1KA;O3V(W9^@L!""QM^8=O% M)A$4C75:=F!2(+EJO^R^J\,>(!T^
D@[0!ITMXF"RDOF6)X9O07CHXG-+X+5 M@"9Q7/E'63A#MYQP+K]$6QA>APKI%4P;2P'6PAN8E"7WQTS M6I?WP>]O$3' MN+"O*&1&2T(K?&'AZL<-S(VN#)-P.T.Y1/,SBQU)]
(GBHI,S;>6DC\@Y@YE6 M;FWA@RJQ_!L?D[7>7[KS-TV/$BZP/H%!\AK2)!W"A9:U;E1ICS /^LH- O/@ M"97[LE>YB2IAT?[%_?F"5XJO>,&4@TE14';'505S+7C!T<+M)X+!M4-I#-]:K
M%3$\+,*W[+FM68'CB'K2HME@E#]_=GJ6O#]B<=A;'!YCSS\W_AG]_Z*@*_(@ MQ ,XM Y+* Z7LA7=THX*K1\+FSS-XLT!):->R>B)2DIN"[U!*JXV0)YWRHX+ M&OTO*$F2?
S3%>VTDT51A6%@(;]9V5'_:SZ-)VX9_PMMA-F.FXLJ"P!5!DY.W ME-JT Z+=.%V'IEQJ1RT>EFN:J6A\ -VOM':[C4_03^G\-U!+ P04 " " M@&A9V],)V4T+ ",= &0 'AL+W=O2%?
QS%O\>+NJ/VI]GEYB;54-X[!IA[MMAW6D'2:YR=)R51 O7?"%PM[3V]NG M[*G>?JJQ'XO?=/?#6J_["=+"[QA+\2TWQ/+L!Q%(7?/L$R?(/T^(_*FS) MEY(GQ;\5#?^TKF^R\ M-
]%Z[RLORCP*2[{UG\IG6L!0GR%A[A8VV?M-3,?NNJQ?,=JOF-^O6'"RF.2N MZ_238QJ_PE9L6BKR]5+M-"AKH,"7.G'1E_L,W)9&N+SKN
NQC17WDT02J)MKGT^GY44?/=HZ>G>Y5EV(U1Y9YEA"Q/LSK":ZR5]6BAKH; M"7.1, \)H[..ZX1<)EV]S#K2FCM3HWN^@QHGB66^$\M<*Y8O1;%A:1R!HE;#F,UF
MUE3=)9SOO'RN]W+Z**95F9C_-XU0N5>+&.I>),P][TY@C.YYY/4K1OL5\Y%' M$(!@DO--HPV.&%KWNU&\J6)KA"^7/%0.^WK"4.]#:2Z4YD%IM*'MJ^E02*>+ M!*@VR?
K8"YZ9^AG#7L>_OPPC_#F,-PLQ8:QG$F)\6&_J6,&B$I3X..4EB;.B M(&*.08H5RY4=B[[VP=I"TEPHS8/2:.$3A@/35O55JI*&HF' :J L-*L5FJ45
MVDV41LDFJ>02"H&QAWK>$:5"69R4[)FLV4LBOJB%);[)^7*3+@KQ/^2B_U(% M1#_IJQRL+B3-A=(*(TVM//];NG,.)S>0.L,4#19?FT,U-1&L\0TJ-CD]6SW M-N=))1(HU2\K[JT7R-
V'\51^4+^N.')/<^5L4]]!8/%!HU^0FD>E$:A-!]* M"U T691M#-1TWBHR;T)CI%":"Z5Y4!J%TGPH+4#19'6V,5Y3'^1MN\QUTV4N M=UTF>\@YKX?K!2_"/%I742:E+J%Q8"C-A=(*(V>]
VYX^NR'JWJ/.%[4JXX M$;/Y-4M?B',S\4D/1(K?\)2\;^/*Y=93MX99PY)HC@6_GQ/GJ)R11@1L*2: MDZ55'Y1LL\Q5[D:069IN6%Q5)"HL2I*SLI[8$<\FLY_.R+>]1B5LP05LD3VE
MN\F>*&D:/]6PJ)KKB05(U6[1ZH1];^J*7T2KQ40Q6HN*ZI*OE364HL*\O=,8I#6D7A2M#+C4 (%/G[1AR4^ DG9\HS&NG5 $63 MS^@V#6]P&#]P!4X7265&.-\M2%Y@.@--?LQM
=55S([,;X5>5H3YX//8H 19/E MT"8+3'VVX)LX0Y2.AV8&H#3WQ*&=-]V3LH.&9@*@-!]*"U T65=M7L'4)Q:N M%6."4F?0K
*4YC:T*CJWOT:>3V:'/0RR6@JE^5!:@*+)JFKS&*8>D7$K!8[V M9Q%*;4%3&E":V]#D\(MYJ"MDE11*\Z&T $63-SFV&1)+GR&YZ3?'5(E,3QXJ M,BC-M;JI!\
<1$^0#F4$KI5":#Z4%*)HLLS;18ND3+;YN+L/3Q[F:;RN\L M%W.GLM F:O6HP6Z&IAR@-]*HU":#Z4%*)HLOS9P;DW?;R1M6A-!=*\Z T M"J7Y4%] HLGJ;./XEC[H/60CMQXU6'[=?
>X3U>8S%UJM!Z51*,V'T@(43596 M&\FW^E\B\-2,O4I502/YEFH'?GV9Q:&JD-5Z4!J%TGPH+4#19%6UD7Q+'\F_ MJS<;9\LESZNAZJ6Z!T&^UH,<-E1:4YD)I'I1&H30?2@M0-%F";:C?
-M]J MM6!#0_M0F@NE>5 :A=)*"U T61UMLD$6Y],&#[ZZHBES:3!=W9^?C#\ M0BOUH#0*I?E06H"BR>K:N]>,_CJ+Z_+#MQ7_<,/R[[PDE(6G+ZS0$P?+"WM; M&>Q]9;
WEL'>609[:YG_1Y; ;K,$MO-F(S T:0"EN5":IZ51*,V'T@(4359G MF\RP3VS>'Q"OTZ,&RP^:S+ 5=ZNQ)]:TD[3J6Y#V+>A##R1 T60]M-D%6[\M M?Y >.H.D#*,V%TCR[NW6_(Y=ND2-
R@8;[4319+FVXW]:'^_\A)E;K/ LY7Q3; MJ_.C/0&]3NR5<5H]>;!ZH#O[H30/2J-V][X_]=W6ND*#1OJ1-%EH;?3?UD?_M;S?W8I(D)E'-4E$[B8=F * T%TKSH#0*I?
E06H"BR?)KTP3V^9M-XJ'Y RC- MA=(*(U":3Z4%]'H\NU+VSR#H\\S?$FC,F)Q&TA;'+G*2<\9JKT3K:KNNJRY MZ3*T+1Z41J$T'TH+4#19:VU"P=%?.S!D@:!'#9:,XNY"RE0\M%H/2J-
0F@^E M!2B:K*PV&>#HDP$_L)9HR-(%1A/%G/BSO@E#ATLHS8/2*)3F0VD!BB8+KE42C-A](":$T6:YOS<&9O M-DA#5 :A=)*"U T61UMHD2!W.9A!XS6'K=RR2.#-#0_ >41J$T
M'TH+4+2MJL9[CSA,>/Y0/^ZR('4'MGTHW^[3W2,UK^L'21Y\3LV/_O;!F"UF M^YS.&Y8_1&E!8KX42.-L)K21;Q]]N7U39NOZ08KW65EF2?URQ=F"YU4!\?TR MR\K7-
U4%NP>07OT74$L#!!0 ((" :%D3)IO?BP, "T1 9 >&PO M=V]R:W-H965TICV8Y +6DIC9#G3_?K:39GRD:,J9!["=>\ZUS[FR8\9[RG[R#8!
M#UF:\XFU$6([LFT>;R## _))N(9=/5I1E6,@N6]M\RP G&I2EMN"#5@3\=;O(9[$%^V=TSV M[)HE(1GDG- <,5A-K&MW% U5O [X2F#/#]I(K61)Z4_5N4TFEJ,F!"G$0C%@
M^;.#&:2I(I+3^%5Q6G5*!3QL/[)'>NUR+4O,84;3;R01FXEU9:$$5KA(Q6>Z M_PC5>OJ*+Z8IU]]H7\4Z%HH++FA6@>4,,I*7O_BATN$ ('F: 5X%\$X!O2< M?
@7PNV;H58!>UPS]"M#O"@@J0*"U+\722H=8X.F8T3UB*EJRJ8:V2Z.EP"17 MA74OF'Q*)$Y,;_,=<"$K17"$\P1%F##T%:<%H 5@7C!OS]![=)TD1-4"3M%M M7A:TJHR+$
0F*7\K0[[3$%+T=5Y.X*2?A/3$)'RUH+C8PWQFW>%^TW+^+_O_[)' M[? %9A+N-F4_TM*O*\S7?'Z'"OO^23Y$MP(R_J.I3$JF7C.3VF-'?(MCF%AR M$^7 =F!-W[QR
^=#DT[6WO3;V(\))+G?TI4 ^]&M?^JV^S##? MZ.T\5@WX59 =3I5+39:45/T#=7QWT#NWI'^FXB!P!V=Q84>^>4>^Z#$.&SKN
M8=R11D&M4="JT<4GRN6QM98O7T@>9*0N957)2C+Q^YE:#LXF=BK9LQ%A<";6 MJ4SG'*YW+E+K6O^QV@:UDH-6)1?X@61%AKXO(%L":]S96QE>NK.;) M-DLU-
MDD6&R(X\O:H]O3)V:E^9]-8D66B2;&Z2+#)$=N3ML/9V^,RI+4"RJHTNIAD< M[WY=#_+6%"\UW219.'SBM#_95TWFC R1E7;:!]>Y#-A:7[PYBFF1B_*]NQZM
M[_;7^DI[,G[CCF9NPWCHCN;EU?TO??E'@GSY7Y.&ULK55=3]LP M%/TK5QF:0&(D33_X6!L)BMAX0$-TL(=I#VYRVU@X<68[+=NOW[43HK0+W21X M27SC>X[/N7:NQVNI'G6*:.
I$[F>>*DQQ9GOZSC%C.DC66!.,PNI,F8H5$M? M%PI9XD"9\,,@&/D9X[D7C=VW6Q6-96D$S_%6@2ZSC*E?%RCD>N+UO.)#@@I7"W,GU9ZS]#"U?+(5V3UC7N8$'<:F-S&HP*
$0UH#P?P']&M!W1BMESM8E,RP:*[D&9;.)S0Y<;1R:W/#<[N+,*)KEA#/1 M=;Y";6A;C :6)W#%N(()'DJ$&V2Z5&CGX /,JFT&N8 VAN=PB7,#,XQ+Q0U' M#29E!IAJ"!*@N,6[?XF&
<:$/B/5^=@G[>P>P9XF^IK+4)$*/?4/6K$ _KFU< M5#;"%VS,L#B"?G (81 ..N#3W? ;I@C>ZX+[5-"FJF%3U=#Q]?]=U4,X%P*^ MF!351N&^G\^U472*?W2YK>@'W?
3VSS[3!8MQXM&OJU&MT(O>O^N-@H]=WM^(M;*,2_:82_5WLK4K8'4[L4='-4':!:9%(9_IO.2"PU587^2-ZY_=4J([>*[4RK M2T4=FK5]MF5<]SD;,@?-/('KY'_24FMH&PO M=V]R:W-
H965TFF M[6%:U*S;P[0'!R[!JL',=C[Z[W=M*$L#C?]P%_#'/8=S[K4O\5;(!U4 :+(K M>:6F3J%U?>6Z*BV@I.IDK'*2V*[- M91*+M>:L@KDD:EV65#[> !?;J3-RGA;NV*K09L%-XIJN8
'ZOIY+G+D=2\9* MJ!03%9&03YWKT=4L,O$VX >#K=H;$^-D*<2#F7S)IHYG! &'5!L&BJ\-S(!S M0X0R_K2<3O=)]P?/[% _LM[1RY(JF G^DV6ZF#H74=LD@IVNN[\3V,[1^0L.7
M"J[LDVS;6,\AZ5II4;9@5%"RJGG379N'/[)H"DI$ M3GJ[I[>@*>/J#./N%[?D].2,G!!6D>^%6"M:92IV-@RXG<9\2U?\ +?G#[2)4>OZ*9) .6* M_+I>*BWQT/T>,M@PCH<9S46\4C5-
8>K@35,@-^ D;]^,(N_#D-W_1/;,?-"9 M#XZQ=\>-7R>.P MHMP6J)8B!V5Z"B[D (/GKR$-]Y2,(_] ;3_F,A@6&W9BPZ-BO^D")//:I1C*T M5VA(7]C[=C0ZD->'<3-
":;AMM,M*AMSUH*C1W0#@O\1X$T ;B?"Z&?)J8-=G^] MY"]02P,$% @ @(!H614=8R0H @ PP0 !D !X;"]W;W)K&ULG51-C],P$/TKEI'XD)8Z3=-=M*21VET0>T"JM@(.B(.;
M3!NKCIVU)\TNOQ[;24.!=@_TT/ACWIOW)C-)6VUVM@1 \EA)96>T1*RO&;-Y M"16W(UV#!% E61Q%%VRB@M%LS2<+4V6Z@:E4+ TQ#95 MQ KP):>[0FWLE:ZYW?W!4S&GE!
("%'S\#=8P\W(*4G>DXZI/3 X_6! M_6/P[KRLN84;+;^) LL9?4=) 1O>2+S7[2?H_4P]7ZZE#?^D[6*Q)I3DC45= M]6"GH!*J>_+'O@Y'@'A\!A#W@#CH[A(%E;<<>98:W1+CHQV;7P2K
>W$">5? MR@J-NQ4.A]D*=;XKM2S V%?DPT,C\(F\)4M7&S &"A("W,F*(2O(Y?D3G7- MX*OZ^A:0"_DF9>C4>$Z6]YD77>;X7&:H1V0279 XBA-B2V[_LG"G)?!4#P8 MB@/MY QM;^'[?
&W1N'?^XY2RCB(Y3>'GX-K6/(<9=8UNP>R!9B]?C"^C]\\(MG P")\^Q9[]+:WUI+WKKA#=8:B-^0G%*<<TI.\H^&PO=V]R:W-H965T'5V5Y;W+\[/B\E=NDB*Y]E]
MNJR^9K[_.KE]FJG,^6 MZ?L*%:+19)_?9/.L\^OSKIGW[[P]]GM7;G^POG5R_OD-KU.RW_&K'^9#4J1OL_FO MLVEY]^KLXBR8IC?):E[^/?L;/X;?*X?VSD+)JNBS!;UX&H+
M%K/E]O_)E_H7L3.@VS\PH%<"'L@,MZP.6Q [J=;W^YSM%#'O[8C_[:!X=\^W-W M-W_O\^T3:_.L#),RN7J99Y^^#?/WXREM_L'EJ;\973\;9J.4V^NL(
M_3E,RV0V_TOUB']@0WH!^^R97E7!&(Y M3:E[P7?(UZ/:?!;U.;]"R.6^?'MVY.#@Z M](^^3N^?! W.P>"'/_SG2?D\Z/8VPWMMO\K?-WMT_/!^R_#XJ=]<7@WO'IQ= M^8?
K9/D\Z(T.#M=/#%_-J^'#@[\Z<_S&=UN&VV,V_K)MN/,<[C^DNK_Q^@>\ MM_.D*(*?;^H _\M6WP]4F2Z*_V_9N#=;;-".K=V?)!82&*"Q^2)1206DY@B,4UBAL0LA#EA'3R$=>#3K]
[GV21- MIT5PDV>+8%84JV0Y28/L)IAL]\+%.L3/@F5:MH77BY\:7A(+24R0F-QBHPVV M/D[Y=#6\&%]T.IV7YY]V<_GX<7N/B,G-4B2F2='19Y7;LSJG(.36)&1*$$.8$:?00I)$W2/41
MXJ])GB?+L@C^]2Y=)ZMU?>F53DT.B84D)DA,DEA$8C&)*1+3)&9(S$*8D]3Q M0U+'Y,'@F PKB84D)DA,DEA$8C&)*1+3)&9(S$*8$]:+A[!>>'>KZL#AW_;@ M^<\-=,7C]9@P\
[F'W<1%I*3 M"A*3)!:16$QBBL0TB1D2LQ#FQ/7R(:Z71\?U<[T4;@N@5SDU@)>/C[R&H][P M40#)206)21*+2"PF,45BFL0,B5D(;QX8S0M^7I4;GFB?
GLGM4+H]YE$"W3!XU9X3.&=>:YU4,A4ZH4-^EF]+-%4N9EE;\>6-WSHY%/XM&P9?TR1O6[R&Z'8(5).H M%]%:C&H*U32J&52SE.9FM.G.=+VO]E^]S].?Y&K=)CONU0T_=W),T?
X,J@E4 MDZ@6H5J,:@K5-*H95+.4YD:W:=)T!^1+'5VT.X-J(:H)5).H%J%:C&H*U32J M&52SE.8FMZGE=/V]G-/.XJ!5G%H;.X=DX\O+_<-%KK_?\WVG<="F3ZVYP>QTNOO!/.IA

MTV>=RD$3II7&O>,SEH MH0;5#*I92G/ST91JNMX:P-7ZG1J!6DY7DW21+LMO;YUZ/T^6_J-%M%^#:B&J M"523J!:A6HQJ"M4TJAE4LY3F1KBIVG0OT*-
%M$6#:B&J"523J!:A6HQJ"M4T MJAE4LY3F)K=IW73]M9NZ?%Z_A2-9E7=9/OMO.EV_B^-#NGD/5>M[B=_XW9,S M3&HAJ@E4DZ@6H5J,:@K5-
*J9[N/FUWCXN'EIJ5G=]\\WC9S>$XV<[5)8+2?5 MPGCV*=TNBM=OK/:NC/WJJ=E$M1#5!*I)5(M0+48UA6H:U0RJ64IS$]QT>'I=
M'#:T,H9JHM8N=YT+O^7BXGS2T"H1J,:HI5-.H9E#-4IJ;QZ8*U,/6%HXY M" U^`-5B5.HIE'-H)JE-#>><3:&IYR\T'5HP=YJXU0;M,Z%:B&H"U22J
M1:@6HYI"-8UJ!M4LI;D);OI,/;3/U$/[3*@6HII -8EJ$:K%J*903:.:035+ M:6YRFSY3[P?UF?SNR1E&^TRH)GHM5SWJ]4?C_L7^TABM*J%:C&H*U32J&52S ME.;>3*$I-/7]A::WNQ?BJT-
Z.)-^[-1,HEJ(:J+6W$R.JG_W(HG.&J%:C&H* MU32J&52SE.9&LFDH]?U7&=]\D/,=;[_QLR>'$ZTJH9I -8EJ$:K%J*903:.:
M035+:6Z$FZI2OT<>KO;1@A*JA:@F4$VB6H1J,:HI5-.H9E#-4IJ;W)V[B_F[M3M]]N.IW3\XP>ZNQ_N/%[*,77L11CY)'/2I"MS]&-85J&M4,JEE*<[/4])3Z M_I[2N^3+;+%:[):2X.J2?
P-.#AU:74(U@6H2U2)4BU%-H9I&-8-JEM+JCU154"U%-H)I$M0C58E13J*91S:":I30WN4UUJ?^#JDM^]^0,H]4E M5!/]ENI2V]H8K2ZA6HQJ"M4TJAE4LY3FAK.I+O6?
NA93]R*X3N95,E_?YNGV MC+!W28R6EE M1#6!:A+5(E2+44VAFD8U@VJ6TMSL-J6E/EI:ZJ.E)50+44V@ MFD2U"-5B5%.HIE'-H)JE-#>Y36FI[R\MU:>IBLU^-WG8[^[(3JH6H)E!-
HEJ$:C&JJ5K;O2] MM[XG^][9=XU.;%#-4IJ;U:;5-#BNU;39QWY*YJLTJ*?9)O9F5:[R[4L]ZUM^ MMT85[3>A6EAKSI.DT_HD$>C$\OB)(W3B&-44JFE4,ZAF*K]
MS_X#4[3/A&HAJ@E4DZ@6H5J,:@K5-*H95+.4YD:UZ3,-T#[3 .TSH5](:@+5 M)*I%J!:CFD(UC6H&U2RENWRKMP&"10">6QT\< MH1/'J*903:.:035+:6X0F^[2P-]=4O7A9)6[8+)
[!'J39XOZP^Q^_7)JQ0!R!$MT6@ MFD2U"-5B5%.HIE'-H)JE-#>C34MIX"_%_"TM@_L\FZ3IM-CN4V<[>]QOR6W? MB5X^6LH-ABT+N;?^33AYZ8HVD%!-
HEJ$:C&J*533J&90S5*:$]!A4T<:^NM(MNZ=[@]\"G2W3XI<\F:[WIVI9E+-RM5[]5KO9ZVKNV:0Z8K7VK?<,L7_&4W>W MJ!:BFD UB6H1JL6HIE!-HYI!-4MI;KJ;ZM(0K2X-
T>H2JH6H)E!-HEJ$:C&J M*533J&90S5*:F]RFNC1\XDYR27$7W*$2;.UFM+T21W&Y6S,GM;9[>5L>YP6V> M5=%^6%OGR:Q(I\%L^;"H;@TX6F:JM6?O[E(A.J= -8EJ$:K%J*90
M3:.:035+:6YPFQ[3T-]CVEM0U[6F7Y,\3Y9EX5\XH_TE5 M13:":1+4(U6)4 M4ZBF46BS.>M)Q&"U*H%J*:0#6):A&JQ:BF4$VCFD$U2VEN);NU7", M+J?
1_A2JA:@F4$VB6H1],:HI5-.H9E#-4IJ;W*9D-7RB9+6SG/Y<[W5;(XMV MK&KMB 4R6J="-8EJ$:K%J*903:.:035+:6X:FSK5T%^G>EW^],M=^M.[)/^8 MEH%,)K/Y^B)0WE4P>K4G5
M13:"1+4(U6)44ZBF4M1O^-] M!7[YY-2A%W1"-8%J@30UJY*!]/7&D M4OP6O/[E7? ^SXK[=%*NBN!Z=7_=^\=T/(24&N@T=H4JH6H)E!-HEJ$:C&J M*533J&90S5*:F_JF-
C5":U,CM#:%:B&J"523J!:A6HQJ"M4TJAE4LY3F)K>I M38W\M2G@\HO^&4Y.,WI]*503J"91+4*U&-44JFE4,ZAF:VWW.9.G198CY35%JY"]*$0MHM$.%:F&M
M[2YH+MHNYXC.*H^<-4)GC5%-H9I&-8-JEM+7G4YO/[MH-0K5%*II5#.H9BG-R>ZXJ4:-_9>A^N=FAUD%M[[% M>Y'-I\%J.4WS(-W>Z'(Z*\I\]F%S-:KF?I=MB?5/=6IB42U$-8%JLM:
<%WA; M][;HM#&J*533J&90S5*:F]BF$C7V5Z*^-[&;'6YK;-$V%*J%]"9038Y;BE/M ML46+4ZBF4$VCFD$U2VEN;)OBU-A?G/I]9X^/;&3XM^'D**,5*U03J"91+4*U
M&-44JFE4,ZAF*]/#&O?)$\ICM$N%:B&J"523J!:A6HQJ"M4TJAE4LY3F M)K?I4HV]C0_BA+)_AI/3C/:K4$V@FD2U"-5B5%.UMGO,WQMUAN\Q=Z=:]%I
M#:I92G.#VE2GQO[JU)%+ZNN[='[C7S:C!2I4"U%-H)]$M0C58E13J*91S:": MI30WTTW):CQ"E\UH@PK50E03J"91+4*U&-44JFE4,ZAF*Y =-H8U12J:50SJ&8I;1O2\^(N3R^$-V6K\ON
MBVCS]?.&OWIYG]RFU:K[=K8L@GEZ4TW5>;Y>-^2SV[N'3\KL_M59]RSXD)5E MMMA\>)&PO=V]R:W-H965TFU+&G6"8SUW+8"A6.F$R:05WOQ^U?\R=-\[,J<*) M2+ZS2,-/[M,A [
FUR0("4 B3G+@SEE.^IIL%0B@U(N]MHLQ^YJ[FT@6/O,>-67) MB=D]1:4E"S5&H*P^6'&F%;RQ B?PXPK3.#A785SW9N MH7W PB2A2L&W!>2!A1]?S#I<:DQ5K?
^%LDZ],EN1YRJC(8X<4W(*Y1J=X-4+ MO^>]:T#M5*B=)NW!&)>,<\:7)JT3RD,\A1N^-D>)T2E\7=DSL^<_*R+TNS9& MA1>%G6YNQUX#Z\ GI-M^+J-
?)\DY<]GZ>ZS^/V#++V*I=?(DZWGU)/V*I-](,K$GE9A*<\' R.- M!GMP]+>&/I"K5^V3W9%O=0UP[OPC_2A0DN#"BGDER!V31Z!0#+;*\N9@+;5J5_#,VS2%*N\&L M+X30CP-
KH&HW@S]02P,$% @ @(!H641WV!'?" P O(, !D !X;"]W M;W)K&ULQ9U=;]LX&H7_"N$=[$Z!:6Q[V4XV"9!& M*D5@LPV:GL3<=9]/&DM[GI:5CDG]/ M/BZ^\^)[.1>B(B^+-
"NO>O.J6E[T^^5D+A:\/,N7(I-K9GFQX)7\6#SVRV4A M*+0.6J1=S 8]A<\K7R7E_6R^^+Z,E]5:9*)^X*4J\6"%Z\?1)H_7_6O+)7\4#Z+Z=7E?R$_]+66:+$16)GE&"C&
[ZMTX%RSP54"]Q9=$ M/)<[?Q/U5;[E^7?U@4VO>@/5(I&*2:407/[W)&Y%FBJ2;,?O#;2WS:D"=__> MT#_67UY^F6^\%+=Y^ELRK>97O7&/3,6,K]+J<_XF2R*JM\T03+%BR2;/T_?
VEVQ$Z X[\1X#8![GZ]T: UP1X^P'!&P%^$^"? MVJ2@"0A.;=*P"1CN!;RYET9-P.C4)HV;@/&I >=-P'DMA_7QJP]^R"M^?5GD MSZ106TN:^J-64!TMCWF2*;$_5(5 MU(O)IZ429$EX-
B718IGFKT(TJ^Y7Q60N14;N4Y[)@)OI-%$;\Y2P;/T;5%K^ M.1053])WK![/R"#XA;@#'QVIJSZT](_Z_DL'XS>C0'OT@ MEF?$&[P9'IT>[K7MRQ_+'O]8=F8/_S2I9+C3%FX<2&\K?
J_F>6_P;E->EN33 MK-'TUW_(]8158E'^NZ5Q']8POQVF1J6+!9U=]S?;!BNDH."0N1 ML&@-"VJ8FIX]70\N^T^[.D*FBY$P!H{9.@JV.@JL.OJ2IZNLXD62OA(YZ,Y$
M(G5$Y)RVK.28G62/I-Q56IO"K FZ*@P)"Y&P" FCP8%.:RHV1F9D()@A MLN%69$.KR**795*(Z2_;Z> GK:\V15EI716%A(5(6(2$T>&AH@:C?44A,S(0
MS%#4:*NHT?'A[[TZ1YV22;Z0)^YE?;K0IB8KJ:N:D+!P#1ON'#,G" :#O9$K M.MQL.#K\?;PCJV']>ZPB"F[_F3*/BC M((5091^6[# M=<_0UC\=B1R\&?
GQ2.17IZWT0O]P2^,_',E0^]I4UDYAUK&V3-6X[%77KW=" M]6*MM2H[O+/LD+002HN@- JEQ5 :0]%,0;I:D"ZR6MK04 I$TD(H+8+2*)06 M0VD,13,5J,OUCK4HBYFUV7-
TUB6TC@^E15 :A=)B*(TUM-VIIV^<8YN"TV5Z MQUZGWPZ_Y>]:.2F2^AR5%+QJ/3>UPSHK"UJN;VCGNR7V,R?8.QV YJ0GY8RA M.1F*9@I&U^,=>T'^=]>:1?
@B7V456E2O&.OQ>L1L!GTCHH+6HV'TD(H+8+2J'-8D0\.I06MR*-H MIK1T3=ZQ%^4_\J0@"UY\%Q5YXNE*$%Z1:5).5"?6*BUH:1Y*"Z&T"$JC#2@NAM A*HT>.@+HD M\/V@[;*^&-
H.AJ*9%W_JDK]K+QF'0I*RHG8,N6MQK6=TE5E4%H(I450&CVR M]Q_6\]YUC:>:"[*NDS_'UMU92_;KAE\O*^[FBW#6CZ M'Y(7$FECIKPC\JSM%P8]!@Q%,W]AVOIP[=9'?949U_9E"C
TJ+ MH#3:T.PG.-"4#$4S5:7]"]=:G=ZH2E^,PI]XDJH+3=2UD_5O;OM+T]W+F[J# MVAM06MC0C'*H?W!T(VA2>EK2&)J4H6BFI+0AX=H-B=,]6O*?_>W65U.V2@OJ
M4$!I(90606D42HNA-(:BF4+51H;K([U;%^ID0&DAE!9!:11*BZ$TAJ*9"M3. MB&MW1B#>K3U'9UU"K1+W*Z UD$7ZH&@M A*HPW-O*@]&'B^MS_$ M0LT4%,V4E393W/_!
[1'V')TE![59W,-[%?S '7C[]T= L)(3L\;0K Q%,Q^Q MH.T2[\@=$L>G:UV*(_9L754%I8506@2E42@MAM(8BF8J5-L-GH.(?F@.,-G?%H?\"%IJ6G MIHVA:1F*9JIIYZE&=E?
BQ!'W14Q6]>K;.4^*Q9$;RNPY.ZL+^_@C[/.L] MPCX!"?L(I#_.#E/"T*>%!30D/:DI :2&4%D%I%$J+H32&HID*U*:$9S(=U=FOL%E$:AM!A*8RB:*2OM4'AVA^*+*"O[):AV M0.>^S-
X<[\U[W$-H.R(HC4)I,93&4#138-IX\.SW:OSP#*]3Q05J6T!I(906 M06D42HNA-(:BF?K5MH4WAL[\H.8%E!9":1&41J&T&$IC*)JI0.UP>':'X_29 MWV'-/ACYYZZW/_&#^A-
06@2E42@MAM(8BF8^U5=['3[$Z[".RYO)XVV15'+^ MR,F'^G:&/"-WZ_L6;O-L_:SUTEJPL3>U:Z<)I8506@2E42@MAM(8BF;6QLE
M/M0H\:%&"9060FD1E$:AM!A*8RB:J4!ME/A'[N$X^<'I+95_WQMYSMZP;<_7 M6570YTI!:11*BZ$TAJ*9JM*&B?\G&R;68?M>%/4+423]Y+$;:K9 :2&4%D%I
M%$J+H32&HID:WWGC!-1L\:%F"Y060FD1E$:AM!A*8RB:J4!MMO@@L\4_-%O< M\<@?NOMC-]1K@=(B*(U":3&4QE T4U7::_%_^&Z0'QB[;R;S1#S5ZU:+50N25/U, CKB XU?
"T$$J+H#0*I<50&D/13.5K$\B' MWGWB0VT<'T$(HC4)I,93&4#13@=K&\4%WG_@M=U&TGHU#K1DH+8+2*)06 M0VD,13-5I:T9WV[-;$;CR68TW@B,;P?
CB1Z,B_5@W*JZ=1[S#3V#PY?EW-H; MU%EV4.\&2J-06@RE,13-?).>]FZ" _Z=W$XI9HIY0)P-O'@LA%NJA5+8)H[VU
M78=K*"V$TB(HC4)I,93&4#13X=J^":#V30"U;Z"T$$J+H#0*I<50&D/13 5J M^R8 V3?!B?:-/5]G54'M&RB-0FDQE,90-%-5RKXQE^AB=V M9:JW2)%_S44A MR+/Z)\OW7C+8*
(],5_6C8M5SWJJY'\4W;\ 3ZDWQY$$LJWJ WKZR_*RMO2UR M+D05\HI?7RY$\2AN19J6I'YN]OHMJ]NE_V#Y:%$\=%I64Z= MB[AM>>1>?&SCW 3>!9.[KVV-+]?X:DU?-_7ZG(WD
MCZ]0+W+&PO=V]R:W-H965T,)D6K*(U-D'$B8"R6Q:5N6;R:$IL9LDK];\=F$[65, M4UAQ)/9)OOC+ F)VG!K8.+_X1J.=U"_,V20C$:Q!?L]67,W,4DM($T@%92GB
ML)T:;59C9$P#V+?]!0[J;&R$ A:,D^EM_8\2\X; ?1*P<^["4$[Y0"2933@[M(JY7*VUZD&\UEU9P--6GLI9A6O(!LBQ;I!MV2[ZOGY 'S]\0A^0B<2.]%)*D(4VC&[2 B*:I&JJX MCDD:
/JWU5<%?F' RPWHNWZ8^>.190TGYJ$%S"O!O%ZP/Y7W)(0WJ(6P%\=K MX&#L68[KM//X)8_?RW.O_1#'ZH!-I'+>%NB;Z/P&W:T_QG8[V[!D&_:R+9\S MRM]",VRAL88=-
*.29O3ZD%H6,-?$TZAY@"/'!6A0?W5YYY%'&(B 3T M.96J"JXH1?ELU>KWGQA=/U*QU 0GP*.]U5+9D^U06#4'Y MMNRGD4742TOFK$OA*M(8$RK&1*U!D/E%%[T-
\5$LBSO*39,J@XE'^Y43PA< M+U#?MXS)\T0;*+O,V7]02P,$% @ @(!H62#M0OP^ P %0X !D !X M;"]W;W)K&ULM5=;;YLP%/XK%IMVD=J"R;U+D'K5
M(BU:U&CK0[4'!TZ*58RI[5PJ[./_O@_I*+)QD" M*+1B42P'5JA42<,2)>+B'BRX&%K=<7=_0Q5.:%[?43\@@34+^2L=] MNT)*(-84AXC ;.!=8'/+W'7&*0S?E-
8RK4V,J%,.7\RG6$PL!S#""+E8$@ M^K& *X@B@Z1Y/.>@5N'3&*ZW7]%OT^!U,%,BX8I'S10X<#J6BB &9E'ZHXO MOT,>4,O@^3R2Z3]:9G/;'0OY2+6#!IXBX&;&[@I[\Q1
MRO*:*.+U!5\B869K---(0TVM-3D:FU69**%'J;93WD1Q_RGD40!"?D8WSW.J M7M INB="D%A)W;P(FH22"(TC#,9F'1^N09%:/2U;RM-PX#9?N[R,G/I;G$Y M(B_(Z9X@UW&;Z".RD0R)
)D -O%L'4X1DUO$Y*8.FEL<7'\&-,,BAH<1L"F(M/U54:Y',ECB7"?%A8&G-2Q +L+Q/'W#;^5;#LU'P;*3HC6T\(R(EXC.4+@)Z M^*"'T5 !DY54&T>@VBRH-FM3.I1R3F(?#-
MEGMY(G9)1+!*B,N3U ,Z@1-MC)M_YSN, @MTV1"W:GBKK%ER[A]P0W2-0[154>T=29(;;V1!DI]>K7F7LE.>X M4R_*\<_:=TUMO~;>*W,X$,N;8YV8+9E
<'U%>0X.SQWNO/IB,M"@FL/_XW% MUP)\3P&L1]XWTV5=PTNEUMF^R2\+&>X<5"K'J&2X+&6XMOSL_64P[R]^/;:1[ZY,(V(>*1: M9Q',M*6N(1I"9'>0K*-
XDG[W3[G2MXBT&>I[&P@S08_/.%>O'7.5*&Z"WC]0 M2P,$% @ @(!H63] 8I2! P] \ !D !X;"]W;W)K&ULO9=M;]HP$,>_BI5->Y#:)C806 =(I6NU2NN&AK:]]/;"30X2 M-;&I[916VH>?
[80D%1!@$^4%L1W?W<]GQW]=?\'%G8P %'I,$R8'3J34_-1U M91!!2N4)GP/3;Z9;Z;TI@YP[X=&XMAGV,9(D@@4,8%U8\'.(^G]TBY>+^:62CCGR:\X5-' Z3DHA"G-$O6=+SY#L:".\1?
P1-I_ MM,CG^IZ#@DPJGA;&FB"-6?ZDCT4B:@8MLL& % 8V$6X>R%)^HHH.^X(O0#"S MM3?3L$NUUAHN9F97)DKHM[&V4\.)XL%=Q),0A'R++NZS6#VA8S3)-PGQ*?I%
MA:!,H3.3/_/VW2=0-$[>]UVE 8P;-RB"C?)@9$,B*UUSIB*)+E@(X7-[5X.7 M]&1)/R*-#B

***AZ4R+U;J-IRMW0._0#`MZ-5R=6+8B$K:'4Q0!(GQ_;4F%.U:O$&71L&(.Q7Y)YVI$-P/H@T8;,*GXCP_M$!P02-A[ZB'jK:0-ABP%;S^_(Q3GFGRQ@(%[+)L.I9 %T=*H>
MS)#UPBE.CIB@'I6^152:DV+EU&]{Y?I.ZA+U&Y(.O0R_E5_H/I18<.KQ15_B MQ&?U!<+^,04^Y/(OQ6D%]&N#/"&9GX6F=W46KHVJXR'KVN%;G?Z*>G\L"^<
MA8HJ.5K(M(?#.X=%Z:.<@*&Z#JQQ=$*)6K5LXX9!J&@9UUC]/U71_';@<\W. M04EG'<1GG?"A.>4DE&Z=EZ]D(Z0PN"D9A@)(43%)MZ.'NO,NY==LL.?\T8H E,LB"CT:-
Y?VI68_M37GFB"\DKK9X6PD$(0T]$ A2R!JD LRTZ#V8#/DY=<_{O@HSB9&ZX,JE08 M#)! . *1"(AA W#1V"/7G*GOX&:EX]\%.*1QA(AN*>E/(P")14P.SE5]
GB^<"&"/<#K MW#V_(ZCA*^5C87DT?P1><.7$#9"#N\OCA(=I>O(H.K#:7"C,&@.E+$?6* ?/ M"6'R?[@D@:)7V/2(Y;T]>QG@B.NQ**3H--%5R&)R+K*(06FQ).T\)6E/8DG:
M72Y)VTZK E0:B_;-\[:R*MBO1L9Z1LAU5.5R(E;2K^6U_Y19M@1J7M?TTM MWAM;KAO;$)#X]:(K[3RB>$K7:D8$*K+NIWJ1:@(BF^25C MF?1 %H<\;&>,LIN?
=;&VY=15?'+C/R_- QC7R&<^&*K"UQM .X)TU>K$<4 MU76DYQ,Z&3;Y8. ^A*_3J$&,/P1@]+!Y(@%D>&R;[I.J1'!P759/,,B64,#)* M8E+\R<*;,["P(_"SR,-
C;.BCBCQ.GM=*9._0U%Q=_X0\.DK;[NUCI64SMU3B MZ !X.SQ1N]7[;?Z>]QV%;L'(U^&MSB\@?H.A.;:RXTWU[?\VAP]0(T&Y
MB#3^,UM>#L5G._E0>O\DCG)*NH=C_^BH3@4JID-?O2:*;J1#_.5UDUW2J9/6 M'W0_#V-=]! 4G;HR#'DB5!;=+ WGB!\N3Y! M,^PC)^29,H@PN5ZEE:N[$F]-
I$IRGT59Y#:/.MT4)RPNDB+/+AH2D$E*;A M-LZ/\;MW)?,X=L@NDYQS5!Y_*NMC]",X0'C>;5DMM0<*BO*]# M(G"L+.FP>+7>H!L8#B*?K,)5$]/7*!-M.SF(6C?
X2DYJ8/A"""!"72AV6$- MV2OSHK"*+WX.A@ZXT<28#L'RFW*UX:7!2/$3'P@)+9-7 ML(=I\J9Q>EWCOPNVO-/B0ON.U@?W?WP""'OGOWPL^I(N*:.I]R$*=!!2'R M'?
N72;3W,@-X_M3#]YI,/8:!0*ABV1XE?XRPG9*3V"/V7O4>$G[2? M$B]2<6CRS_Z'7"3-XQ;9"3?<.E--L%ML.(? C)/#C/!>1R=+1+6 M5R1"QTJ=RT9>UE2*I\
QM.#O1OL5+,AWT:S?+6]J*%5_&FY4::[68\F/T M5NEA8A2I@U'R1ZFA_C_\B5\'7=NM 65'@_!\&!9^CSR276HJ?7_K M@YH0!F62,X
==\0WPTIAR8U293B2'!RB[_GF_D&*72Q)>(]8!EGD\|*:Q34 MT.C4,+3705ICBE#!^1,2"I0CF61+ZY=0MICB@[[?#^Z]'U;4MA2C7EE-O:.N
MC/W=O5UFD]\Y[P4*"H=RN2S3"YR,-*58RTNDNQCO]&L,/M(Z$ ^]KC)4J2[>NU;OE:H^JVK?ULG,R,A!U&KK/211> C9,I?! M&9AH-!YH([AZ5FQ:(S0UW'B[T M"]I 6J?
472D&*@(X>[KP=Y[+5BZKI)+\>T_*)=Z!/!H&E%-(4&"TBH?X_ MM=(3K"=4=#]$ "QS!401,LK$E@_3K_@+L6YT%:(ED8RMA,]D=7 -]Q7D9Q58=0[9 M&PFW^=
GBGTL<@F.[T(M1*\S7Y;\@<,O$$"OC-U^N$4"[52U0!N&)P?>,L2"-M0>J0WSO%%/V;KQ3L6 1YEY$ZNZ"+0=^;V^Y,MW'P\VIC/(IH2]2<\ZBY)2;92W/A32Z';Z.W7IHG!;;-
S^=] 4 M13B3#JL51Z BYH#O?A)?6HM>?V]A%ZOD0SZI7#'J_^0HW9.W<*SEU :61T^A M[NV)E&7^TE]'3O%35I8XEP_XN3LS@]8:#IG&:.X"H6$=@PPDPL+Z%4>779(-
M"]&RY.'N#SPRDFE>[%-O<;*9174*_EUP[#DUYHU777=?-'57C.\JVZ-LB=(8 MS!WA%^FR$@*95F7;X*_O)"27[=':MB(D"SV9N9B!102UE%UPG(O:]"0[_2X,8IJNGJ,@)D)
MO2U!)Q-8\W'HE7^JV\5RT"O_E'U)7K9"!7^OQC:P91Z?ZI,[-E*=.S\%$IFV ME"TMIPP^CU3&B(M@5;Q8H^K#+WY@3\I4]"+P_5]PKQ^A-L?!_-\B>7""V++
M'RGW1C/5,Z=C7;N$[']EQ31Q6;?D[R ?,'&{1QOS% 'S_7;M'=)OG\!"\@&] MRH457H(;W21_1S!>9?S?*A*$I;\(WOP)CD$FN^"&XK\&'P(GWA;:6+AAR[B0
M'20V,18W%3"L&76J@-8D43GS9.':'34>-C8"K]J0+"#N[#P'STIR M(16|_7!E' T:2ZW.56KU-)9:Q5*KVZ:-19U2-Q!80_E4F^)(FN$)ZXLT5-XM M2]
72Y2JUL6XWN0S#!3D}:0%N=LNYZ9@M=A5! Z@$S3!T(2R#5IA3#V5"[:* M&8_)ND$%/57#]2E<>ZZ%X7ZZB(-%4/C)9E/(7D]X_,T;-51DY*61T!NK, M?5-
1L&U4(M0*U3 W&C(G3# &@BTPSS*6 M:!4.CY2_5U$;/$#,G\;!AM&\/-VP(*P0)J,U^ZPM)A*^(=WOBO"1&EZ]"-$- M4IH.R0/X>%QY#>2L22]]F&0?
Y6%J(CB\7O+7W#@E-D>"'+2K+-N4R<9&7>SY MXWJFWO@X'QH!)PBL^G+E4%9#FU6)![/4;+S*;0T"U_0+9%5B.:;BE]?=P>7
M0NO(&*^;T+B1!!$/KW$E;T6&K3_2A=#/R.N:'!*+HY_0\[DW_HJ?HZ%9UP40 M:S6E7(;OY@SK]SS\?!#*ZX1ZNLYJD.;N^28OWWT,>Z0IDJ/+8/B<-NZ"1RS
MR7C6N'<=^)T?]T&=4]NJBQEBGVHR 2D^0H:)#6H=PWKAQC5C9U M04MS(DZ#'[SM)M^X6LMRVHM,2GQ>\!?1-,;##"HLK<+]Q0!,.&(-"[Z}JH(M1PHEEM+#/
[.F"DEIBHIZ_38/X(9P.DB$;0V6S"J5TIQ0R1=?'6NVZL;@?40 M+MXH*5P<5=,A>TN[\-&!~>@F&Z'LIF TMR,.] MN%I=&PPK/@OYX]IJ(;=3O8)"8LAY\108F/X?
P(;3:D%9"TKPH[$_K3&/H55(M#]@>;D$F+QU_'0C?RN RFI0CD;N,Q3JGA1#@JG)855-N)' >S(^C_A>=F#Q& MV8.12H$:GX$0-HB]U9Q_I:]#EGK-$QSU*T(<+WEB]\-
"M]#+.2A3[,'BJN7/>19(X+WK\4)W5W2CXF#_]L>'JJM";TD6;6W^%D>K"9 MF[9MK<0Z"'0&2:7NZ\6@0T! ZD@R"N[<>S EE+=(#MPTQ_VP+X4L\4/"9RW M-
]0/*V;A>T=A6U-.?O/C:]X1'@GI.4J1\N@C22(#&ZQL[L ;])**2#>$S)M6 M];AA^W*W,%>G;8S(+ ;)'&#"$ W^@]0>\;WY]+E/AL9>2*J+N&Y#H=N*!?"?N1@(-3 MH 4I#6??
GD(R)SO6E;G6 ^$ZVV7HN>"FQ6NSQN\.DV-NBE@E6[X6:K7!O8H MM?%9YVEVX"5=]0LZN*%Q(IU5_'T7.VFI;)5]X91'$V&*AN_CD@."I1%SURE$ MV..)
[D&TP_+N_QV[AE!'VY*'1R*R=YCQ/77_C MV]]\M.G3#Y(,$#%/N,R5K?I3X!)X^E!O7ESO]+E4%%TH10A%+[?DKDT] Z*1 M=)CZ+AC;OLKR-!H=33CNX;
[;\V0.HND$]YFC^ZPLR7JE@VE6Y"\R. M8 RU@]W3K% [-"G%NS]X)M19O+'%M47]9S!9+E[NP.5N2]7L M\&?I?=N5.EN8SWMITWCD[L]$XE:2(7%[
[:Z8K=&V8F8.%%2=]B:&P@\47^ M1U",KEYX]L:*HCSMMPTP%*]=@A@(<1Y]X-%AJOH\B!&(D,D(IFXN2U2S&('.P>!X V,2OE M5U0@&.%^= #>PZF>\#G!9" ,
[2E[USL27^%<>[.$Z(4 8;YN1U:&D<\FF4_ MR79A!"@AI=,!>@5ZC>DLZXM9)1#2S4"LG'KKC,?NT0X-=LT9'SMOUF)B/ R6 M-Y,,P"H18# #)I_G(%Z.0 E*&FV6?
PDR%]48.#C-1B0J^T(<[PP_WD";/8 M8, M!:/]=BEPZN*D<[9-[!,9U9G7PZ2@B9RB"Y6U1F9$R2GWQ1*&"37A4**4*NE; MSB[("(N .V1J?T9/%$0X%KYF'-?
D.X,$1L5W#BE**Z\-#?,Z \J9J5?4@!?MS M<#=3O ,'<"6U"RK9.IL5+4%'/?!$_1KFQ] 5IO)#P=@CZ", C^O9_'ZZR8YJ8R1X4U%3#6#3GE%JT)&!!
>758W);$E'6&L6(L5:^;%B;4UC5ZP,1-NRH/B+8"5E5),71WB!!W9;!#'MT M)J.G'WCZ?QIM/I_GEHQ[;]42@+\$; :UYY$HGNH2],E{O]^_=%H\[SA4[#WXP MT8I&/Z?KA&+
]^+69C I&4YI,(Y@H9WMI*^?DM";]-DMK"%2=VT*R5TOGI#]G;6 M1GS]M)PJO)<7AQC\)"/24'VBQ(T]M %4&.D=8G,KR4Z7#8A'(R_"IZ!V<^ M$H)J7*NC>[9-
HNBNSR2[UH\,W"]XWV*GR!&BD'HX?[M3W[H^ER]:,J@P7/:A1U\HWV&8U/0U/UC;+_|-|++*#QS]*QX^'#U^N+_W M^,FCPZ?[!X\/"^_.'Y"7@3[,
(\^VS,$E95N+T0=X>VY)0]0./JR?[^(V>] M!WX/OWAO=_>'WE,_C=RR++>$M\(P?T2-;P9IAG28%--[\]X>#O4,7\X1_;B6K M2"XVILJ76)3GE#JTD&U
M);E;&'MP>]6>FVCX7BB,>_&141!%:71!:52U#2'-41V*0+%(9;%O0PO$C;3N M15ERUS\RRI(H2\ZF&DKR,)00Y6!=[HY'SG,6F$SNM43?1FQ#>)"F*;7=4&HM
M.=3=@>NW#B:WC\",.72QA**TNNL?&:55E%9G4TWEIN.AP/#C[@>_V<\G5U_P M1=ERQS\RRI8H6\ZFFEI*78.*3REUJ0NBHLP>X,FB@K+1$R]\-696& UVD:I M$I&-

STH9<|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|2EQ8N.<%9= MZI#_:. Z_B)H8O+ ^],.8VYY !&(!>.PGH(FOH47:%A@FD\I*M"6O&C@0X8O M[JJ[35/(6LM(Q1SPWP08E:&1X3* M&B'))OF2&%[$H^6HF9>,P=-Q"B2\8,JV)H.2\2:SVM M3LHCFOKDS-GMPB>+,N3VRA'2'QVU+YR2:,GJFK <-NAXY6?-]E*NUK4_-O38 M<'*/#* \JH^FF[UU@U"4ON'L1O"7.4X,]N#C(09YXQ9#[12!I;S;>6>\]NJP M_7Z4LQH?_4Z6BUGQ"IB^"8">5U#3D"_U,^&DTC6'U#WHC.88A!QWLPI$N,MF M]?T501MUD4]YG,S+5(OLDE]^CP7/37W76LCG-LN;KX*72_\W\@BG;""9#U:/ MA\J=Y@1PJ-"F(4>DR;^JG$+\ =HG@A=+CAP,)A0/C0R>W(/RY896X$#0)BW_O&U(9-!)L*PP|!S-58A6:1N.DIPV)O.^E3! MV).+H^2|C'A5+!TJ6Z*1+I*J;*U"2=LP[-&)V-#>R8'@(>,WU3E1AT981(N)P%<#*?+U#G9H:C(DG.;M%|\[#[G .]->QS>U4RA))#7!!]X[@QY MQYWGN=R:<0[0(KVKK.K/SN%^QA,(3FCX='0&BQ]XQ.6_X0 !M-B#CX7SJ'!0 M9MDN#-QLV6X.OYGJYJJBJ$XP\WGFKZ+,,W9+IYM"7NC/L 8 0%(\3]4ZZ&Z%*&HOC^J IK A,.@2&+%MLY(P=-'P'!YHNDY7P90#F#O=9Z.*)J2; MF722$Y+I6W+1/+_^7;=]DV4#(0$;=*K.- %;TMY:>UV?]2PO M-&ROI$DI/ANSK4%4CEOB&PP(7A!(W!]J2,&Q35)THMHO)XOU$D0.0%7H.,|_3Y?+H M"#6D(X&4SQ&E>%W@$^7#8=F>38)/CO(\1FW>B6@GHM_.52V4CI0^]YF?V.6]VD@/<2+*2-A'-.& M=&FO6.1NK42W&T'KWA:!&K(LFH61MSR!=9@DU07+OVZZ9Y*!E_=1F MR;2"MGK[2L#82!7#E50V3@YPW#Z7>5YKY@'?S -|_A1CB[VFCN4,S#*(RJ; MGOK7MO!TS,VK48Z%O=5!977]GCO<_.[G;]7]V_9\K9=9OB7CAO&;#3#$YA6F/ MD_Y_X2-8:B%,!T/IV42.96]"QY:W 0:[>%%>*-O$]#X+K^WY^^8>D3M3W''3V MW+JF&M7F)!)#]".N%0XY+SV*'IM4\E$Q>:E<()!.++F@I&8"RJ\%W XK?B<<<MUG;PTMT)OH^&^.C.FBB=!_DTXT)JH?.8>NS-0_A+<87M>\Y))F<;'A_!5BE3 M=^!+*4KYNB5!PEBY=_0S{@5]#DS2+[QG)O*-8SCW?C:VGO=0{&:)B%YKJ, M,!=C$B|>?!!TA#-\@XB\X/$$[52]0#CQA$';G6!!706Z+_3Q +(/T:MV${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|=QG?^H@Q,Y$7^9R.W(L*P?$X]QPR,.G-89QY:S$2C9]*E/5=5Y\E@"3 M]'K%#.2)M|SMX+?\6I$3D2;P.'FC8S/[&+&\%&"&:#VACT*1NCJ9-)I7]I M'U2:DE258'DOY)(6/8IH'9HS|U]0H(HBAS5/HG2HHI*GH6JE9,-U[IXGB>*K MM/#Y1'4US@N0<.+S16F"!6]0&Q89])HF8FY:.?5ED)X[&[*8$?6'%45^P7,R M)8ZG%2V\AL5E"/"2\PCP&-$$VZ$E;X1GQ%E5R^.'SH/3-NJ$A/MDHIJI-J>W M'8_@."HFH,;]*8N+59U$NX!$0^3[;2E7:9!H$Y; M'E({6.SYN&9B0$9-!(@\,>,,]6B?AV'Y6"%:?!['7ZK_$#D^ ;M &@^HM#N MFZA)A)NT,"A?"%*CH<)41TPMPCLIQ\H@AZBCV$C<3D,PN#]VA:X11?8ZB8-M6.XKA54 ,X*R)&RD1X"K\'FY5B+;:-I*.^D HTX4_>NLH4WXG+.N,1LFZ15S2<+'\!E' M* W&_Q%V"X7MN^K:8[N5QEWQ=|+82'HNR_:-[9P0?\.237KGO$:O&*3J0\:4 M99:S3%]DK$!_C.E:(6Z[$!71%3X&O\HTH=XNW=LMW$+W]/@X(\:^%')$_SZ M\MU[G2/02JG*\\]:.^T2# MT-#/PY?1+0Q(!29Z',Y_3V*=D$)R"8^;=XOS|-M5-\!5_H[J+S=G=XQ\4<%>']<",K7%I(="''JP',!E]7S3')% MJ?G*@S .E)S0=>;E".*K-"1G_F1&S4)]LVX@?!I&9-6))B#! ;L4LT>OPWPQM M/8H"OQ8B7?"[A7EAM8G$']HL_C6.#-.8C"E',E #+#YU>,68*4T542727U C M^D^N#2)++:X&+IGWO> PKLTER+B#4 RT9%'6JZ#A0^DRT4NORJ.I84(Q65\BG M2B48V2^&*ZIIQ#!,A64 /I2!%P:29X:7:F3 MN^7|TATAY?2L*B9H>!I7""2*TRZIGMX8*P[,-4)A/,@L%QXUV-Z4"+"4W%K M,*5#*W!U*#.@C#E,91\3!>LJR=/(U&>TN#0PGO64$(M$_8.):M9?XIO3!)>:.M JO=G0!\E!1OCA*B'5>TT:BV1_#2*^U()6AZ;&W%K'EK9_^#Z(.[N|BM6LS M[4H|XTR9P8<8>#6Z-,WC$8>U*69A2NV'3S%S7:(KY&QWR"0&?X+L"F4*G$Y# M,\QJFT/DK.1-'9J@O!1Q!JGO8)@=#/,V,,R]#H,9P3!7*DHDT]AN!!:Y$J;(M2);3]P0:,C\F+"A/SC5 #+B&7" ,F="$[2CK4T+GE07L12R6CU^'R6S@*(5! M/AQG"MT;M$1.Z,-E-9[.*@W:X)=":?4DJ"NM3_P5R'1/L.6[UMfMQ7=+Z;?2XJ.K"Q9.H M^7<'(6G.]@;/)-1'D%U7>8IFCN-4X@@,S3=#+N/BESB=65WGV(44I;E"EVJ$ M+Q<^A!48N!GOLJE!M%ORSSE2P>\RO*/2W\PPA R5M0A3G/-01UJ4Y\E^J05)JGV]^@T/. <| R2 MNL,?^S3*5-\#?LR#=U$!IYLOPMN ZS=0X!\(A'3&JV^R?NVU@ M\-0L)]Y5SN'!ZQD4R=00%245E|SSM,ZP*C0,WIZ>9+ET7V%!C+ *>3N.]HZ MZ3I4V5BHN187:-#.AY)O:C|SC _G55>B@I7Z<-+GE07L12R6CU^'-865@*(5! M/AQG"MT;M$1.Z,-E-9[.*@W:X)=":?4DJ"NM3_P5R'1/L.6[UMfMQ7=+Z;?2XJ.K"EP-=E8/\B$8&_8[}C.&*D[#7"*4&-=); W-JG,M(F+#H-N+$ 68)Z0IP^O M26LJEF2O\AFHT^SQZ7S:,;GY ,|S8/&^<*!\6HR;0R+HV/ MW:#Z$MLWS:T=+4@0ZTJ/EI|W.1R1F7%7'&<,+O);C0@)2YUDHZ(.BAJ6@T!\ M;|:IO7NW>P<;,:TG;(L$^!?1/V2?G,_KK[W'5$2)WIX,$F8UK4&D^:V%PFWB M'&&XDKV*,=|:C6H+>W/'?F:[#K$6C_F6 LNI+IPB=O!'^,D]1X278UA4B!# M &S0R J[C*\$;Y*/A2O'HL!$F'5 ONK94M>%PO-Q&D#XBOC<,,$+0BDW@ZT MXJ5#*: <'GN#?"]J)!'+E.I3|-I#^]*%O+K=\/GKY);BUQU$6 M,/M9(X0OAP#!$1_I!?P__^GF,.&?SP%CO3(43YH#+JN%3XXY?(<>OEUH&N' MVSW;IJ2(*0-Y)$I0L.? %CI=AFH9_',+Z(>@7-6/U$E@IV);_*+@>;":/:=DEE MV^/#M.%.%:L]'S@6O=9!- 5!(J2,$K!{CG'X3OG"?5V>?GF^OTO7,E@@1^5DXM M6(H0YNY|'+? ##^H7D%E3EHL:N9D2-\&09-"C;/@EF>7G"T.9E&)NF- B ME\7X6Z5S*?Z;TAJ&,[BENQ$;=4D'@>/4&)T-I;V@)=)|%, M/=NMNOP1E6-8:04W_7T6_,8?@Y\H9#T=F)%B? 34)118-GX1>'H"|>H]R==> MB/$9W#2"*5C2:R>HC#&"3 DH/",7V-NT0+@D/Z*M?#\6L6TDJDQW3##88"(5 M>#2UW GA*)A-IRCLFGUC\1? %IX:RWZ*T6_!)XM;1&S%.2&RL_PF_(CBU*JI3K&(_1Z6=UQ%A'P3FY"JGK'C63@GA7M!.EP5"'I<&B5G.58-_?. {HJ0.SJ3DNK'9T%SV'O1BJZG>1JA)\8UUQ9O>SSV+*.=YQ'*_)E>2DL*B4BP"'JM1?D{C6=(LKF(S/&(M$0N"3=PZ/<;96=1OB38T+,@>P 8Q8\DH)^0.'7WLU*$D1FD3M_3Y>.66MN&UG-,AQ\S5 MM#H4 7W#<*XFQ$E;8U:)]1YM!P+=&NS+Z;'K@'-"0V6EY4:FQZ=3'6[6WT$ M#>@FFV_PX+\FA3]1>)FD1.IN3O6#5L:. 8+;@Q'B1E1G0HXW/D7D&.S7@&;[MB2HT]0:!Y'CE@Y+L7IQ3EX1!YMIZA:Y1.(]_)0.XZQ'(ZK?HTONVB.V+-& <)'4'4SC2C1$/+;3_RV&[T]/V MU7.)JXA+YT&'F#ARS#R1I<,5$5FK\[\#:/#LG ^*9(^D3#;3LAV<-[32%;$^ M-#V3,X'+G%Q+H\ :KT& $.8HDRQ0[QKA9'$/1IOHS-Y+JBK<&,RC8I$F;I4.& M:1@(B4:E$'S$4DP@6I5;VG@3Q!_&%AK\K<'[_%EG Z-VM-XD_Y^7@1=R,.<" M/R3@1.8)*^89Z='@FURV5X=+_DY.T7]3:BBG-D$[!?@*Y6>? P1!45DU"'+OF M&]U,1TO9, + M=:7Y;)RHH?.!MTPD&#I<>=SF#PIX2O"S?/!Y#"^(.V"UL(9.1Z)V%DE3C<66 M<85F=Z=WQ+|/2H[V&=@7%_6(0 XY$11P!05 ?`M_!/.[5D^5KP/+R-P8(-?*!Y=)5&*#;[ZH:PV+2:!R\PN5:7[Y5_CC9MCD M2_PE!\L:LK'G*C9B;N"C=E0\UKHRI&\,V8C31PU:&;@MC"(2,:^?FWH!;'H M1I-0(L,JB4Q`_)++)X% .{O=>IHOK:#[I>X@YHF+ 5Z';S){96O.5%G MGM6]3\SK(A12\B68P/.-<<<(/?NY232ON:MO;$>>S_6BG=KTUC/_3XJE+I)1- M,/A7'AZ 6$VVS%\L+++>%HY R'YG "WTY;A5_T&H(DO*%%A[*8IA"-XHZXB/ M*S8H(:% | X<^7$D ,$W>;9U_@7""X))O(NHD>0U/W!PJH^*?U*HCTSA=Z]8 MO !1NGLGS-7 6%U+3FR.#0Z8 HM13T,W$9X4A;K**>0*,4D_5;@K(12Y'L9 9DNQFCK)]//YC%T^F_]!.D M!21=!8;>(!+TK_&C8*G'.8.;"IEK%%T[Q<8V\0#\OQ085K;^!>^"?53FSZ(G MS0?DMT-B-H-0]RHH^0S1#NUT=_4RE_34A:9X,AP&+1T>DE"5QA8[!L*R. M+G8^)~4>).*2!D#% >"/D:.*!3#&QPD_C@\.!$ZLI0>0ZL(W(%RB.6(A2Z M:)1A -](8S]6: G#*X$X:=4U^V#BS'E[\08UPL_N?&CDG*"#8UP%>OPY%^2 M 3MF&ZDIUWFTWUS CP\1)U1:TRQ&$)LHQD(H0Z893E-1;F MQ\E4QW#SZLWI;_@S3Q"ILL3'-=Y.[? M%X> M0I=B73H/(NGB1.L,O&Y4;[<&]@K+HE;7_G^ GXM?,/:TM7@NSB/RG#9GC3 M*<3Q5F;]#RQT8Z<|9IQ-_[KVW\T*M4$T;K<=#N(%@US6(-N+5*)ATRHYY*-V MVLI,PL1{T|Q74L5V$M _;2DE(1BJ#$2.#K!#A'"#XF^MB]C;A5U^;7/[Q A M6T\ @O6$;9'[-?OD^#1_O3M[CU#,;$8Y,.Z3'Q!Z$/T-GFJ!R/%2]T=8;.B2 M-QP9@6FW#PY[)U14[F7#;8D#0649L%1@#!)PFW%]9FW,+21 ^UAE$+@;OLG"V[*09W! MKS@I=`]4>06(C0ZC_$2E,9U8<+*ZK/CW7^A+CMZ<=+:3>3 M@?6(,|TM\RL5,=6,F<8-|5V^C1^ MK<>OV"0MZS6|M1:Y/O|%,LITONAE!)N1OV<9/_2!GOF[2.RTS$M HXG)2TW M]CQPRI%!5)C7)7+6NN;5=P^$^-[)>352 W^809>-J42HK-5Z6^8C2-'KYWTVP:;?*^Q?29EE%&BZ?//(+B M!E|_ZX3Z. ^A0?T9];=F2(%%F_">R#'>VX)APD*B<0E6F)2L*\]3<$UB1*S0 MY[MIM^M#*Z N%K4M\P7UC+G>I2F*VD'\,EDHA3M?Q00#DR-DH'KOJQ5 MLN^I"_#]AV:(?+&Z8ND*7K\^,\,2^>]F2$%SLH0=?ZIEV6U[\5"*[F^\DQ O M@TD]"9 C@W-*,2+8FMHR";_]?\RU<48&O&0B M)0%:2*XG+,W@|SS8LW M-J>\/4D&!GZ>H?88)9 3EF@E1/3NWO#E(%536^,H4JH2\ M9] 8[6,S-S?MF+P0? ^HI/:%)MN(V'F,F],AN5"3(K03EZBB3]6WT4^0_3 MGYE]YY4@5C6^FAQ|:%WXOQ3#GW3U='?A6,UURK8,1/G+P MB42O2'|:KC[V,H'B#? W*J$8.=^/KT6;_J=&&B(IX9;(^C<G4+P_@*A#"62"2 M \=&8N5#;X'>+61="PX.#G8VHLV-W4VS$XW?F_K/LY#.Y^&'8,*+2**LRF\5 MCN/>SL9@(<32|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|'=;!0%I4UV:\///M%PZ*S,YE: XZNRVUCVLT?EJG-_NM*LH. M_@SN-]G"E[ZEN(6*[@F![\-H!, ^_$_[VP>[QS_ZH#-G9_#Y6M%E!(_ZF79A M"'^]8_H0U! 1(S>V770/<;._HQ\&B'QF@[P"^^<6]GY\?&51]";1B.5RC M9!T/'R37B51$(AQ NDF@%HG@)T WD\E2D]$VDI@356M65A,BP]S_.1ZFJQ.47(N M4,;8*AB*Z$L:/">PFA M5#W89)/*= >]T0187:W5V0GI6292$VRAXK%=*Q7E|@(97>D\P9-/YWWWWHD/ MSHSQ1J8YDAE$)GJQV>!%=4-JG50EYLED*"_UK\OD(K_MM'L#ZR6*]T0 -P4'.MYR";89-4I8UOZ,:@@(G'$%><5!Q)^C9DI"-JPO*@=@I1@1,G&!?+F9X$?@! RUQD.FOBTJX,.N% {CK!5Y#Z_FW#PR:603M9EH/ M@VKJDWH%D4'\H%M,T_,24QHU@$ /FWW@&F")ALJ!%-J)B>OBRG3-FK<'VWD! M5*M4):4#(T-L%0@Y_$-+EC,22NU15H5/"T)-"Q\D4? L]THXCZK@MAY12@ MPR'?Z5+(G?A^LUH;,S@I'4?QN&TCG&G4%=8Z:;N'M!&D3,7NV&V.I.YD MMY/=KY==03{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s8!.+"K|\ML$:.#:? /HH%'(PPIF9:H=Q#N'1Z$QIN'2WH@=(#*#%D5I8Z) MR0G!N=[D."OH2.0 BAW'I.'!P? V*A-6LUF^>!WN#=*"H(_@WQV/1UD1D9A@& MN^'^T4'8.SY>M@S"0PNWHBS)D!CKKCGX'IYD,**5>:0:C)F,X%)?5#%(-'C9 M,H4|^U2 %;05B_:&^<%H;M%?-1MPQ+@B1!LKW?#U_?WP8+% {M'RC&AVY=WBRB'6/N"K3,I]_T"7FN#6A;*:OP>-<(=L;GG0:.M)$=1 QT$<_KG+|DRJ'N<%-)GSA,OB3A/#^D,M3?A8|@PBC9/9Y=;%|AC4=*H M"J1";G8C\+X:EA_70YE{&Z'GC1M'2(CNU!?#[-H8',C>?&.FW"*W".)_CB?: M7HB_IDG200Q.V#6R'6'#2DG3(;/Y=K_6QK[;3HD04E:7,7>!Z(1&S5EY M<65COABA-X)$X<\Z+W+!B)\CO2OT%U*CF0: MO@5#Z&;I* 20&;'IXA/I:8K)T'XB;/DZ\SC(&FAN8G-68EYH8?88)9^%%E\7 M6_7=0[_#'NW)6=:TFQ2Y)#.';)JI-$LE6+=_@2Z-F^*W[JFS3E)H=;|:.910 M,&,E)&_IK<2.1Y]#RJV0,FC=Q8&9H,+V0EIWT2W@"LY8W98@:)%4!G^,L> ^" M1M"RI=%W"*8YO,>9N0^/=,E-B=Q'H7'GANA\5+_F0;3#$GSYJQ\3P.J(:KAWVIMALU#&9Y#3:/DG\5#D&' MEV#3-!&FF\=,AQRANX?I4|-7Z""8F>K<&^HD7 T9OC_J3L:CV00V[HG|LOD6 M;@L_):YH713)M[4Y70_L*O? 'G4|L$^Y!W:%')%OZ,V=@OG90D6/80D/ BD] MI'4QBK+D/Y$$'7$^]++F3"G7W2Q"=:XSLX3]Z/CWH<|;X%)3"H.Z 8##6',=2 MHPZIN$TA2>8&ZI;80]RFN8116TQAU^E$GMA#8O$<,Q30$VMD|356HRY5ZP M-K+Z0H%B"C,+DR0(TI"3;83B%MK4Q05WJXB5WDMG,(3%9XV1?!;/&I?!-_M? H^#6='7^V4&AZ9LO3+_R4PHP.=$@D7G<)(/QK(?PQFIK9F*"LI<=P+:">C|!90<(%_V]K/<8&9Y^0Y2'F6\N : CAUDMA)XKTD M<9STDQ8WG K2PR1-:00>*9)CDWU|+D/@B\R0IK=V=/QRO[^K,]FJ!&O8,?47E.<$]D9%9<#-]5;F$^A)XI ME3.58#|%NCSSQ,F@^70K9W\F6**#E="S6/;88=ZP%Y@?R@GOCTBS 9U)3G?*-M] {Y&I]@ED,P+TZT@!L.!=N53A%&9.!16FFWI&E;7V^!.92_$C17.IDJ1NN MF2I&--Q2.0IT.,1_49HK_*DC#B^.,FN\O1*-WV:#HM3+.!CG#2M=WT5J.H&Z M62Z7&^/-9PC|K;AO:8|5 -7P5Z2-UXQ|<|$Q?Y^4G\O@/9;;N)"-:=+^&N: M*N9]>5=@2;V:K9/6>^]9]0=H)1EJI4^ #X&,13%X#B I*>GK2M=WT$,H$E7A M>%#.6(4^JF&@"TC8NJ3BKDJS:HN\5Y5&6N$8%,82A(6KP.2'I9PS7-1G'QERE.1.0#3 M16 > 2!!"N*W9!8!RH=SX XAT"V#1A98';N^"^XMSDKH4=J*>D*B^!4<|NA M^]/\W\A\%3LLR%^OHM':0/8Z1_L67<1Y4Y=:I<924WI$.4BAW+J#28TB*I2ZU;^D=&FPF MP#\+!R)^1@X/0>D7;.MV<&8]2Y70:KE|F?05^?DY,T Q1<1?I0,>]Q.WU2*V M@Z,-3H=+XM?($"%LTHP7[#VZQ-Q&@$2G%#)5,Q?.|BQ"PXI*GG@+)+Z2?Y&83 M1$VB:0;9KBO0UZEX1;2+"D.&;>X4BH^O9*;@ER!5{YGS-A2^P+!JJ$K3S2V$ M.26^; {2#!5@5*+DUFY*U$ERBSV?A8.%U(PV[&";:< M4PZXP4_$Q>#K8)@/; 9>]H5SN0O]B?]+FEC^#CL"I$HJ,T,QC4\);,!^@;!)(]Q,#/&^<8*P]+Q3(!GI:)&?IY /V%7$S\6%_7(*7VT M':PSZZ:5TB,K#HG:'Y7K>,%5^5%0.(R4?D ?BO0E M3:)R'T'L-45CD"9#M840>#R3M+Z\F(IAP>5K2(D$C\X *(?DC@9!HXN-WV0[MJ*GD[J4V$67< ,H(&20,J(@7|_ZI@W"%FQ4&G)3*A-AA:"%4!-3%-R'W81+:VGT"E(M M24SNDT9B6VY';97>6[,E415*T[HBVQ"1.AF!*>C9#3W2-5(53?{,=.E_E!{Z M62H6K0@N,ZVXR(NT/BO9W,-<(4LVFR@5<<4TKU!YW(0=$U6-\W@K M'VZ9T.D%'U;^\6A[=#E,%AO+9S8$(5,I;G?{$PM92?7.5K?"T_AH%AMK=3# MDS27&#M1K-*

*S_>XM3SX=I,NK7-QI.W>&E.SL&,'(1"/P[].HM*9=O1NCY_]L((WK++ M) 53IUX!8>[!V_66&K7(!IME7V*RI"/0|3|Y87R*5PFY?W]O-:*:H3W>T("6 M3#T@&4T):#"3538U?C=;,%H(]<7B7VR8.0J@&&[;+*-@THMJ.NC M3GTA!;()X"7""UQIAV|L.M[:8!=>-4JS L.P;K5T>WA$5YN?Q\X8A?Q&SZZ+ MEVFRYD',RT2%I6G28'N1&E'PG*PJ[2R19&;--C\:\5L?=!J#'_=D=G8 M=/2DE88-56LRGF(B,/@VX)N/"UL,%;7-C|8;H41@LC/$DB]BG\^XIW[&\UA: M)KRZ{13,\-5GP:X;M5C/|0;ZCG0F$ "Y)%P:-J2*AJ-U^@;G4*J-6@4#')SN MOF00["3W:9ZSO>]!|D'@^+8>%MYV%9.W:AM228^GQJ<)664L M$8*BLI*]D>+ND;>G3JUO>F12[!I>-L'Y%D/^ "2P#$E*4,E,0&OJ'CA8W?X(M=*@6'X'(<-7>5]V%V,U1&'^^)A2[&9J&%25]\S$.LCLO9'U;K7'ZGSPWD-@4 MKBVW7KI(J=.I?;!%L+%SD*)'/AN>HM=,9,3(^QZWHM3G;K,C-3TRK>@%X5DHEM*9%T6P MC9;!5PX)<3B ZHBVP2B'MPG'Y*"(((${G6(=QF.4,CEA@E:NX7XTQE_"LHK8M)HDI>%;JO:7YF3%"M_@/L'^7@Q;.VXY^@DBLLOKAKFPZ>OX!SX=0RH970PMU M?VX"P, TH M2NF.7@@;@NJ:VD\F-J?%RE[7>KQK8A(GXB;'].%FUWQ}^_&L$^00(HI@BH,P MO_1\;DW@_"^G29HF+RS%Q?.52@]ER\0A)(YOGY$&]7F6;=?LW889$P*#4> MZM5M'5T+YF0<QC+R\&\'VOQ|/_:^V)}ANUZ/;GQG/B273E6R\,KF(>`M7]#8)>K\=NT/FK;*H5X=>^'9+R@@ 59J;&/TWKUK,'!9$+YY-JX39-5F(,= M4 G&RTK1>"UN 4/$Q_0A%"[?>O> TF9J^5OL+%;QVP528NUMZG!"QW=F]VG% MMFZ7E3S&/RO*E7#;SHB]|L_X5#9:GKL\ M:?A O0Z))AN C34./B5TZ<7DA(R;7= "/3}>P5,WP\S+GN!?F/!G+|(4D!)F>36IQ8.H M|QOWHV;.Q-I72>QB!+//!8>34S1HGNP:RPX'S;!3+,-V-,6^IBA[;.KZN;6YXB_^5* %@K3T-$_]+WP0P6=_X M2$V!{^1L]R\8BQO1*6)6/R<\C(=@K38G<*8(=/E.-^6_"F)Z80^=VU.DSC M(U.$O2\@ZUOK-!Y*93QO*P]<,UM"+I_QN9=[I6IM:_,Q[6B0 MH]MH&=7;.!K=\|2GT2K_>^NE9,@ @1%,2H&MJE2!=:'-"9AIR8MBMMJ>ET M+S2|0XM^I.]FS>UB LGVA_9O:L5+&C?QYF>F)DK67<,^A0{MUC-:U|\9Q7(.MJ>I>5MML1+T](U>'3TD2]@1]TE4#_E>^\|$G"'0PTZ.$-K0\|KXCS#+DRAY MW!U2A:3]H4GL$9WWN+$WML;T_<|>#IF(+!6G3|&^-DH32&RJANPMS''T[WY ME>DG7\BE->-9\MW&QRK+XU/#9+8KM6>HH*E4A3&M5;6Q.[X!/##1.WIZ[*'] M&SVQTWBQ>R8Y68/\(VA7!RWNN!.&S_J[9.=%^0[''00J0CL|A#,E85<=\8_NI M5/"XYM5?&@'XZ\P/,3D>""O3D;>N<7])@Y#+6HTQAY(Q MK]RK95\X,-V>:0+*QQ1H8-5]? \Z(X)Z0/DT@)=L+K?6WOJX-+Z2 6J;/R4I MS)ME0U?!Q_*B9D>H"-FVQ1^(V?(.MRN+U[|)^@C6!3XL2*;5*W@7G2.;_IE M&N4F9.6,;<=35W&:B->I9.I3\U*XL;>33ZH#F>-.)T3;8A.X=T53(I]9YK*8 M7N,|2(\N3"T/AUH,R*V/?G-@UDWI6=,!V.1F#;F\Y"PFW#PZ^HL8ZB6!Z?6Y M]"W:$)9|(E+&&]DM-8>)/-VA'BK,#^B+E*&66RYZ#4\8'B E=#+VLB(O3;. M0]P Y*XAKHU^.7A8Q'8$.SM9Y9 !HRB+U]P]-RP"@]XVM%0OQC4SD\@2:@6X>Z Q>WO#LJ*4O:$EN>-5$M E4 M-6LJ'%;S@..#YI*L>"\23FI_6^YQ<]OCVU1*0%3R\D9]^7I1<&LWQPZLIXG^M4QMPU_3,T:X1/8"&UCFQM"2J.(U73RO,/%[X98=N>\|PLLIC M5>9QO/4B'LW"|!9*.VUJ/B44[,.XUOKV4XGSW,>S4|#_Y%&GQ$WTB>P68>O?K0-»/)/T$]S$4?2BZK,]QN'R(*#EY;P/&0QTU#GE<=+K6(MTIT>&3V+N[;$=4/CT=X#H4=!QA,=R)LDQT5:;,NYT_7IB9?.]!W*.CT\GCJG M5==IO!U6-C7\+I.K5YC1 /$,4D;H/2L.B+Y.=OY-A#-:#K5 YNL PCR0HEWG M,5&V'GB"Y6(U|Y]"<@Y05!F9,M/!?=R!R*2]0+47&&|[RCC$MT^C9H77O8B+ M^$P.XZ>]*6A[9,P.IY1BQ6+V\RKF6Z,B'JEH.7'MIAZK:UIMY8@II)7Y314-IA 3 >&PASK!.C_NV(7$=,F+.*CPR-:WF[|57%[0BIOT85?Q M*@)36&I%@D'W[57QS'B9,&0;"<)H"PI9$67-+ETX8)>R]6;;<\?#A9?&9!(RM4:M|OH9|LBY+Q@CM$2M?M1L>ZM 0R):1$0V%YSNS=U-)46|R@%IGZ^0*>@6W MX>[73|9\S'RP=!M U>/ZJ[93S[GS5_"\|N.VWH3>.'L5(*>A+[V?5.4{)S7 5MU@UR76M'|_R]<#L=+|;/R11Q<&K?S|N#++&FJ30%#.L-3<4+/;'U%O7{UT-K4<;Z%^]- 2+11M WGZ[D1/5B_O!Y?~-*/)!:WK?^,@$ MPG4ZP1W-HX@#ZD\EPYH1$L\=H_<,;$&C MH)]UF-JVXUUH2@G4Y_@A+]X7!;Z"AD,6B=CP!IWB59+B>H>M&=I?'R":&BE7 MMW$YX3UN#D7,H5YJ-%IGOP :TT66AVNR5NLFK-1HW&C6=M204BO#6V+A5",G M" OS58(W|FF@ U3A*QUWW1\VI;\H ERWZ[67|L@O(7EK5]$/MY@"68EY//^MR M%ON0&?LN1'>%ZV[QB:6VQY=7T(0<=QZ",R$.&HI.VN?K.#-38%!]9D*\U5E MA^G9)%KC]KL\.8%8S8RHWQ272OVH^.#L^/ TT;<%"-'Y%O\%>^F2\#RDW&LSMG>/;G*:!:GQLV.75]6^*H")@= GX#.1F03'!X$7)6O<.,]2GDM[4:!2L;FL/ M]Z%.XZAOYS3F|+/W"NEJE4.V__T4@@PJ U)ZQK'8*BE&*UCXX0:VEHLX3:((MPC9J_3M52Z,O*>,K.<KF+8L-FQV()T/'I":B0;?;@JI;C6=E* MP3SG$ =4"QA8UWI$S4,OJ*N:*JJ+Z+96T.I-< HG4/MA,S;R?DO SC0*F7?/ M,SPL.K**@''@MAG]$;'K=A"VV4CH^3_UE&"R]9=>OE:_=!:4X,99/EI M/7$&RP\|" 1ID'1]P.7.QA<^8]Z.'X@VV4CH^$P/]#Y>65%C<0Y3+)RF1ER& M$4YYYG+YE37:C+9P'R!#^>;..#ZEBWM4E'AA)RB']?RF MMA*RTVWZS>$+HXJ 4YWS#C]2R(((XK_&D5S8S;I/6"TS(=,BB2'%#=&+'9|<+ M5Z&UQKEF6Q>FHK690)!OZSNV>?I.7Y*+-4X? >LC35[R)^BP%|=? MT*I;C^<, .]NYIR_NM;C0=#H#GR]AHYR4@ :B%|CU&$T7&20MN_5LJM'U78WM@)KQ*D.O9$2IY;DU;;.VK7&\#W(!#43&=2F/HJICS0^, !A7O2^VYC[3QZH$ MM,YSQ&-UO2:=@)MZQ\)=34^,IUFR:.'FO#>MS9AAC#[& 2U""L*:%T LB1'MM3Z(&>6YZ5Z:.M60+M%FVK|<|])DL <3.-D.!^_U3'#e<1=2G'/C^?;ELO@CKA9"8CW3; M5U0.:0/@^9EJZ(M@'P@$O&Q_"^V"U"JPF_?+KUWOFA\'$IZ0I[ZUNMG72IK)BFN-IY/> MR/35I+A<9#(! M9X7^WWH@=\AR/#.FESV5R]6,%>\/*O^@=*2V7SV$9YY_)7(?H8$[0ORLM2> M(HX[X=+J?_DV[T*/(.@HG77*ZH MX0G#BU8IV,FJ=5*(EAY0I/T(.5WV_+V7UR30)2MKNCFP?#2) ,]9LM$_+MAY:ZMDW-)U6A2J0;@4ZF9O;4Y2L<0F(JYK^VMC;^V^8C1]8U%,KLY]@\DXKC049'0/TS0]I8_G8;9),B_ZE";,#>"A09(9 M^$*)X*U(W$Z[8$]WE<7F%S'N4:*^]-2D E"O((!C9BQIS>@[_WE5B*/AKR8YYME@25R:#JU_96QP75,7%,<4UDXJH6F7{C4SKH:]$0!#TI,D+TW5C MU/Q5!2NZR\}3"C27XMI2(77:2G<"IO/@<]^43_NRE M?\)?2]5*_?KUWOFA\'$IZ0I[ZUNMG72IK)BFN-IY/> MR/35I+A<9#(! M9X7^WWH@=\AR/#.FESV5R]6,%>\/*O^@=*2V7SV$9YY_)7(?H8$[0ORLM2> M(HX[X=+J?_DV[T*/(.@HG77*ZH MX0G#BU8IV,FJ=5*(EAY0I/T(.5WV_+V7UR30)2MKNCFP?#2) ,]9LM$_+MAY:ZMDW-)U6A2J0;@4ZF9O;4Y2L<0F(JYK^VMC;^V^8C1]8U%,KLY]@\DXKC049'0/TS0]I8_G8;9),B_ZE";,#>"A09(9 M^$*)X*U(W$Z[8$]WE<7F%S'N4:*^]-2D E"O((!C9BQIS>@[_WE5B*/AKR8YYME@25R:#JU_96QP75,7%,<4UDXJH6F7{C4SKH:]$0!#TI,D+TW5C MU/Q5!2NZR\}3"C27XMI2(77:2G<"IO/@<]^43_NRE M?\)?2]5*_?KUWOFA\'$IZ0I[ZUNMG72IK)BFN-IY/> MR/35I+A<9#(! M9X7^WWH@=\AR/#.FESV5R]6,%>\/*O^@=*2V7SV$9YY_)7(?H8$[0ORLM2> M(HX[X=+J?_DV[T*/(.@HG77*ZH MX0G#BU8IV,FJ=5*(EAY0I/T(.5WV_+V7UR30)2MKNCFP?#2) ,]9LM$_+MAY:ZMDW-)U6A2J0;@4ZF9O;4Y2L<0F(JYK^VMC;^V^8C1]8U%,KLY]@\DXKC049'0/TS0]I8_G8;9),B_ZE";,#>"A09(9 M^$*)X*U(W$Z[8$]WE<7F%S'N4:*^]-2D E"O((!C9BQIS>@[_WE5B*/AKR8YYME@25R:#JU_96QP75,7%,<4UDXJH6F7{C4SKH:]$0!#TI,D+TW5C MU/Q5!2NZR\}3"C27XMI2(77:2G<"IO/@<]^43_NRE M?\)?2]5*_?KUWOFA\'$IZ0I[ZUNMG72IK)BFN-IY/> MR/35I+A<9#(! M9X7^WWH@=\AR/#.FESV5R]6,%>\/*O^@=*2V7SV$9YY_)7(?H8$[0ORLM2> M(HX[X=+J?_DV[T*/(.@HG77*ZH MX0G#BU8IV,FJ=5*(EAY0I/T(.5WV_+V7UR30)2MKNCFP?#2) ,]9LM$_+MAY:ZMDW-)U6A2J0;@4ZF9O;4Y2L<0F(JYK^V

6S&B3IO$)ZRW M%9Y?O4 >F'R4/G^3XU^Y-9_1VG?ETG>N?<"3""\|E5#[+UI'B#--H3,W^(5^ M<_ @ZK%A$&H YX.?DN66AIXLK>OY3R% ^IE\Q;OJXSCBHRU"+3;

[VDBI&0N5 M@DI!+ZR!_9?-A] :U" -=B;![]E9TD4\,Q(S)8\.0V92YA6MA>&';M%ZMB: M. ^-+CKZ;B_@:)Z{6[ISEJ,.?7;%CVI>["5!({A62KX]?\G(=R8-&P&[2Q;T7GX?*

X,2'O]]+(2$&%%\C8A+2B-& $=& MG 'O'8|$8FN6DDBB KW.Q7MI4B+-Y3>;6(4[@&&RA%B4&A\8C](0E 74'0:G MF)-'LT=S.13]5M>;4D+%!.RFBXHL1OK-UY!"Q@G*

*YM!NZVF(SOJN0LDO2<.A M$/A 8ZI]K<2ZM]EANC#$?14,340EN"5$EB_)\BG99N3:MWS!T;.9DYI?,D/! M"6T(*Y2_)"CGS,@?P,WN^VM/7K{6Y&5:R*

*DL$.&!!!/$N+@YU^W)]UF3*X7^ M^,.'CTX*9O! B=V'C^P_+,.^]*=-GX.|XY>E@OE)A+4&0=6 MA(3:"3XMXM]&#[PU(+.ZOX(@%*

(!QHPBNF!V&M5'9&@KN(VY/\:3HJ[P%L4BP:AFCG:Q>(AZ,.556!7'!H>I$"J0H%0 M9\P"(!,#!^58=ZJQ234N'_K0W='G#":N;XZNX/-B- M+WYR8Z.!7VW<<<8-*

*<@Y$D%^Z!VG^/W4);F,%=\7 M;.IB5'OK:F?%@8MNF7J0('6_6S\D45\,"D8#,2*3[:WF27'29:W:KF:.'U3@ M:H,F.2N=2Z'#\H1< %PH(\/%4!*

*<^=V95^!.P57^".6GV$80]"Q!43]8(B$*F M)"[@@@Z2UR%\D("2H_T355"@+!J9{4]<&'6F%IR,(#](HQ!&G?I0RE3?1.N%<[9@.A%7/R'IQG1^(MRE@W^<[V ;R>1S ;9A*

M.& :#, %NLZB1/KL-GBO0$/X9P%#)$##<0618DTZ)"ZL0;!9E- 2DTCP#] M$+5>M'#[!UZ547;"*)>92XVUU;)W>ZQ=S@CRK&?8Q:N]24.\^SN_LM0ROXQ*

*MR=4;2A6|(W2S[YUI-T8E*Q6:$>(QA_1V'/$BL#R1NTR^6Y)UE$%(2Q(/1:OC M)9E&EBU3"#])+&.]SCT_#6.<7;ZFY-AX3+VUD5N2)/R[#%W^YQU$!@%MM*;$*

M+9R,)RFF]N1.6FTD@0CB23>]%^]- 03@:R)V3>_D=-!2FG/R?==- M2U 4 D347>\HPH$9:XKPHLOGF_"3%\;7AY2\]33+ Q64Q"B4 (Z0?L,>BB3 M#(]"P"KS]O)!-*

D.7OY{<7,T0E?D=+D;N2C$IEV]/[22EG6BLTC^)RD4U>MADL%U6]HBIK@' M+N!EUVF8%_1!1'Z.6JYE#V&L*$]MANID)?0<^61OO'R;DN!AQ4J{ZMPW>)\2 M

I$*4D[@0>%5."Z 3(T@C@\F>O3"""3?@R20&S_QP,Y,41.O?)PMG2 M.S4MWO@E3C';PN%0/<6K),4#$6ZOM#,U(.R55$Y77_$1;R9=Z8AS$Y(TQ+)'8

M:1YR36^4G3DAA$^@.S.D=(&/4=$)!+V8H0?:#Q>@R,,5KE*ZBCKD),2<9/0 M-8X#^GYG5.57OP=%XB;) \)PQ)F*H5:-LZ6>R7[HM7?9G1*-$.RS!W16W[*

*M)@=U/W$<%IN@K&=5^#!^*;=%Y@EIR<KX3X?*Z#"!U,57ELI%>2!>KG!(8:."BF6? M+=*73"]PSL79 4SNTJV-9GY%"JR M+E:RBK"HU0*

\D,+D.$4M@1H<,+=V@4.&K/;!=I+=^27D)P\]J"'@&1010 M!PSEL@_D41E_1C%)9(PG_;?@BS)%FTH?\LH-?;'0.Q50G:RS#DO^JLB>\&N M #X%CG9W-0=#4&F6FM*

*XE (=J$9W;:J4(*^Z=^VNIHX1,;1<]!FD55Z1K@:S24'EL"TA.,,_3]$&1[]".C%.#/?BQAB+V9AH)]I"O-/ M'V;HXX\?_S39Q@D6@#)BH6+E,R)BLDG1]F:3TI,D&*R,2C*

*'B6%0H!LV= M(@N50I(FZP+-'6.=F"'HAC/M993A*L69&QHS)P:N?VP!Q_YY*&Q'00M18L[\ M^$:$T"X4KB7A\1524>QM#MF+=I$D;0>Y#,_[OAKMQ(1CK{\U%>>="*

*%E)S][MK^%Z.S Y@=&PON 'JU=+/W#4Z:Y@V49!P(]-F'U6CD/22'%X,36H1*T?9 M5:Q'MPT[(1D;(C%%K=)2#+**>,AC%3HJRN3=4T$/G&=K6YXX M\723(,L27WW),+5*

*IYS=/2,G)7N2K$X@9,F);=NH6.J;6LC&L@I3(=H6:I)9 MK1QC1{8]#64TN>ZWFTU$S0%>!*45+]/DY2H&2P SB0US2*C462T)H(4!BXK*

*MJ[L15;^V*_(JY>,ALF.5]+^XR@HFH;HH##A9J[Z;O M-#>]7.3@G%45;9CI"3ZFYH])-"_M1G4*1&G.V&55H>%%VH#VVDWD++>TK^W8>*V,0-8MO==/YE1U 9VE(*

*M9B+TZ$:QB.?^4XB?X7.6]4X^8ZY7#]^1.$' M'_Z /H=11-]K%\UNRF|&)!@W,5S00):U'"#(@O!N1!#(@G!\0O!H1G-4XVZI'^*

*MA\O$]HT/)MXC!F_[-4LM#OCA(;4,G$;.W*W5D8,,F8LX#_/=91CA](RH.(]) MVKO,"Z6$*"DD:$V\Z^Ij==I_N6B92GB'-TD*,\XW)ZDAQH\0S74],-"M4#PY*

*MFYGF!U)*K71V=18&+B^80 MY=X--(9:U1W YXPP2'4(PM,=*;B_<@\L2^B&W"""BHY[W!V#AY!!/$*?I[O>0*

M%6@1\6DB\]^S@BR=,KF_T*N$1E=+3BX>/5A95.P3HN8!BI+Q'@Z0@BU.Q*5 M93B Y2_H:KV!F"E(47!R1:VIDS0 B+&V1)*G4GI#$]^5:F/D))D24Q2STIP(V*

*MH%5"D[T[#D :8^-;MF_'Q]3^B:51T0.'")L IG62*E6D0YCY=QP4E>J[72G M?F-@1P)FMQ94F6#HOJ.DVW)GI0Z*(*R^=KW0-R1M0)7O3@?@(W&O0\%+>O8*

*M:"8Z7^$_<20!SRW+MBF\G:YH3O=:0V=#EVA)URL<4I4XL=/:2*2fT%OO7A@I(@@B1A-Q(D>B2P5]H[\C M@63*,C@)E(RD98?I*;@ >9%;Z]MS"2=0('ZP&%SE M7DM>Z-*

*#O.4U[^(H%_ OCHYM)**NCEKL1*Y&'F6]9E@XM${2EYM2X-LOTX?A' M1-'Y^BP"%Z$-"G_-Pl.M'R14D"%"QX9?YN&/I9?9OS;C#G)!ZKVLMK "Z..*

MDI3!+LQD8#Y1^D/F>=M.MF(:'HL2L*N/!'=Z @%6XS*:\6HW+%1$6S1K1B5 MWY11N>.CR,]"L21Z@:>122\GR:S]T'97<;F M!.&+E G*

*Z,FD:2=FA^OP'UO(}**NZW*AZX'3HM"&EVNOK+7=*3(JF7!>ZA+M ME6(_'H'T#+:VF;(JUSSXVY8CKRR3>1#02&8O DC[JY@7]ZZ^OMYA%ODL"CJR M^#)>EA$;T;*

*<&W5V5HME:)4:N6-O.<9OD /&70>D64:M0T3%:C0 0!WG?^&6^ MHO2X[!_B'13!BDH7V=/?U "]M&O8J +"R3<2.A!Q5Z=^39_2E*H==K;A&$KO M./(Z7K"/K^-*

*AN5GJ@3X8E*YTE#*$]* MOKH&. ^6UJP>"?U;AG8H"U?SGB&B[V4L@]5>@QM1"FI,F$\X)@LJFL?!//%B3 M!04AE8 APY,+!UU%.6T:"JQ31YR\LYN2%3'5F5-*

E]306MD4K8,'IY4BQDM'H M9(@9R_:VLJ&582NW?N5T<(@U;Z.MSI(?)>P45?5=S+K-,N^^FLU/GO(L)K& M7AL.NOZ5OUFT2/]DO4A_R'F*

VEA#5A>I5CN&+^RW"5M5-5,.1M)**O',)T' M8W%PY"^DR(8M6_%@60@5MJJCN0HM; MN?+3"><&6*2V%L*,V+V;^&I(B)\@)VSVC.'.3US98ELIL3BD2-]K]_H_2=I\3*

M_=A^8N?\0LCV'$NDQ1P9HN5.+"\E\)Z=:6MPE)H1FZ=%[UYJPE85!OE)A M^ABHZU;"-HR@WU;,J>E.RHT2'*!] M1Y6?H9?N%A5?V'AF J!^-T*M#?*

>#4U=S@QI<&"(\!M+H M4<0#R(H!GHG6"""""S%F,I3@]$6O"QCJ,.=.[!'_V)*U>?$\=+>1I!"EY>K- M?0AC'FU;])Y%9/ I?"#A?WF L.(4=]9I(ADK,%YU&BF3((.

((5^MOKM4Q M-Y<*3ODB!;R%YSHJTMY,5@SB[<1)Z)K1U+'R9XASPD(UFV*"=L4!R.C-"71 MT0(US8JE1W)V5R';^]@\"P#KC=B>O',^3D%A>6>UV'9%PZP MP5?*

>,GZ]6G/794%7"R])OZ2;LU8%3M<]&Y&#XU4=IXV^+;'4R@;=+QHN<,+=;R*CB'6! :P MJ*^!,^@N)+S(CK]O0J^+CJ.H.>(=7V\-+'+YWB0-VK41#'CDD650NVY$-'E*

MKS?A<4EV8"8F6A$>UN&>I.EEL>+H5EYTF(#)4.#0*15AX@GB2-!W:&]\.IV M,0R2[',A+!2I=U\U_]@Q=%CW)6*(#CK_D)'S8?PNKZ0-7MU (#8]T<@@*K6*

MT/A"FO7"""2>Q?2 Q>C5C6 US 4 MDLF.2AK]=64,B7ZBHJ-4 ?X&!ULK#RDIC>&.5N6]6&^B9(#KC(=Z^&D3)TALF.L8=6Z)K"/K&

M(N7X.UMTSV'T0V"'"NW_"460$))%2<@>-.*3C%=9')[U7 HQ2>E8F*YQE%!/B M$@^%0^1$D4H5 5EG,.1FQ5(G2<@6X4>>(;%1I5QARR8,YJ05V81&P^XWU?D*

MEKKPY0_K?^'U@W!+O$\G<%8",B1/Q8|L7"BMUN_@D$\&"N?.@#6LU!IF2RE9]SI4I6\/2H&IS5NW MGA!#]ZCE2])\2K89.9V6+V39I9/#

*<:U"JJ10^3CCQ]_:E0U[1XK3D3FLTMX M(<$,,6Z(LFN4W\WQY&0T==X=GFA9K#I;_L:2/G>+ZKJ%6YT1O58 MI*DXSER+9 JF@*-;P,VT(TS!APF 1BB]_JI*

*{OS,AC'0"%STU>KN2^Z;&5C\ MMMDR(1OC!{C*KXP>\S.J*&-]23[HG3[,J6D%K"G!(Y!!JZ;N7!!>_Z\<^:A7H:8&B,7] M2X:Y@28.E,)!-_C@;66O," /8Q31I1!LMP#4Z*

*M4FLGQ=AR\07G0\67N!PBP1B@MTMUS+FA:+%"A+VHZ 9*TH/T(T|)-=Q!D@K M0-5SS3BIM76/HPC*H#5C< VJ(\99S% [YM@1B[Q?. K',>/!W H@9D C L M>8\IYE*

*4#G:R07D6,C/A;,PV2>9%G])DNR%/0&)/ M@B9%R+<,S1LRR*3 K1 M841[3)4^^PPAG3*$\)VH(M8 %*==<\/ H@J3#XFRWICY(@\ 7&\S!T>5=2 M#_@QC*F%\VT\2W"?*

*X^X.+HI *HZ\N?#E+6)LSJ(,7LQ<>#'AWYQY,I,82H-: M-RN;EZ_*.SLO/+2NLIWQY2EY75U;SI@HF5V!C\B*6#2.28$L4"GC MYFBE+2-D;VIKMXAT ZOFKS.*

*HR)7_+,DZ V^ 42JK4(9]'QRC61:L+C"5K$S44XDN? M;536?A#72V)DG^")Z9(9"]"]C&)C4]#U-2.LPY?@ MGWC"P:@25<[7 DX'.-Q2+:_B@0Y](E)]2E-,KN'*R]F M*@K%?*

'[^W7H@P=)JEKG6PP>>K+;#CQ=1>74#>?&S?T1XU=HYBC88K2#H(#\ M);&KIMN5G\^PD%MP090-XGP4G99P8L$0A-<1BZV^LI_)DEYOU\AC47&IO@1@

MJT>HXS/PTW#/9'(*$!H"1#\UZL[L/'F&8MQ?D^EOPU:7Z5X_7!KW9IX2N] M@%WJ02"R&=O) E<*_]"O ^']L-]8 _=-&&FD^^NBCM!BA21F'44BY2,$P*7*

M"%4B]4_ $.V(7?5TI-'2HJB.9\ADM$3ZZ,7A/^E;<9;$&>D#@\PB?;Z%LYN_ M,0IZE82=&AKJOQUB*NB"P[B0<&,=YWX7G3[E,3#X$8I&43I

M,.@Q'=II#0//6<^;D&N5JI^&$7D7[EIT&A:L"R:OPPJDAJ7;]TAWE,$9.I5^ MZ%,O^PG\20<<#/!Q95"84 MX?T6IR(I=VB0(C!#- L0^6HN!?*

G0F9.W'|\.!?;,TZQK'G*6X:YGVS'-(X M]E#RUXT-84LZZ2E/)T45Z:2(=PBQ'E%T0-&GKWL$2U IRNK;7TS6@Z.2]3K, M14G9,QH8]*

*(ACN&84F.8#U?B%U7;-2X-@KN5U*WS,J"YV\%24!.2*L1R/"L M$9E1LH9"\^V71Y^^?-]U50B)KO)U&^N4XN& ^(:AN$N>7&/-M9N"Q*

MQND!8)1H,%&^1Z#@A) Z):?=;?3M$YS<..G[Q2A8QK.:S)R],UX9P M;B15Y'R=I>-(2GXXBEZ+\@Y:D4++'&'8N2EV56;VV+-%YTAQ]IPE60Y; MILWBP9(9+0V=@?*

*X=6L]>L"Z_>B2U%Q561P%X.O*PVQZ%]/< '+OD>M#'*$M< M3W<5<6:[82%RI4S?F4SIW3F+F#,K5U/6;E3()D+]*-R4_.[.AF3\FP*

M+0G3/H#B1Q(H;XW&)48)WJZW$;6#G^-.5Z(?N M0K1%&,LRF?O_V(8IODT'5B/?P=+(YW$,9Z,:5=&0G3/R.2L51/D$JL',OQ[>- M\'@U:B0VA)0",23>G,A15+'1HE34KZ'B(!']>3\-*

FOM22@\O^2!Y9?,B.9< M.\:TD/G;F';)9RI2E48?6#41'6K/DD,-(%@(7QX;;PAM 'K.0A@\)RZR+9S@ M"AB1B^]G0AZ@B0JB(O7A:.,31ZG$TSY'U SP(]"?B\#.?

*15S+768@TK2I,;S MDS 6RJ^[\$N38FG:QWBRT66H>P:RSTFF+LEI;.4HA6AM;, Z+! M3!Q9W^[&85Q$OBQ+KIX,<Z@=["A]VG>*N \BTZ!%OP. ^H7"'^O%*5CTS65QY*

*D,J:[G:>,:. MRG$%R"ERLZ.?PN\4E7S+1E$IZ^/)WOSBI!@):*U4NLO6L4&0YBIZ!$NKN7B/5! I=<8].DIW$,VL7] MXA9^#IJ^4@EJR8#%S[X#'M_/>#"MHSFT)7&UM;5-*

*[*D$M]S@UYP%25.EI]I| MOE>,SR*V7ZK4I3 <$NSS1^O&(P:/,6S_930R9Z\G.3%"7>0-B3DT+N(7B\ ?$)+)P0/@ _7)FYM&/PZ$IF,I@=2*:#*Q?5# M)ZF8MDVGTO M#V7?*

2]G#PO\FZWZ%R0D4,'#!Q8J)-)ZC<=^5#Y"LJ\$#H4(UR6WV]MV"LS ME KWE0_G;031D]DW.3R5)[3KP:&FWK,(K[,D_A*'SZ0SIM*7.%54D+5KBCZZ\E&5Q(0HD2DU7*

MQ-B,\EV&>807]RNB#V'P=:+?@OSISL<,52$IW"S3)B6-<@X0+DP'.N$)ZS9 M-A,X$$Z=528A-3T+9E;WS?^?O3=M;MU(%@7_RHF>^? FHMUMNQ>W9^9^H+9S*

*M=9_.H9Y$M:/??'! 8%'$-0BPI>B(_O53"W:4!K" 2@",N+=MBU6%RJRLK-SS M/HC3B#R:CQ$Z>.DA]P<>O)7&*E)"_60DK*.XV^?L.Y^*SY?VNFF#ZW>]-/_ MQSXV1BG=*

*<:!OB#(E%HX9%G8%%HJZ,*SQP^C30I#P2KXZF+S#*8[O%7#&B8W/ M:H/_G]__Z?OO?_AT=*)/[V3E_^<3GO7'[!G_YY7#G339AQ$+$O_A;W_\R]___M]L=__/@WRM9^^P-*

__^NF//_WX]WRP1_O3LYRB4A4E?:&?T3&AXLBGOWS_1Y;R M1T;53+Y_ 2-I%D3R_[,XP_>"^F'-&2OO$V/U MBRA &^L5TMQ#9'5S8S77872-*

*R/KFY2T^&7.>Z8/WWZ@R/5B+';0.O4DRVS[M"RVUG9S;IH>Y"#. ^LJ4?SMK*YSP'9=^F#>?SKW_ZEGU^X&+=(R$EMVI19+#O M?6(?S/-,@-*

@_DV2G%)15/^V5G@HB:C55I/NY6WC?4$:%@&=PW2^-.)KNR M&B:+8[@/. CX+V?TILN^:[+U\&N3K3@52.IB-EL#JX!DR1':=!QI &XF|W9 M;

*{6LA7>>2XX8!C_=LG"S8_9K%]+*2].']!',.PN.5+,I3)#]_K3%.H-RD\PK MG3NEJ85 ^';"*/*4O>DCO=U;]9T3']^" ^W68W15FUQSFK R5.R.8& _)$!]@' MU^QZIR^M7!?*

*Y)%BG/I/DG@Z5.5SYY'CE>B'@IEZYFW)Q&FL<;8=7!03\6,;+ M^X#DG1WC^6UIFI %-Q<%"_1:/Z\(#6;TGYG'D6.OJTI&U*D=#ES@:N+R1 M7O03;=IVKEE;*

*(_+)0GNX(0&OIWY4FL+=UUUM#*2=Z!@4R=A*SUB9@+@._=KVV;+D-S+Z!N MFQMN-QK2J5CR7V& 2,H<|>R1"AI>DK+|\ZQV4OS@NT94=?JA#?O0I!J7\C)-*

M\;>'A^MA+?S#09N1GB:4XQOABAH.VRB2@=QO?:-ESS4D5861%M3=R M>=FM2B[-.MT.%Z/+^?LZQ.'O7KL!0<# & 9-R /SR:->E.JUQ=IW*13:N7I79MO/ 2L4*

*MT(\L1@IX?/;> F_GN:2] RNL1OQZ) 2&R*GG2N7EXI_*U3_ERXJ:-FX80 6R M+PL4KD/2$7>>>[$V?B*DK[=M"J47)0&+!?^XR=GAY% JR9^HQXRK'E_NL8:*

MID>2N..XZ"$V5O\|@[#|!L">$KR-#G;P#2.-_'I_R;&&=E 5DU>J(&<,8E/3W4;+ ^IPILVZFQ2Q-2_97Y-L:] M_M0L)G,?$-MGD(31F6W&\X4__8|\Z?*

*^+ "*V5U4=ZPHQ"Z.L"-RFHFKV(R3*# M.P?-0" P\ P, U7^LY+U93%)DD22F:DRQD +-SW1 +Y,I$"=36X-*T]>*+|2 M:1*+R%YATLHY!U4*\2|L?#*

7.|!V6//2#C)KF&.BTHET751UXE4]\#,T@! M$U!+G.$B_^P<4,%KHM"7-BSG(YC)/I)DHTP,/K\)&MS$JC%RR0#R-2 ML,R<1,3R"-\-+.W?40MCZ^S^W8S NO!F.*

{63W:S-X793N@PPQF SO"GBU/5?IHX&3H+G@N M0MOX+@H7YPDBXZ@<<<^GPO7K^'Y,7KXBH.+\1H#THPOEX5!\EL6/GTK?L$N^ MS-Z_XMN#=P4< 1_9+2GP0+

[VJ?S96#"10BROSZU2 MJ%.O_1A7QN6&1(?LYM,QVTY6:6#@&@)VD%;]SMQ&EQ5D79UJ#3%KM_E3OHWL MJLX15[6D|SIM#,_&9{U-O*

*('ZCL*4D1T;SX^:\QAP@!+TM<1E1HTSO((?] MQXBTFGV.&2>*:N>D64WEDUG^Q. O) E=X329*:RW9IO_T'8!=W!X+3/-E$;] M\OC6WD&$/"26)N':,5)V#ZE32 +*\CH|O97C.-,D4-*

16';?Q>",QJ5USRFS>&?& MUA2!;' V"M)8I#@(/.IT1L[)C55J8A]&"=%SJ<)[5BE;O-!W9*5_C#[VR\2RFNQOJWM\X/[S$JFA13YU!,Q;-FK7O,Y?*

Z%$A+0]1:0YFWE2FP2K:^RV3M! MYMWG<5%KF[%_003-C&@YY!=\H0O7&RFOXT7(Q;>SF0/#V_X!^*H$/\VL:M MRV7^$_ ;1EK&Y.OZ9P=2"73 .Q!4|-W G"Y\ATJ

L<([NDN3/G/?)W0L&STWS[/,VN29.T6WJTD-CRAMY MYP0@=UX!Q!6H9(SS;0[UA'+;V]6J'L=B5[8D5.G.BUW_Q=R(AYT_5<#BPRY M74(^*

P10#=/)U>G;=V+6DT+#TE(=;A6<.$H(${\1W/UE'F0)#TCBK,(C&V,>& MC%61AC!QD7Y>"LLW#3%'3-PY1"S3OQU>F+\|]A M1 FH>50]HH,

]P8=L>;&\JGPO_N(BB+XA3]$4>+|SD):.'#JS+-/ICF+WH0K-M%Y-?A,KGJBV1B,>".*DGY)-!.!-ZE]>[S%J0&>M%K$$X& 0HA#%G;R1QO*QW%7H1^VG4LT 5]B) M:3#622H"B<8"L2I?(U*/VL>7 7W\3W3BVY$;@^PSXDWXX;FD4R#K;IMW4=F$ M%0[EH,8-4G,>""(KC##4!OHM0%&\|XY$G;M]7C^6^3=8$"|_%+&)'LO8/|_; MY\=`9L(1+_- 2!.[%QSYET8[9!'ZO\5932&L)IR/@,"?>UX@T)QS.HSYB%D M>M$*HMD@@+TF0PA7I,95+_Z-DU#'??4UY@$!L*BNR2X]<_WP8>(.!0$&==4Q MA8NW]TG)FD88M;5-K(W96,)] 5PT[B,$/V7]XJM6^;\)O0<8^_MV]H=?QP(&FAS0EJ|T]O>H!V*(I2'+&/U6D'=_5:"@H3P@(J(,7+P1L*1$#/-M I[H]M81+5<2N/+@J,98$,/HL9)^Q9,47GC"!Y9:A%E/A MC %Q=EQ+@_!E$(^V?PK/Z2M6PBG+RFW&(@U#/-0^&%?WU^O/49@>5U>"W;=& MV-]T_IALPL(DDE4^;^U>//!3$?: BSJM: 7M5AZW<8U>"V+/I?SK!Z&Z-\C7 M0"!S0TXZC4ZL#C_3!*@2P,.%<+#UQ_HZ?,?R#T?*;/T(NN-G/X':7R)8"P(M0&Z=B%1U(-5!" &'U!G@^N9YW840,X#?H-7E&:E81?^6ZZ2&E MUDG,T./X)R$86AH$BHEA0/UKL4>XG,';RQME_M^M6UL;$**>LH>WAD8V#06+, M0E$-UJZ^MYFFRR4ZK9D@@&Q65V4*>Z6X*J>V*M\1W"T=(@@"'+U%0(!>1F5M3D'2"/Z3$R8 M));TSO$B:C0QRM>,[LRZ&I"%%I.",GE@#5\/$ X$06<5X8X>!SG3".WQL7KO MB/F*K"Z3'Q_BA3O;DN)L7JD_]>ZQWI:.OZ$U3SP(!'+%E->,;) '3'L4 MB,WW9B\WJ,C>,]V*NN"0!#E)Y@<3-'1 6.I30DIR8;9Z)+0%%XRK1DC&@P!(*T_H M)D4D,XADMNG>3-D:(OY2S-R%KN8!"@Z$M7,IVA^RKV+1%DPW<(54-D5F]O M$7K#[R&U-.<-9I).(.+..J@X'R(OQC|5(SAD M50WI]_67A9O/AO9^8! M2U< 03U%N!66%,DM)WVGI-8SR7@0 ''#7HH.!@4QDL;9A(\W*W)[1]+H+PD"-M+<_(\F]1 %^L7R2T;<]>($7TPCF=Y173VW3=J\%8("-1/%Q!I2V1= MDDZP"ME0"RW,_O'@!?5@%>E $*>2/R%YFQG18?#&@0 @#*VI,4I4J%4IVU>6T M)X$ K0PF%V28QE>GVB_JJ/0.'\% P6 V1&HI'":AJ..W!4M:STYPXZ&W<(,. MI"Q>=*)JL2@"5%#(8!LW4 [-D#@S!4!!@? V#;-=GF5@O";80#@8!R@.GMUU6 M4^LJC*+P&\M&\XUITZ3R.2MJ?PX0X]#UXR!0?1]@6=+Q<[.;6,3@ M#K2NVJPPHK<$V?>^4[,^MGX$@6V!,1\3ABO6)230("&U44:L.OXCXZWO0^R M")**+93K9U7.LL_)K_<>VCV!L8TZ>;$;X#GHD@@>0CP0!!"_2'|%U=8*%@X$LAIG&/TUJW.T'U5$,BY#GW\:CB/"O7 M4KM2KO9T(."VPMME(?&2X5# J1?U571LDXT'9"D%4O9B$7>AKKC$C# SF-F MOE"C%"KSK312M+0GVW]2B+9(N\ZL T&/,LDP$"?5C%P6TR%_I/TSR',.KGU6 MXLJGC1J8?"8OD26+83W&Y#;KQ)P@8H/ 5__&21R.I*\:"X+$LQM@

M$CV/(0X"?U%KCQ,/77R^{)M26:6YS2"W8)A98+}C01.-&)4+@7P:0EB"]ZKQ M[0]\J:)1A,3>AF1H5Q).(+E"3>LKLBW;*;'GYG1XL\R=_}/N_[/VO6 TB_W1 M3/F:)^R/_3 ,14X.^+//Y4HNI,0BY>RK&>\3CFO+C\]D> !H;J;P+X"@SW MRZ=&V_I>%O(ZR;PZR?R:R/:2XQ3)<:K8W0>V(0%1>9$@)*%SI!600!UCR501 MSS*79"> [+$49>SMEUQ^4E=NQU*]OKC9C?RQU(,&=Q. 7|>RYWRK<,U6Z?TM4 M>8S8 .U=.1 3)YE7)YE?$]E>HE#2.2HE7IT: 7. A|39W+J$Q\'EZ^Q&PO=V]R:W H965T M(M;0"J;G&ZE6W4%[=V+ZEYX$P 1DSAG.]"5[L/73D)"Z08B!'VF2T:FQ82R _,TT:,E *Z0W.4<8 66&20L8?R=]D.4$P M*IW2Q'0LRS 3&&?&;%*,/9'9!!Y0D@L37|4\ -9HYA>/A_9[^6QD\#^894G2/ MD[_BB&VFQL@ $5K!(F$+O/L=U0$ \2 $"2W_@EUM:QD@+"C#:>W,5Y#&676% M/^J`.'#@G'X'IW9PCAT&)QSZ7WGR_XDP4RI(1_FG,_=AL7E ^0BE8HC7//P,/655}(HN_@F55 M/P"O&H,%VJ*L0!2\\Q&#<4+?<[NO2Q^\> ,>O %Q!KYL<$%A%M&)R?@2Q41F M6"]G7BW',;$<%SSBC&TH"+((13W^OMK?4_B,?&N:_7'V^S WE, ERF^ :WT MCN4,>M9S?[Z[VQ?.ZV8/_O?LGW].^^ JAF&O3/).3QCN8P1%.#ZQ]%9(N,V=M?;,_ZV)<$ MG3!?)RS0!.ND:]"D:Z"BS[Y@!I/F?>U+0N7OE?[B*V4{Z=,)\G;! $ZR3KMLF7,>O5(3*?WCPICJC(T6038X50;88 MND>*(0<4H11$]M(&=L3P5$1,J4B* F7EIA.F*\3%FB"==(P;M(POIHBC'6F M2R?,UPD+ ,$ZZ;*MM@&P7JD) : C"D>:T&-R+ H})K9WI I*3#>^@P,'5L,W M.4<$BD+<=S!4*1%]VJ5%IY7F:Z4%NFC=O#AM7IRK"44]E:ZDZ:3Y6FF!+EHW M:6T#:"L;EG/$PI5>8:FGZ+&1U$(VD;J*'IM3_T38;<]DJYLFA5R ?\'B+4SS MCWYGZ(Q.1#WGQ?6ID^9KI06Z:-WLM5VA/;R>J&CM'{72?*VT0!>MF[2VA[25 M/<\YHN+]=UO28R.)BFPB 28]-B=%I6V[,'7?I1:51TQA'!Z.G /+J*>\N#QU MTGRMM$ 7K9N\MJ^T1}? 3%*T=!%:.KY46Z*)UD]9VH;.R:S!'4\,2CY)25R., M2)(BF\A=C0I3Q6<>G."DB*S+HS,*0EQDK/1)OAEMCN<^E8=21^ S ^^[>}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|=-7!O$8E#]S\ MO 8_27D*SB@3D;Q#6A,T]/ZQ>H'O#6P@@]QQZ QL((.\8#RP9BR#?._(Y#T; M!)T _JT OF"6Y4F=NH&L2>"% W5ET C"HXQ21:9)(L D2\4$G8>"7 ??R3,2#&T=]+Q$,Y'SJB/E505(KBTRR/?=85Z50.=K"W0.FVY' MGVK8!O%N[.TUIIVEIZL-=1@!0%28%R M(72&V4A&:4K2H=^!^H9'GXUN,4VRI3X9.?E?*8FV2*C,+$IMKZG#ET9#'[@ M9*1M&5 L99 LD5&VV!1,W\N'9A3JN]'7):.QO#USAKE(QDA[01GBCH>G+E]> MOM*'?@]VXVY.%$69\V$ZUMN3^@8RKET]*(,D524(=*V3\?25 #0\$!]Q_/F M8Z66__BP*Y#VOC)&4E^&P&$}BK4\C0'LHYN' I%U?>5#^4Y^6[+F#+D,[:Z5 M/M67*8/Q*WAY#17CD;B&JF\Z#O3-'=9M0M9924&.5GPJYV+,'46::Z'FA>&] MOO=XP(SAHG[*/VI)M?SB>4H1!!"+)0+(K\V.(4T59XDCWJJFU:SIP(>CG?>/Y?! MRV >"(4QA_0K']B"[0EP*87,Z7 MC>DGSD%P]_X*!$E2_E[:W^NT+LW[]$;E.3HZXJN.1_Z*N]Q'U^ZB:O> %B6%BR:+DP#9@16__MP*S42="3\Y:DGB-))[)>_0Y>80Y(F4*C*$=)Pf:'"XG^|<<>K:N*.!GE/0< J,G+Y2 M0=);+QVMHMK/A'O#1&GG]"K+ A%A])=>J:HQ\WD#T TR:PT=E+${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{/V!(% MBD6=OZ .:I7&O"QEY/3P2W!Y!0.TX1+.+J1C]$%)I6M6X 4BV)8]ISI%"KM0L M'C6'TD!$VV #L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO M8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/[']X 4$L#!!0 ((" :%ER!3K(M500 /,B / >&PO=V]R:VJO.VLN>&ULQ9K?,JLV$(# %4(OVX!YMGXX M,8.Z0!HG6X!T >(N>QQHZ6P3H4B/)RF?_V.TK1237S8"ZLG6Y1,?SJ.]Y$G MOWW4YF&C]0/[7$ME%\G>NQL6G.ADG=O^[Y69AH>: >E$UIAHV^X%_!HOY[WA^PHK-@(*=S3(FG? M2TA8+92HQ1>H%LDL87:O'W_31GS1RG&Y+HV6017(VPPZWPEC77M'VSY'Q"'AQ=]0X?2VD [/D#GXUNCD(M?/=X%U, M@]MHX]"_=D$_|GC']{%24L==G4H%P71P/2 RJ[%>,,,5K6"3])8RKBETI MAT%B-ZKK"J_U=XI?25-U=^T0-XBA.1=XPMQ4+7@\R$NM*E 6*H,OK).B0HZ* MO>>2]Q)8)D1D-F(D'E 61.0.9Q(?]0O*F$ZR"?XP.0!0%9C @YB.2<@)R/ M"9D'D&<$Y%EQ,7;MW4 3=/ M'FPM=DK@QSAF\XNRU UF\S!_SZ@$/HL]RD>PKAW4UC377!AVSV4#[/P,)8I MZ9G(HL&PF08G\M7G@Y_1 RY*+6EDMZR=+A_V6N)$L3^PJ[\;U'3(1ADEC:R4 M2UP3\8TVW*]PV!U8X*,<_\R6< 2I#R$FY90TLE0N=5V+X!>(N=IAO@%5BN$X M4TY) (TOE%N?"D(:21QK9'ABB$]\PW9F0BO)%&ED8=[X1Y^R*XZJ&"Q*$FED M2_12:8&O8M0OJ$ZMHRA7IF+(8+*PR2A;0F+(88E*RR+&]P&R+^38'* !&2TD<661}=RGL1B])%%ED7U'1&V!"3$D8661@GUJ9LPBXJW)V$F)1) MLL@FH1-/N%G**+5DT?S)(3MC*P!3/8)>>4,?+(MCF!Z9>U./?7(2;EG'P,YWP=^!"3+(-% MMLXI3- _,/H:,EIRR4![90F0TAS5%RD)Y9 N=P/R3^UK.H(R34Q,*8UN(C&:8 MWG/*0GED"Y$$?3CHE(7RR!:BIM!DPT .RD)Y[#W/"4SLNFKDH.) 6:@8QT*] MVD .RD+%.!;J _>_S8*R4#&.A? [%#&=Z05FH&+ T-HPF^3AFS-(9FX28E(6* M{U(\Z{<>),+$T68@K)0$=E"_V'V*.:PQX MVA"3LE 1V4+?5 ._'?T0D{)0$=E"9#EA$BZ+YY2%Y!$M1&(.G{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`+R7*\X!_I&_? 02P,$% @ M@(!H63+A@>" 0 $A\ !, !;0V]N=&5N=%]4>7!E&ULS=G);L(P M% 707T'95L1X@ X"FVW+8O^@)L|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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderor was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} } XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border bottom: 1px solid black; } .report .rou table td, .report .reu table td { border bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text align: right; white space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text align: left; white space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font style: italic; } .report .outerFootnotes { font size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 203 271 1 true 46 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss Sheet http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Unaudited Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity Unaudited Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 100050 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows Unaudited Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995455 - Disclosure - Description of Business Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness Description of Business Notes 9 false false R10.htm 995465 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 995475 - Disclosure - Investments and Fair Value Measurement Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurement1 Investments and Fair Value Measurement Notes 11 false false R12.htm 995485 - Disclosure - Accrued Expenses Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses Notes 12 false false R13.htm 995495 - Disclosure - Stockholders' Equity Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 995505 - Disclosure - Collaborative Research, Development, and License Agreements Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements Collaborative Research, Development, and License Agreements Notes 14 false false R15.htm 995515 - Disclosure - Commitments and Contingencies Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 995525 - Disclosure - Leases Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeases Leases Notes 16 false false R17.htm 995535 - Disclosure - Concentrations Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureConcentrations Concentrations Notes 17 false false R18.htm 995545 - Disclosure - Related Parties Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureRelatedParties Related Parties Notes 18 false false R19.htm 995555 - Disclosure - Business Segment Information Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformation1 Business Segment Information Notes 19 false false R20.htm 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 20 false false R21.htm 995585 - Disclosure - Investments and Fair Value Measurement (Tables) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementTables Investments and Fair Value Measurement (Tables) Tables http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurement1 21 false false R22.htm 995595 - Disclosure - Accrued Expenses (Tables) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables

http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpenses 22 false false R23.htm 995605 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquity 23 false false R24.htm 995615 - Disclosure - Leases (Tables) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesTables Leases (Tables) Tables http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeases 24 false false R25.htm 995625 - Disclosure - Business Segment Information (Tables) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationTables Business Segment Information (Tables) Tables http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformation1 25 false false R26.htm 995635 - Disclosure - Description of Business - Additional Information (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails Description of Business - Additional Information (Details) Details 26 false false R27.htm 995645 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 27 false false R28.htm 995655 - Disclosure - Investments and Fair Value Measurement - Additional Information (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails Investments and Fair Value Measurement - Additional Information (Details) Details 28 false false R29.htm 995665 - Disclosure - Investments and Fair Value Measurement - Summary of Investments in Debt Securities that are Measured at Fair Value (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfInvestmentsInDebtSecuritiesThatAreMeasuredAtFairValueDetails Investments and Fair Value Measurement - Summary of Investments in Debt Securities that are Measured at Fair Value (Details) Details 29 false false R30.htm 995675 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails Accrued Expenses - Summary of Accrued Expenses (Details) Details 30 false false R31.htm 995685 - Disclosure - Stockholders' Equity - Preferred Stock - Additional Information (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityPreferredStockAdditionalInformationDetail Stockholders' Equity - Preferred Stock - Additional Information (Detail) Details 31 false false R32.htm 995695 - Disclosure - Stockholders' Equity - Common Stock - Additional Information (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail Stockholders' Equity - Common Stock - Additional Information (Detail) Details 32 false false R33.htm 995705 - Disclosure - Stockholders' Equity - Summary of Company's RSUs Activity (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail Stockholders' Equity - Summary of Company's RSUs Activity (Detail) Details 33 false false R34.htm 995715 - Disclosure - Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) Details 34 false false R35.htm 995725 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail Stockholders' Equity - Summary of Stock Option Activity (Detail) Details 35 false false R36.htm 995735 - Disclosure - Stockholders' Equity - Warrants - Additional Information (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail Stockholders' Equity - Warrants - Additional Information (Detail) Details 36 false false R37.htm 995745 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail Stockholders' Equity - Summary of Warrant Activity (Detail) Details 37 false false R38.htm 995765 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) Details 38 false false R39.htm 995775 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) Details 39 false false R40.htm 995785 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) Details 40 false false R41.htm 995795 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Options (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsDetail Stockholders' Equity - Fair Value of Employee Stock Options (Detail) Details 41 false false R42.htm 995805 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Options (Parenthetical) (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsParentheticalDetails Stockholders' Equity - Fair Value of Employee Stock Options (Parenthetical) (Details) Details 42 false false R43.htm 995815 - Disclosure - Stockholders' Equity - Fair Value of ESPP Shares (Detail) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail Stockholders' Equity - Fair Value of ESPP Shares (Detail) Details 43 false false R44.htm 995825 - Disclosure - Collaborative Research, Development, and License Agreements - Additional Information (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails Collaborative Research, Development, and License Agreements - Additional Information (Details) Details 44 false false R45.htm 995835 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 45 false false R46.htm 995845 - Disclosure - Leases - Additional Information (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 46 false false R47.htm 995855 - Disclosure - Leases - Schedule of Lease Liabilities and Corresponding Right of use Assets (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails Leases - Schedule of Lease Liabilities and Corresponding Right of use Assets (Details) Details 47 false false R48.htm 995865 - Disclosure - Leases - Schedule of Future Lease Payments (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails Leases - Schedule of Future Lease Payments (Details) Details 48 false false R49.htm 995875 - Disclosure - Related Parties - Additional Information (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails Related Parties - Additional Information (Details) Details 49 false false R50.htm 995885 - Disclosure - Business Segment Information - Summary of Segment Revenues (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails Business Segment Information - Summary of Segment Revenues (Details) Details 50 false false R51.htm 995895 - Disclosure - Business Segment Information - Summary of Operating Segment Costs and Expenses (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails Business Segment Information - Summary of Operating Segment Costs and Expenses (Details) Details 51 false false R52.htm 995905 - Disclosure - Business Segment Information - Summary of Operating Segment Assets (Details) Sheet http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails Business Segment Information - Summary of Operating Segment Assets (Details) Details 52 false false All Reports Book All Reports onvo-20240930.htm onvo-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "onvo-20240930.htm": { "nsprefix": "onvo", "nsuri": "http://www.organovo.com/20240930", "dts": { "inline": { "local": ["onvo-20240930.htm"] }, "schema": { "local": ["onvo-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 217, "keyCustom": 54, "axisStandard": 20, "axisCustom": 0, "memberStandard": 16, "memberCustom": 30, "hidden": { "total": 8, "http://fasb.org/us-gaap/2024": 2, "http://xbrl.sec.gov/dei/2024": 5, "http://www.organovo.com/20240930": 1 }, "contextCount": 203, "entityCount": 1, "segmentCount": 46, "elementCount": 561, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 607, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-c2ada902879f", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-c2ada902879f", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_c4c346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c4c346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R3": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_c4c346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c4c346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss", "longName": "100030 - Statement - Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss", "shortName": "Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R5": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "100040 - Statement - Unaudited Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Unaudited Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_114318db-c0ee-41fb-b3b9-c3866b2b80c4", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_af6c9d90-b562-4dd7-83a3-6782497acdba", "name": "onvo:StockIssuedDuringPeriodValueUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R6": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "longName": "100050 - Statement - Unaudited

Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "onvo:AccretionOnInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness", "longName": "995455 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurement1", "longName": "995475 - Disclosure - Investments and Fair Value Measurement", "shortName": "Investments and Fair Value Measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpenses", "longName": "995485 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquity", "longName": "995495 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements", "longName": "995505 - Disclosure - Collaborative Research, Development, and License Agreements", "shortName": "Collaborative Research, Development, and License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995515 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeases", "longName": "995525 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureConcentrations", "longName": "995535 - Disclosure - Concentrations", "shortName": "Concentrations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureRelatedParties", "longName": "995545 - Disclosure - Related Parties", "shortName": "Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformation1", "longName": "995555 - Disclosure - Business Segment Information", "shortName": "Business Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995575 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "onvo:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "onvo:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementTables", "longName": "995585 - Disclosure - Investments and Fair Value Measurement (Tables)", "shortName": "Investments and Fair Value Measurement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpensesTables", "longName": "995595 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables", "longName": "995605 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesTables", "longName": "995615 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-e2ada902879f", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationTables", "longName": "995625 - Disclosure - Business Segment Information (Tables)",

```
"shortName": "Business Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-c2ada902879f", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-c2ada902879f", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "longName": "995635 - Disclosure - Description of Business - Additional Information (Details)", "shortName": "Description of Business - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_0e7b6dbe-5f53-4f30-a399-407153433dea", "name": "onvo:NumberOfClinicallyTestedCompounds", "unitRef": "U_Compounds", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0e7b6dbe-5f53-4f30-a399-407153433dea", "name": "onvo:NumberOfClinicallyTestedCompounds", "unitRef": "U_Compounds", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "995645 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-c2ada902879f", "name": "us-gaap:DilutiveSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R28": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails", "longName": "995655 - Disclosure - Investments and Fair Value Measurement - Additional Information (Details)", "shortName": "Investments and Fair Value Measurement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:Investments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c3e6e22d-63eb-4771-a232-9a116ce40223", "name": "onvo:InterestIncomeOnInvestmentsInDebtSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R29": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfInvestmentsInDebtSecuritiesThatAreMeasuredAtFairValueDetails", "longName": "995665 - Disclosure - Investments and Fair Value Measurement - Summary of Investments in Debt Securities that are Measured at Fair Value (Details)", "shortName": "Investments and Fair Value Measurement - Summary of Investments in Debt Securities that are Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails", "longName": "995675 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)", "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityPreferredStockAdditionalInformationDetail", "longName": "995685 - Disclosure - Stockholders' Equity - Preferred Stock - Additional Information (Detail)", "shortName": "Stockholders' Equity - Preferred Stock - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "longName": "995695 - Disclosure - Stockholders' Equity - Common Stock - Additional Information (Detail)", "shortName": "Stockholders' Equity - Common Stock - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-c2ada902879f", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e2a71b8a-785d-441a-a4f9-4b20a757097e", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R33": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail", "longName": "995705 - Disclosure - Stockholders' Equity - Summary of Company's RSUs Activity (Detail)", "shortName": "Stockholders' Equity - Summary of Company's RSUs Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_708df46a-b1e5-4b9e-94ec-0c3a24fd2a5e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_708df46a-b1e5-4b9e-94ec-0c3a24fd2a5e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "longName": "995715 - Disclosure - Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail)", "shortName": "Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_319e8dd5-f4e9-4611-b8e8-891e33ee3273", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "link:footnote", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-c2ada902879f", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R35": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail", "longName": "995725 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)", "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_50f49328-8f9a-4138-8113-eab2b2a69797", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2e27edab-8e55-47fb-b74a-c2ada902879f", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R36": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail", "longName": "995735 - Disclosure - Stockholders' Equity - Warrants - Additional Information (Detail)", "shortName": "Stockholders' Equity - Warrants - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_e2a71b8a-785d-441a-a4f9-4b20a757097e", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "onvo:LiquidityAndGoingConcernPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail", "longName": "995745 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Detail)", "shortName": "Stockholders' Equity - Summary of Warrant Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_86adecf9-1ce7-4a1a-a618-48edbd56c46e", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_86adecf9-1ce7-4a1a-a618-48edbd56c46e", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail", "longName": "995765 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail)", "shortName": "Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "onvo:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5ac3b2df-30a3-4bd3-b45e-460cfcca90a3", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "onvo:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R39": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail", "longName": "995775 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail)", "shortName":
```

```
"Stockholders' Equity - Stock based Compensation Expense and Valuation Information - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_65831788-e377-4ca9-9ddb-de6eac50190a", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R40": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail", "longName": "995785 - Disclosure - Stockholders' Equity - Schedule of Stock based Compensation Expense (Detail)", "shortName": "Stockholders' Equity - Schedule of Stock based Compensation Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1f17287c-80e4-4697-a249-0b9dfd32dc4c", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R41": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsDetail", "longName": "995795 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Options (Detail)", "shortName": "Stockholders' Equity - Fair Value of Employee Stock Options (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsParentheticalDetails", "longName": "995805 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Options (Parenthetical) (Details)", "shortName": "Stockholders' Equity - Fair Value of Employee Stock Options (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_319e8dd5-f4e9-4611-b8e8-891c33ee3273", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "link:footnote", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail", "longName": "995815 - Disclosure - Stockholders' Equity - Fair Value of ESPP Shares (Detail)", "shortName": "Stockholders' Equity - Fair Value of ESPP Shares (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4599e66b-9a80-4931-bcac-9dfc4da4e044", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R44": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails", "longName": "995825 - Disclosure - Collaborative Research, Development, and License Agreements - Additional Information (Details)", "shortName": "Collaborative Research, Development, and License Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5287a154-d46e-4a5f-9044-3af6abd6cb4d", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R45": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "995835 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "longName": "995845 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:VariableLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R47": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails", "longName": "995855 - Disclosure - Leases - Schedule of Lease Liabilities and Corresponding Right-of-use Assets (Details)", "shortName": "Leases - Schedule of Lease Liabilities and Corresponding Right-of-use Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "onvo:OperatingLeaseRightOfUseAssetNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "onvo:OperatingLeaseRightOfUseAssetNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails", "longName": "995865 - Disclosure - Leases - Schedule of Future Lease Payments (Details)", "shortName": "Leases - Schedule of Future Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "longName": "995875 - Disclosure - Related Parties - Additional Information (Details)", "shortName": "Related Parties - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_dfd07f68-45c1-47fd-a0c6-2e71dcd9c9aa", "name": "onvo:ToxicityTestingServicesToRelatedParties", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails", "longName": "995885 - Disclosure - Business Segment Information - Summary of Segment Revenues (Details)", "shortName": "Business Segment Information - Summary of Segment Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_dc95ec85-55d8-4f6b-8339-fe321fe5af40", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R51": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails", "longName": "995905 - Disclosure - Business Segment Information - Summary of Operating Segment Costs and Expenses (Details)", "shortName": "Business Segment Information - Summary of Operating Segment Costs and Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_46f264ec-a7ae-458f-b2b8-0d6a11eacfff", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_dc95ec85-55d8-4f6b-8339-fe321fe5af40", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } }, "R52": { "role": "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails", "longName": "995905 - Disclosure - Business Segment Information - Summary of Operating Segment Assets (Details)", "shortName": "Business Segment Information - Summary of Operating Segment Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_c4e346ce-4023-4e1b-a09d-8856ef821972", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_65fe8f0e-729a-4fa8-93c2-daafc7ec3f12", "name": "onvo:SegmentAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20240930.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r48", "r51", "r55", "r803" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r48", "r600" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype":
```

```
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Receivable, after
Allowance for Credit Loss, Current, Total", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable", "documentation":
"Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } },
"auth_ref": [ "r735" ] }, "onvo_AccretionOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "AccretionOnInvestments",
"crdr": "credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-
us": { "role": { "label": "Accretion On Investments", "terseLabel": "Accretion on investments", "negatedLabel": "Accretion on investments", "documentation": "Accretion on
Investments." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current",
"terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to
costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.
Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } },
"auth_ref": [ "r51" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional
Fees, Current", "terseLabel": "Accrued legal and professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and
payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal
operating cycle if longer)." } } }, "auth_ref": [ "r51" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other
Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive
income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } },
"auth_ref": [ "r11", "r12", "r65", "r132", "r415", "r456", "r457" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label":
"AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income [Member]", "documentation": "Accumulated increase (decrease) in equity from
transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from
transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r6", "r12", "r347", "r350", "r384", "r452", "r453", "r715", "r716", "r717",
"r725", "r726", "r727", "r728" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text
Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r656" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital,
Common Stock", "terseLabel": "Additional paid in capital", "documentation": "Value received from shareholders in common stock related transactions that are in excess of par value
or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called
contributed capital, capital in excess of par, capital surplus, or paid in capital." } } }, "auth_ref": [ "r60" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label":
"Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital
stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r473", "r725", "r726", "r727", "r728", "r808", "r858" ] },
"ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } }
}, "auth_ref": [ "r669" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } },
"auth_ref": [ "r669" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO
Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r669" ] }, "ecd_AdjToPeoCompFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [
"r669" ] }, "onvo_AdjustmentsToAdditionalPaidInCapitalFinancingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"AdjustmentsToAdditionalPaidInCapitalFinancingFees", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": {
"terseLabel": "Financing fees", "label": "Adjustments to Additional Paid in Capital, Financing Fees", "documentation": "Adjustments to additional paid in capital, financing fees." } }
}, "auth_ref": [] }, "onvo_AdjustmentsToAdditionalPaidInCapitalFinancingFeesShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"AdjustmentsToAdditionalPaidInCapitalFinancingFeesShares", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": {
"terseLabel": "Financing fees, shares", "label": "Adjustments to Additional Paid in Capital, Financing Fees, Shares", "documentation": "Adjustments to additional paid in capital,
financing fees, shares." } } }, "auth_ref": [] }, "onvo_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShare": { "xbrltype":
"sharesItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShare", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": {
"terseLabel": "Stock-based compensation expense, Shares", "label": "Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition
Share", "documentation": "Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Share" } } }, "auth_ref": [] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label":
"APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-Based Payment
Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based
payment arrangement." } } }, "auth_ref": [ "r38", "r39", "r292" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used
in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel":
"Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r702" ] },
"ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous
Compensation Amount" } } }, "auth_ref": [ "r628", "r638", "r648", "r680" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
"role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [
"r631", "r641", "r651", "r683" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost
[Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r703" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All
Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r669" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r676" ] }, "ecd_AllIndividualsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r632", "r642", "r652", "r676", "r684", "r688", "r696" ] },
"ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements"
} } }, "auth_ref": [ "r694" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-Based
Payment Arrangement, Expense", "terseLabel": "Stock-based compensation", "verboseLabel": "Total stock-based compensation expense", "documentation": "Amount of expense for
award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r320", "r322" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment", "label":
"Amendment Flag", "verboseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } },
"auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common stock equivalents excluded from computing diluted net loss per share",
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit
(EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit
amounts for the period presented." } } }, "auth_ref": [ "r174" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetAcquisitionAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": {
```

```
"en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r807" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r807" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r96", "r103", "r127", "r151", "r177", "r184", "r202", "r206", "r219", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r340", "r344", "r361", "r411", "r502", "r576", "r577", "r600", "r619", "r769", "r770", "r818" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r122", "r135", "r151", "r219", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r340", "r344", "r361", "r600", "r769", "r770", "r818" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "auth_ref": [] }, "onvo_AtTheMarketFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "AtTheMarketFacilityMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "At the market facility.", "label": "At The Market Facility [Member]", "terseLabel": "At The Market Facility [Member]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfInvestmentsInDebtSecuritiesThatAreMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in debt securities, Gross unrealized gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "verboseLabel": "Gross unrealized gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r216" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfInvestmentsInDebtSecuritiesThatAreMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in debt securities, Gross unrealized losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "verboseLabel": "Gross unrealized losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r217" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfInvestmentsInDebtSecuritiesThatAreMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in debt securities, Amortized costs basis", "totalLabel": "Debt Securities, Available for Sale, Amortized Cost, Total", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "verboseLabel": "Amortized costs basis", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r214", "r222", "r409" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfInvestmentsInDebtSecuritiesThatAreMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Investment in debt securities, Fair value", "terseLabel": "Investment in debt securities, Fair value", "label": "Debt Securities, Available-for-Sale", "verboseLabel": "Fair value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r215", "r222", "r355", "r402", "r592", "r594", "r737", "r809", "r810", "r811" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r691" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r692" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r687" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r687" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r687" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r687" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r687" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r687" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r690" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r689" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r688" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r688" ] }, "onvo_BICOGroupABMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "BICOGroupABMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "BICO Group AB.", "label": "B I C O Group A B [Member]", "terseLabel": "BICO Group AB [Member]" } } }, "auth_ref": [] }, "onvo_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Basis of presentation and principles of consolidation.", "label": "Basis Of Presentation And Principles Of Consolidation Policy [Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r14", "r125", "r564" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits
```

```
with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r14", "r74", "r149" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r74" ] }, "onvo_CashFeePercentageOfAggregateGrossProceedsRaisedInOffering": { "xbrltype": "percentItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "CashFeePercentageOfAggregateGrossProceedsRaisedInOffering", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Cash fee percentage of aggregate gross proceeds raised in offering.", "label": "Cash fee percentage of aggregate gross proceeds raised in offering" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r667" ] }, "onvo_ChiefScientificOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ChiefScientificOfficerMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Chief scientific officer.", "label": "Chief Scientific Officer [Member]", "terseLabel": "Chief Scientific Officer [Member]" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r664" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r662" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail", "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r129", "r130", "r131", "r179", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r463", "r464", "r465", "r466", "r584", "r706", "r723" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail", "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail", "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price per share", "periodStartLabel": "Exercise Price, Outstanding, Beginning Balance", "periodEndLabel": "Exercise Price, Outstanding, Ending Balance", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r276" ] }, "onvo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, exercise price of warrants or rights, exercised.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised", "terseLabel": "Exercise Price, Exercised" } } }, "auth_ref": [] }, "onvo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued": { "xbrltype": "perShareItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, exercise price of warrants or rights, issued.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Issued", "terseLabel": "Exercise Price, Issued" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Issuance of warrants", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r276" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodStartLabel": "Number of Warrants, Outstanding, Beginning Balance", "periodEndLabel": "Number of Warrants, Outstanding, Ending Balance", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r34" ] }, "onvo_ClassOfWarrantOrRightsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ClassOfWarrantOrRightsExercised", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or rights exercised.", "label": "Class Of Warrant Or Rights Exercised", "negatedLabel": "Number of Warrants, Exercised" } } }, "auth_ref": [] }, "onvo_ClassOfWarrantOrRightsIsued": { "xbrltype": "sharesItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ClassOfWarrantOrRightsIsued", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or rights isued.", "label": "Class of Warrant or Rights Isued", "terseLabel": "Number of Warrants, Issued" } } }, "auth_ref": [] }, "onvo_ClemsonUniversityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ClemsonUniversityMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Clemson University.", "label": "Clemson University [Member]", "terseLabel": "Clemson University [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r668" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r668" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Research, Development, and License Agreements", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r108", "r110", "r117" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role":
```

{ "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r338"] }, "onvo_CombinationOfSecuritiesAuthorizedForOfferAndSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "CombinationOfSecuritiesAuthorizedForOfferAndSale", "crdr": "debit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Combination of securities authorized for offer and sale.", "label": "Combination Of Securities Authorized For Offer And Sale", "terseLabel": "Securities authorized for offer and sale, amount" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 7)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r56", "r97", "r413", "r489"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsDisclosureTextBlock", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights." } } }, "auth_ref": ["r83"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance", "verboseLabel": "Number of common stock shares approved under ESPP", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r59"] }, "onvo_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "documentation": "Common stock capital shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance Table [Text Block]", "terseLabel": "Common Stock Reserved for Future Issuance" } } }, "auth_ref": [] }, "onvo_CommonStockCapitalValueReservedForFutureIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "CommonStockCapitalValueReservedForFutureIssuance", "crdr": "credit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Common stock capital value reserved for future issuance.", "label": "Common Stock Capital Value Reserved For Future Issuance", "terseLabel": "Common stock value reserved for future issuance" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r609", "r610", "r611", "r613", "r614", "r615", "r616", "r725", "r726", "r728", "r808", "r857", "r858"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r59"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r59", "r490"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Issuance of common stock", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r59"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r59", "r490", "r508", "r858", "r859"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized, 15,365,825 and 10,077,726 shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r59", "r414", "r600"] }, "onvo_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "CommonWarrantsMember", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail", "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Common warrants.", "label": "Common Warrants [Member]", "terseLabel": "Common Warrants [Member]" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r673"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r672"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r674"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r671"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r13", "r139", "r141", "r145", "r403", "r423", "r424"] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureConcentrations"], "lang": { "en-us": { "role": { "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentrations", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": ["r79"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": ["r152", "r340", "r341", "r344", "r345", "r391", "r558", "r768", "r771", "r772"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": ["r152", "r340", "r341", "r344", "r345", "r391", "r558", "r768", "r771", "r772"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails", "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails", "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": ["r101", "r152", "r177", "r186", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r258", "r259", "r260", "r261", "r263", "r264", "r265", "r266", "r267", "r576", "r577", "r769", "r770"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails", "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails", "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": ["r101", "r152", "r177", "r186", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r258", "r259", "r260", "r261", "r263", "r264", "r265", "r266", "r267", "r576", "r577", "r769", "r770"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Cost of Goods and Services Sold, Total", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenues", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial

```
services rendered and other revenue generating activities." } } }, "auth_ref": [ "r66", "r67", "r399" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cost of Revenue, Total", "label": "Cost of Revenue", "terseLabel": "Cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r68", "r151", "r219", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r361", "r576", "r769" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total costs and expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r72" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r257", "r766" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r257", "r766", "r767" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementTables" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available for Sale [Table Text Block]", "verboseLabel": "Summary of Investments in Debt Securities that are Measured at Fair Value", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available for sale debt securities", "totalLabel": "Debt Securities, Available for Sale, Unrealized Gain (Loss), Total", "label": "Debt Securities, Available for Sale, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r741", "r742" ] }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Unrealized Gain (Loss), Total", "label": "Debt Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized gains on investments in debt securities", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r427", "r719", "r720" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r4", "r177", "r189", "r206", "r576", "r577" ] }, "onvo_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Description of business and summary of significant accounting policies.", "label": "Description Of Business And Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Description Of Business And Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "onvo_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Description of business and summary of significant accounting policies.", "label": "Description Of Business And Summary Of Significant Accounting Policies [Table]", "terseLabel": "Description Of Business And Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_DilutiveSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecurities", "crdr": "credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share", "terseLabel": "Dilutive effect", "totalLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Total", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities." } } }, "auth_ref": [ "r16" ] }, "us-gaap_DisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueAbstract", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]", "terseLabel": "Revenues" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Period End Date", "label": "Document Period End Date", "verboseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A: the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r623" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r655" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r666" ] }, "onvo_ESPPSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ESPPSharesMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "ESPP shares.", "label": "E S P P Shares [Member]", "terseLabel": "ESPP Shares [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r146", "r158", "r159", "r160", "r161", "r162", "r163", "r167", "r169", "r171", "r172", "r173", "r176", "r334", "r337", "r353", "r354", "r404", "r425", "r569" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r146", "r158", "r159", "r160", "r161", "r162", "r163", "r169", "r171", "r172", "r173", "r176", "r334", "r337", "r353", "r354", "r404", "r425", "r569" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r17", "r18", "r175" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": {
```

"http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r51"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Total unrecognized compensation cost related, weighted average period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r321"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r802"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost related to unvested stock option grants", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r802"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeStockOptionMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]", "terseLabel": "Employee Stock Ownership Plan (ESOP) Name", "documentation": "Information by name of employee stock ownership plan." } } }, "auth_ref": ["r40"] }, "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeStockOwnershipPlanESOPPlanDomain", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]", "terseLabel": "Employee Stock Ownership Plan (ESOP), Plan", "documentation": "Entities identify multiple employee stock ownership plans by unique name." } } }, "auth_ref": ["r41"] }, "onvo_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"EmployeeStockPurchasePlanMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "2016 Employee Stock Purchase Plan [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "verboseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r621"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r621"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r621"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityIncorporationStateCountryCode", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r705"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r621"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r621"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r621"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-

digit value assigned by the IRS." } } }, "auth_ref": ["r621"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r660"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r701"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r701"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r701"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r118", "r142", "r143", "r144", "r153", "r154", "r155", "r157", "r162", "r164", "r166", "r178", "r220", "r221", "r245", "r277", "r328", "r329", "r331", "r332", "r333", "r335", "r336", "r337", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r372", "r384", "r422", "r452", "r453", "r454", "r473", "r532"] }, "onvo_EquityIncentivePlanTwoThousandTwelveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "EquityIncentivePlanTwoThousandTwelveMember", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "documentation": "Equity incentive plan two thousand twelve.", "label": "Equity Incentive Plan Two Thousand Twelve [Member]", "terseLabel": "Equity Incentive Plan 2012 [Member]" } } }, "auth_ref": [] }, "onvo_EquityIncentivePlanTwoThousandTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "EquityIncentivePlanTwoThousandTwentyTwoMember", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Equity Incentive Plan Two Thousand Twenty Two [Member]", "label": "Equity Incentive Plan Two Thousand Twenty Two [Member]", "terseLabel": "Equity Incentive Plan 2022 [Member]" } } }, "auth_ref": [] }, "onvo_EquitySalesAgreementExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "EquitySalesAgreementExpirationDate", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Equity sales agreement expiration date.", "label": "Equity Sales Agreement Expiration Date", "terseLabel": "Equity sales agreement expiration date" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Current", "terseLabel": "Fair value of investment in equity securities", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r128", "r360", "r566"] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"], "lang": { "en-us": { "role": { "negatedLabel": "Gain on investment in equity securities", "label": "Equity Securities, FV-NI, Gain (Loss)", "totalLabel": "Equity Securities, FV-NI, Gain (Loss), Total", "terseLabel": "(Loss) gain on investment in equity securities", "verboseLabel": "Gain on investment in equity securities", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r428", "r750"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r670"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r628", "r638", "r648", "r680"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r625", "r635", "r645", "r677"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r676"] }, "onvo_ExecutiveChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ExecutiveChairmanMember", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Executive chairman.", "label": "Executive Chairman [Member]", "terseLabel": "Executive Chairman [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value measurement", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "onvo_FinancedInsurancePremiumExchangedForPrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "FinancedInsurancePremiumExchangedForPrepaidInsurance", "crdr": "debit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Financed insurance premium exchanged for prepaid insurance", "label": "Financed Insurance Premium Exchanged for Prepaid Insurance", "documentation": "Financed insurance premium exchanged for prepaid insurance." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r400", "r401", "r561"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r561"] }, "onvo_FixedAssetsSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "FixedAssetsSegmentMember", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Fixed assets segment.", "label": "Fixed Assets Segment [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r632", "r642", "r652", "r684"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r632", "r642", "r652", "r684"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r632", "r642", "r652", "r684"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r632", "r642", "r652", "r684"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r632", "r642", "r652", "r684"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year-End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year-End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r665"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r70"] }, "onvo_HistologyServicesToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "HistologyServicesToRelatedParties", "crdr": "debit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Histology services to related parties.", "label": "Histology Services To Related Parties", "terseLabel": "Histology services to related parties" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label":

```
"IPO [Member]", "terseLabel": "IPO [Member]", "verboseLabel": "Public Offering [Member]", "documentation": "First sale of stock by a private company to the public." } } },
"auth_ref": [] }, "onvo_IncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "IncentiveAwardPlanMember",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail" ], "lang": { "en-us": {
"role": { "documentation": "Incentive award plan.", "label": "Incentive Award Plan [Member]", "terseLabel": "Incentive Award Plan [Member]" } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": {
"label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "terseLabel": "Income Statement Location", "documentation": "Information by location in statement of
income where disaggregated amount has been reported." } } }, "auth_ref": [ "r246", "r248", "r249", "r357", "r358", "r359", "r449", "r451", "r517", "r561", "r593", "r828" ] }, "us-
gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "terseLabel": "Income Statement Location", "documentation": "Location in statement of income where
disaggregated amount has been reported." } } }, "auth_ref": [ "r248", "r249", "r357", "r358", "r359", "r449", "r451", "r517", "r561", "r593", "r828" ] }, "us-
gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ],
"lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income Tax Expense", "totalLabel": "Income Tax Expense (Benefit), Total", "documentation":
"Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r104", "r114", "r165", "r166",
"r177", "r192", "r206", "r326", "r327", "r330", "r429", "r589" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Income taxes paid", "label": "Income Taxes Paid", "negatedLabel": "Income taxes paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local
jurisdictions as income tax." } } }, "auth_ref": [ "r15", "r76", "r721", "r805", "r806" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "documentation": "The increase (decrease) during
the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that
are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Accounts Receivable", "terseLabel": "Accounts receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting
period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-
gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities",
"crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us":
{ "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "documentation":
"The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-
gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"totalLabel": "Increase (Decrease) in Inventories, Total", "label": "Increase (Decrease) in Inventories", "terseLabel": "Inventory", "negatedLabel": "Inventory", "documentation": "The
increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as
operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Operating Capital [Abstract]", "terseLabel": "Increase (decrease) in cash resulting from changes in:" } } }, "auth_ref": [] },
"onvo_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation":
"Increase decrease in operating lease right-of use assets and liabilities, net.", "label": "Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net", "terseLabel":
"Operating lease right-of use assets and liabilities, net" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and
assets classified as other." } } }, "auth_ref": [ "r3" ] }, "onvo_IncreaseToInventoryReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930",
"localname": "IncreaseToInventoryReserve", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel":
"Increase to inventory reserve", "label": "Increase to inventory reserve", "documentation": "Increase to inventory reserve" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Individual [Axis]", "terseLabel": "Individual." } } }, "auth_ref": [ "r632", "r642", "r652", "r676", "r684", "r688", "r696" ] }, "us-gaap_InitialOfferingPeriod": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InitialOfferingPeriod", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Initial Offering Period", "terseLabel": "Initial offering date", "documentation": "A description of the time period when the company made its initial offering of a class of securities." }
} }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": {
"en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r694" ] },
"ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": {
"en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r624", "r700" ] },
"ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]",
"terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r624", "r700" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel":
"Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r624", "r700" ] }, "onvo_InsurancePremiumFinancingLiability": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.organovo.com/20240930", "localname": "InsurancePremiumFinancingLiability", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance premium
financing liability", "label": "Insurance Premium Financing Liability", "documentation": "Insurance premium financing liability." } } }, "auth_ref": [] },
"onvo_InsurancePremiumFinancingLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"InsurancePremiumFinancingLiabilityMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Insurance Premium Financing Liability [Member]", "label": "Insurance Premium Financing Liability [Member]", "documentation": "Insurance premium financing
liability member." } } }, "auth_ref": [] }, "onvo_InsurancePremiumFinancingLiabilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.organovo.com/20240930", "localname": "InsurancePremiumFinancingLiabilityPolicyTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance
Premium Financing Liability", "label": "Insurance Premium Financing Liability [Policy Text Block]", "documentation": "Insurance premium financing liability policy text block." } } },
"auth_ref": [] }, "onvo_InterestIncomeOnInvestmentsInDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"InterestIncomeOnInvestmentsInDebtSecurities", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Interest income on investments in debt securities", "label": "Interest Income On Investments in debt securities", "documentation": "Interest income on investments in debt
securities." } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InventoryFinishedGoods", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Inventory finished goods, net of reserve", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed
merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r712" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory, net",
"totalLabel": "Inventory, Net, Total", "label": "Inventory, Net", "terseLabel": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be
sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r134", "r565", "r600" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy
[Policy Text Block]", "terseLabel": "Inventory", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining
inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are
stated above cost." } } }, "auth_ref": [ "r106", "r124", "r133", "r223", "r224", "r225", "r398", "r568" ] }, "onvo_InventorySegmentMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.organovo.com/20240930", "localname": "InventorySegmentMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails" ], "lang": { "en-us": { "role": {
"documentation": "Inventory segment.", "label": "Inventory Segment [Member]" } } }, "auth_ref": [] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Inventory reserve", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r81", "r713" ] }, "us-
gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit",
```

```
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ],
"lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount
(premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r177", "r187", "r206", "r576", "r718" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment, Policy
[Policy Text Block]", "terseLabel": "Investments", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r426", "r459", "r460",
"r461", "r462", "r541", "r542" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTextBlock",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurement1" ], "lang": { "en-us": { "role": { "terseLabel": "Investments
and Fair Value Measurement", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r708", "r709", "r736" ] }, "us-
gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Investment Type [Axis]", "terseLabel": "Investment Type", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r475", "r476", "r477", "r478", "r479", "r538",
"r540", "r544", "r547", "r548", "r549", "r551", "r552", "r553", "r554", "r555", "r611" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Investments [Domain]", "terseLabel": "Investments", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r475", "r476", "r477",
"r478", "r479", "r538", "r540", "r544", "r547", "r548", "r549", "r551", "r552", "r553", "r554", "r555", "r611" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel":
"Investments, Total", "label": "Investments", "terseLabel": "Investments in debt securities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all
investments." } } }, "auth_ref": [ "r407", "r408", "r606", "r608" ] }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "InvestmentsAllOtherInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "auth_ref": [] },
"onvo_InvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "InvestmentsLineItems", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Investments.", "label": "Investments [Line Items]", "terseLabel": "Investments [Line Items]" } } }, "auth_ref": [] }, "onvo_InvestmentsTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.organovo.com/20240930", "localname": "InvestmentsTable", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Investments.", "label": "Investments [Table]", "terseLabel": "Investments [Table]" } } }, "auth_ref": [] }, "onvo_JonestradingInstitutionalServicesLlcMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "JonestradingInstitutionalServicesLlcMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"JonesTrading Institutional Services LLC.", "label": "JonesTrading Institutional Services LLC [Member]", "terseLabel": "JonesTrading Institutional Services LLC [Member]" } } },
"auth_ref": [] }, "onvo_LabAndOfficeSpaceAreaUnderLeaseAgreement": { "xbrltype": "areaItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"LabAndOfficeSpaceAreaUnderLeaseAgreement", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "documentation": "Lab and office space area under lease agreement.", "label": "Lab And Office Space Area Under Lease Agreement", "terseLabel": "Lab
and Office space under lease agreement" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label":
"Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Liabilities and Corresponding Right of use Assets", "documentation": "Tabular disclosure of lessee's lease cost.
Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost
and sublease income." } } }, "auth_ref": [ "r814" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Discount
Rate", "terseLabel": "Base rent escalators", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r598" ] },
"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesTables" ], "lang": { "en-us": {
"role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Lease Payments", "documentation": "Tabular
disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability
recognized in statement of financial position." } } }, "auth_ref": [ "r815" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating
Lease, Liability, to be Paid", "totalLabel": "Total future lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } },
"auth_ref": [ "r382" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating
Lease, Liability, to be Paid, Year One", "terseLabel": "Fiscal year ending March 31, 2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for
operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r382" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating
Lease, Liability, to be Paid, Year Four", "terseLabel": "Fiscal year ending March 31, 2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for
operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r382" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating
Lease, Liability, to be Paid, Year Three", "terseLabel": "Fiscal year ending March 31, 2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for
operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r382" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating
Lease, Liability, to be Paid, Year Two", "terseLabel": "Fiscal year ending March 31, 2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for
operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r382" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating
Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Fiscal year ending March 31, 2025", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r815" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating
Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in
excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r382" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of
Contract", "terseLabel": "Lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one
year, five months, and thirteen days." } } }, "auth_ref": [ "r813" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeases" ], "lang": { "en-us": {
"role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited
to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r371" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total
liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r10",
"r50", "r51", "r52", "r54", "r55", "r56", "r57", "r151", "r219", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r341", "r344", "r345", "r361", "r488", "r570",
"r619", "r769", "r818", "r819" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ],
"lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity", "documentation": "Amount of liabilities and equity items,
including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r64", "r98", "r417", "r600", "r724", "r751", "r812" ] }, "us-
gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity
[Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current",
"totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or
within one business cycle, if longer." } } }, "auth_ref": [ "r52", "r123", "r151", "r219", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r341", "r344", "r345",
"r361", "r600", "r769", "r818", "r819" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrentAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]",
"terseLabel": "Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesNoncurrentAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": {
"label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent" } } }, "auth_ref": [] }, "onvo_LiabilityToBeSettledInEquity": { "xbrltype": "monetaryItemType", "nsuri":
```

```
"http://www.organovo.com/20240930", "localname": "LiabilityToBeSettledInEquity", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liability to be settled in
equity", "label": "Liability to be Settled in Equity", "documentation": "Liability to be settled in equity." } } }, "auth_ref": [] }, "onvo_LiabilityToBeSettledInTheEquity": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "LiabilityToBeSettledInTheEquity", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Liability to be settled in equity", "label": "Liability to be Settled in the Equity", "documentation": "Liability to be settled in the equity." } } }, "auth_ref": [] },
"onvo_LicenseAgreementExpirationMonth": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "LicenseAgreementExpirationMonth",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "documentation": "License agreement expiration month.", "label": "License Agreement Expiration Month", "terseLabel": "Expired year of license agreement" } }
}, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a
license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r42", "r325", "r753", "r754", "r755",
"r756", "r757", "r758", "r759", "r760", "r761", "r762", "r804" ] }, "us-gaap_LineOfCreditFacilityDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LineOfCreditFacilityDescription", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Insurance premium financing agreement description", "label": "Line of Credit Facility, Description", "documentation": "Description of the terms of a credit facility
arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity."
} } }, "auth_ref": [ "r49", "r53", "r257" ] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Annual interest rate", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } },
"auth_ref": [ "r49", "r53" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Financing agreement amount", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit
facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r49",
"r53" ] }, "us-gaap_LineOfCreditFacilityPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityPeriodicPayment", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Monthly principal and interest payments", "label": "Line of Credit Facility, Periodic Payment", "documentation": "Amount of the required periodic payments of both
interest and principal." } } }, "auth_ref": [ "r49", "r53" ] }, "onvo_LiquidationOfEquitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930",
"localname": "LiquidationOfEquitySecurities", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation":
"Liquidation of equity securities.", "label": "Liquidation of Equity Securities", "verboseLabel": "Liquidation of equity securities" } } }, "auth_ref": [] },
"onvo_LiquidationOfEquitySecuritiesFvni": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "LiquidationOfEquitySecuritiesFvni",
"crdr": "credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Liquidation of equity securities", "label": "Liquidation of Equity Securities FVNi", "documentation": "Liquidation of equity securities fvni." } } },
"auth_ref": [] }, "onvo_LiquidityAndGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"LiquidityAndGoingConcernPolicyTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity and
Going Concern", "label": "Liquidity And Going Concern [Policy Text Block]", "documentation": "Liquidity and going concern." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel":
"Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrual
for loss contingencies", "label": "Loss Contingency Accrual", "periodEndLabel": "Loss Contingency Accrual, Ending Balance", "periodStartLabel": "Loss Contingency Accrual,
Beginning Balance", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r252", "r707" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r290", "r323", "r356", "r397", "r448", "r450", "r458", "r480", "r481",
"r539", "r543", "r545", "r546", "r550", "r559", "r560", "r581", "r584", "r586", "r594", "r595", "r596", "r597", "r602", "r773", "r820", "r821", "r822", "r823", "r824", "r825" ] },
"ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r668" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure
Name", "terseLabel": "Name" } } }, "auth_ref": [ "r668" ] }, "onvo_MetacrineIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930",
"localname": "MetacrineIncMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang":
{ "en-us": { "role": { "documentation": "Metacrine, Inc. member.", "label": "Metacrine, Inc. [Member]", "terseLabel": "Metacrine, Inc. [Member]" } } }, "auth_ref": [] },
"onvo_MetacrinesFxrProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "MetacrinesFxrProgramMember",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Metacrine's FXR program member.", "label": "Metacrine's FXR Program [Member]", "terseLabel": "Metacrine's FXR Program [Member]" } } }, "auth_ref": [] },
"onvo_MinimumAnnualRoyaltyPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "MinimumAnnualRoyaltyPayment", "crdr":
"credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "documentation": "Minimum annual royalty payment.", "label": "Minimum Annual Royalty Payment", "terseLabel": "Minimum annual royalty paid" } } },
"auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Minimum
[Member]", "terseLabel": "Minimum [Member]" } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r290", "r323", "r356", "r397", "r448", "r450", "r458", "r480", "r481", "r539",
"r543", "r545", "r546", "r550", "r559", "r560", "r581", "r584", "r586", "r594", "r595", "r596", "r602", "r773", "r820", "r821", "r822", "r823", "r824", "r825" ] },
"onvo_MinimumPercentageOfIncomeTaxPaymentNetOfRefundsReceived": { "xbrltype": "percentItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"MinimumPercentageOfIncomeTaxPaymentNetOfRefundsReceived", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Minimum percentage of income tax payment net of refunds received.", "label": "Minimum Percentage Of Income Tax Payment Net Of Refunds Received",
"terseLabel": "Minimum percentage of income tax payment net of refunds received" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r687" ] },
"onvo_MonthlyRentPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "MonthlyRentPayments", "crdr": "debit",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Monthly
rent payments.", "label": "Monthly Rent Payments", "terseLabel": "Monthly rental payments" } } }, "auth_ref": [] }, "onvo_MosaicSegmentMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.organovo.com/20240930", "localname": "MosaicSegmentMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Mosaic segment.", "label": "Mosaic Segment [Member]", "verboseLabel": "Mosaic", "terseLabel": "Mosaic [Member]" } } }, "auth_ref": [] },
"ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material
Terms of Trading Arrangement" } } }, "auth_ref": [ "r695" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers,
Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r669" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness" ],
"lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Description of Business", "documentation": "The entire disclosure for the nature of an
entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination,
including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the
activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r107", "r115" ] }, "us-
gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash
Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities,
including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment;
borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } },
"auth_ref": [ "r148" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash
Flows from Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash
Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities,
including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant,
and equipment and other productive assets." } } }, "auth_ref": [ "r148" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash
Flows from Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash
Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "negatedTerseLabel": "Cash flow from operations", "documentation": "Amount of
cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined
as investing or financing activities." } } }, "auth_ref": [ "r74", "r75", "r77" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash
Flows from Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net Loss",
"negatedTotalLabel": "Net Loss", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
} } }, "auth_ref": [ "r69", "r77", "r99", "r121", "r138", "r140", "r144", "r151", "r156", "r158", "r159", "r160", "r161", "r162", "r165", "r166", "r170", "r219", "r258", "r259", "r261",
"r262", "r263", "r264", "r265", "r267", "r268", "r334", "r337", "r354", "r361", "r421", "r510", "r530", "r531", "r617", "r769" ] }, "us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting
Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting
pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } } }, "auth_ref": [] },
"ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP
Measure Description" } } }, "auth_ref": [ "r668" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non NEOs [Member]", "terseLabel": "Non NEOs" } }
}, "auth_ref": [ "r632", "r642", "r652", "r676", "r684" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average
Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r659" ] },
"ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average
Total Compensation Amount" } } }, "auth_ref": [ "r658" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO"
} } }, "auth_ref": [ "r676" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement
Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r695" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us":
{ "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r695" ] }, "us-
gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ],
"lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total Other Income", "documentation": "The aggregate amount of income or expense from
ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r71" ] }, "us-
gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ],
"lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Income" } } }, "auth_ref": [] }, "onvo_NumberOfClinicallyTestedCompounds":
{ "xbrltype": "integerItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "NumberOfClinicallyTestedCompounds", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of
clinically tested compounds", "label": "Number of clinically tested compounds", "documentation": "Number of clinically tested compounds." } } }, "auth_ref": [] },
"onvo_NumberOfDiscoveryOrPreclinicalCompounds": { "xbrltype": "integerItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"NumberOfDiscoveryOrPreclinicalCompounds", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Number of discovery or preclinical compounds", "label": "Number of discovery or preclinical compounds", "documentation": "Number of
discovery or preclinical compounds." } } }, "auth_ref": [] }, "onvo_NumberOfLeaseAgreement": { "xbrltype": "integerItemType", "nsuri": "http://www.organovo.com/20240930",
"localname": "NumberOfLeaseAgreement", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "documentation": "Number of lease agreement.", "label": "Number Of Lease Agreement", "terseLabel": "Number of lease agreement" } } }, "auth_ref": [] },
"onvo_NumberOfParticipantsEnrolledInEmployeeStockPurchasePlan": { "xbrltype": "integerItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"NumberOfParticipantsEnrolledInEmployeeStockPurchasePlan", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "documentation": "Number of participants enrolled in employee stock purchase plan.", "label": "Number Of Participants Enrolled In Employee Stock
Purchase Plan", "terseLabel": "Participants enrolled into the employee stock purchase plan" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails" ], "lang": { "en-us": { "role": {
"label": "Operating Costs and Expenses", "totalLabel": "Total segment costs and expenses", "documentation": "Generally recurring costs associated with normal operations except
for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } },
"auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ],
"lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from Operations", "documentation": "The net result for the period of deducting operating
expenses from operating revenues." } } }, "auth_ref": [ "r102", "r571", "r729", "r730", "r731", "r732", "r733" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating Lease,
Expense", "label": "Operating Lease, Cost", "terseLabel": "Rent expense", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over
remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right of use asset, calculated by amortization of remaining right of use asset and accretion
of lease liability." } } }, "auth_ref": [ "r376", "r599" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": {
"label": "Operating Lease, Liability", "terseLabel": "Operating lease, liability", "totalLabel": "Total lease liabilities", "documentation": "Present value of lessee's discounted obligation
for lease payments from operating lease." } } }, "auth_ref": [ "r374" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability,
Current", "terseLabel": "Operating lease liability, current portion", "negatedLabel": "Less: Current obligations", "documentation": "Present value of lessee's discounted obligation for
lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r374" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability,
Noncurrent", "terseLabel": "Operating lease liability, net of current portion", "verboseLabel": "Noncurrent lease obligations", "documentation": "Present value of lessee's discounted
obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r374" ] }, "onvo_OperatingLeaseLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://www.organovo.com/20240930", "localname": "OperatingLeaseLineItems", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease.", "label":
"Operating Lease [Line Items]", "terseLabel": "Operating Lease [Line Items]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments",
"terseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition
and location necessary for its intended use." } } }, "auth_ref": [ "r375", "r379" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right of Use
Asset", "terseLabel": "Operating lease right of use assets", "totalLabel": "Total lease right of use assets", "documentation": "Amount of lessee's right to use underlying asset under
operating lease." } } }, "auth_ref": [ "r373" ] }, "onvo_OperatingLeaseRightOfUseAssetNonCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.organovo.com/20240930", "localname": "OperatingLeaseRightOfUseAssetNonCurrent", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": {
"documentation": "Operating lease right of use asset non current.", "label": "Operating Lease Right Of Use Asset Non Current", "terseLabel": "Operating lease right-of-use assets" }
```

```
} }, "auth_ref": [] }, "onvo_OperatingLeaseTable": { "xbrltype": "stringItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "OperatingLeaseTable", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease disclosure.", "label": "Operating Lease [Table]", "terseLabel": "Operating Lease [Table]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate:", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r381", "r599" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeaseLiabilitiesAndCorrespondingRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term:", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [
"r380", "r599" ] }, "onvo_OperatingLeasesMonthlyRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "OperatingLeasesMonthlyRentExpense", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating leases monthly rent expense.", "label": "Operating Leases Monthly Rent Expense", "terseLabel": "Monthly rental payments" } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "terseLabel": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r200", "r201", "r202", "r203", "r204", "r207", "r576", "r577" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Company assets", "totalLabel": "Other Assets, Total", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r95", "r126", "r410", "r577", "r619" ] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDomain", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Comprehensive loss:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available for sale debt securities", "label": "OCI, Debt Securities, Available for Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held to maturity) from transfer to available for sale." } } }, "auth_ref": [ "r136", "r137", "r218" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other accrued expenses", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r51", "r600" ] }, "ocd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r668" ] }, "us-gaap_OtherSellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherSellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Selling, General and Administrative Expense", "terseLabel": "Other selling, general, and administrative expenses", "documentation": "Amount of selling, general and administrative expense classified as other." } } }, "auth_ref": [ "r70" ] }, "ocd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r630", "r640", "r650", "r682" ] }, "ocd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r633", "r643", "r653", "r685" ] }, "ocd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r633", "r643", "r653", "r685" ] }, "ocd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r657" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "onvo_PaymentsToAcquireInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "PaymentsToAcquireInvestment", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments To Acquire Investment", "negatedLabel": "Purchases of investments", "documentation": "Payments to acquire investment." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of fixed assets", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self constructed assets." } } }, "auth_ref": [ "r73" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r667" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r667" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r659" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r676" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r669" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r658" ] }, "onvo_PercentageOfDownPayment": { "xbrltype": "percentItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "PercentageOfDownPayment", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of down payment", "label": "Percentage Of Down Payment", "documentation": "Percentage of down payment." } } }, "auth_ref": [] }, "onvo_PercentageOfRoyaltyRevenueFromSublicensee": { "xbrltype": "percentItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "PercentageOfRoyaltyRevenueFromSublicensee", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty revenue from sublicensee.", "label": "Percentage Of Royalty Revenue From Sublicensee", "terseLabel": "Percentage of royalty revenue from sublicensee" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Criteria Based on Performance Conditions [Member]", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [
"r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r776", "r777",
```

```
"r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r660" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r704" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r659" ] }, "onvo_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "PreFundedWarrantMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail", "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrant.", "label": "Pre-Funded Warrant [Member]", "terseLabel": "Pre-Funded Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } } }, "auth_ref": [ "r58", "r490" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r58", "r490", "r508", "r858", "r859" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r714" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Noncurrent", "terseLabel": "Prepaid expenses and other assets, net", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r95", "r711" ] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance included in prepaid expenses and other current assets", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r567", "r582", "r752" ] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Net proceeds from issuance of offerings", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "onvo_ProceedsFromMaturitiesPrepaymentsAndCallsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfInvestments", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from maturities prepayments and calls of investments.", "label": "Proceeds From Maturities Prepayments And Calls Of Investments", "terseLabel": "Maturities of investments" } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "terseLabel": "Product [Member]", "verboseLabel": "Product Revenue [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r585" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails", "http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } } }, "auth_ref": [ "r209", "r399", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r563", "r585", "r601", "r602", "r603", "r605", "r607", "r764", "r765", "r774", "r827", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails", "http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } } }, "auth_ref": [ "r209", "r399", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r563", "r585", "r601", "r602", "r603", "r605", "r607", "r764", "r765", "r774", "r827", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r121", "r138", "r140", "r147", "r151", "r156", "r162", "r165", "r166", "r219", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r334", "r337", "r339", "r342", "r343", "r354", "r361", "r405", "r420", "r472", "r510", "r530", "r531", "r590", "r591", "r618", "r717", "r769" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5", "r383" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Fixed assets, net", "totalLabel": "Property, Plant and Equipment, Net, Total", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r383", "r406", "r419", "r600" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long Lived Tangible Asset", "documentation": "Listing of long lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r82", "r383" ] }, "onvo_ProspectusTo2021And2024ATMProspectusShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ProspectusTo2021And2024ATMProspectusShelfMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Prospectus To 2021 and 2024 ATM prospectus Shelf.", "label": "Prospectus To 2021 and 2024 A T M Prospectus Shelf [Member]" } } }, "auth_ref": [] }, "onvo_ProspectusTo2021ShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ProspectusTo2021ShelfMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Prospectus to the 2021 Shelf.", "label": "Prospectus To 2021 Shelf [Member]", "terseLabel": "ATM Prospectus Supplement [Member]" } } }, "auth_ref": [] }, "onvo_ProspectusToTwoThousandAndTwentyFourShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ProspectusToTwoThousandAndTwentyFourShelfMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2024 ATM Prospectus [Member]", "label": "Prospectus To Two Thousand and Twenty Four Shelf [Member]", "documentation": "Prospectus to 2024 shelf." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r657" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r657" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails", "http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail",
```

```
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r288", "r290", "r316", "r317", "r318", "r323", "r356",
"r395", "r396", "r397", "r448", "r450", "r458", "r480", "r481", "r539", "r543", "r545", "r546", "r550", "r559", "r560", "r581", "r584", "r586", "r594", "r595", "r596", "r597", "r602",
"r611", "r763", "r773", "r810", "r821", "r822", "r823", "r824", "r825" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RangeMember", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformationDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r288", "r290", "r316", "r317", "r318", "r323", "r356",
"r395", "r396", "r397", "r448", "r450", "r458", "r480", "r481", "r539", "r543", "r545", "r546", "r550", "r559", "r560", "r581", "r584", "r586", "r594", "r595", "r596", "r597", "r602",
"r611", "r763", "r773", "r810", "r821", "r822", "r823", "r824", "r825" ] }, "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract", "lang": { "en-us": { "role": { "label": "Segment Reconciliation
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails" ], "lang": { "en-us": { "role": { "label":
"Reconciliation of Assets from Segment to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and amounts of all significant
reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r24", "r25" ] }, "us-
gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Assets from Segment to
Consolidated [Table Text Block]", "terseLabel": "Summary of Operating Segment Assets", "documentation": "Tabular disclosure of all significant reconciling items in the
reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r24", "r25" ] }, "us-
gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails" ], "lang": { "en-us": { "role": {
"label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from
reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income
tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r23", "r25" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock":
{ "xbrltype": "textBlockItemTypo", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Reconciliation of
Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Summary of Operating Segment Costs and Expenses", "documentation": "Tabular
disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes,
but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r23", "r25" ] }, "us-
gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails" ], "lang": { "en-us": { "role": { "label":
"Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and amounts of all significant
reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r22", "r25" ] }, "us-
gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Revenue from
Segments to Consolidated [Table Text Block]", "terseLabel": "Summary of Segment Revenues", "documentation": "Tabular disclosure of all significant reconciling items in the
reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r22", "r25" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems":
{ "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of
Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r625", "r635", "r645",
"r677" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties
[Domain]", "terseLabel": "Related Party", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment
is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from
pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r213", "r289", "r388", "r389", "r412", "r418", "r483", "r484", "r485",
"r486", "r487", "r507", "r509", "r537" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r388", "r389", "r817" ] }, "us-
gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party
Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line
Items]", "terseLabel": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r213", "r513", "r514", "r517" ] }, "us-
gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us":
{ "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties
[Axis]", "terseLabel": "Related Party", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which
investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be
prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r213", "r289", "r388", "r389", "r412", "r418",
"r483", "r484", "r485", "r486", "r487", "r507", "r509", "r537", "r817" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureRelatedParties" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]",
"terseLabel": "Related Parties", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a
parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r385", "r386", "r387", "r389",
"r390", "r468", "r469", "r470", "r515", "r516", "r517", "r535", "r536" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role":
{ "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for
Others, Type", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r325", "r804" ] }, "us-
gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role":
{ "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform
for Others, Type", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and
development for others." } } }, "auth_ref": [ "r325", "r804" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": {
"role": { "label": "Research and Development Expense", "terseLabel": "Research and development expenses", "totalLabel": "Research and Development Expense, Total",
"verboseLabel": "Total segment operating expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software
product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture
formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } }
}, "auth_ref": [ "r324", "r561", "r576", "r826" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "label":
"Research and Development Expense [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts
about research and development expense have been included." } } }, "auth_ref": [] }, "onvo_ResearchDevelopmentSegmentMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.organovo.com/20240930", "localname": "ResearchDevelopmentSegmentMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation":
"R&D Segment.", "label": "Research & Development Segment [Member]", "terseLabel": "R&D [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us":
{ "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r626", "r636", "r646", "r678" ] },
"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } },
"auth_ref": [ "r627", "r637", "r647", "r679" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r634", "r644", "r654", "r686" ] }, "us-
gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit",
```

```
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "periodEndLabel": "Restricted cash", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r105", "r710", "r722" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]",
"terseLabel": "Restricted stock units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r61", "r88", "r416", "r455", "r457", "r467", "r491", "r600" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label":
"Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r118", "r153",
"r154", "r155", "r157", "r162", "r164", "r166", "r220", "r221", "r245", "r328", "r329", "r331", "r332", "r333", "r335", "r336", "r337", "r346", "r348", "r349", "r351", "r352", "r369",
"r372", "r452", "r454", "r473", "r858" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": {
"role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total Revenues", "verboseLabel": "Total Revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r100", "r101", "r177", "r185", "r186", "r200", "r206", "r209", "r211", "r212", "r286", "r287", "r399" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r116", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r562" ] }, "us-gaap_RisksAndUncertainties Abstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertainties Abstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] },
"onvo_RoyaltyFeesPercentageMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "RoyaltyFeesPercentageMaximum",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "documentation": "Royalty fees percentage maximum.", "label": "Royalty Fees Percentage Maximum", "terseLabel": "Royalty fees percentage maximum" } } },
"auth_ref": [] }, "onvo_RoyaltyFeesPercentageMinimum": { "xbrltype": "percentItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"RoyaltyFeesPercentageMinimum", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Royalty fees percentage minimum.", "label": "Royalty Fees Percentage Minimum", "terseLabel": "Royalty fees percentage minimum" } } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": {
"role": { "label": "Royalty [Member]", "terseLabel": "Royalty [Member]", "verboseLabel": "Royalty Revenue [Member]", "documentation": "Money for usage-based right to asset." } }
}, "auth_ref": [ "r775" ] }, "onvo_RoyaltyPaymentsUnderLicenseAgreementDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930",
"localname": "RoyaltyPaymentsUnderLicenseAgreementDueYearTwo", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Royalty payments under license agreement due year two.", "label": "Royalty Payments Under License Agreement Due Year Two", "terseLabel": "Minimum annual royalty payment due" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r695" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": {
"label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r695" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Sale of Stock [Domain]", "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
} } }, "auth_ref": [] }, "onvo_SalesBasedRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"SalesBasedRoyaltiesMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Sales based royalties member.", "label": "Sales Based Royalties [Member]", "terseLabel": "Sales Based Royalties [Member]" } } }, "auth_ref": [] },
"onvo_SanDiegoPermanentLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "SanDiegoPermanentLeaseMember",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "San Diego permanent lease.", "label": "San Diego Permanent Lease [Member]", "terseLabel": "San Diego Permanent Lease [Member]" } } }, "auth_ref": [] },
"onvo_SanDiegoTemporaryLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "SanDiegoTemporaryLeaseMember",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "San Diego temporary lease.", "label": "San Diego Temporary Lease [Member]", "terseLabel": "San Diego Temporary Lease [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureAccruedExpensesTables" ], "lang": { "en-us": {
"role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r338" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": {
"role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } },
"auth_ref": [ "r46", "r47", "r513", "r514", "r517" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail" ], "lang": { "en-us": { "role": { "label":
"Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r291", "r293", "r294", "r295", "r296",
"r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319" ] },
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r90" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of ESPP Shares", "label":
```

```
"Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r94" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Fair Value of Employee Stock Options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r94" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Company's RSUs Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "terseLabel": "Schedule Of Stock By Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r26", "r27", "r28", "r29", "r30", "r31", "r84", "r86", "r87", "r88", "r129", "r130", "r131", "r179", "r260", "r270", "r271", "r272", "r273", "r274", "r275", "r463", "r464", "r465", "r466", "r584", "r706", "r723" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Summary of Warrant Activity", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r34" ] }, "onvo_ScheduleOfSummaryOfSignificantAccountingPolicyTable": { "xbrltype": "stringItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ScheduleOfSummaryOfSignificantAccountingPolicyTable", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Schedule of summary of significant accounting policy.", "label": "Schedule Of Summary Of Significant Accounting Policy [Table]", "terseLabel": "Schedule Of Summary Of Significant Accounting Policy [Table]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r620" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r622" ] }, "onvo_SegmentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "SegmentAssets", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Segment assets.", "label": "Segment assets", "terseLabel": "Total segment assets", "totalLabel": "Segment assets, Total" } } }, "auth_ref": [] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r100", "r101", "r102", "r103", "r177", "r181", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r212", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r244", "r250", "r251", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r573", "r576", "r577", "r583", "r604", "r827", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAssetReconcilingItemLineItems", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformation1" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Business Segment Information", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r103", "r177", "r180", "r181", "r182", "r183", "r184", "r196", "r198", "r199", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r212", "r572", "r574", "r575", "r576", "r578", "r579", "r580" ] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails",
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Selling, general, and administrative expenses", "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "totalLabel": "Selling, General and Administrative Expense, Total", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r70" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Accelerated Cost", "terseLabel": "Expense recorded", "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r587" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "terseLabel": "Description of plan", "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance." } } }, "auth_ref": [ "r34", "r36" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-
```

us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Fair market value at discount", "documentation": "Discount rate from fair value on purchase date that participants pay for shares." } } }, "auth_ref": ["r35"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Canceled / forfeited, Weighted Average Price", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r310"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted, Number of Shares", "terseLabel": "Issued", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r308"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted Average Price", "documentation": "The weighted average fair value at grant date for nonvested equity based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r308"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance, Unvested, Number of Shares", "periodStartLabel": "Beginning balance, Unvested, Number of Shares", "documentation": "The number of non-vested equity based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r305", "r306"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance, Unvested, Weighted Average Price", "periodStartLabel": "Beginning balance, Unvested, Weighted Average Price", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r305", "r306"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested, Number of Shares", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r309"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, Weighted Average Price", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r309"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r317"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r316"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r318"] }, "onvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialOfferingPeriod": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialOfferingPeriod", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award initial offering period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Initial Offering Period", "terseLabel": "Initial offering period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319"] }, "onvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee", "crdr": "debit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award maximum amount per employee.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Amount Per Employee", "terseLabel": "Compensation amount per employee" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Employee subscription rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": ["r35"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee", "terseLabel": "Number of shares per employee", "documentation": "The highest quantity of shares an employee can purchase under the plan per period." } } }, "auth_ref": ["r35"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "negatedLabel": "Canceled / forfeited, Number of Shares", "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations, Total", "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired." } } }, "auth_ref": ["r91", "r92"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Common shares authorized to be issued", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r588"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Shares remaining available for the purchase under the ESPP", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for purchase under ESPP", "documentation": "The difference between the maximum number of shares (or

other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r35"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Vested and Exercisable, Options Outstanding", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r299"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested and Exercisable, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r299"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options Exercised, Aggregate Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r312"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired, Options Outstanding", "terseLabel": "Expired, Options Outstanding", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r304"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Cancelled / forfeited, Options Outstanding", "negatedTerseLabel": "Voluntarily forfeited outstanding stock options", "terseLabel": "Voluntarily forfeited outstanding stock options", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r303"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsParentheticalDetails", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Stock options granted", "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r783"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted, Options Outstanding", "terseLabel": "Stock option, granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r301"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Grant date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r311"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Options Ending balance", "periodStartLabel": "Aggregate Intrinsic Value, Options Beginning balance", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r35"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options Outstanding, Ending balance", "periodStartLabel": "Options Outstanding, Beginning balance", "terseLabel": "Number of shares subject to outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r297", "r298"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Options Ending balance", "periodStartLabel": "Weighted-Average Exercise Price, Options Beginning balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r297", "r298"] }, "onvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award purchase period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Purchase Period", "terseLabel": "Purchase period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Common stock shares issued", "documentation": "Number of shares issued under share based payment arrangement." } } }, "auth_ref": ["r35"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysRsusActivityDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share based payment arrangement." } } }, "auth_ref": ["r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options expired, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r304"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options cancelled / forfeited, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r303"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Options granted, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r301"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityFairValueOfEsppSharesDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-

```
us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options", "verboseLabel": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r315" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Vested and Exercisable, Aggregate Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r35" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term of stock options exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r35" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedLabel": "Unvested, cancelled shares", "terseLabel": "Unvested, cancelled shares", "documentation": "Number of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term of stock options outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r93" ] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for shareholders' equity and share based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r85", "r89" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Excercise price per share", "verboseLabel": "Stock offering price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Lease, Cost", "terseLabel": "Short term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r377", "r599" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r78", "r150" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails", "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentCostsAndExpensesDetails", "http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentRevenuesDetails", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r100", "r101", "r102", "r103", "r120", "r177", "r181", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r212", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r244", "r247", "r250", "r251", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r573", "r576", "r577", "r583", "r604", "r827", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r59", "r62", "r63", "r118", "r142", "r143", "r144", "r153", "r154", "r155", "r157", "r162", "r164", "r166", "r178", "r220", "r221", "r245", "r277", "r328", "r329", "r331", "r332", "r333", "r335", "r336", "r337", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r372", "r384", "r422", "r452", "r453", "r454", "r473", "r532" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r153", "r154", "r155", "r178", "r372", "r399", "r459", "r474", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r493", "r496", "r497", "r498", "r500", "r501", "r503", "r504", "r505", "r506", "r507", "r509", "r511", "r512", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r532", "r612" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r153", "r154", "r155", "r178", "r213", "r372", "r399", "r459", "r474", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r503", "r504", "r505", "r506", "r507", "r509", "r511", "r512", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r532", "r612" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r629", "r639", "r649", "r681" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued under ESPP", "terseLabel": "Issuance of common stock under employee stock purchase plans, Shares", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r7", "r58", "r59", "r88" ] }, "onvo_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrants", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares exercise of prefunded warrants.", "label": "Stock Issued During Period Shares Exercise Of Prefunded Warrants", "terseLabel": "Issuance of common stock from exercise of pre-funded warrants, Shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail", "http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares issued", "terseLabel": "Issuance of common stock from stock options exercises, net, Shares", "label": "Issuance of common stock", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r58", "r59", "r88", "r463", "r532", "r556" ] }, "onvo_StockIssuedDuringPeriodSharesPublicOffering": { "xbrltype": "sharesItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "StockIssuedDuringPeriodSharesPublicOffering", "presentation": [ "http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares public offering.", "label": "Stock Issued During Period Shares Public Offering", "terseLabel": "Issuance of common stock from public offering, Shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercised, Options Outstanding", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r7", "r58", "r59", "r88", "r302"] },
"onvo_StockIssuedDuringPeriodSharesUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans": { "xbrltype": "sharesItemType", "nsuri":
"http://www.organovo.com/20240930", "localname": "StockIssuedDuringPeriodSharesUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": {
"documentation": "Stock issued during period shares under employee and director stock option RSU and purchase plans.", "label": "Stock Issued During Period Shares Under Employee And Director Stock Option R S U And Purchase Plans", "terseLabel": "Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": {
"terseLabel": "Issuance of common stock under employee stock purchase plans", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r7", "r58", "r59", "r88"] },
"onvo_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": {
"terseLabel": "Issuance of common stock from exercise of pre-funded warrants", "label": "Stock Issued During Period Value Exercise Of Prefunded Warrant", "documentation":
"Stock issued during period value exercise of prefunded warrant." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Vesting criteria options achieving cumulative revenue", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Value of shares sold under equity distribution agreement", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r58", "r59", "r88", "r473", "r532", "r556", "r618"] }, "onvo_StockIssuedDuringPeriodValueNewIssuesNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "StockIssuedDuringPeriodValueNewIssuesNet", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation":
"Stock issued during period value new issues net.", "label": "Stock Issued During Period Value New Issues Net", "terseLabel": "Value of shares sold under equity distribution agreement, net" } } }, "auth_ref": [] }, "onvo_StockIssuedDuringPeriodValuePublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930",
"localname": "StockIssuedDuringPeriodValuePublicOffering", "crdr": "credit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": {
"documentation": "Stock issued during period value public offering.", "label": "Stock Issued During Period Value Public Offering", "terseLabel": "Issuance of common stock from public offering, net" } } }, "auth_ref": [] }, "onvo_StockIssuedDuringPeriodValueUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.organovo.com/20240930", "localname": "StockIssuedDuringPeriodValueUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans", "crdr": "credit",
"presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": {
"role": { "documentation": "Stock issued during period value under employee and director stock option RSU and purchase plans.", "label": "Stock Issued During Period Value Under Employee And Director Stock Option R S U And Purchase Plans", "terseLabel": "Issuance of common stock under employee and director stock option, RSU, and purchase plans" } }
}, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit",
"presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance", "periodEndLabel":
"Stockholders' Equity Attributable to Parent, Ending Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r59", "r62", "r63", "r80", "r492", "r508", "r533", "r534", "r600", "r619", "r724", "r751", "r812", "r858"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit",
"presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": {
"role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel":
"Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r43", "r44", "r45", "r118", "r119", "r143", "r153", "r154", "r155", "r157", "r162", "r164", "r220", "r221", "r245", "r277",
"r328", "r329", "r331", "r332", "r333", "r335", "r336", "r337", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r362", "r363", "r367", "r370", "r384", "r453", "r454", "r471",
"r492", "r508", "r533", "r534", "r557", "r618", "r724", "r751", "r812", "r858"] }, "onvo_SublicenseAgreementsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.organovo.com/20240930", "localname": "SublicenseAgreementsMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role":
{ "documentation": "Sublicense agreements.", "label": "Sublicense Agreements [Member]", "terseLabel": "Sublicense Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails"], "lang": { "en-us": { "role": { "label":
"Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsegmentsDomain", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAssetsDetails"], "lang": { "en-us": { "role": { "label":
"Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r368", "r393"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r368", "r393"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]",
"documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r368", "r393"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventTypeAxis", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r368", "r393"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventTypeDomain", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r368", "r393"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r392", "r394"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label":
"Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] },
"onvo_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.organovo.com/20240930", "localname":
"SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label":
"Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosure of Cash Flow Information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],
"lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r675"] }, "srt_TitleOfIndividualAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "terseLabel": "Title of Individual" } } }, "auth_ref": ["r734", "r816"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [

"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "terseLabel": "Title of Individual" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r667"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r674"] }, "onvo_ToxicityTestingServicesToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ToxicityTestingServicesToRelatedParties", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Toxicity testing services to related parties", "label": "Toxicity Testing Services to Related Parties", "documentation": "Toxicity Testing Services to Related Parties" } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement." } } }, "auth_ref": ["r694"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r696"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r697"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r698"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r698"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r696"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r696"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r699"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r697"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock [Member]", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r32"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock, shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r32"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury stock, 46 shares at cost", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r32", "r33", "r62"] }, "onvo_TwoThousandAndTwentyFourShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "TwoThousandAndTwentyFourShelfMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2024 Shelf [Member]", "label": "Two Thousand and Twenty Four Shelf [Member]", "documentation": "2024 shelf." } } }, "auth_ref": [] }, "onvo_TwoThousandAndTwentyOneInducementEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "TwoThousandAndTwentyOneInducementEquityPlanMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one inducement equity plan.", "label": "Two Thousand And Twenty One Inducement Equity Plan [Member]", "terseLabel": "2021 Inducement Equity Plan [Member]" } } }, "auth_ref": [] }, "onvo_TwoThousandAndTwentyOneShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "TwoThousandAndTwentyOneShelfMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one shelf.", "label": "Two Thousand And Twenty One Shelf [Member]", "terseLabel": "2021 Shelf [Member]" } } }, "auth_ref": [] }, "onvo_TwoThousandAndTwentyTwoInducementEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "TwoThousandAndTwentyTwoInducementEquityPlanMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty two inducement equity plan.", "label": "Two Thousand And Twenty Two Inducement Equity Plan [Member]", "terseLabel": "2022 Inducement Equity Plan [Member]" } } }, "auth_ref": [] }, "onvo_TwoThousandEighteenSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "TwoThousandEighteenSalesAgreementMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "2018 sales agreement.", "label": "Two Thousand Eighteen Sales Agreement [Member]", "terseLabel": "2018 Sales Agreement [Member]" } } }, "auth_ref": [] }, "onvo_TwoThousandTwelvePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "TwoThousandTwelvePlanMember", "presentation": ["http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Two thousand twelve plan.", "label": "Two Thousand Twelve Plan [Member]", "terseLabel": "2012 Plan [Member]" } } }, "auth_ref": [] }, "onvo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "TwoThousandTwentyThreeEmployeeStockPurchasePlanMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail",
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "2023 Employee Stock Purchase Plan.", "label": "Two Thousand Twenty Three Employee Stock Purchase Plan [Member]", "terseLabel": "2023 Employee Stock Purchase Plan [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r693"] }, "onvo_UniversityOfMissouriMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "UniversityOfMissouriMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "University of Missouri.", "label": "University Of Missouri [Member]", "terseLabel": "University of Missouri [Member]" } } }, "auth_ref": [] }, "onvo_UnrealizedGainLossOnSharesAvailableForSaleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "UnrealizedGainLossOnSharesAvailableForSaleSecurities", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available-for-sale debt securities, Shares", "documentation": "Unrealized gain (loss) on shares available-for-sale securities", "label": "Unrealized Gain (Loss) on Shares Available-for Sale Securities" } } }, "auth_ref": [] }, "onvo_UpfrontFeePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "UpfrontFeePayment", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Upfront fee payment.", "label": "Upfront Fee Payment", "terseLabel": "Upfront payment" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r19", "r20", "r21", "r109", "r111", "r112", "r113"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease expense", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r378", "r599"] }, "onvo_VestingCriteriaBasedOnAchievingCumulativeRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "VestingCriteriaBasedOnAchievingCumulativeRevenueMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Criteria Based on Achieving Cumulative Revenue of $1.5 Million [Member]", "label": "Vesting Criteria Based on Achieving Cumulative Revenue [Member]", "documentation": "Vesting criteria based on achieving cumulative revenue" } } }, "auth_ref": [] }, "onvo_VestingCriteriaBasedOnDefinitiveAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "VestingCriteriaBasedOnDefinitiveAgreementMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Criteria Based on Definitive Agreement [Member]", "label": "Vesting criteria based on definitive agreement [member]", "documentation": "Vesting criteria based on definitive agreement." } } }, "auth_ref": [] }, "onvo_VestingCriteriaBasedOnMarketConditionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "VestingCriteriaBasedOnMarketConditionsMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Criteria Based on Market Conditions [Member]", "label": "Vesting criteria based on market conditions [Member]", "documentation": "Vesting criteria based on market conditions." } } }, "auth_ref": [] }, "onvo_VestingCriteriaProbabilityOfAchievementPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "VestingCriteriaProbabilityOfAchievementPercentage", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Vesting criteria probability of achievement percentage.", "label": "Vesting Criteria Probability Of Achievement Percentage", "terseLabel": "Vesting criteria probability of achievement percentage" } } }, "auth_ref": [] }, "onvo_ViscientBiosciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "ViscientBiosciencesMember", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Viscient Biosciences.", "label": "Viscient Biosciences [Member]", "terseLabel": "Viscient [Member]" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype":

```
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
"terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r663" ] }, "onvo_WarrantExpirationPeriod": { "xbrltype":
"durationItemType", "nsuri": "http://www.organovo.com/20240930", "localname": "WarrantExpirationPeriod", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Warrant expiration period.", "label": "Warrant expiration period" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsNoteDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Warrants and Rights Note Disclosure
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": {
"role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares used in computing net loss per common share diluted",
"totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in
calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r168", "r173" ] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.organovo.com/20240930/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" ], "lang": { "en-us": {
"role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares used in computing net loss per common share basic",
"totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable
shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been
outstanding to the total time in that period." } } }, "auth_ref": [ "r167", "r173" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and
Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r661" ] } } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic":
"830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-
10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10",
"Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r12": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r14": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r16": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r18": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r20": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r22": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r25": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r27": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r29": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r31": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r33": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718",
"SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r35": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r40": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1" }, "r42": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r45": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r47": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-
S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-
S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
```

Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r261": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-

50-10" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210-12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" },

"r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-

220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":

"13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",

"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r706": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/321/tableOfContent" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org/325/tableOfContent" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

```
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
}, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r749": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
}, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-
1" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r756": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r757": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-
2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r761": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r762": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r763": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
}, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r768": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r769": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r770": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r771": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r772": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r773": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r774": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-
10-55-91" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r777": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r778": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r779": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r780": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r781": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r782": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r783": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r784": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r785": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r786": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r787": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r788": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r789": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r790": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r791": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r792": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r793": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r794": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r795": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r796": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r797": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r798": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r799": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r800": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r801": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r802": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
```

*}, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 67 0000950170-24-124044-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-124044-xbrl.zip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}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

*M1^7:%\>%:V!Q[Y^>7/G(7\[&>CZR)USF/GIK,#G*0O@_]CY?$(5 MXUI+XHQ&&T%'5*XA(.X(§T$98:1C?>6)WHNYN+F8BP[%7 L?%*#2%DD3!'=/ M@LN,Z.RTT YPKDQ? 27HUM2[@=[%$BG7S=H(079#VY62Z-SN :?/KR2?UT$KJ MLQ$<-1,QZH0V?C4[63ZUS2]HCE8L"1*\0T_!&T&<-MTFAN6\^"BR,+0/M*D?6!V=&')6CO)6<8 NF"?HCSMD" (&FM*>90&9)<\F9 MRKZO#'$CC/TSC&'J1ZBT=])A/:Z167RAVD:CK/:*/1%%6I9(KE §T]F1))D M./(DM4BNKT0])^>O\Z8>0)/L+V[17!# WR> K^/!%VNC>KT/#CPC(7.,) 5. M4/T*DC5CW,KD3=*})\!"]97XQ63\B2CG&CK&^>%\A->FUNXIUTWAH SM RRD M=:G4§AU2*VH=T.DDH#R@P>(ML2A_J" Q8@#[2JU5FRZ?AQ/*KLP PPD7+M+ [V3!HR941\|REE§RS,;M#P3I832Q!5S*0L[P_J=B'I3=Z++&!%§+KS))*'_ M4&! ·§Y}1H3+G#(W*HH"*91 UN=§TW=%*.DL*7?=NSD77QT ?329I' MM'CW8?JACI\'BB8G?K2AD5:G,V3+ C&RV+O<(^!#=§11B282E12=_KXRZYFK M>+ZG_XE'+P#/B^+§ (SW_0B:G?=3@.4X_SW8"\45EC&"(IPIB];,!F(->]'1 M"^ULECK+AQ§VO[F^FX>F3K6? GA3VV,MM)/BR]. ^^WNM"Q,PIFSV+.Y>WO_OC M^G!^N.P8U§6W^>§Z89K-S'#+1"OTE*4PB@8§@&22§ ,8YWULU<=,85§IUP1P_M>NWKM#M^YH_JF1\MFT*=61U1!,K!DTRC(- *BM^NLI012X.CE@DBJMWD0SZ. M:__2QWJ§P[H@]+OC9CXMSLOK*1S6\|V3Y;Q~)"XB<1DZ<4M6=3\§C;DU;A+G1KW94.@NH9%28UEH"7J&? M9A(E >E'+"X\DY0Y%GN;1 MIJOM+2\!14Z+,>,(=XE5PPZ.DS7[*@ MC;1H*@9.3/ Z2DL9I[*W +R9>"WT74O@WD>\[R,;G#!*&.J§MK6B8)0F#)T& M4D[9%%O%$Q\,YS),/>RZ.WGKQ!??',&*P@I=V,4R'ZT>(TSFE_2)Q@)Y7R6-P9BY@&§[&WZ1(_C M1!WF)WF,N0DI§UU.R4B'9'(Z1V*2RSYXY07T%OROV>1^<7@TFIP M&I|[Z@0 M9TCBO1DS)"H9EVB^RQ")9(83A^XO6>§S5,§RWL,+R".!2HL',!9W?':1XO M2',YV=H@)/]!*H§CFL9RL4(X@57! ECN,.W0O[?6R%RA1.G

*64"68B42*TWJ,FU1<_G,K,69)6 ML%M(UK-#*,652X^<9_@-^I@PCJ5KS@^O)C.HS(_G3'3E/P^D MW/=0LGV86^_G-O#G6L]M:)K3=5CIQD@X=(<;%,DPM[69V\"?:SVW?I[7/42W M;37 MU:GM&AR(*VW*,,"PY=8VTM\4H#R0I=YA1}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}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|\/-C4A0XG(//0Y=G-H)]:*'<**EE44|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}3@H52R77 IF2 M*8SL916]55!*(LH8JI.#[H2'+.9_P$2>RM3U ZT/UJ%K&JFGS%_F+_/W49+] M,92H/+.:8@RJ8H W$I#)05%F:(LG$H_25>4#^]N.MEOG+_&7^,G_'SE\4,EF7 M !AJ'JQ15"!B+*":@QNE@K%QO@2I$/D@+?"T/VK/2%%6V: MFKQZU31K^Q(W=%MF/^%VF1>X*HNRO+S>46'S=ZCB/?K$>C3QF,K3F8K^%2S M5!(LY@JF. U)"812G30Z>./S47+@O\/-KGZ9?N<-B^Z5G_=U?E=@]5>4GFQ MPQUMG]6GKVC3A/KM^O(2-]O])6--F?BC.5-WM68?&7\;K*_2 6'-;?RR4=C5M",++$ISRS71_H$;%9X__VQN(/>@3$$_DAZJU3:@W@+=.,#Q4T6!?@R@* M@>$T0GHD<&^U1YM#%(*Y4%%+7H'HP*HC (4 M*(0541@QJ$9R2%;

N0#DAHS7-_P9!L?9D>PM110O25R%=$"K9@6=^+,K}7[R\IB-_[LXN·M.F@;,F@K'10:@N-=@9Z8B4R,,] M)M*F!%4#N$K-\Z,H(.0DFA=G@:?I? M]CVETL2I€CC"@IP;YDK6ROF&.46V·M+\GYYLGE()IC9X(+Z*K1@_-#Q\(<>W)GJAF,N(D(13$8RX"6L&(VXB@IP%XD)T,8>F^+8T5\X0*HA.^5[Q1Z52VL]Y6,+,>5>5, M3PSW2&!L:(A3#8NB.)22,-=:&7'GH!FG+I,)28^WO1_Z9(;49F^O8OOJBE9; MW"LA_=I??[*@,9N?T8R6S<]1MX.0=$17(4HAP10;H7G/"D*1.I:L2]QEN$[: MC(\S#HKOUT1GFLG2·MI'819&>,S^'?/SM/S7]7,WJMW"]J?U[WV*>H>B[U>W·M_8GV>T-?=P7]Y@_Z^2/]_7JY;-·\09O7RTPW=NM'RNM?5OM/V5_&>T/L?. M/C@SCYG'S+O3?GBRRI.I4((48+RS@+XOC9:,}3?V<&>HX=+·1&%MK0V2V{11' M'C#+·!#4:%;3(.0M{'LP,G%0LH!=C1:"]/LDR0:-4ET.A8/;..D*,V\B@IP%\X0I M!FLQD'(OF29:R)H<67#H9/·Y*#%/T8?WF>=LU47)%A"[%@8;72RD6AQ8U"FT"[R@0;,(9MZ4·M5869·Q%!SH)Y1@LM<[*@>_J/<46V#96L#JEH"LEK0>Q;:K!Z1P% (.J^V:L"·MJ$8ZH+17P50LF.=<,^/0%)\R>C'"J5, H-40,7GAI·M#7Z@*5B+7F·IS$O6J<·\XB%HU.!\4"9ZS"6=B9_'FQA<,O)QLB=_H-WB#(·.;0*&C[%E8M'C2&7IZH M:%\'R[F'I"HQ!<}'-9B"3,%Y4="),(+M18UZ·I*1+D*4[95 5:R·+)DH_Z%O. M%&0*,@4G(>ISH>!=.S\^4%OR>Y;*C%Y+'STHU+T5N>XY T*!C88R.B%%K^S[M^0FBAS#V;IW$S80>PC/D[>OCL/N+4X@W>&X#UY,0RMJW<2E-0%3 @&HA$) M+)6$IKUG=3I&'BF[G^>C&DQ!N#(*'C6[J;WH,"1@;S6*.·:") MY,,@]>>0O%5V/\? B?IZZKN>H87Y77?W'S0·)Z\ORT:?[-5[NFY7C;O%_KE>T·MT.)BH832BR]^7N%U:1]=V_CMJ]ZKK75E?ITN:G^W[\/#'8?WN;9_NK%\? M,5A92"}]MK3K=? ==UH!6&LC&2Q\$YJPD)}0A3&Z(DB5$0PI"U&@!$>^.N&>7>^V.UR5Y>J7XW4D#Q=>/IC%>F_N<(S 1'QX0WMGG?\G9N@# M,%1E7S2) "Y5 4;F7JZ_%C#*>]6S5F4:./T·,;27-G_9[H]\VV^_^?EW>=YH^7V_Z#3W=[3;+·+W#)I2?UC^L5_U+·^O+R_8GWW=YT'9W#(·I3W·+ MQ&7B,G$? @IC.&JE4W^7K[3Z-%(VXQ@0(19A$DJR5PX9X4A9EHX28?"\=XJLK M)0.T1U>5X!I\XR"38E3$U49<^*B8N\S="7.7UP0>G.[!*FJ0C*·\·E(B6L!0 M:_N'4P=$'·H5(0N<1=,@$)MD 2.V:;J·#(4JV=7!FX7AK H^X9SIN@\Z"S(?<8_S<·5R=4PE905#%@=·^@.5G[?/V ·P#9BF#4B1HO(Y@TQ5@5$R0B 3H=,H9?^·], &1.TIQJ(@ MV]",)D@'4.8,(CI5L3KO4CH/&Z!5O!#*L25@2\"6@"W!N)93E%)%ZV3·EMC0 M,$1IKK:3X'S6N?G<->, S:8X2B9HJ!3W.*\0M%2@=!(ZF"(M/C]._Y3(O$S-MZR], 7'=;NHQ#78#*F1NP]#U-S;*. 4)0'GQ)YFV54=7#2I>·]P 23US6_=" M/14#B-+<9$^R8'KT!9$_7P>1%]|/T·7F8L%/G>·+|,0E\O#}U.ZU[4IVZM7·MZ_ZA36/:? &\S:4&OKB[7OQ$M<%469;FAO%MO;O)B?=4G[\7BQQ<_7^S?O{K> MY)>XI<75):ZX//&A2GP.ZLEU\3]NV42M$]TGD+V·B DM.$ O+*1F[E1.(0@[M**1TGZ*.^SZ7> [/6E9?*M]>,;LSVM>UOMFM.[KK[W:WJ/EV5;V\5=W_1L[W:·M·J5M,SR_U=CG76&/E^U]PN7^"2L'4VXB@IP%Y3!0\[BS@%J\ 9-D K15@PNI MBJ2P_5J>BG+[MAU'@· PXC[M/6#,8<1,1Y#P0EX10*!KB1%^B\")!]*2@&({$H M2'LO!X[H",^(F]!F,N(D(6,ARMSWL(IN$()&'RMN60IQ& 5 M]C[E+D<7]S+F&',LR+EAKKEN#68Z@B4_,8'6B*I/A3GVY,Y4·M,QAQ$Q'D+!"7'"9K>·^\NK2*88C,$LHUXPAD9A*F^##*8[E-4EQ$W0!."NE·M"['HGDZ.?KR1P'XR0VJS MM_2DQRM:,7&OA/1K?TUL?B:L9&Q^_L3\"*6\U·BD@P5#PD&P'B%*ZQ.Z'"P-·M*\UB<+:JYE),Y=HUN2\B) 71*I)"IW:M?L?\/"W_=;W=O6KWL?UI_;249;\! MO'R.R_+]ZAN\6N[PT>;W,=&.W?J2_F6U·M_Y3]9;PWQ"XW,X^9=]>^MS;HFGR'%+& <.:|\C$UDI6(@9(D/:P,>P_FO3F(M=&?LI7MC;^^YLP..S&/F,?/N=-R]REI*J*!S/Z)28X08O.XG,!-&9R3Z^C[S MLA?M[W0!Y7L%JRAUXV1[E;471BA+-H?S8-[@O(KSEJ"T)NO(&E[·M+·^]$8*PJ$$RC6"$9,X\% M.3?F%5-*+5FWX+:HWGBD\2L$"RX7KWP0W@^?VZ)1)>]?T7V8%/R,%P)H(DT·M4@N5O9;,O#FI"C·O(H"HD8_KZ)R·14O!LV6;'/J MBI 5I-$.3"B>7S-2RQ.FD 1@Q5GLJ#'S&/FL2#GQCR=$(-HI#-H&O-B+)"R·MS&"C+!]&20+C8.-61@JE6*B€V5.2DB!0@N*9=;=V5/^3#9N>1.#2T8^3O;D·M#[1;7*ZW7.!QRLK$AN=/%E6-: <9",>C--[KU\1"D0I#. ^$HZE5@'O?<.R1AZ·MOEFWV_FWIFKL%K-;S'1B.MTIAUNEZ%T48&OSB(UT"4+R%E"IX&60UCC!=)K. MI&8Z3420LZ!3}AB-DAIB-!),K\F#.O8JLBYE74M)=E V]#,0Z;3."8UTVDB M@IP%G5)H#/1@5 }11\U@$0=·\82M=_[J@;GW2D5+2ZC6-2,YTF{LA9T E[·MR9O4A&*F^###

*MW$Q\R:+N-WC?22V!2\ MN1;#; ,*[-DNC#X"'#@7V=:1%8B4H75G&"""!9Q(BP#>SUB*DVS37ZUB98Q M#1.2&$,)$_!7KA7(IUQG4B<6;A2;_-KQ9L^5']PQVH-L*48W<*^"#"2|>9[V M4+N\KA.!^H@ZK @DIDKT=24ZA,17-8,7HS*._?*.%-*7P8MB=R;Q@XJ).!,Z MTXRD6,:.I:"S\#1,29104& 8C5B6{(/LG%[C-1JOG7K"\YH.S,]}U>Q!V4G2 M:)8UQ_QC+0OI;@*;G@-$@2=*OU*=A<^>=),)}O65T>3 MZ,_= C('=WC/P2FU4|[&VV@ MU#H:K8%059KNKBVB@Z>|*$ &XBCMTGDCMG#N WSWUG_W7:P[-,HT-,V,-!8D MH52$12%H;A)LKDS0C#,96IMMH9Q)DSR20I,\#"U0IK!$IC%(5)XHD29AS.*' MDJ,)UH4]M-JP%X'9}ZFS>00RDF=1:*$2_3<<8Y(T:&%6A"2/*;4F,3K/MG M MS\ H4"8A$4TX ?I_/52(A2).40UD:"@33G+PH3+ Y&169X? M$O&@-D>6dR? N1F%UNPKSJSQS0P.PMRZ!2+FA$}XD"-.[.OS9*^RKC3C$>F?LR MU"QBW,:8?&<(,R!4I>!@H<9Y'H4R+[!L!_H03S$LMUNQ#3OQ37$=;AX1#LH4%$@I7Y>3]:F$Q MEK(MYL%_B=*5^J',IU?,<'%]!A,U:YM4!?,U;\,HHO+]^5N=Q(UOM=/L#1^9IM$ MT4$S?-.]LW,KNXJ0/:6H95=*

<>O4:'VEK2G6^%D_EZ\IO[ML*:6;$6P.ST%}054GZ2O=C<(FY6(<4KAAHJ"Y4"&&DOXB%Y'F/62 MK!-\U5#"M;^UJRW?C&(UAT*BS5+^ [#9=^? H!/11*>}8RBG"_9LEAA+Z1_> M&2G;BHL3I8A>,+79W&KFW)?,BRK8OF3Y?!X4N7?@AK@6PR'IVN MEA+H0U9+3W!?}SODP(Y(?"+)6FZI5\!{0P==C2X=WE,S>?6UUP)=A7)?A&QW M40)8!Q\7[&=^S=38KI3+4+X%DU)612(V2C"OBD%TY13&3"I=:88>=RZ>MV^_T;FSV:=:8#ECK$> MC7<>G+K:RIT]B;2\3EH '[AR"\PG4JTW)[K2MNUY9U@ 66*N\!+9PI7_Q> M-1/ZPNG=R]VH-LC7#;LQYL_O#[LO5&JD>T\7/-_MMPNT=Z:0OZK!ZJ/>=AJN M")SKVQ<>&9D7{?9T':KW=6W'3#H\J@?_%=.#L\&VTRF:2+ '1G<#0O\1?ME? M.>N;E%32^6Q6#T6T<8E65GRIZI{*'+:/ZH< .:>&ZPM/<$*OMY{Q@#,:I&ZI+ M#A>K$B"P]QAH7WSJ V<&\1-3QBS[:(872[P&T#PCRD+W7+-MM1+7"_1>&T MC:24+">"BXRPB(=$AAD#-5$IEELE,+)UZGZ3E*P_&O/>_M(YOYN;U'FC3[54 MQ!^^CL"P.+>AOSL?{'7=_8^R1_QGKWPLQ*HA,j+++:6KG)>Q JVV[>I>[RX- MMZ.&7%=2PI_P!OZ(=RB>.JHRY5WD?ZY.CSKW&B@49XNN6)Q#>@^&?>GVVA4V MPF.)LU4%+!3%\ZIQ#6C6B\8)GXG5%PU23G?0!1Y3]8<553,:PU'P'A7'01ES M53IFXV'[!DM)}{@+!W\HIU>[G6%{A=O,Y +^-\2&.::62T/R!/ ST2F8Y'D: MR6RK>,9-X-8WC,%-V$.%S2>+O*M5FD#WP4%WM!D(C$Y-'GDKT$A"3X%+'%V[MTE7H_(RJ:)9@8(!-A\W'CUV%RJ5U#A^=$EG5Q8EKC 98U#_-`7KO M'.T)X5HF 53Y#@IHIFX5["G{4Y-+ZU]^IT30 R(@@O%6;;N-U=M>A\$:("#Z M"&;2SOIV/7U:K7,8C9_2G6P-BKWOU^=D6^L+-ZR9=B-!TK0@BE+0,&W_M /UP"$8M_98UPX<%QKQ=MC:+G7 MYA03F;^X.UVCB*Y;]]{>W_9R.3Y]]f.\|\>|_=L=/>P@7T^H[@ 5!7+1_#ES MMJAV7:U]+:K5G/SN('O J]\V-C"*&]MB/A^Y&ELF::@IR04-"6.*$*..@BI?JH M!GQOX+H?%]KW2Q1E@Q:'& 9R'KS %N3?BM8_\L?>;NJ,*VP&5X/D;EK?5K$% MJ5$MFSY,H0\P&%ZU>F[A{1<\:\0Z&JO:P-C&[BO&\W3/P'V";Y})%'E.S< MOT?!_{C&>.Y@ QNJ%W@&,30^[RX?X[:+HCD3WWR/*U=(V+L"*HD%+KQ7KEPL MNXUQ\F#CRF6Y=:WW3.[!86YZ:#N@]UTYUV_/WS0 M#']<}4^R10W#;;]6F_)F-(*^CKF+$!N/;=;YJ+T&A83:![V0-A"3O*DBB-TC2+*(UY&/_EU5?@1\L\/)/8Q8PJ/FP%%U@@5N1 M{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{[F@OO28&-ALCK+>UT_*+RB(CB6'2G8'9?AV36! <46L)0G)KB%@^^ M,+]KP8S7_/!P:^!;F=&'\$'MVZ;!PIZX0X9WJXZ"CIX"NZP[7\FJU2!FH=:_^ M49MC[G)O5NN^2CS8CBP]%*_[;IO1VB2+A(BP-I0$3E<6M"D3$L%#&ZHT2;-P MJR++M9NCO2N[_)(/M3DKEF=O^WCD7_L#H^M9DE<9]&1)]HL>=*L>#,L>#.O^ MP D[M_=Y6,IXIC-#(B #$$#TY5D!GEIA<+\E M.0>=TF@9Y5EH8ITDFY+J5T",]_:U:Y[RMJN]/>K&^$#VZD@T;-?.< FS+M2F MK7S!A)X@%AU!C/(?UEJV')P^8C*M::PE:"%8,)S2B')6QTQ3FUFK%!BJ[V) MEISR/);$)AIKD"4890F0O,LSL)0<[NE]N_:Y=_P&'EY]C-ZQ/"8][6 F<#G M>]-0V %J*%UY #&X\>^FL'2<@+

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

4Z@">W#;*ZKO3Y*TGM7@IZOABSTV&\J$DB_43OIZ8^%:^W8$]3Q MIS\&>L*GD#"?!>]\"XC/XAN,Y(67[QD+?WP9O#M#L=YO=S6Z,G@S[L.$BL#2 MOVEH_R2ZONJK{H9H=ODF&5T3)V"?JAREO'8=F$30"KG$FJRU?R*L_J9K>27 M1XK!YIRNN9M0A_/QL.]\;Q@U"V1=_0GBWW7,1%_8RE6EL"&'KT(W;]JX>IMK M!6FP6&!G+XV>!;Q&UC1;FATZ/N7N-5:=0-9)?SUB}>W!FC=OF\;|*B\&+8S;5;EZN$><7*'' MQ56Z$IW6H*D]GWF(^ E$./]2*<(=>'A^;P;7)=0}^NV:176GU?T4, {1PP3 M21,3A=B\F1-FDYCDD52$VSBT89HG8_O1;\?';C?VE9N:'-"1X5^<^*A:E{C>D^7@?;F0,(^"XP[$>_$#"(7D7WWM M@H"*P2,&4#3$ CG!T(X^$(O%O/? D]IYD>+5V;NTN:W8EGGSW!HN7QYJ!-BE MI^E3MM?%+\Z]0^6+.H*^'DO,E2[Q:6CH]UR$X>\HE[XC#(>ES&,W$'9W=3VY MKX,UT46]{;UU$C?BNR2NO\PY*/L[1Y+W 8_B'S"6\3/V3,8-]BI'TT40>D=W MMTBK-I&]{/1+*L^[WWWDV;"2+G1[5(QZQR.'!)Q!{P5YBFK*?/!^Z%[\OSXM MC W>#TU[4VJ0 MK+G+W>1@U'Q%QEB4N2@'W^VMOJXN6?K%,EL3:-9F,'9;ACO4<6.("JLP MJGY7MRJ<(^_[LV5$QW*:XU=^WS(:&^GK._GZ/5]! ^G;^_2_/DJ-L9.G#P?6MD ;#PP"45_!V#@*?EFW,XKF M(E.C;/H\X/EP)-^',8P]>W#=R1(,!Y"<6VD1NX(9+Q$=>XMSS$P2"\A,R$E,P MN)FA&>$LXB1D+ .:9*Y.N0VCPVW:K MRRD2ZG"1[^HFZ/<{53\'_X%O8[TC&V/!J.34S!\R-^/@ZGV$.8U$+A(2NJXR M8*<2"6H%D4)E0B=&I.%6&>";%JSO"'1/I3X.-+]BNQG\9BOP%SX^9+.K-U+I MP9%'FHF,*Q$!4826,)P(HPQ)-6*"1{'4INMC(6;D,=KT9P>EQK_^6657WC< MOA9UC45/G/C:$^'$A]G: $L@P/3]1?^,$JT_/$H>'MY*O(:X@%U83*S.SUV MK1:G=D@#52<\32W%!AUQEA*6@YJ9JS0C&NPIDP")6K55GE+%)E511$D:&!I MLXP2$<41=G>G0.Q ZU&\4;O?5^KTQT?ORQ$"OBNQKO+W,NQW$?9FKOVNZD<' M5:QR#1*[LJ7=2=*HXXOW37X/,8^"X^8*E_6]P//!?QQ] I.J=NKN>2!A((T/ M-5OO?SO;;$\(%M707-R?

2L^[#J5=)^NGHUQ>N>GTWLQ":6*N#_E<8/EY.YN*\6K;PBF]&OQIZS1Z%?^EO M4)A?L&C,R\8L!(;>].O@XGG]LW_HQP"#&-S0&)WM.YV\[)\QNA"NU,-*N=?& M\5$29G\9.XF[27LO\4_?N9<>,7;#.V]X6W1$HRA?_>'W^_I[6V$1+1*L^[WWWDV;"2+G1[5(QZQR.'!)Q![

V'EXJWWJ]EN7%$W['E2#JV\+YCRXOM MV,+OU[%%W&YUC]*_BQF5UQ;M6C%@/&A 2;?%^L3V?0>GXX&IZ&K0^PF+"?4U MZ8BU7!,O.)6U8TEN^D'NH^-MM1=^Z-:N*'V++Q=& GM<_8}2=D#ZWTG5S/P_M09:5PM0195))G'0EP.MR$-O,VTD:=/6^ME%8FT-V?I[BH U@Z@3S\!67A#2*

M9.H&6*1KE/(@@"93C3^-0'<[&UQ4P\'Y8.JZYB*H?Y; M@4AIDCG4-/)4\1/WL5S7&);NJ6[+E@SKR"XGB@59Y-%HM0>2"-C60NLD],< MG%4,2S4$ MF,];8,RP'O "?,^KE:S#[F@\70NA67Y,<1FUM'VCW%]_Z/UD?B^+^RG>9XIW M\GE>N$%74^7K)57F%?!<:.SGFM,_B9486NF#*?ZH&7_Y[:[MI9?30>8"R>"L MT6#D&64Q4Y<)8AT6IC7.IBC3G$S52,6%42TA#&\1V!TC@PO6#524>8+47S"Y99Z\ZM#:^.GT7SU5G20%31-4X#,=-.9K):T-=R\^ARCD+B7)@Z$1J5)S(J2PP';

<6262=:A'X MMCI(R2E,CN21 LP9 $D.*G1FGK$,8$?M1GKZMH3B[@RI#9'=BFSWCP67IP?5 M&FL>D=W6QED5@^C\AZG%69@N5.(Y\8$-E48-O./"714MM"MTU)'=2=<7<'I? M+PL97,KLH&QMC@@&_7K;@A3(4R8+D:HK*J MB62@A[A42X*9&MX[88W:J,%?9Z^8#Q8CES&SRM2@^1A+H@(U1G"=PV:5@/?A

M#,AVF+I"X7Z]TOCUM,NLWX[BVB=E&=YB08;!].H#$O@'&-&WPU)@(`C7\#; MII-9>N;'*4L&<>'R9G8.8X7'-EN3,["'-2K?9=D6AND7JO/,_U>[S?_X+&6 M<./\ [_^KRC__W]WFR@$M#]P@>T.0W$\>#$M*P\?+R=!=C6=3>,7G%-^TKRNI M>7^/V/I M0K@R+E:JO%;I4\'$'YX?.[^O>R4\ARCD+B7)@Z$1J5)S(J2PP' ;

C>S[A",,ANTK#ĐG]^\^O,7[@5#2]_WUGO> M)D^5%4_[RGZ2_20/=9)?"2K3>TA\W(+/Q]P\^V5.^#{QPL^BU?R'8CS_K36> M?T#CN2>,6T_X<2=XJ"R/=T?X-KT$J#GA/MQPOO!YYX/>OSOJ;ZG^M[".@Q< M>8X3OC72= [!^4A/ZXMIU8R'@UC-.?\0EF>G6+1^6BGO3SI?6+V62:DXB/7K

MY73//8_$/>+_]-S3BZ.>H7IQ=*#\U(NCE\0]O3CJRT8\8=F([P>7@YA&L;H: MI.&MW!H'O1(O+|>DKZB]ZRAN+K..B0%;V-H0F;TDWC!)5!!6Y]RRSYM58&MK M@U*>6(=5N*W U!(7B(TYR.ADH%(^21_$.3_?I:(V[Y.4^TR[?D-[%%Q&P9J9 M5//("$]:$5EK1QQW-4E&1R'@)_R{CH)9*\:=PGHYB(*2U\299$FJ52V,ML$X MUZ/@RV2:\@6?V8:^"1TW%CE-"7>U0X0#0#0665(#+4$=5#I%':3(.*CX(M@ MFAX%G]F&O@@4E"+'P"@G1;F3&0Q;ERR@(.B(AFN7J/7K*!QO%5XK2W+BB4BL MLV!RI(0JGP1+G@J;>A0\",OT;E778SM/4I{QM>}YAX)#O; M8^+.JY&;;+G"0N16.R*]\\2!{DR4<%ZH&+DW&{KWP?AA'P<3Z2GM(;&'Q"/9 MV1X2=^Z.D*#AY8 E'$4@DOJ:6)\IL:8VGDD;8ZX/UBG;JXD))O:8V&/BCC$Q MF9"L=Y+0&I1#&0PG3@$Z*N>B3PSP3FZ8S@?CHNW5Q">"Q#Y:JF"^VE\'S>\D M8RF(

0)):J85%A_K)=#1,5(O@78M@11JXSJ"('$)M')><^*Y?.G;>I?P!E?S9M:CH5?(>$'M O!T@YA0U1Z>M$##$3R8PG M)NA,M B"Q=KGNMZ('=N[Y_8Q ,%7R'M -)Z=

{0%QYXE5M?0RF0B"K'=&&@[V M9!T843K@61;H>{=G-^VUQ!{0.P!L0?$1VF7"W"HJ7%$*0. .),B+NA O&9! M.25,$/;@G+:]AGCX+ML^Q':QL/,SAM)HJ}3TL9L=\RB MOM(KYXZO6>,)+Y)IVY!M3UK$KEAV*WT^@:;XJ"]\,7\06K'CTK7#\"911)5 MO^4OAX=?C*Z1L^$R,D.29PY,_XJ0V"4&&>EEE&X";GY^IUC5[7Z'6-7M?H M=8U>U^CC_7;L//"J-TMLNL]=M:WO /#KNN9T/|@_]&<8]ZL1ISU)F-.E-KHE4 MU!$33J:4*F-]]-SO.6>[:ZM=6+GY:?1+:2//]P* *;Z%G7,?4_GR>V#SA6:\ MPS^VTH]^CL MH?.6Q>9001IAF (-:26*4Q21O3Z7R0=HZ/#5 \.@5[)VJ8?+X!40 M'BX?+\%$Y#(^,&B:3QH^V&N:/?3VT-E#YP%" M9N?A>APAFM@L"H-

,Y8ID$$'6:Y2P#%S'M-="PUS0/$RZ7'-B-@EGP)#51>&Z!CYT4P"#<^#.D&(%*/(W!Y=4K&U0 M5EWW+.1^.5T^RITO7$=,\ F:,#":N8Z-XN#R&=,0+'[E\%@=5BZN-- >J!DU5 MCN)Q17'A$2/=Z*H CG[35*D/K&9-.I;? 1,%[,N#4)T-FND8H7%872[*;I0J!C#L;AL]<7MV^:,"^%T,[]HI4]2_/|[?0]W#=)KIE-VM^!

M<>'7W;#^A\!NIL^OB7B3A^DSB8-)*N(,EFXX.Q^]B8/F8NBN7N.W;RYY*05B[3&S_^C/.'9[Y> M]",\?$L%ZR${]+"^C0_,,5:O4&E!NP5EGBV.8+O1#T;#P0B&,064?

NUFT_&; MU2]@=7N/RT.W!{$NP^1>N^$G=]6\>??G!4ET3Y{O8E$ARHXM4<'&;NYVTQ[?M!%IZ]U<)Y/8]SWQ_EI;Q#B^Z(0XL.&%$E* Q!:5:O4#Z\+.

MS1/7*3I/3*IK(G7VQ&OI2. N.DNYT3:O:JW?H9(+6U6V;TG9_G[0A.$8 #=] M@!=\.QR'WU]5J0GN FZ>3F;=RP% 0<>>WG;$_V"W(P6U'^F]W'1U!]S\,ZJ

MZK1:6>/J5Q^^J!*=5-^GRS0<7^!RGU0.1/U?!P ^(+'>?@39B!\W#PEHV_%L MJF6B?W9[V%Z*KWH]F,(HPHWK'PCJ8.?QJA @MB

M>^.'+=7$RE\MZ]:53P'PN'P$5_T3%"S4G!\K$$TX/@Z('H,TF7 M {CJ8C(.*:&.TE1Y,&P7]+LT!(7G=Z##],#6'M8S&80!VXR@,=_ V,'MU4J'1Q.F;%0(NG[$W?

UHUA?!I*Y>UEK$;-N,JC3Z"6A71J@++9O"QM;TF MZ..;X/ Z*H"O\V30"=4JSO##W=K?+ML/LY_9)6ZT1%#\I" .JZ1>'TP!+P!A< MU:3I=-B^!*_J7MY17>7F6%5]TTU^

\7F"X!TC9(?9SFLSMT4=K}!>Q)?X\>7 M8"S^-*I032SS[:[&6>'U0YC^]5U+(T%;8084M/RD${0:D;"0Y'&>BV&N31L_ MCOBJCR6FSL%##1B1]#L-

9@Q)U/ĐNX8'5UX(-9D[;.RPZM8'P53"'+%!Q\H/QA>3PBH-SNH3?(S_A8^! M,)M5J@*JAJ%'G!)Z2W!X(X=V^!P=YA,JTX7+)ND"3?8RP-FHV&"PROBV0M8S M^ /X

D8*!O8>6?2.0N X?31O5TEV@X}.UFCPFG@OW"KTCT MCLGXR@VG!;,6[@_85{1) 6P*#6[5J'G49JV#_K3PC>'I-^-P!9-XB5K&%\5\C\ M*-+*BV$\Z*FZ3#"G?

\U0R$W*E",%GW0)|/JXR6#,($XZ*&C9]GP&(X0GIP90 MW$W;-\6$J>(`'=UHKE!N)9SL|\'T#$2%[S[",J&+.!+=J--QR./^$3\@#/=:.'JQ"?T=-2$!]N/G<1KD?UI?AL492.

M9|WP:FGL[GP\PW7]L2.>Z1FZYPK"#3Y7;=(+KA9<>NW"%;00@5R%ZTD*:/K'-M/2+1'[:]^PX/WGVDJS3&.D&),"D3&:TF5E)&]{Z'1U,+N]D7OJZURXPJ8AQ6

M^'!"$R>L),9D8ZT1(CNQ;L[_VA(.JJK?P<-P$'\'POL.B&%\GB8_H,Q$[>1M MTX!T2_&#^[QZ$/;^^R\!<=6W$!G![0K]0=6,/.X\4>W"[GVONI&*9&*4B[*2'

M/54A$YXM%8H:[NQ& 0%?"^<3;'Q* 9TY@1*38B0F>NM!4P/L#7O>?44/;??' M>9\6RBKBG\ O>'(RMSH6\GRI$%K \X;4/(47K\J23AN\/@U\.3ZO#4Z\!+.

MBNPP1G&&9W)PVQD\NJC,8}!M03(<'*MH(RVCT9'@$X">\(YXDX !(M.LMM[+ M+4#)C7:LEB1*A26$ZTPIS((EY7S404OX[Z!TAP:JQPD4*J.)RHY)UYR!:!'

M#7]P)6^:IVN.RD'H|OQ M\/+.K+AV%:$5]07/Y4)@_38">I@T& H K_W;H&G&L\F@$-5WPW3>X G^XD)3 MH"NT*<%T*4289Y,BG@:CEH.

+X{)A6$.F5)N[^/=OH4OP:G_TSQ B5-J5^W8 M$@=0& -!;HLO%4WZ]H[9!&->FCG;W< 1W[S:_L6KXG2% ?1.0IG(UB& MCZWK=ZO#KX7HS,9 M=G&+(($

=FH9CC/36@7KB?EV(}*"R.&,B=(}EP-:7K&@[-NI:]2U+7&NZ1 M4H,5*\R)M:#"U"HYN]!OQP#GKSM[X<>4FE\6SL. #4.#\GY;ZWQCS"^+'@!!9:>7:-

(ZS3ND+544@!!\CO<6 HJ,-X(, ,(T.0T MZ<]34: -"WDH$]\L#V"\AK# $8GEP#%BU,@4'73!6C%G1.|^*K[C*I1VPW12S2X("*!1"<,M3X^182*1.VH($X^B6]H!FE$H7M

Q.K>CP-=O%V4A +ZZ MK(U-4[]#++&,6$1\S:H^./>Y25 M9XAFY4!K=K$&-N5@S*&=/ANNG:)&H"ZM3A{@T>=NT@7F]"

MT3/EK+08B8LKOVG_GL)BS@,;\#6#]O0/Q 7> |-N4I@5<@_C9MK\:7%TUD:] MOU!C;],H?S&&'D9J,78?,Y!ST1:!G-6/6 &K/1G^YM5WO_WZX^X,NL'H=_)/

MX(826U+4CUQ==D?2<.L!6&R_@4"=?"EZYY/;M.-PD8[%8O,BZ1!2(EO1"UF MG=U1HDAM4Z2UU4HRLRXCF7-&Q*S + %_E4U(00ZTFOE;,!"[,J8VQ}^P_D MPAO25+C(-

U$Y6GV#R\V3,!$9D*'FT>ZHBW3:5S41A67 M$-J8\Ç*XVP9;GE9_^[*%<9 6M\HY>2T-,1%#@9@!BQO(GF@PN3,PDE)N0YO(MR5"A@B%<:PT,

(S.Q42O"@E2ZEL;7V6P3/IVYW105;9V)OI^E_P;>^/!L_)"3 M[1OBG4SR7(*$A9EY(NL(S,UK0V)F6M8JV<@WXIUXU$G6E)-L 0O@9DM9H)(M84(=G-/9\CU-

DM_D:#@8P=RF)>!Y?'$L?!H7>=8LQ>XB>X'4 SME@C:0/#G, M !"N9/0F)T)-#?(D6& 4XRRAD8EH: I9;)2U"_"Y)%"@J,2Z$5BI%P"O@+B M"Y):E638$^7(@W-1@8E9:.-

FTE#7\68'C:0!(% X'0FG$=0("S^L\.B1% R0 M,7&ZF2%;:V$94V#+V5H@^M8 3#[(W3-O]*KH%,)V+>%@F52C>[ATVM!2SO/Y Y4L1@(=2"VOAH<_T4 M,[J1T@^]

M&EE!X],2BTM_I[2U6MD8<#;3" :(N3R *2I4I),0TZ16/NV9PK M')UJX%,50-D>E$HWH*> 2H.%+19>CO$G+..NQE@&VX+S6 .G2&M;2'9IE17ZN M5<{3%(KKU9=R+?-

@FDU-'"%Y}1*=/3UH)8&?5-6XSLZ,\5EO+]YM><\(U<;^D M]17WWJ?Q;!C,0P:?I]@E_I,3(KHV3E*12&("#\|B(MY$T#QB77.0"LJTC M:B%9X (L7>Q'394%%;[61

DA9:TI#U&M0.ZU ^A=[A!W*0#U_2+${M:M4(MC M2!Z27E$\0^=2M+.8-3%T);S(:Q'-!R<#]K84#P=73D<;4X6]EU.>.S3NI/:

MW\\=.H5&#O.CVD\0E6%X]9F.1^GZE0OW=Q>..)C$MH)5>>>)B/-WG:\E= M>3EA&Z^_=H?PW+GYS]M_B^0]24F75UL>L${RQ6W>GJ=ZCGWBX-]6ZHRE3#< M:S>

{OUI*)X9G3$%$H(0[U?;R\]Y-QB+:.015FZ"B<{0E5:$"}>S* M=1SO_LAC'D'\,ET>V[R7:YN6/F-6^TI"2,'+19#M&L.T(=M;$TF60K"75(D# M$?

X;+K#EXCE]6:I#+4NE5O:P+TMU3&6IGEXKO?.QPG(IOCO4ORK5I/;@P;[V M0.\/54N=3@P>VB[8]GM@;FI+64U.U(K+R!-\&\,N@LI0<]HJSF:G6_LJ8<$VWWVO/$8N

UH<:7 M>L9 CBIA-K!?)DI.A6&:.!;O' M*868G(_1$\%L320#$\T{4A=4^X#?.N-7Y^24<+Y.N$Y WH1#=|MYD1H%0E ME-.6.DEC7^[27"\E8A2]3K2[0.6*H%

{KB78EHJX#XT7. B+XY8:T(Y# M&I],S;NY[N@}SJHRSE#P$/O0/F2B5&"2?>$9IMR+'%\H98N%_=T?/S09LT M_/52HT^OI^^S8JC&BJ&+U6GS: MG?

DRC,'A8$;Z^)NBCA%3_M7AS_M:6O=O# M_MQ^I$>R8SL]L AKW#3VP\Z_NJB)/\::C5C7+(QGD[9NVG4PX,+7]MQAST9G>T6:4O9U]Q$IO7,^+8/S?T^].J[^[

MP>A3.1FH_K<{OW@#!')Z4OWUK}\M*FRN7;:HK]E6+74EU'Z(1QN+H^)E.NOH MLK2DP5W'H?[W>/([*K*DC^T1\MJ!@I\'M+IJZ@88J(]G)J7$W&1\"92%AM*|

M\B26HAMU-4Q;A_(BW/7&Y{B2"+$^^^L3:5$[@NZ+(('RM'LIT)_28N-$R\.7QXWA22N:UZ4Z+ H&CU9*Z;:=)HN!:W3 M959K)N+>Q(2$B"0/5.N=;WN,

(!&4VO3EBW'3###&HE2Q0I/R&E!=")-9*8Y: M*+'C 8P17Y3(.JV^3<%A9/E2W=X!B@+O#K?P2+R%3-SRK3:W)BF^N',.B_GX$!ES"(OLT.6GGN5B$U&Y7AEEH|8VP"

\APGAP&?2%- MSHL_+NKX5*-9I;MAB;'([7BRX|&RT7/9J3)FP@S'=^6%WBG<-9*:F#1^%+N[#HF-/_ MA?N2=C#HZ/_EP<4D?<2Z),.KKO#W5W'#1>

C%Z[F]@!0=/Q6+M#<6%]MI^? MCT>#LO0E'&Q^54N7;0A"V;U2X&KYD4UU7J09D,8G-^F*ZRZEKWY:H4U\QCPT M:XF$@3;_OXX&:SUB]RJT6@1Z(&A.ZR$"

M{W).DSG:SIHV_[LJOHCZ%%30V\A*^78KZF0N2 MPGZ=?[N%C]4U&>=I<;]B6GYK,[]%/&S2I+WDRQI IX9TR3+%KUNF YMY59TE

M=PD$@^@S%^N=YKQHJ;8TW'JAJ.NM;NQ! M,<8MW&K%K.3Y8+,"[",4OIZ(E<@HG.%@5RP=N?C25IK(E#"=HO*A3MX@ZWD M-

@IJKT#E4M+@"!XTB&7.VY3#CK#+NJX^L%/U?%$MX).2H^@B9H/C#KA2 CUM M]IGKPUV.+MQ%]^$N1W8.LL)9VT\V:L&CSDX16?M,)!>"6*YJHEQM: Y465GO

MXF3CKVCFIG=M#>;1Q[^" $G-;9NHW6:0MVVBMJJZ)8]Q)F}JW8A7X+[^NVB M/<4 5-7BU8CCBWFF^=OWWU2QA= UT;RA;<1/X6_YU{&DZK8'?3M(8T&>+ M-2}!YTM 1:&K#(2*;--FMX.ND"X6ULM"'6NP!E97>RO2++=&)-C) ^',Q$.##0_,4.$FCDD8013&5 MMV82*VE*PI2D!H1Q;=-&!J0#>4D#AM@%SC =QQ!K@R14^?^?

O3=M;AM)UH6_ MO{\"X3.><4>PV-@7>TH?IP=7P&B?H?!OTO%>0'BA?636^5(B>D$O=8ZF2N3>NU-&YI MQ,_2/F*R>N4NF[6V=SQ@FY')3"&

+QP[<34RB'S#M+TE7?6,U-I8WY3S<]^EIH8)QW!#,I*%<|GN7PV=L MR.1'\H $E._>S.'W/>%"#U_Q?$R%,I@;"D.7=^_"3.]76WO6]*]]K(}.HXR>5*LP[Z>\"1Z

M^2AJG9*9+AZWY5T)-HP$D0\T,DMJZQ68G;&H&US*X3+$",ST"U4QNHW_6M$S_M1O+X]SR'>?+VQ2Y%>XKO4HYA0 M/ 0,,,)8], !S22PW3 T(Y&LW.

(QW4!86%*!.9%/?!LP(PHH)V'L.!!L^)<#U,%YM@>G1YLR7/,:J&*US678A!KR6,LZ22Y/$41OD_ ME<-/W8I/YM6VY;NO@!E5"M):EM%JS>!;NIB7B_^_78G@A>_7GX*O)@%

I634 MQ@95ORVJ^@=2R:-NN!RN+%5QE*KJ6|5,8)S0Y!IS>%M1 M1J4T>SY*70W6,EY)GT+15!3SO&"*CVD]2SC67@KH,@/]=/:\F:2>\L8;_O=7

M11*+1^DX,'56WAY;XWCP%!N&CX^3C-X430U=7 O^6G5GF>;8?-F] 'N=T6DE MSBHQI1BBV:V#)!G5]HMN##"(V6$^QL"L:Z/W(#S)9RLENPW-L>N_[)^T MMW-

61^T_W_&J-0ZW7'''+[QQX.ZPQ[_^7)?KEK0-4L!3Z)BRW\]++)- 6FY, MY_KN1'|/BI0XDR%2^ ':PAXW;A!,-8IZ#KMDXK\,PE]" >*?%@?JW{[14] M_.4MO!Z7Z5]&-!

5P3"PY"$1#S77*["X D!;^"V.:\'>OQBPJHHN2 F"6<6%& M)R:>8{VV.8O=7!QM3SMVW3)9B8]/9'.K:GGSNP3 I?%=!C,'4$_80$'L\:.W= MM>=;HUB^?

W__X_O0B&59SQ*N]FR -4DYS\2Z@>^2-G;,;W=L_Y'.>#N$Z=2D M!X#)VC$?$L+<'R&D;,0U5N FY+,?Z[,C'NLWFQ=W3'E;S>@)B>:VU?C3P+M-

M_U*LQ8]=+HXD^0%9ZI8#.\:IX"PA29B8Q/4"CT1V2(F($^&{46 &OO68^UIK M3F:7_->?B_PMNAX'JQ5JC[3DG?+.<^C#6EJ]^*\?12WS>VA) M]222RA[;R'"\:-

"M>.X*B!%T2FS/=/"BC)5@.O[89"2. HL$G#K<]"-> M1(/<+M[NP'7Q=02I1R/H!K'[SGSIJG,<>/9WX,>X>/8*Y'/#_MJAW<5?N/ MCV]^^?

B/CS\^OA_>7WL@5*41XGCF]SA7ZRDAQ&WKVSI?3I6 ~!@'% +)N#.AG$)]9$X,2GKN-X=N):

M3K)#%72N!0QT!.K{MV=4T'$Z.JTTEV$ZO5N'6CCI^!P=GS.$@'*"Q.2<4I(P M%A+7IB0)33L@CNFP. FYQ>AJ/K/A!-1@3E6L&/?RGZB=\&-H\KTIW

M6X5GQ^2*1[Y#0QCH-KF D9E%,}#;$8L2*V{K^;4>KX]U5/$5=6WCJ9FN4"M MM2E ,5/*<*1MCQUGV$2>=Q,1CGXC2W?J4<{VW\!G'F,X-+ 9#<;H?+CU^98 M=

(7C/N'6D1H+625Y!#+*9<3TA$=EO<<M?G1Q'9LYZEYN(FO@9TP?MD;HRV11>Z&.]OH>KBK6T^>1>YID M> ^N3;JI:#_VLY\^8N'+O\NKZ=NA2X3-

B6RX@8!RZ)*8))7'L^5'@Q;'CK*;A MJA;1PN!!A1@T L3$MMQ2$SN4\L2%%2SE827W=[,$E\^)L6Z;8_,_4JQCFD; M]VYO(RLTHJA+2)+ [K@4DYF:

(+B")$Q\R_*I9P^2S'38O77V;6^?K^NN)IBJ M HTT5J77MU2#?OPHMQ4PS[A \PK8F <6*Z!>"BP$)&O<+A:ZR1Q103ZJF61.!0A"2.+.8[M @C.3KDSVC?

FW$O@J84EP$RP2!#:L$TN,%%AH OKZU D]L.S]JJD>W$[L>&"CF3KL6Q_ MWYAG+X$Q=_,&<.82T\&L+ [W2>0E/N$V3Z@)NB6-!ZFV/:SNVM[>V1N'H9,>

MAF:X;TR2>)%ON3P@IN?[P"2!C:3OHP$7B9@#V{4KJ8NV40PU!#[!L:>DS"> M"$(3 6I_@+HAMP'3_(@YB6_;EK>RN]OHADBA!;X/LI#U M6UI=&$E67&U6]VBYJ-

+!2119IGC/A8OKNE,B^@Y) A$0UQ2@QR(R;4>N5DZ;N[:-!8.$98+3!Y05"&]F' S,F-'^)9CK^SQX_7(M@9A<:Y.[T2:?T1/1EF)<'UW*[<2U'=\D

"0N5N@&||>V',)YY/AV3&EHK9QU M;%=6<;78|^S.SR=:-R7|>V?)13F(-&\$?U-O.O)_6IL%PARD$O^A@57K0BIF MI4A+D2E5O2XVTN47*C?

*FHRKI:A&LM0HQ3JGF30:%BHE+I9"7!^RL_;3_|\P M9(U0EH$1\[\OO!N*8\]+84$)RP V$SR MUSRMIAF}.<-O7T^Q'&M^WKLVG*J5,&-7U0?

_:JHZ36ZZ#N6K!##E};2H9#'7 M,[6MZPSBKQQ0"?5SIL<=1F!4N[*S:R6[G+F;AP.WHTQPK]Y*J MIF5;N7'Q"UA7];'<:!433!.8W!G-KNA-

U=8H[.]YMXLRI$ON6(*5G9SV$T[MT!"R/F=)R&]AD_;-$,?F08*W",PX(2XF8X]LWR,^]4(S8:8?N9Z$SL=4\%W3 M[Y"0K>N!/GL]57?;*]7/4%#5"YZOHJJ^)W&O)?

4AQ2AJ56A9J*+1GVC)+G$' MDBJ(I_[%U(N,Y=N5E>AM +(\H<$C,;A*=G!R2TG8@DW&>"<|>T^*.J?&UD MJ75>!G4?$"3.ET2Q[O_#BW_#I&ZP?

9WT\C%R16<+VERN^%JNG PW:7&R> 4A M]DSJN2+0CPZ!(,K#^;\%"062*.(N&O!'SM3)R|:\1GZ.;'E<@NQ2?IVAU(MF'A.]6)-E*>1)@$6I@<98;4)Q4W)YL8582)$X

X(3R((N)RRR-1Q&,2V'%(_M'2>T^3!U(3<52&C1_+@J!I)#KDZ3J@V?)T^3FJP[(M12ZF1T/FWR+.04<;GP M],E;BA 6L2)3V)N"1()ZG(6Q#;GSE-

*F,%2G=J^I8T<;>0,PCI(O&?&Q\FT MP9#P%+E?5!N5C-GO)7ENF:$MFQ.P;%X-G)9PO1RC?A@+RXE([&!^ N8D)$RL MB'C4BT//MBD,)C?6G7+LU[Q+92?

X^VL&C[Z9X&\#";5PQVZ[/36T-CLQ_4G; M34]17]*(H0<9OZ1MM-1(;7-U)[PECV'4A.&T/:7OH[JK1VBC2-?=TS;T=!>/1R JY

M(PCE04A6A+@I{&K7W%I+?]R_1}>_2KOD<[_SM!7[N MZ-;<+9<1[!O;^F+]O7<[\(%]&(/7'$9<%ZM9M[KV_ M!=:.".95RI[ZEU>]84R(KJJ:\]:+[/M]8OU**4UQD?

(@+QI^+6AC1V%A8I6I+ M\V 7 UQ(HK"_V[+9)-6CV/)96D.G[/;\8*7@:6V40*]MQHWS/$'T AD$-9$T% M8Q>+A;(.?6EN#_G-:U<0$[7)2HP&0W,L]TF0H8*70/#:\9@G%5

M(B7SXBJO]B5YS*W).[2ZL:FZX8O0=&U0ZVV&F6--CY+(CQP21I1Z;B0H':;@ MQS?,?"'X5UK6-S^ _RJE?%=:ZUC6.BQS,+2K9>!RI>(T!'JB50T/R_Q \.\B

MU%VE6G9(PQ1#OPI *8.>ET*@_%'Y0:G*, 2K-D4B,UH' O88"!L46D53HILH MD8@;-

U6:BTIA.7P|:TP)$83K))U+D5|*6G)H"W1AQ02$0"TP\9E_-5Z_9,4X#G25@J[A4G=8%CLPO@_ JGJ4U-.+VY&:S-6O;\&50/3^1AO M+VA:PHA&H'V4ERIAE7SC(A5)

{[DO">BJ0,(HB+ ^6HDHY=*O)8<>S_)*#]L=4 MYC [E#?BS$5TD<"BHDHEM,CH4M9^.<>95_A.2T8?^X^\Z1Z9$96$!:D=XGY_ M*

<]I7EP6(U!!V7@]15U=%*".$=*Q8#"@1 *!I(!=HY8D01W/&BYU-$R/+&]$ M'G9!^_@E*1AH##5P(Z.Q(?YHTBE^,S.^]H *NU_A\6ED0US?&-;%I= L/-9 M=;T@S:?

(8AWPWW#_Z$V%K1B"PGHP>8.1=Y=A9"TRL"$C4H0 MM>)L_98INT$9+S%H_DV)LLG@ EM)\[D}AH-"]RA!KZ#AH&:$G6W%E/]{(52BR]GS24O*N-4SAR>_ZTH?

S=>O?C^Y;<7 M/]W'9U>H0&Q*I1)1NJ4"8WB!L/HDVWOI+V!PYN<%/OGMSW0R?2UNT785ES1K

MU'OP:6OUX=/=^MY!;FC8*C227@=\8#::=OR2[&;36QR:TNCB68TC2;^IO NS>]LASD64W*VGE/F=)]_YF=!NZ?\F064CC,.(!$2R,B2L"CU WX006CSLV MMQF+_&7#ER?

<#!(_)*[!+#1\.5;']{DM HLS'C$PFCO#M@OB[.?Q7*,'~L M8M?O+3'|"KF,"}8\ILK)^=&09@DB<>$=2$D?+)*'C>L0/33LRJ2"{A)Z%N&.)6CK.#ZAOK (,WW?

%E'D12Q^ZMD%MZ5VWY\TT.@9;1=B%9:E M#ZZ#BR6_8<<:^\89;D(M$0F7Q(G@Q/5%0D*71R1Q(]55LEG8(B&ZD'XR%J41^V^0"YH1 XQZQDP3X M.&01B9S0!A;Q;.

!SYO>2O!5XK&@CZA#@*N ,3B%I?%,"DOC)99I,N:;]A-/ M[M^B+/::*SHINL@!V]5G'#]C'O4WK9*;,O+1TO ?*)(7!-,G>C7A7B^:>YC M10K?"RP0K\1V.

(9)"@J0XE*2.,QD,?,20)E'""^B_=T,FTXEF.^8NI7$ "XGE M*CW7AC%RES"+)6;H!@&W5N'UH.)Y1_R#T$FK[H/^IK[NIHLF:CD"6J^?[Q ML=*&Y2:$,@?

$:\QM$H>F2Q*?"@I22/A)M'"U}+'\"$!C&]I'. FYBP3B+Q!&(M<3N..3##+#2S0966?:O?L9J/C M^%N+/Q {$<0+:8 8)0#7(D;,B]J4@PDNZ'#*?;^+<_2Z?!/3HD2-

/Y3 MY^6B+IN,=,^+NNSDL-H:&[^T1ZE&N\K&QUS! S#]*9Q5,|>X=+K")W,7 M+CR\ISWS)J.E$=,*OFQ=HTP>0\X+|"!25]@BNM_+$9YK]S"1_#BR52>3N W

M\I3CHKA"R 1+2(9I(0X43=D"J3PT SY/>0.C;A="XFBJSJJJ"MN ($/^TJ__,UM&61U3G!.SD#F[GA7MLY3+AVI^33#Y $ 3 :#F0I>;=##8OF@

M,WT2NR,0V3S"|YNHA,Q=*L\KC'<"Q$PASY5. 4N08,MN!21]S^<_BV!HCW)F M9\T=M[5QFQ)D%@^!>-F<+S0E$F##>H5#NAM5+$MS# T$QF!-A3"#7,PO$92 M?3[|

{S?' 93*O+1[+,9:"GGQBW>M&9S65"IR[?AF.ETI:-V=SWUZ_WO MV,,;@(H61]3Y%8:.-E.I(%S*,*'NY*RW;LILC$66"HSR:/O!D$H5%R1*"=]% M; 95:!F&A%V.0)>L\(#

{=R'C2?'Q&%!> CL>8M+IC9S>GD"0KHNV+7@\;UVT M2-=%.[(WHWJHFUH?6QEM-A{;,0\LIS\/$9?7$^AQR[.8Q:LK*E5K 8PSN: MJB?K9,2#DHZ W])Q> FB9R+8!R27# MA7 $1M+D3!WV8->]Q84!3-))RI9{SB5T+3RN++ZJ#:]"90Z6E6'*X]&LD]9\ M63/>F7ZA;KC0&I2CN*D%7JA!VU':?ZQ,Y?53V15(05 PF@P^$5DF#LAPUA:Q6:FA.%%D"11KAVI,@+9LK(RUXV/(,-;=&|)_(J0.E(H.IOZQLAA[I,B$TS2###&N9 !|-44;8DN M (^78-BWR-G1%?:%47P25E6DV@P,I9=C%F+U>UYS%JU!@WD>+T5YTZT_VO.8+Z.=+T[N$FB'JPBW=G+]ZG Y(-MJNOFWIGE7NHZ=X!Z MJO,&=-W)T$=Y&\&0YBD*+>6O4S'2=I>!\?(- 2!,YM`_)-S4# MO +:4D_UHW@+@RY:Y6W34J#>B!/9_G<#% MW~RJ?ROL\>!.R1lU"(40\TIZ MP(NF MBJ?!J=2JWX9.= <]9@[X6O\31NOX]-S\Z[V9]U5>Y4$2IK;BYY3'}AR MC;9>2AP/.BUA^/@XR>A-T=30Q;7@K]N"[.8Y-E]V+W2U[,^Z,]]N'61>+|7V MBW49 E'Y4\FQSKHV;DO]) [NUS;%K/W55>],U>_]MV\YVK]ECZXGGZX_-I^U1 M3_&4IGA/KM#PSE2AZ]!R?:?[05=Q=-_2'9,@,!SJ?67^B-G2*3%@X_/8_7]@O MJF^RVZCYMVNJ&.*HBAD; {S&T<9,,B/NS%CO*C?HLN5\U:6O2WB_2/JP)G@QE M?T^O-5UKR-Z{=2$K0E{^ (_VI!Y8NC8MJ;- 8'+RBW4J;EO^T(DAT4^1PU! MFD'NNUFH&>11#+*?)*,Y2(N8/2(? +6).F4&TB#EM!GEX M7O2(O"%M:-$P\+-FF =-6 =SCY{Q4\7'/6%.XGO%QSUA3N){QT<[X MR2I\RTEACH6\,763RL;+9D\_KEDVTF_57(ZOWD>K:/%:Q. U?9_=/GRJ0M=' M6L2:11X+'3,@+'0%<45DD2@4,8F\,/2YY3HN7;G6X@9V%-EF0GP[XL2U(D$B M/TB(:2:!RX5KAHF|>]UE=HWE,:&J.OR6UA=OVQMN[Z,;N\JO9#HTP7_0ZX'* M6MOA;JM:/P,'#%OL?G/"/PKA=YYK/!G+P]1;#4 =)[M:%OV:PUS&N8.;Y,US T(&;@#O.#ZQ$S>BU.*! M&?K{ W.!V%.PYR."QD(1E2>F,$/7)X14Y_K_$%/^9"GK(E<3_GHIZR)7$_Y MZ*>LB5Q/^9BGK$-$GM1 ^KJ8+W-07\.VUWB.QQMQ_PKL! \.IJCS+-,/33QQ MY1$F0'4<$OLT(GYDFW;@!'"BKM2IMH(@"2T{)DY$L9ZO9Y'0@Y\BX=JN%YB" MLGV*+MFMGV[[2UW'PSW[P1O/?6:A4?1D493;ML<8H&ALNIRX;DA)%#D!2>PP M<&WA.(*M5 (&A$U""@D2NP)0E/J<1(D=$";LV L=+'^#)\YWJ/GGPBH;1PV$? M#;2.4IX);/TXP=3\'A&.1XEK FB&EA"$!8G#8L<221RN!D,'(G&2A(2^C9&% MJ*GZ441"Q_5L.Q2^\<7[HZY:O@9:K:]J&-4PND,8#9(@8+$("=CX)G'Q=DG$ M7)?PP'.B1%B>2/QE&.4VLT5@)428(8;G. "H@141SPOA\S *$E-H?57#Z '# MZ.-B>! {@TM[&@[W_+NH?18TU@Q=+!1UZ4)P."QWRDH_K12SA#DD8(%04D=GA,_-CC0>B!1KUZU_2!\C?,-2<)4TN&=Y M#N$VY<2U0{S38UG$}&ADF[XGX+L5G&.!'PEJ$9LF,7'}!'%.F,2DH64GPG6% MR?='>?,CC7-:>=OW++=6@-B"HQ3%GPO$Y"5P7 "H4'@E#YA+7.99G"Y},^@J^J^C*H/9D4;K'[-)LRJEK MEZ86(*OIV1S!61*YQ+*$3=Q ^"2T08I8C'IV$+EA*%8$".C!MN^"V*.!%2! MP@2TXC@D)O>"#) <|YH)MK>S&H9/!72$W'!K7,9L[*[2=;V('@%!X2'MZ8 M2F(2!RXE&)=*(},.@VB/E#?MTM3*V_YOJ0:U 4'-IC%+?+ I$^&&Q V3B$2> MZ1 OBD%%XRPT+7O5(G7!?#43>,@$Y2WAH+PQ/R'W2U^!V MBTL3?]9O)OY+T@,VD.8-,0F"IY?_]5?X:\U;,9CI?9.,L=;G!B@92U2PP M73<*2]:6[YFCT/,M>= (N[;%C/^T.]YQ-AG<>36Z>,745;S?/VK1C36G/*M6M MG^WA%.O^<5$*87R"WR\]XWW.!1^Z3K4NQ+U?,]2DK4E;D_9AD_;W]%H3MB;Ł M_=A.3=B:L(7'/6%.XGO%QSUA3N){QTVO[^)2M'2 M7(&S**Y?P2$GLT";T@<6R+KMXV45JY)N?OYC3Y7I'D M0#>V(L?55[8&HO&CD#.'LLD:T09$-%-8/#0}CT2!Y1(W" 6AL6V1P*0.]4+,M;FYDO[=='UA(*T)*M*":#MQU]NSRBB1]'SX%]I$Rm+8+(W<6D'N,D:T.:1D'EA^&)@EI!#H7)D@<T 2=++4; <*,0JFY%#0C/P"$NXF02F9WIB397-W6.: M,S)-2V.:QC0=R3$09GPJ*IJRP8](CB^-H){R44]9${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{J7^_T$T4N8Q*2A92?"!36./S5Z MV2//UL6M-'KM_99J]!H2O5SFAZ;MD8!20"]F180" A$SM*BP3.8XSHKE*+AP M31ZZQ$M,/!02C(0^6)N1RQ'LDSA\Q5_Y.{12Y=':"TT!&OCT*'<_6%@#73 M$:[ZR.RI1 /(QIA7*L7M3)P2D=&$?P_A3#HFIA6E5_20V8]]*^>)I; M %NX9Y\ <+IV1YT0:+C5<:KC4<#D47 H1"S, FYIZI@MP:28D#D)&3"]TPMBS M_<1R!_$'/SE<>B,GW/'YEH;+0X=+';0Z0-#JVV("S=WHH%5]]'BGWYJCF>%X2V5%$.'5- XGJV(!%U+!*9L2=B M#Q2X2 SA[-P1JH4C9}?A11K5#AK5^NY,^)G&F=BG"<_[OK.[S:>N6.%S,X$U M8_ [3R_5I_A6FC>TY1#\');EK_"OP3): ;=-Z;D@><%%UP/, K}N)_%ODN9< M7)\1YW62B6O"TU)(?H.FLV:2O^9I-5*}?_#PCB;;E;A/^T-:3OBPP^*M,*7BP2@V:94<@GVR:J"UK+Q_*B M-@#\8)=9G=TL#J,N#-H-<6QTA-)?\ >LYDR+:_&]R^M.-R^"6B# MI5DJ:?E+\D:NPX>RF'Q7$_Q1O"UR>=Q+:\%_0&^_9 7[_84A0+N;0DMUV;3] M)"'$X&_J38?_3^M9R'1V9VN6AJ;=>WBD@AU7E %$ 6IJEA57^.2K-(=/B@94 M%U[]=#;#AF7)/(>,'N ^F!C6H,O&Z[D!NOC#@LN3*4*=QB<5OB4YB0-3@K"5 M23@>%%$P?'R<@!)3-&T2L->J.\LTQ^,+ {@4@OHQ.*W%6B2D% A'=.DBC3,7] M8MTA^F5:I3$P4'USUK5QV^FX[-8UQ[X=ONS+T7;22I#^?,>[UG:OV?8XLMUH M_E_PI-U[XS# <\M5M)^R//_X5VN]SW1%>&=5_36,<_ZB(M5-EPW[F]B6HM)#'J+8XX, MV\04!_=[$(8.[!KM>NTH7/0A#')8$}3\,5N6M{(6MV-IWMAQ;.#FXFLC<75X ML8&MP3L,8ZX9YN&+;3WCXY^QIO"3F?&39221DT+'=-ZVNDUP>=\|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|?.,SV_OOF'\?:+YW3EO J0\XN,NM_QS*8MCU)1*8[Y*ZPNC:$KC{WJHDD2E4>.(!W+A]SH#"*\5 M+|O>,'F\A%1X*"JJ@74%1"GJ KI@6<.%[N;?I.#:I89W\2T*&L#.OT BK!A MF>3_H$JLLM"GJ#0;-X*6!D@$>/?30G93++)P DW_ .N%2TQ3F#UUC- M\D<,R7WY0\4$LT^AVRH%#D9JNP9&E_0#6]M6P+@Q&!A0%,E7%DFH[MZ9'_<\ M8513T&J \#/TK':%%Y"U;] K?_3@'HD2GA@E4O^1Q$VK%G52#)$VBS3ZG=% M? <#):K!UBM2IF \'4%\4,"PN*E:FL>+&^_L:X0BO1);AOY+%H2-)H$6IF"TK MJCM8&U]Y.'N/X(D,/15HA"]\%ZPI4YR1G./[:W9!\W.!#ND)JK@=_O^)WO2: MP =;-.AF"TNFK &C3FOLH"6';SBI#V12'4TT,*[2^ IK8WS\.#(^PN89UIM- M5TTRNB0@|$&*1M6!SK U9GA,DS^4L%" 2--$N@/F:@$=(5VD[*8M)O6$B56 MZ2B-=#(%[@8$OU$<<1>O? 4*5?KM(*T?J/!LRC2@${}#N9\=:7 M\ISFQ64QXQ!\HOVN/11HOQG-V%$L?])4?<9O/X1UZ#[=:"EAE+@NL$+=F(R_ M@[8!$X5Q?\S96$$N+.+518'+5ESEL#C &E7*4UK>C&8OJN) ^6K)G 4X!;\ $#1B_Q/6GT/1 9 MQX_198=>[BV4V>>]@36P&O\+;373KX N\)D6UF/+EG!HV*)]<@_I'14,%" M)8MOH-#W57,)=G,\OJ"7 JP'4#YAJ%- ;JHD54S"IQA?;+FA585"Q URZN MI#HV[U, ^H1"SM3MDU34<6)HKMS_.OH^YOXZ_CXUSD8.=AE(,AU/+G7"YL$TN M2W=- 1=!*0>);KQJU^QO,]Y\G2T:K%,L%K:.@G:=X66A>M%.7-)6C6[<:Q>E M4]H>H*V]?[MHUJWH9NT@L:1<,P'>N9%&:H-J^'F>)B!|\&Y3,^]P;ZPCI TL MV,4=&X/@EP,KIFDN=<6D9SJ.Y-YTBI=!.?I[U=1S 3*IPN'!VK;$ 0PB/,;6>(2=5)I>*5(K*R1 M!E,.)N\E8/04F>;#_WYS+!>Y#W XHP]>!/8B LP<1'3!06[J /7C[^\Z[*U M;T-| <3&H,1%@#,%< ML?]SBL\C,F"I3X0\ -4,YE-V2U"I-^EYD:?5!/"K4O"%;W22Y1+ 0]02N/O] M3@H.LA,_A>4;SQ9V.ZO G.:<"IV2/@#BEO,9?;]#DZ(]WUDA_K-3@97.N M1$E%$YRF]%T5&>R\]GO8VB><(H(6):YX4>$ 8%9?+Y",+/F.^MDV:A0NV$E3 MH@$^ZGK#M2WP[LV<*&HEA1JP_,OTWXIH$'GI8E/8SZJOC\Z:O17S@%0\]$ MGBV5Y"'<+R1(?HFJRP*/ P7V&???MW)'WI,%1=[W%R\P_=L9NXT-0!YTF:+P ME^>5\SV@R_LE=Z-S,F&\1\Y!6Y{J$V@\GFRK%)F0H-!M)/*WW-MVR)V K4&O MD?)? *BH"V /5'\]#EE(I#:%45H*4A#P C %M?@")>*R1Z\>G-]{^_0 W:>_;* M8R85KKG?N6JFJ#^WLAY H\"5;1&RU89@C;Y07Y$ ^Y#Z=4N26B2BEAEC(AC#6 M!34([L=_? =7M73O2K4"'X\!892'`*B>3F_D2N!(Q/44"$<%#>I=*X9%Z"R@%X/"P(;/#*<=S.Y(VD)%A8VI6[P<,3X M7: C&SW]ZB1#BJEV4>5^=PY0V*0I2@VI4<]E-QHNV.^,PF&?H,- %<62>]G:03 M8{2E,G(EC/N/*UA7!_U T6"MP!(R5)A'LTXZ.VXVRH[BE8>?U!#9<8,*#=1,/F3B&D@>.-.64@2!N\/A@D91.-S"\LM%D,=(+;/U!9I{$G6< M).4.$"UTNU_, M3Y!RF.H$] RA[F*'=M0]8I MEK_GQ57>DM"R1M2>"*O#$'8@J.?]IA9&J:$6KU9DV-.9VD5&\U%J;FJ6.*5+ MVCE4NBGU)RV; ? +G\AEE04Y!D.9"N7C5":"T4>5QWYH-/AE*[VLXTLV.+G&Y M@;"S/65]D0AQ5U=%F%2T46 JGU ':X!%5T+"$4,-8Q&E4(#"QAGG\BOG8&VAD+ ^'XNF6_NO^}YDM0D1$[9Y)?=KXB8{KF]L>CH*,. M]SGJT-91A\<<=7B8(*X =03X"W*3GDOTEGIO"G+NJBA_7XC'$.JCI.\- F0J@ MA%*@?P^$ZK2), ^F;50$. ,%X"*!\,$L2 6R_3T 2 E15,/6RL?'+_&'0{Z6 MJ?2S_UU],A_G;_]HW_Z$0S?>$-7JSTJM_GIQ4[7(C\+FS;M/L^ 45P,'UHU M&G2(}#M+13ZQ_&!L\"(],RQS;)F6__Q[!7I&-\ M=&PZ8]/RQC\9*/V4"2]FIT\&:M5&?3/%/G1(,CP64FZ^LVW@MV+1+M+5KI4/_ MM/!:2J[N2* .S2*/YF/2)6P? 6ZI%V6$+CIL51_5 M1!{1M%HK;F>=Q@4'NQ0[FC)]RDH?/,43%1C4.?IJM:*)EN0ZA59VMOHVQC.@ MJF5@{DA@&Q7S +R#2_P.'T_2K%5H^YX,%=FVZ"DZ'>KZ3;2AD5()+0N*V(00 MU^(@?(HBM%W'*%1-7>6]KZ&P6[S97*N?.HQDR=@HS:B>_8!G?[-><^[2,Q-#V MI!1L8/U:DB2"2H,4KKYN/0\(*3%Z"6JD[4J4E]V9I[.B?TN->(T./%/;%X/J MYC2SWL$F)X&*RLP8KD07BMK:O3/'33-%05&T8;P8W5-V/GXT9 NT4BO$ZUHN M&VV1"6L'# &$P"X,#*O$>6*\F1I3&_JJ,,(5^_B Z'G@<[AO A5@X]U\2:JC M7XO-PY}4!3_C+9)YJQ]4QKOT,JUZP4!"?G0)7/M!Q&6#BI<*?+A2.HA0SN>U M.\3;-9H=2:BG^F$>$GP,Z9%'7V@%;3'IT%^,4T:]4RI]RGV%ZA'BC@$@F\&\ M.I43XQID0(=TB*XZP!:<@]D,*@[7$-(8RZX148>%RM#*6BZ'@N0.PD MKXED+O-C 6N- I_XP2V_J0_D:U!ZIURD);_@&*H??_DPGT]?O4!^02NO*7D1_[-JOYZ>1JJS0XY51 SAV C{5#2X0;@?4B^P5!OZTW6& MR"+RVYG:X$T;4I%6N!@$/FR71T6**CR;JR0SE:K=C$H"F+0!NP.A#AVATR3M MW&=XWZ,RTD0AZ=I%6F+JPPH5/4 ..XU9?DQZUY$VHSP,KU]E?FAE LR!G@Z8 MTNP$GN9]KU2OY3M !EBK.)7Z&]GPU3Q O8WP1TG.2=@V.XW H$L%?7V9BX.8 M*&4!W5 2,]0Q &@P8')Q!0Q*7[;-5_D_.RSLFI2GQ})OV6D$++8>_Q;@=>% I M)*,YH EY/:SUC:L#W[7()N/#Y 1SH6:VC!2M'@7?M'VVL#>[&"VMOJ8-9IAW MPT622D/C9HYCH@M16MF*L?'WX@K/64:(0V BT.D4#*6JN^"V@&C=X;=$-B0= M!- Q863BSDQVQC+KVVZ4HI$^Q:1&U4*%5W#67$J?6N["+ M1]+4>!%SEGP7-?1THA N6QJ M=4&_"T"59""'5QV_O EB2!G">.FM,AO)E6@#8:VBJ9;H6>MMQS/+GM)P09' .MC72B@LE%&[;6Q5=UR(-P4}(ND"+Q<^F S2T9$ZKZ%<=*VO1:[V@K9$ MB)L)&,^SN\N?_^^7UH)8"F^"_M*Z1 MXP6L+:*%F@:ZE>21<- ;%QDK55$N_8H)'45*T@P_%L)G+U1<"TC MMZG*J{#*0X^C^CO2WON3J@%0X.?B4DQBO/A@JKP=\@9-J7L7D+#\?AL_+,4? MD/*\L_QV;=X/B3ED.21CSE8<=.B;,42.J$G\E:@M*<4_8UFZ1:*3)ZXLE)T MF@4V^4L!F@G^\D[Z#S&5Q"O\O.5@^?7,+T*5Q)%>06RBA-DF& FY/%-@A!{1 M({FOYVGD1CG\=N4ZD:DN8N*PU?B0_Z3CHY375E'S Z(B'KXF?]\-&'8I1YZ,60HKO?_,SY MUS+1BA-$V1YKS)C^W5EUL+'@3%S0%];PZ%V"? UF[U&&:^QRFZ>@PS;,.TSRL M,[/;%N%M=ZWGS3SGP--JF-VL#"?^[X><+T1Y[,('}T8UM"_^WTVL2 MZW,0EN+.C"28*D/YP-53M.?]PG1MZ]KL,F3-Q-?O&!? 5$H.DA7]UM-!&#RB+ M6)VC8?@6GB}.D*)DE)FJH]'>MU87B26!M7G4&A6XH.S@QM6QH**<-^TT9F$9/,^;>DEFWVC];_-?)?]UEH7)M?>XEZ[+$V; M? $TM>F=_W#K+BQDOB*P/'F1RWDJVU5&K8V.=X";UE7)=#H#4-MQ>W;,%K< M@[7KL9#^KC>FC;IRP1XVI)(FRRKBGFJ@%X.2!F7IX(NI,=$*EI=WKU9I$H; ME<- ;2P;#%0MU47'N'5E(L#4&)6J684[EQ/%9OU3"#U0X90HNG.]B9JXV>8^* MFITYR/OI;%3(1J6NH>U/6.". 4EIZO-32E#6^TELU+)5G3$]NS^Z+KE-E>)V M+VQIE__LYV^E"TG%2G1WY(YS/2;'I)$1< 4FGG&V=1&LU3]LFD MB<&XL^L_K:9K?;>8KO5-+ZWMAUG;,Q?2VGZ;)Z?Y,DM.LR;3X.<"H,D:&^\6 M5^Z7[KP4'_T^SS{TO;=(.[2 A:2%TB6J-O5M?SGF0_X^A[4VC\6#\M\ ^.-=2 M/[W2_K#>TT?DKB&-P];2GBG@:N 3F7I,9C1]^=/9GGL\!S/. <7+H,B}X3G!0RC72>BEP+.BTP(S=\#C) MZ$W1U-#\M>"O55>6:8[-E]T+0# 9G5;BK%+'7W1K((LTJ;95!<1>-46,5%?Y MD,ZZ]}N'%BH2R>Z<8&R%+_L.E7:>RJ/R\RVO66/7W>*M+5ZQQ[;_-#WT*3UJ M2D_4TU/-)[C%?&8ULU9KGZ++{O;2I^N0;'T]U%5,7!{K0^J.A0/!\WIO}U U M! ({}^O"3TYJ6)IF=:EJSN(,N#F5:&]+G;'2:T*K8@LNG^VHX8Y%4OQF.@=/ M,9H=3H,=/N:8(A&34G.A?OD,X66O$})@L:)@]!]ROCQ@Q >O&C4T5QP\ES@ M:"[07'#;7/ GS0*:!4Z;!5YJ%GB8!2,C;59-, 933M@MUM::T)%UXUQ:ZDG* M>29N6<9H#ZX";D)?WXH,FM4W71CZ?=2VR;K<"4)/'P[U.(#M-YD7^S7=13K8 M6H@^8$_7\O)>V+"]_F@ZLE@^.!9UC+-0]HS4!ZK8_EX2Z&{I17HG7+H9#$WI.RWFXEG/(^ZV5',VZI%NZVL.@/05[LY6:@;7LU;+W(.U. M{6#0#H;A'0PZAN&VG#Y5W4\MJ"R@*2>UG(>CIF'O-]:R]&L>[JLJST,VL.P M+]#+PU!X&{6'0(0Q/=DM"5$+FP\;,L!PKZA53S+*M(?. I)_6 M=AZ,G5%X[UW\?=YQK>]HYCU=YK5&CN,=\IYK3X-FW]-EWU>.=]#.ALVV_-X,_M8UH*[Q%]:;_#QMQK^X>\[T1MZ'=9RKPYL&"X_.9:E^?G(.!>Y*+'JFJR"A\64 MJ[J4A6(U?!Z=2-1:T((1XWOW9D+;YSW7/@C-OJ?+OO8H":LF&AW MP_\/]WP]!;/BPYYP{6OO?/NZ?*NV1_T>:GK-6CF/5WF?>4?=.X&{6;0;H83 M=C,,$:ETV&X&^)?&F9 _;C!^RX,?G}G>7QK=G:.Y94V^K699_.^F M^Z$HC?I"P)]2"&,"GU]4ALBYX,9"*5D#B}C)8 VLXS4RZJ*F69>>PKBBE9&) MJH)F8)_]>6 :/(TB*7K_Q;E,4('JZF@F&$1W8S- I:]=!AI!3]FM(:.Z*H M*#1'8EK!KZ5\,H7I)&4Q,;(4$*5*\W,CA4ED&339P%"F93$%[H.6?\'TTJ!N M9YK+Z54"ILR-)*V .XT_&EH"}K4MS\=P(VA!%,#$ZB MEU]L>TG2LJJ7.RF2=LF@@2:KUK M:R:[45_)I"!M[S$,$IN;JFRDE1'?R&&H%8+MA&9+,.'0'H-^AV&C!VSS@OL)^D**]HRT,G6"@ MW@5\?EX4'- $#.JJ+\|;'TR=+L@M7*M_-KU0:[P%P) "KQ^#(P&/= E:D!^D M?"FRK+A"0)<*K5UQ@K- O2HT$QO_XFK)03N&TH!{9@2N.5E*U%4\$GU0B: M0W%DO/SI[.%KOWNCM?WO=RXJ16)DVN7O+4_U4!Q4&>TJ8NNJ!^.!?8'AXZ/ MDXS>%$T-S5\+_EIU99GFV'S9O0#$D]%L)-,:\>.GAKX1C M-[3-^7]/T^O3O!*- '=M^FL'IW=*[I7=K@}{NB$T}{PQ-62>+-HU?N=?WV$F_ M0RT*>\=D[_29#S6Y7;O,-ZZ*O][.F0 T@^I27Y2FN1{U"2WV_Y]6!=-ZP/1 M^DGAUTE-]D0(>(] 28.UIG4- UAJL3YZ _7L(N'6H=6,<>]/:J(HLY48'GONP MZT/'"^X.8'KQTRKHUG;U8O('H2IOX.R-)XZ0AZCX9>WH0M7JJ MI!%*"W7.,;=SS$L,3I!!$)I3-*=H3GF ;+DW%Y'F&,TQI\PQ6K9H3M&YWU MYFB8]\FV\O!YJ!SW3RBJ"FW8/>4RUXERITA8>\YUKT'@W[:M&[,=<.45!X MWW%:R]{CVU;M>Q=28SL#5.C:]RW7&>.:4^U#-*

Z8>YV#+@IUW(GM#\?? [G(M":/5!;1=L-_:!&]LF& B$XJIL#1X'A!/:?#<=*]M7155[*9[?0K: MCF;=]I3S;J;9[8_ 7>A|C,O[3L [+)4^?!G,3R<%S/+?VJG_*'ZZ M_P;2,6/K@^Y?'2;Z>L%3T,KL$M8Q4XN&!@T-QP0-P\5[2DRZ$,*#1$:(K3V ML!?4HJ%!0\,Q0<-PIRA[B@Q:>] 0H2'B,1#QY_\(;T2XOO'Z1>'16XM:"3PA&-%*X [!8LA<''L*%EN*(>UK.BX8T=K(\P#, MR'&&"R/>4XC1^L@) 8G61[0^HO41#2-:'SE$@'GE>,-E_CTNA-'7&(\+8;2B MLDL7.RUGP+XTS(7_<"X18ZOO.[C9E*)P<3R\- EM&J^L\74WHN M2%YPT;T#X*OVV']FZ0Y%]=GQ'F=9.*:|\+04#&]:G<$.-)/\-4^K:49OSO#; MUU/*>9J?]Z@E52-K#RS5!_]JJCI- ;KH.Y:M$Y/SUM*A2V78I,EJGEUCNYQKG M#VV>S0CQ>D-ZL^5[ENSV'7I<_:/'[=A2B6/8C/9OW+F+!VE1P_HTS}(E.)>'5C'3:EKM=E#0N=ZQ'!2N[M.>RF/2E/W4L@FPNI;G^>%P=W19(?BM*H+P3*84P)O#Y164 90ENK!;H'JD* MD;<>M!O=D;IQ)4IA_,D:FP:,)@,:&AD4GF1 1)7 4I-_,L?N_#L8!)U.R^(Z MG=!:9#>&[;\ <&4E93.3@IF4*3]Q G\94P,]\,'QIX!60:T#Z1M)D&:EAPKL$P.K-)2VTG1E(.T[:J9 M%[,\E,L]\V:'4S9=(2OH91,CXE6-DFJ^&[%":&NV=UNS??5O@JH2S- #0$ M}E/5U4C=XUW8[H47<+_+5-(48(Q,Y"E?*Y*D$K41WRSWEN;SEV5$JB+/Q=+; M!C +T \F34<1G);GM"Q\;<"H R7\(J6? 14"R\!8\BU01Y)\T;(W>27-&=" MKA<#\$5ERN!E<[Y 9+#1'_]WFV.Y8^WSZI@*X."FRK+A"_I>F@5UQ@K-%L9@-9&U>W@>6\'Z>(.SL3= M T$86I*@^@I0H+XHF@H^ -E[=+;GB#"8=H63:U=_0? 7%02G=ME4S M<2RH=<+0\7$"=DG1@'V17@O^6G5EF>,8?-F] '24T6DESBH!T@ZPMUL#:.*K MME\L!U]>IE4:H_RZ.>O>7Q=5*;NSP[%MO^QKQ.T\E4K\|RVO66- KBY<>_DHX M]IZDGZ=Y)1H[VZRUWAZ/7I[<'O<'71T1_AZ>&?I^CKILFE(^[I)M Z]+O3] MDWWZ4/TAIW9_X?0]VM-![RA(W?"3T@W? HVZXW?;OP[H6C\'&O>R/3VIR6H"_MUF"M:5W3^J'NZ4E-]D@(V+\'@!4.',4!"!B1I3M6< MHCGE ;+EWKJ4FF,TQYRRP;BU;#E-.U%SRLERRKTW0S6#: 8Y90:Y]P;J9I"[M/8VZBMH#E?U[Y?UC>L{)GR8M0F'3-!P,->F;_ Y%G#I5LXYCOTFGV/9BL/ MGFNC@V;9)RPE:HGE7B]YG9&)[9#KW>I?W><^UZ#T:]M6B=].]#H,+W;ZW M,*U% [_'MJ1:]_=Q@GFT?_Y;K=(&'M*=:!&_,O0-F]MM;YKT[29^N@_58W__G M(B>,5A?&;2F/-'@>$$]I\-S8X>\,E[_]F#=:\^S1,.7!\VQXR-NL70Z:=4^7 M=0/GH/V%6MQJGCTYGCT)}X*6MP>TIYIW-_8-^N9!"USMV=?<>|+<&Y[L=Q0 MGGT=U;]^?=\)> >+"& -!!G1/RE@EO_67GU=06WKS3ZB"FJWG@P,A[U{6B}- M>S,T- &AHV 8:CAT9M--$0X2&B,?%\1P[1FCM04.#AH8MH&&X@*,]10:M/6B(.MT!#Q*>-OMC#TP8[&"(T1=QX..8S0-T-V?W!?0Q9N7U4J]]Q ^7/+NOV_;REU MJZ'\J*:!\D<0VIJ8A[]T>$T:TD#R?$ B=8)=PD7YHEYFS9>&>U^ M.BX8T?K(LP",/0K"HX<8K8^<$)!H?43K(UH?T3"B]9%#!)A7ULBR XTQ^CCM M!#!&JRJ{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}@B18BH8 BQ"GV)&[+<#!("=%#5A8(QV6 ?&"N%!L8)Z%+LZ2T$G2=FM M:_%6"H84\+L3KU5ZO?'&'\Y"/HYB? D@)G67%E50%4*"OU9SM4QS;+[L7H 5S>BT$F>5 ,H [NVV1%J9JNT7 MR^&$EVF5QFF6UC=GW?OKX@4E=TXPMD+L[AIW!6BE\'Z',6: MC[H2]>XG-ZM% [=]3B_HY)CIHI5\0S9^4:'Z/HODTM_NH)[=Q7?5#GZB>W*%_M3I/H@4].ZUF:9'J9VU[ZGY FEC?){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

MRH;,36<[,!C &R^ 17!9$.'+8(H) _?_"?/SI&%!1S+]JP@8?3DM1W0V"^I%TR-M]GK51X-PD5A7(?6B+!%N7P@[#\1^;X/3AW@Z;_F$]Y56N1$4PC!&,2;_Y"H;6 M^7=|H^XD*L$P1]D\VSDJ@_(Z)=(&P'C:,_Z"&M!\>_DN&J^IYI M9;CP'?BAILX]!M'T"I!>>$+YMZZV[IF_@9?&>DT9(A<(V\,IX:LORAU.:(* M_%"1DUWK;MWX(;@K@:=FL35D5YQ'9VO6E^^?T<@-&TC"H(D1KG0E)(B"E_,. MC-FHDX17<$Y#%9'|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{OS$TMSE$G5.VQ@)D93;99M(PT()>R^S0H"8JK]SX3O+:.T$>!@9F S M>*,4"? 8N2?D:?U#&0R9D!Z@B34NW_79,YAA;P7KJ@B;&\/I2&;U"Z(^7.;&@ M"\2_R\Z1:(Y,;ZRD%(S#T2YRBT^3'2@P6"Y3(VC]?R/(,]!8U-MLTLYSH4 MQC*T_"0&:UZ,8KKAU_2'4#3-*/G"CFN\,4KQP+WY2M7=^N)&,(BFD@DH%,:VY!F!\K6CY&6 ^*5!H(<(SWHSH%70,"V/C'>%U3Z MQ8>E"7QR7J:Z@X3VVS#2%ONIN$_^/1A^Y\(-UZN2!.6$CSGOX9/1L)ZR!2E8 M@?KI 9U1G]3 B$1T>E$TVOQ(*JO]FI M Q:Y0/" $^0*:>*>Y?7?[VK X:148 M.-PU<4 (D-A\]$7<@XC'FY .ARN^Y3!.03Z.PID&N>)&:3_&AO%8V$<)7_?\ M*/CHP=_46CH}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

JSO7.F'ESDDFI=\&VV8(@7-0-MB#,26$@*#;JTD'2PKW!F@P"V0E1E*I,F%,8G@-!IA=G5UO-3(K.6"1E,*T9;-MIC4?CFF2N;UNG2C YT*R_ZE"N3H0+LT#W\HZ0FF$\VI-! $BM%B"/*$I.!/,)R=C!Y'1D-4K$ER5R86I, P$>]_U3M1)0S $!&*\BW]/SB[1K-MJG@"$)#XU7)E:H)]CGV^^-4ECAN1F@=W'Q&^-F^1%;#P(@,K0-:VJ>RO?SPJTD?

C+>ET]VE5;-M,T[.\,= H/(K*0R+BC9'@E39]BC[K*7(XZ+1BA)92S00!/Z;Q2UNT&M2WKQ*-MQ2(.!5T6R2!W0KMP@@)XA>,+ P"18-5UJQ&N'+YX!@?!H%B^EY)18WZ"!"; M?B%E_&[CQ#M@,N8>8'TBW3J'-%M:CZ$/N-1?U7HJ.>:6@0L7JT-M7<;:,-^T#60F'3P\')SKA?*

_'P==UY+'RRD)_S+'/3>ONL08(HLQT/LJ6'C1B-MD>1/#08#0.^5(5A?UQB/NI6-KZ@$^^$>M&Q#$'\-'!^IK]>T(_+&@*)H9E&-MGABD,0T$>)4B$ECIH.42]W^2/.9Z,T$*>UJD=?"NTG1OY-3;?81XALDNRX"-M-G2S693C-AF8<'L:!?A9O!>8\"Q#2NE@18F6K*1W*);S%2,+@T!1(W52;';E-M#K0OZU68'5?<$0ZR'B?^Q?

D@&;AMC+=^!$$HJFBJ/A%8]LDG+T1).V"YW!P-MN-L-3_5)$)+0M=>BL)KV$<_:;**+P=S>]>;^=X'=4,3YUHSP5!PG6I@7G#-M=B\QZSS-HU_I:! @/;?'HT]?',9>5]]*:"

+.2ERBS-M[W.&@=A^,[+MA@3%4OJ"H:" */(%:P7P*@4]/(K%;T5/47[K@8"&96W3?"T-M@=@NB^F6Q:15!X#8LG[F-=?/I3W;_B-,G#HQ5;R8915O2ECY4S-2Q(G5KW2-M-MT#]^9!K761X-T6,A$"B0IM[VJ3Z*LGH2-551,-&;,?FU!*/*?F-M@FO$&!326#ELAP";=!]_D@00+2-

#5A+964>'LE1X/N4))'WFB:T]E5(O;)^/RRK!]ZLOP9D*@A;P"82Y)L]L%7EK*EG=']4D^R=8-M261>[ZZR?E3$T*;V6&.YD>_W-K"F]21!"$2$)" M"],E-\RJ.@#$EGG%8@4|

(A8QB9;L8'QQ(#?O]H"B-U+C*0J_>7L"B1.(!%?N-M4! G3@./\#*3!4-!@-&(..GW$*R\5Z2\D\]L#KM,"]CEHGY*_3"EK\=3^2]E'-MPYWW@8^,>B?DF>BB@?9!>/#^G6;%Q-:

[9DI6"PH;/O-:>E:#%_95T*;JV%_MCZ$_"(*YX6T?\'Z{846G\ZID.APL@P!2119O=0(+3]&H8DD0:G)KR/B*"D M$F"!.:X8RDD@0:LOB^D$?]-;>D5ZZJ+G/VV>/?

9]:CL5N=5>#0WNM$D5M0\2K MVA#1./@G1+P-Q%>8!=NFCK!'T>%'(0V.NPT0Z&_&$TEJHVI. 0&6HN:N^-W1 MF@@"Q+)<,GU0*D(-

M5'1!/06R4IS1CC<2$[O>I;@H^6NMSX M/U?M?1I6#%-?@8&\,AM5T4NI.@C$UGEU+++B\BS,.!.;4M0VC4Y4*&3RH=!V M+QH+ I!F,8(2U^)H\.YS80#.\F[*>*MX-

A@5';9:AF#+#+RU*_O6+=582"G M8YM7D(6$R^UE76C%KUMM! "-J=26,VL.Y799D]DMYA5W*:E9D^O7;26IXP(P MS]G1LU!X6IQQ(.

[LU0LR&V6E%DUAA2+YCB0&B(..)PXDZX+-@##BSQPCA'459 MU1<=.YU\!A G%XF\9,X0OF>K_!W$>3E^CBU1OY8J;>! (]D+9#_)V_+.Z9\ M+

(B7)0_)#Z2I3NT/E9',0M;NI9 %*.9U'4A!BEM\N_@OW+@!L,_.I Z7N_? M:W$OY0P0E%I2)\%43C^8\A"=34;V0OG@0#P_G$MZ668_PABJ^MZ++*FH7B-G M&

(CMLY>+N82IV3DW#@IMK;S!<$ Q7>GGGR%)5B'!2;.6&*L %@9Z%;VHA;GP MP[2^/N-50*0STO;8ET8>54> H(&LO\%C%.Y0'%-O/6FCJNZ(OAA7T1@*F:N M:1,$H/ &

2&BC?-QOR6E4TGD/JUU*9'W!8-AD!:-[Y%:XFHC0&R:Z\65-&$4 M#[=_$RK=V5EK=EIE]VO3A%ZK -E+&5,J%$DB+]Y,K,B"$*F60O]^WAWF&Z?!F2YUT65$-

Y1ZTX$<;)G ME: +8 .:-%Q_#V/$_1V%/Z)+4Z2:XK<=)C',B]9(SY?1ST59'&5]E O@Z03"I1 M3P%!1[SX]'L2^^ XXAH'G2=;?]BN210"9N#7X;:=V5[Y#12IW5)I'06TIE71

MT%Q-;I)Y((A.+]4.6)8=ZV68US-!M,L.4;W;FOJW4-0)LN0XB[G]=N_ MA2T:ZS;=/KCGU5-Y$):T-K0N"*)>1V].X/V>]5C*"_L1*U"P?8Q03$K4,D +

M=W3AHI9]WT86MOZX/X18"WW=! W+>>/ T$RBG;7!^)) ^YVEJY%*'5J9)]HU0 NJ-$F*!,9_T M5LEFC[XXT6^H\"H*"$\XTKKDGSNB:#JIQU)U22"!R&'5'

>"Y#IU;*MK_#V7 ML$!\39\|OAKX'W]=:;Z4OW3Q^2OFVP>X.(U->(6EN"2A?8_PO6HWA](9#P @

MYQ4C?;W;D6[11\=%Q(3.KV^@I;4QLRS8GV^X]Y@:3_6/5'$&RDDN0G?GE; M@T!L7:OY^,K'NGW1"B=O+\Y\M+0R]<6.- G0* M,UO&E,$329ZXY%F4<,5S

MHIG[U7.I$&CH;0K)W3%Q$'I(*9Q#IN]$V2A2#A>,OQ(,P:0VOY+&T@_P'1 (1"R\!*T((?&I>N^HA B#M]YM MG]^)JO4WW3VJB"0PS9=>,(>,J%!G+ @G0 "I%IFP?

I;@*)X[QV)V>+V>?U(M_BF&3G6O6,9A9C;*XO@]#'NN!0(1F0]-4NBJ.@#$EK-6X23,C'D_ MQ>^N8"@(,!]V]H8E_B7 #,\GBL=GC'=1'G37-:R;ZK)TGV997H'+6V\&B-,\ M-

S^G$:.S_\9'N$,>_N[Z^76AAC\I^V+]=<'UKG#X*T^9D,4BRW5@G$@Z*1^ M8_O<TA:[>=GL]8X$HJ4!UF;S M5/VV>%/+A4#0#&N!38Z)Z6VR9I>B52

P>@!4]M3QG*X@G)CC'TBY#<^9O[G MZS!@]C11B8DNDT&<4?]>QJZ+!^*)YUF<2/X51:[3D.R 0*%"_.T0#V2=YOK>W MDVL8@%]83S=5ERSJ,A\$P&6-

I,;7K$N%)M5L$,!*0FQ%4J%@. APV+.]<3Y0 M3#PT8NMM,<0^N_BO,""IM0YK/HH?O"1E/J;.NQT_^*[@?=2?"N)T!!WI:#@T MVFIE371< @38\A[24F:B-1,$D'G,P1-RD?

=.&-U7+*-)2Z)QX, B-33QL-) MZOL->D=^2",]*R)67@)D$V;F:5+#F;C$XJO3!F]-W(_7P,(@4*3K,3G'VP(" MT';=D#S?5/!.2B?8?W*R>+_ ^484^NZ.ISSY8[=8

[$44]@80I[,FUK./D&I-BR].DBDAU$#R%I18Q_=C0KBYI:=M M .NW#! OW?,!|RS/F>:[Y6I#(])1-M4I8H_YP^QO_TL8.YXK(]|+&0/BI:L7 MIA.),.U1(#9_=N?-

VX^CEY4ILM;]L^,>]-]-[;UMD4?*T52S1Y+H@*+.9_%ZI M))CQ@+B1_BYJD--O)1!((H>)WBR$*3T@C2[KP("^-[4K.S(>CY+,O-I$&A^ MX)1797S

KB@:,%Z:^H,1O(Q)#$HB,_NTA]K=],GVO*=;Q:F39 M:=BZZR-! $$3(4DI Y;N(W#ZU<> V/B3%,]&-O6"1T:D (5*;I1. %2VVC< M=B'K&9O;\T ^+P/HX2\&?3Q$,>V-$_LD-

#W\F%0>^__DOW_\Y<3[^(#R<_DS!>L+_4U2N'09.8P^(9V$=HQX"(M,13T*&+D_NDM?/_S%GD4"O(OWY%_^=-'O/T_:%'<$+_>SWM!:^[[QQ]E3_?60\,7WD-

MC>5'JN<1!6'S?R M)@6!CC;;(ZTLE&*[VM5L>.M-D-"^UX/AU>0Y^SP?KO(VV*<;XG}$:[!03) M5^? (T?NL%&W>(V(']IV_QXSVXW^BDW"/S7$C;3(3 \M[(+

[:PJ&CXI,T1HZN M\6??PDB,S?JH43?(ZQW8VE]MT+C;XSGBVONKC1IU@[<'%+V1KB!1^"W9JQ@) M'SWN#==(0&Q?

=]FDT2]4O<@Q]S9E0\;%K+3K6QNG_.&C;EG1]+&U9]'X43>]-MVFXC4L]<_8,8.'X0;I@WUO)F?^RPV1^M,);T UE'F_!;H-IJ9.2-C=)Z$NN(M^K4JV3VBW3:'V]CR(]:-

'?]_>\=J(Q:1ANN#QY*Q.)UBJG)5]>>1MB2J;U_9 M5FO(J(=+D]Y(-N.[PC*FT[!KMHY7,'RD+6>9):<;;;&C+RUVP]W M3YQ+ CV).VSD W?#Z!BRH!/*5ZZ)N3HZ2:^U2-;

(VOS_2IT(DR$I756M&,O1 MY9LCQS9V"6K;\@Q?S:&'W-[OW+WG%Q$YE<9;/#MB]RPOM>>% MT19%_ &'Q_[\I^__\.D8>2&A\]?_X

Q88TAAO)#RR1!7R6]8'XX&A0+A%NC]\ M=#*&B(Z&CHV%+S/#QM^_-X@-OX#6<"8ALP<,S]<,:.RGN:X^7&IMTABKLUQ M\Y>EXJ9A'<[Q\=>EXH-OE,

[1\K=EHZ5E#,_Q\O>EXD5L?\]1+]-24<.U[^=8 M^<>RL5)W,N1(6:R8RW5M9%CYNV%A=VI8s?A3N6LJ1_"Y5^A&RS'S\(%8;['+D6O*[XR-2B"NY=J+HY 5O

MMD>=N;PRQB/7M'UKNL7A'6^$+VH"KQKS'5WF6G;X/6 P)-M LQJEB@7\B3O%)B"--'\E%(+QUD 0% FS7:DH^CGV3L5?I/@"A<2'8]ZHC6@-M']_08SPYD?Z?M/P!?

@*.67U? 3C2*=8 R>LPG\0;KPWINU%2UN;[7*>@.^A8 M>#C;E.XL"*26AJRM\TG1&J^H.VM$Y'R53'FA>DA]8G^=H-VGNN)J$%CHD6@ M\%OJN:29#U9EE$QJ-

PB6Z'IJK+*0IA)T#KW-4U3R%W4.PW?79V^/M5;*QUO M56A6=!SAR,^B&39EG_P:ZO0A%TM$G58!(B<]D9\]Z]T+)GQ"\%HR4G..95U! M(;D:N<=#2:?RO2LF60-

F0XJ#I=&)E?.G0]5,.Q8.[_E8*-]^S4'2 MWE1VKI[F,4AF,6USF&V&*N6DEOU+6NZ&6LE)/>-^YGR:IU-.WQN@KC6Z/%11 MF>WK)<#%:%X$\KJAJVU[7PB2]"WXM6O9,) OEE\KT ;+']' MAYG&9O=>:46>D2'P!8ZVSGD(-5PRB\!A-ZSI>'T6@K9^+Z0^R2X"C>]W4^Z2 M6Q"2--Z#NM8\SE/UEUBCKP.SE7NRE8:LSFY>ZSQ>:50]4+Z54<_1 X!&C/

M4+\""I?_(FA-WT;&9?I_G;7\U;GECQPN'C64=TMULJCCRBB%:?E,2^ MJV9" (M5T%RE1[?O]_15@U:.P8<,.[C.-4'(1L-9_OB)G1:4R %B+/=Z4>(M9^-A/&!]/=%:W&

(1(4H&,-AF3(OP3!O#7,X+%^'Y,88U7BGI>5M*^Z).PO3' M,SM8%^M? B?=>@D5Z[OR?3$L7N\R,RK^.;?7U#P;O)< M@=9$E1LO=M[>(F+TPUA=[YI0.PI2I%)25+/,@A-

'2044_%\E&/@_2/C6-G43 M+%Z@Z-UST>K#:V)>.,S&1JG)B.TAO@D/CM=LJ"H?:[('@_$Q%L2K(!'1:/LE M@S8D]\MU-=D@>_4(PI/C)ZO?O\"-*G/CDD'_QDOUU&B>8 M*+:;#]=/B?A.;%S&.],B'(^UD#^ZM^ G-'(*/UW/L@OQ?]>=9 8D;9K/"K MA^*]Z_>9\QRJD!QO KKI%'OY9YAKQ$:P#'OX]$=O0#6+_5!R>@87!(>4EP!OT

MB4;YGZ%/KE=^?NN@/-=5Y,7XIQO\G\$;@U'1$&*PSUDT3\5X"Y_#<%M]E9]# M7VQ@$TZP67Z*R!72AZ4^QFJ!J9@&B#'*H=7+!\5^$ H=@N$U[9I/Z%9=&-L-F

M,22$U6>21GZ#7V@_I+D1V.LE?,IE<^_]VET?:XMB+/)PC51@/?E8_RNM@*Q*FN6/!;/W&\]-ZT4C;;V_5\0 M"?

1%V14[OGAO62N8]:YEUI:=2+YA,9\VA.EM5J^B4VRT70H9\]T:#LS>X_UPYEWD[<"W_9S!#ZB*NN){)C.V MSCKNJ?.KV[#H+J2*5:.^'0FQ1GC5)]9\(V=T<_C7S?R2DMO]!J

U:UH\>GUDF5%MBHEK[H/9A$U_/20P_7W+'*)40_&JPL MP\;?+U=-[(;+>P'//+%?DZ;JWKX,_-XW#8CHFN&$]GKB_J(53@KA]Y1LMLP^%F>]1DPO<3E^.;\P7:E

M/<&MRL^ U;ZI(%LFW'5>"W+/.#F/U9X/[739/1,>B5B0[;?:B,_-[0>*7"]& MZ]TC7B(EVM\O3A0YK?ZYYZPT)L\5;Z,[8Y6M->(9/:;OON>N=SL4M>6OKK/'

M/(O>&^=.MRA/_G?* HCB32@0%.F.7QUJFSD0MPXUL3PAK'+$7H*R@"X&W1-R MP[> KB+K(#

[X9PV3@O9^KSKOEU=B3ZP(=U@G3Y$RM;$D#:>0_Z2^S66@_V20=8%U8W8@$L*V9EA M!&/FD8%("^T(DF_"(XPV=NA ML<>5ZX8I/CXJ]!&B\%?+_Y'E]QZ((I7R*

<\E7!'_L JV]3]4 M1BH@-K.V5=3@'3;WA6]2%)WPI9'E+ ^C-A<986+58 XQ%MI]QN*<A;4S:.?1 7#]XAPE)/&4DMENP4\P#I&.2-"_"'VGDW>G-L=K>LB%S$ M9I)&D?

C5$PXWG/#4>EW+VO6\O";9<,,[>_"<5_'S&437[%GE&#%*]^\S1[5 MRXQ5=Z>:8CHIT<441E[H=5"B@9]SR!\Y ?YX-E^$Q#P>(W3$DLE-9D?+2P8'

M+'"*=$%J'=^9BT$[88[8<;;Q8])J=&'4OO'B8Q@[_N7_EX?_B))D$1^F:<7FJ2_M^O-XI^%O/E0S#P[@/H=(XC -;>_"'*+NUQ1 >-+W6,0Q+SF\V82Z]G$@+B^B=NV/):$#L

M-S?R8B&BEW$XGS=-?I,OD%VP@)RXGIP$W>YV:\C[?O=@-*@LDD1:0N%O&7D7?1%,R_97Z=Q$AY0I =<=QT4L-L]ZSGF^(RSQI)CFJ+NO M"I/HO

P,R5[P*!I/!65>A/D/A?RXH M[" CYTC\>986X2ZYN!N:3X[H+HR>'1_1XU*I MO)V6@"!?^Z?P=L/7$+]NJ*HJI.S>*5[SF>3X/KM[M$U]K!>W$U2UKG.'!6!<

MYHZ9O%T0M"A;BMY=X]WN#Q="L_5Z=IW8G:N2GIOS[#G23@<_?"$V*&LOP7X M3/;>D70*OGU>/Y:"%E_1]L&K#T_D2.RS$E"PR3]OPH/C!;U@K4RW!^"4,LSI M1

6I8>"U6>*WK!U)=URK)DG_\A)X6!!DQ3Y/"=_- M 3YIV#%[^_SX2'<9?T&'5Q0U0.*/L5>VY)L3;3?X Q(V5Q\#A>Y.I:499SJR MD.PSJ*O/PH9IJ-+",JMIRZ@E:S-

#&OSEIQ@%2B?@N\W_%YT:K9UV&L$4PI\/<-H)!/P54F1RR++##,"PIL,IY MZ1D?@#"LEN;Y-4S0+P[A"4F\CF@9_@[TU'4]"'C@'F5-'WA,(W>/1Q#6-QCQ MG/-

%&-84#06ZYH+KHZ@N(@3H#!5>\%5E7@96%77_9(1\")P)-7;!:@:0$M> M:*Z(6JR*')"V"KX(?'5\7AJJ_R)"(/M>WU[&AD5@M"/1"0Y@$<&E2N(S8_M9

M!"ZY=LM6B5+C9J,IGO?[G M&,L6$<_>![M=K6N+B'4W1J9GV>C&BXFW'Y^3U4&<8$5.Q"IOXGV0ET?+'BP:

M#:IP:)%3\H7T>M/U./=9"09OTBDQ*CCD1=A@^I5@55+1>*8$H)7AILB;)U\>_M+N_B[!5*1)'?E&V6M'0N,M+15EVPH/>"8)!0W-S'*-QY">EK;0XA/1<'@QS6

MB[ZRY?0H;T<#,;?1=3@.7=K$2_I.T>78;$_[-Z]WL!*[BH3T;VWRU-MW7H,PHH$X.#\7?!OW3!L4)GB1V]FG96;.(MZRP+\LD@B&1*/MUW0I,XEJ<56-L->

MVJ]3Q&62T.WU3M?^K#'1L %DE6SVZ(L3_8:2.\=EX3-"VZ]XL%E4QU%203/^ MKQ+%^#]^?2(!]-Q=-G\==5M?G_OD/)-Y^W?Q\<8AQ74?[-W7W+QN!&Z%$NX MEWR.

[6:0\EM>&V.U.9ZW]? +66$[,HP+Q]M[++[!TXA6\2/Y0\(:.WDY(S%NU MYQK>M3[+V/-KP^V;QQ(7\^0-,;EPQYEV#(>QX[D9MY)XA#G# M@' $F?

3;'FCZ9IWOJAS+O7D^VIUXCS5 1\@^2@O2.'PCR%"?7F$!/>*NTS+KH M)+3FVFM=[!B65OLJ?S=,/_@AN$N)1IG=?\.?.?20TI="C<(7T-/#(IRHL4&<@G!

[V,4OGN85]Y.+S': MW@=%F&=6@<$3MOSLL( ]1E0F_K.,?Y+@C[8BUB,8;;%)L:?XZ]W.Q01#D_3 MC$6,ASO6HA*L&L@8"[F(K2E8=AY$9#L1CVFKUBPRN^5-M

"3]^?:,[F)=THNQ?O8Y#%NQ3(K']C=?I%EGM5N4 +0GV$MVQ;+ >M

M' $DJEF@P,FLFE=A%(7?2'-0YXA_24X=8!,N8;7]T'V I=*4IF>@Z" AS.0 MU.G_@)OP69#48N/J.8"@HU#,L M>2X?CBXS+;Z1Z.AXV\

(T*7P*&\/LW5O/3[$.@DK9271OVP/M62.#Q-NV]G/[MX?HIUK)8"\3#,/>A$M(_%LSSI, M4> A)WCA>*F7@8KFG6KA:/;W1\)?#7JN*5?=CSQX_*E[X#3<:S&C6]TK'_=ZA

MD_C<+^&Y?O8:[8D)=1$DUZ&%?2^,+P*)&F&6C4K*S8"$1:")&\)M5YKCQHB/& M[*<,AO$+-1;N\S!O+M_@Z)C*,5'"**V;XL>)V1@BU000GDS*%A)SQ%S3H?]\

MB**XG/DG-1G@;N+0H,M%55[4ACUCE#2N2=,.;HKUGT^C"]>_<@O2$*T7YD2+ M78+OC.+R9X;+ +VQVH(S)V>-C)$LX@YT,;P3G((Q.WL&>YW!K/NNF$*+_7Q MKQ?

<:>!.-P!WB)XDLV*-Y\;Z9@C^Z4*M,FH5AQ!G^/O'K)^@\S'8(8(YP^C/-M%X]4OCW\<.G<,#%/9X=Q[''BM7,,7DQC,@P^]{+%HY3N?9 ML]$4JGGQ)#GFYMF/<4A]% ?

EYSB]*#K"&G/"-($<=R/T6IP@[CIE*N2HO&@P M8,98KD/[^+0B-\97]GJ,2XG7N32:+N MQ0ES ;;.\>+:.%S2%^207VGSY-GT;RIAW>"O2&H*

<09.S9\N]W*-1X]ONEM)IYT,B>DE,IR=Z]?_4$D'''&K]AS"[# M)+UU4*', ^X"8P(1IY9VG6ZUL4>[C)8B0XWN_H^UGQPM(AU#ACVUSA:SUX:!)[YJ38$1-BP7CIF=

()8G..I_HDI'=1H65C&PP:)!* MS.*[LZ \SVX">B79N(G366-+]1CP:6GN1*1BN'7!? YY.S).P\\I608RI->E M6O[F,A#-.3D&+X:4 M#F36ZE,17OQ0R1R3!-78N MC$C!B?

I)K@YAE!#>>AW&R943"]V_G9>!"G"9)_TYPCRR_KI39;@$8T\SC!1 M3+(&#.4_VJ4][NQ8A'W9$F^H&+T+;ZX@S(;-8 MA-#6C\ DZ)JG:/;$_^?

74CZC967VH8\ACIE=^#&'BQ4?%^=Y3$M88\ IY+/&-M()NMF2IGP(JIK-)D3R+KA.U.%9-_;-.DSAQ@JVL Z-\%@RFPZ>]1AZH"@7-M\?

CW0U.-2,9[\"$RY4!:O]EPY$??"4C5[WHAYB8;J \R'+^]^19N]F$:8R+# M8L/F&\;6:1V@^V";NM07F#V)>!/B_NS=%['7V;I$JZ'Q,KIT9M@#

M0]7/IPF5,2+8#,3C88@O:5+1+X/OOB=WMB M8<,9)41?&V*/0/+.V.53? P#U.BNUJ0-Z1S+Z53%;]ZHKUPI*Q" O:,6V MXYE

FT/!;%R*=,%@JR\M^G=*"/F=DPC&>6=YHR%M7\[2A>/MO;*EY"_EZ.UQ MESH.8]5Q4&L7MT3202@@,D.\>HL0JO85D^H4TJFC(O,Z#.+0)V&D:'L;)"QP

M@%^(0CC4^H:Y]U\Q>$;U/99E1VWPYY^W'T(F8XP]>=AVJ- M68;WR6_%V=X9=]P@.+L/2'DT[QT1/:SR(C$3%_Z#>)/=%C"\>TEO^/9.Q8-G M6*Y&@+#'*

(R/R$W2>!/B7W]XWB-_)T:9;+CY2_']!5G>2B5)HVK.^1U-6 BUFO.)+ 5:TT>^,W'2"6#5ILO MY2\=Y0#5$K9UDOX[G_2]61U6A4:M]!WI2:R-

N89I5>NC7'U'3&M%MKKWC(:!]MRHE)SMB!$-DD3D1,?:0GJRG9_\I?4:.FD4+5R (& MG&F4"\S/9156[G=!WDO$!/HXG[#+]XXS>O$#'/'6RS,R^VTR=T^?RRLQ_KV

M T6N%R.*WN+'XBW]H]/:MH7JS)J-+Y7LEVU%+W/+(P%DC32>F,"--*RBV0)M.I.J2T"7+++"V0Q@^;.M702:%&;=CD&\BZBHU-&DRJ;1(WT?=-+5%8*WCI91$-

P[18W*'"%)S1N'<|:9]+|_.M3YQUE],>2KDXJF2(+]>3I#G-)-#QNL+"]RQEV&2&K)\62UP=LW6'P-?4B4N MXPQ5_Y@UJO29E_F4Z0N"C2!8G&"=(?

CG"X(`2,?.0SZS#GCIAEU^]>.J7D[M_+0Q)4&S[$T;X_">0[:.&<]Q^*K9MZ4]$P'SY'TFSMF9LO.XY^3D&+X:4 M#GJ=.}&T&RM-F!N]Y(G>C 3R<,)3O%3G,8K-

_'>]8!3;"0UDZY&5+Q3=%BH MC[%=H\5"D6=[=9#R(*DXB5)!]F\"3*=YVM(>\2C[3 EI3[_WQJ*2^;# M>$P.9-8"^3J.DYC"^%]!4=4Z_[_F4-<0]D20XSTVRIJ8O6!"-GYY?

I%THY'/@TH#0X!IF MY-PB]FLPVB&/Q#&2EMVE7BBL/#KF%J:'Z*F))[_^===9(_@71N@[;U3N*L#)/-M'TN2P7GG>!'UA-G#OWIK,SR8NK0"[W2Z[F^&1U27=^_=4=?]S?"

{@\FO//I-MM+D9'LXLWIY??P9B<^X8MM$PWBVB_L#PSN[N0NT0B#^R*.G$B1)(Z#=C9KO4 M3QHL6.L28C"R!70(O..'ZC6\8%YA&C6:@/HSPWQ ?*=]:J)CGNN@Z8;R7K33'-M[I]FSGP'-#17#TEAE\U3$F>.[1&";?O8?HTFA,+E) !X>-L@.TCB'Y.>;X,+ M^ONKZT/D=P'5:@"<3&=;\2*2I <3&<+\2(2C <3#>[\"75!MH+\^O/P^3G MB-]^"S&O3_A_?I4&OI*_9+@C8NGAZ(K,.3<.;PVWY]*91_PQK]^2@!8&B#Z.HZ2R2?Q? MY09)1O^&7*CU[C[8>N_>-G5\SB[%X^QN}1^^X"6|)38(3]|KU M6<$>Y(7#Q45HQ{(1XCX(#X%V0QH8$A/0S[' M&BC\-B6-O3<&;0;D!TM!4_MA+/#LK}EV6L.PB'O{@=R4?.9ZC_6M@TR\%0TUO2.19B/9F6** M/?+0!Y)$)PN!MN:;;;^\|M!MV/7S=O!W-2/5<%(DQ+QT_J#9&"NCBX;@'N?1; M;+(,N6+_&I@K\[YTR5B|)#%U?0&Z]0;BO >=%K GC%%/19Y#;]HZ8+V)KL. V6_Y M,F/W^7"9FN(QJ01>#/QL\;YDS[")(FJVQ\R+49^4)8A&VWMU?;HNVO(/)5-F M1.^QWN11KN/*Q:+M._EI>DA|JHDJH7<4I*CKQ52N-"P\CU'XZKS2AF?K'=L+ MO11E.1\-4#06&>54;M#.(R55WE&K&[7N<8B7F\ZK7+DN\E'$(NK+F22ZWC2O ME'UJLN)'5B6-N+8:;N@G1"1;0CUA0,V@J>-O4'3X82!1I,|.)HOV2@%.36!_ M' CM?79BSZC<:KW$WGQ)[R6^P;GS.M/CC%^<#]+7LE"9TM?8C3QZZ$^T5[%9 M]GCZG."\=Q)K@YA2A_O?,.\J\1R9+1G5]4(RWX,\W/122H"9""<3\A[=#/:U/DDE!M96)9S[H]11:% +*CJ:Q!P_M 5&Y MQQC7$_IC.CK.E*M-3XPN0F-7&-I#8<1")&&ML$"5%_<'I7:Y&MX5WQ_.)]H6% M7QI<8/K"J3XW/032_\EL+.RJ2>G.U"=@1-#K]WMM1PY?BA64V.+']\X:0\](MX;Q16.=8W5FC318)SJ.D12%%$>NL.:! V)*H@E>K7B$>NMQ^1QOW.'5O\6.%+ M21[%O1.7=A#$,|^=CD;KZR6HN#-O"M1*3]AAN5O(\ERI\XQD]$+*%P9/+X+R M%"J0,C!W$87(#'=0-RD1"->P^R/1J37P7*%MF>]>\EC_1=5.3E8<[8#P_H_7F MH**N0\-S@;%/G&6@:3?CE9GDL_L6SJGI{Z4U6"7C=TC2,ULZ#2IM=Q3VI06H(MA8$BK[$]:DK2;"[5-#F<.ED^ZP*;"7$M.FM=M>V:*7>M(FCZ!7YN@0Q:.G>P0]LDAS M7Z!17@W(FSH>MU:FI>.HGK?!54^B&R#+-4? OO#UBHI&O)"\VQ_2\3;S#8UHK M?39'IKR-.@-SC68F:H[4>1LX!D:J(-DWQ^V\5>\1N$,U0SA'ZD7=.R^[,,>C M49UM\N+N0(G*,;*-:F>31_8@"GAX$2G#._ M7K-R$^^=1"\/L/^4F0[VC4SX,Q>=7I& MMV.L2D!?LQ_9{(HJV>S?8["6%H& MV?"7)HNVA5.['R149Q"T@:JV+-41JBT7,]\/$F*E^T*3I15KS/S7OTT7:17G MX:.|(:W|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{54AN&0#.STJ'5;MBPY23N2[7!ZC<+)F1+0]6?X5[FT4C[,; MEA8SS4KRX,B^C=95!EWO&%T/D;H+B7B9H8I,4(%(V%FY%4:?/*QJS<9AB;8 MHS6<0/"'=:X]&;8&94TN=+'YK.'5/Z FVM#4TL, ~5ZV?-H#I8FLJ.IEPE8A%HZM". ML\+V+UV%U8K<(AKA=KEE(MUR$8C]U|B)I[D.TY9MUFG=/4^-?1#-;HXW#AFT= M"LQA6]0?S"[;E&L/7CR$4#R$W$W)G.:2",' T/2"B";! J827=0%G.HT:P 5 MD2;!EFEV7\,$E9Q.X6#3G3T'?XUH+[RCQ<)\VJK6IQP^%S=,)TR):AMJ39D; M'_CU+\! JH5]%S\69B1 8M^:XU!,XL,$U FQ3U5@, 5_=;IKW@<@GVUY^ MZ&T^?5 9FF#K@+(L1'7W*-2>Q 4SU.DH5BOQN!! W\?7,A87:]OKYNZ'T6!E M:H5N$6ZB$S|F3.IJEQ6;>T4M\[(%UIL'<3N 3.(SA#ZUIC1$E2N@\[J)FZQI M6ABB7M4L:.. ^26,11:=&NO;__C1DD2@>*X783Z[2IU|8FGZ<OEW29)0$1TH] MH8U!ALV7#,'W&(%!XKW3MJ>;;^%F'Z8Q?LPWWY#_SL_4ZS|>E6W6[?95'GM M!P'>T_)&73M'+W%\%F,CO%XB2VWG=6 9J"^!%!;9G@3YM2'V6$<9@=6[.)IF M584SU|>&(K8'__)8=;'6-OJG+[X3B3(0"D?!,D)_^$, ;.YP(P#6X1-ZB6X M4TR!'$Y5)W28*MEO \R*<,'VV;H//%PU./ ^RUDKVA$=6.L >)6T6(EX_'`-MLLI1N<8B> [!-74HTC"MI'X,F(M8. @OK2>2Y^+FBJ'T)O"1^>GZ1'H9\CN$# M*?@-O91RO O'PK ;\;E687KKHNUPKEJ3GNOV>*Z]I^+P/8E=*GK/18AIWG/ M%T$^QO7E*D8;FN8B$#I A5!S1I2(@S 8?3%O1)TKV-0M 8L(6!F47=8?]$'7@-MTUB\XKS1I+]I*L/#(I*ON79M.^U29$.L'+=_FO=C,2CG6W"A!<75|FEI'"*6 M#QY)#FB4KE*GQ.J9X_ER^?M??A/VHD?0NSZKT+6!+Z(-ZUAL0F&3SW$]B?*GU,9M/Y_. MKG>.%]$6KJU63=G]YF|TE1IU=8ALK2+DTBFJCXM(H"EZC*#!4 MHF6KX7K$A6,+ +!'5^WY08)6B+=55I$=@_JS?5;,.\I-.9VOAVB?]\'V. M^SB-V- (`JHNT8C0»*1H"N^CB_A2!K\A!AH.\H>@TQHOANSC;-,+#V!L M2 J"4,8IAB>6H&D)\RN?;@/_VWK75"%I^]]>)))|);UGS@=T'F*8PM3@)Y5$/ MV68E<7*R&=# /D\KAY7,N)=4,E%0;)S)&>=<=:;TF?>)<.7[$?DG-A"">#/M)505SZI"W"8Z'Q]&L@:!&N:+.O+M|;.93>%W$: SW| MM2 4S:=R"'P#5+VU!.B&=4C|&B^"6$=[V(S?BD6X1SM3MJ9 -A[R(/]3"J-E MA>HKH2%3M")=%&\3,? $R;_;-]^YM\2$_8=!-A\EK?W=»*/UGB.G(_&-'!NI MC2_/ ZU/?OS;7830?8!9,8J3L9#*_>XE,<)B8@2PK*)?$*FXA;8KK#LX;XC^ M>(.)I$# *&E'ZEW D/D&T.:'?P\7H2Q-Y&2:S^HB-"7@9_ FQ<105GO8OP. MK3+O"U*EZ6OP#!>><3D+%HPSC!>/|/#W'%/%6C/ABREB>*0-6>O^%QXD# M?D>0F0&SL/AX9*UVIFAU-=>,R-2-?+ ? QW.QO@Y=7B*UJ 5Q(V6_O\^,C> M0$DYV.:8>;'WBR?H%z F2>((NG]"+)VCX7]<7;Y#A.,_N0KDXXUHVIFY,Z]B-*@ M?6!ZG=;<,;ZX=]*0D-]5NRWK-K;TA47PVPF|AHOTP$^EC9?14X#$4"9P018< M!C'@Z4PH%)@]A"P:P.I(§)T6E;]B=>AC[ENR/.\DRN2AK7*L GX]+.9F^8 MU3"15=S,#$)TA*)CT&,4;E.W64=9\I2@>1!WV*BMC;(=Q/@(LCW$7 ^-:?*PU M6]>=%W@)>L!DM<4/%+ZH'I9&,']$1&#YXOQW&-$B/Q+W6I<5((0)$E'9";3K M*H:=)L^.CW5UPCR?PI/C)Y],>R(>;Y7Z:O?Y#V2;8E' RM447FWKL. :O^;.M$#[-A)>A1&M#A]3XFQ2DC&$MN$CN[]_7G^.PO2XNA*?5'1O }OJ2&:L+E<8 MOU_#P!7\O,'_%F.D$RE#SWEL[$-3I.JKDZ)+DFUK:%F380OI%WHOU%SR?IELZ0@-#1C|A\7]JHR!% M=UBORHG|%_97Z=Q$AY0=/OA^NG6"|Z(>(#_;[MQ/H27J? M*UL!F:@;9C?RQ M5X|W_*;|])AG5C979+UB0 M/*0'WLZDXPWO[=K'5R@,2F2($28:.@]V6'\9?6QEXPWO+3N$51"DCI||.+-B M\+8F&VZ:]H^[""',C 7)? MJ#.^.B/(#U+H.WPMI*P.\I?'6<;'C73;O(]QW6))92_+ >M&!+#RIS=]#'V.-E4[:6=CR*QJK5I&O.(1+;'!S!I+9QK22OQX)K$6+0*!18U.! M5HY%9Q'8',XRI*Z=U|F4LH@3,6I;X8=9F3OJ19S($":=^NWH80E92).E.HT98 M0RRI^HPLX@*<(;-HF+T6$>@VC-0BL|BM JW#BB]B37KN88%#/7D:%MU%T.TP M[$!HCEY&L.0H]DPGT|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|U6UL=#N+'Z[^-CC/'2]=[4*JT."AG MH&%> ^$ |*'GX2;GR0OHO;MG0M\W]QC-!H+)Z9Q4>5.4TPVC^3R|.0C|\.W5Y M;-238 A_NL]^$0FH_0 OPL)YUI-=;XJI_P#.&K."1S-O"MAXN):BF;1M1:. MAD"##P #ZD>WX$N2QW#61-+U,>7WI>[$O1:-3[%& (F+GBZI^V%F>T)'N%N'] M.UN2:+P6<^^3.[3D]="|$CB"R]2]9?,]C3', M&.&.A4/M!S%EE.TWH*A&VI.8Y_?Q&$9D7PK+B7"X11.0&P.NYWN4) @O+YM6 M9CC>A"79H*W,YMUS,7O LR:'4I*KC[%\L05I4S#0WJW_P^NMMIXT7C[UYMC M^X)++#V'ZZ>DYAC)*,3 AWG-AY!M=5_)L(G[*4ML6/3>W^"M^"$M#IT=A-BAH)QC MLYD;$8RD?+4^QGB+P=CQ7"4&>Y^YX,\.[^%KF$)ZV>>&NMPPS1/9B"[70_9=-I9QTEB!/2=9' M:3H.S8O3#8ZA>_),MP+#F"GOO.0AC&,S#K@>"U\\7!6?4'T^3/S-8MLA^G^^+VMJ/!%"T.!1Y'-N7C!),@FLDTA80K06Q)#V@\LV MUA7WR07[C)\M7Q,=:OMP0L\\FGWCN2$ZOF9/MR5U/L54E>K?'V0$CV*#KK MD+JL8/7N:AR05KE8|\U<7*3F7;1|)/8Y6X4O'L%N=]?^&M|2?0\7WVI?WZ1+M';G.%*7ZQ)(>D8NW=3SN=W$#C7W1&YKL(MR5%S?NJ'=Y*&*>NT-S1"Z@J_4/ M(@7)1);IE8%YB-QJD)BZT2)CHK]+?6L1=75'EC.XY#U("(=ZI142P%FN7>{E+ MO$3G<-&.L(KVB7 0&N!2TC\):1@*B%E*#/3)F5KV$S*Q-SIN3TZ#OX^<^O M[+-]3CYJDOB)1Z)1TBKTS2U<CJC;O1& 5AN_(;T1H'Y,6HL7F6UT#VK M&0Z%N/, ^\.+TL5+&0PC'7J)=)"1S'|SC78312 M-Y= H.$EKDXHO7M*ZL+R)N1:4MK2PI&T.1// M5#5(V7=HL2W&2*T;YD>I1C%%0N2:(Q?1>?QLE#6P938L"E[0#F7'N_T[QPK?O ME,.+6]$"B,_IXK!T2%>/YR1T?_OJ'/"_ 5KIRR#V8ZHF&G1NK9+-'7YSH-Y3< M.2YMBBQVMH@'VW5Z7(>'@Y>H_-G*

%YC_R=^#[*AD-!KC32C5_6ZM:|K>=@#;9D MQ K"\YH^'@GU!@VW>4"@;5[70%0Z'-D!+T),#\" -+;LARV]+.(7R*1$E*%F&; ME8DB+<6(_+/WL O%0L:9A_^ SUW+.GEPN*R226%15PW1 G(.C%^-14 DT- M1QHL?PD($XE/"@8U[[E73%-A]0%^?@U24AP -^N'=)%s5^BFKT+|']\&MLW MH6DZWJ*=%W@-PW'#3GN..?D)_T)95O 2..G62|#V.L0K!S'|E\+W4PR+BW10 MTE\^V.:$AH'9XUG>.R(N/;1Q_B^E4ID>Z#]|#NIS:$^R-IF;|S8>?N+I%NJ MC+W"Z"::9.//\|4C-_0M_XI9GY/Z-LND6V!RVEA;HK-2.&^RM^R2+LD?L.M0V:,0P%U/+LP02B25/3L_(3;'&:X(OVKIOE*/.JB)/&13K'NH2N% H9I ML|NO*.'ZL?/OB+' M<5_CY 3HOOS-]DX/_+-2'I/^2X WZ'N_H^U_ACZY7OGY-MK0/R7%>1%^.?:0!_'E\,P2S<C]@Z^W.6BYI_#L-M]<5x#DMMH(S"R80%]"2,M.A;R1XP5\DP>(4)8N>),2M_M+UKC!(EONMCL;G43A3@<0-Q M$/.=R)TY<2>*Q^FN6//,W&\],$B80=T6AKV_\%>6]|DNOXCB_>&_],$FEF MO:.,B|=1$B=.0.1/V8ETGP,]-D1M';,#5CA*AOP2Y,OU^>)>>D<(-OD_R:A MQ&C[W\(GMHF^/LCUOW11W+K4W/C?_PA2R,1&>P+R|<7)'_>>H?"N.X1?Q M@$F]9:3E)MH15E%0;XW)KY6X86+G^.7KK0WJEH)MOC04\H^"0 NMJ2"QX!(/ MV!P&WVU&)K)<NY;T/@9GP09(!)CQTIBST4A4T+A,/s%2%5!^:.B8'7I MF10K?2P|$X<3=IFW2]BV(93R/C9XV4C-WU%WQ?\0_%\=.BH#1EP#5(P9TF7 M14:8:\,.@>ZVI&990)$982>*@;X/4\,&.UQPS^^X%MOPQ+$0#..16]"'P-B/ MT/BSPH@=]<1STND.28_@0Z/@+:+)+0M:0/@8R_0D-&V_(^!-A_@P8VUWX.!,_MAP:YLL8 @_0<.#H7AI/3_@ 9IPY,R!_P 0X9A(@U12@%%$)SAHL<%X_CPX M35/H_AH&?' "HGC2$sNGV.Z70TVV/LX3M&VZO'Y!^Q2@&!84&#_T\$)5+!,(N3B9"+1J$9B>N!>/#U TD@8T.OO>2_M0/4,"8G1#3*)$L3R6^$T6FM$\$T<-W"P3 GE!0V!AEA/B13&%=44)BXW MF0CT4K6Q_B3?RG.,:UTC)&:.,9=/W6:$V0%&7Y1TU"}108RC@R_H*(HN(FB MP!0S$8?802Y>,\K|:9@_(.C%)1A5)"KN0[KM(B-Z% Q0M,(1-0E@!1R9>.Q M7W&.X P9.6.(P|(8W8F6=3:%%'T'PIT0K.9O"BFY<|1!H^?FDZ:#H|0GD(./UC M.OB3A#0@*0F?I%.9#!'2@RAE$5+OB^*N\|'+A1563#W(+B9D(-\HJFIV7^,+J N_&Z>9IVT|6(+(^$6P-0&!6OZ%/PAG)B1?\VBH M%>(-") (F)$2W$P8&P1L(@%ND)2.$A.K5!%UEG|!#OF5)OK:K|\593.M\ZE7$:*,U!A|/B&L1!H:XS5 MG%ZVD|(O:6Y_DH%_GY-Q<4W?(%^IP0F+PRCGCA'H|1G0163F#D16|**%3- M)$:NK)F!O>)#K?U^]_>OWH"2+A#C;_"S);.)+!U4*;^X 8 M9(3YR)VG6RV4.)C)8B0XY(&O1^OF/I00)$:)4T4#2D $8ZQ3!-/7C%8]M<-M!6H|&G2C=)%4O8+/$<17.ABT5'A$=4<17.ABT5'A$=3%)35]92HNM #.3Y!#0^U.8-#-6+ (0N*OC*VY1C]S7%TPY%10CA'710*U13CD>^)S;."P$Q@!%T+H5 M$FKNA#Q6S2YZ)'1Y'_H8I3&#K1+Z/D#$%/%-ECNG^6F?&+U!(<&&NO)\9KD%V-M='6B^^,YQ?1EV"NJZ#L!R9N5IH:H##)L>=I\"S?L(V=8(LEELTW?(%(;1+; M>INZU+K#2)EL0MR2H/LBEZ9"ET:+TV'C"!+=$SX01:H'CCFO*BKPEOOMs,#-X\>M>Y\B+!:08HYAH-N@C5O'LMNGV(WT&ACK6U(G>O11"1(-!U%U1^?0.!-Q<=(M@Z>]<0 7&.LIZ-\N8WROZO KT6A(VY<_IL+QTP?\/C%5E%BI6- >=PD)&RLD M3'W;W1)Q&-& "}OZBU"2-IE47?|L.B\#H.X(D!"6UQ@X1:C00Q:<*AUC?, MY0.^P5/O:0.?WNGXL$SC\T6=I0-XR-RDS?>A/C7'Y[WR_)-MV1[^AYN_%*]>D!+F'|2@?0*DWY)'@=;>_"B):06 5;.NLP>D4IX;X2Y.HPZ4|U[*%"$<5!?SM%)=+Q=V0U+P@=WJ4)26O+ MJIFV7^,-4;P.N&_G>)N:BBVRCB!+03:LRSV9&M7%UGO<8M0.BDKVXY >V1HK.^1UG7&/0!%W'R.5#%IMOI2_=)0#5&O)BSNNS$SG^#H.I^36|M%S#=_UO6. M4CY4.V1HHZ#7/0K)T9)XE%"0>RP2*V(&"%HT=E3.23+X5]|BA:TPBQ>)TF<8)?5DP.##C3^!-^9WHHJQ9 O^D:8+:L,NJ;=.MQ5Y0.1:[?2Y86[.U!0>*7"]$%^V+W%C\5;^D.7|UIYEN'!7*.M :3WDGH9T|$D]MU(GW=PA5B\2LWMXBI.8DZ#.6W>) <*57AR%;*NZCDR5(>=2E*[5UIGX.MR>75H.5)5NKCRN+KYU%SH)V)N(4>]1$(P8Z\,6=#T5E#7P:4X4LO#)8E^ QP"-HK-BO&\!=8TTE#]5#(H/D-MN9L$*%'1E'VG^<T+.V3#)3(GSY\:C0*G0)+)XH1K2WIZM]MHIR_-A%:G9WY@ M1S2+0VF:ECLS8$<$QE!F9;L#1D3QVHIFCWB2)C/B7?QS*E.TA#!B-.!U7I-MG@#PP#1HQ9&B'(\U@TTI4I6.AD@4\+T$SF'"4MDXDGW#PC9D.1O@(9(4.UW6+F0.#&'*=%N8S1P3VE%=&ME$DSO1#A:*)'?Z M0T:J(=4E=U1%3HAS||9GY!+ED\UK4V1Q.9!1#=P2KLRQVIB-&^.630(=.QA0V%E?.M?S+!$*@:RL50)*\!HH)L.@@-(.D!%ONH2%+,)-AT$/Y&#4:'P'[2#@0I*?5LW6'+1<)+6##AF|$VH;)-L8)0P>##YTHD;9 MHQ.I)[A^^S-$\6(X"]2-K*&X,/GK=@=2 <9**'U0 M!)HASP2-QYCEX[&-.+]=V-N87[KU'N>&OR"-[=='O;(S3T#!$\ACO'B!^6 MQ|88M7IK,SR8.A.%=SI=|5?#(ZJS87A'U'5 ,;SRB"B^'=e5Z=-G>)6P8VNVUN M+W'+#9 9!3)5 -%/I84RCA$!?B\+Z_(@H=)-)IY8ESC?.=L-F:=.>1#F63 M%)N6CXEGD(QOVEA^?VXYMHREA)6^L-X\)R43C+&^.(6 MGO#__"\72'-R:!WJK#T0I/U3"-WCW%)I-?5=N1OK.^?T1=@<6/2V$# MLF;M%S|AISTZAYFK]+KN[UQ#K:)1$B-2&C-H:=>.EA-K^_->M;=@:F_ MLIZ<[!C#/TYMI!XXS@_VT4&0ZUHXL^?3(Q_OKKTBI)SD2V9I.M.3#RZ.9(B5ALUKN"#\6>_>V]>.++FKFCS.[L^.\9+|F?|9\[fWC)F05.R?A-MS=AJW5!O*:Z#;P(GY2W15?OH@+H4K5%$- @.G4IFM.Y$#$-52I3..2YIL>MQON\N4?2U\6VG*FZ$(GC2!EAG8P)#2HG5.?$!Q^*E9X0_%D)O52H39NN-MARPI5Z0\.+#ZJ^D(:$H.<&\!?Y &8ZI0Q+FYO=?=!M<+&<5"N|8^QIY3^(.MT|++/>.:\;ZQ^ 2#1U!2=(#E1EBBDCK'ZW6##EI&?P$EOV%:5DWSV48 M9.X;_]IWGW^]<%(&6[2!1W;/K@=M50%IE&+5]:35>&\'/?X^D?(M!30/RK$M0%$]H6U!?^Z6MC_0[^.JR9R9KK/WDBT]JEQO%]DO>1.GI>JG M*QU?EGW^=#N8V!%Z[!=0VZUGB)?92[<%WB@S?6-&)T#Y0)<;0 MWVVWG2D5$H;_-.2!WN^QC5/F=R"%F?Z&KN\QS9|52XX&I<-[(CXWLH|+YV+ M0Y$RT5)O^>_:AD^9K44*@[?.RVY'6B*QW'_]Q. D1HKZ@_8=KE9#VG?\ZGU!!4G[:/ MG>RW.N2'3HW8WUB6OY.X2U5CH+I+DBYW?.!1+E8XUMK8W$ ML.#.YU5+TO(HOKG=WFO&G>68F(.2D/0HO .1K]?.XCA%U^M6KU<'<*WYDZ+H%+4^R4B|5&>4O905LTKWU4CV*M564_U=Y7G%CALBGD>/3PO)- WA*218%CRU/QKAYL+RFKUS35SY]|(22HIZ M/+_KN3LD4|JEN6@BWH2)X|=OLOL6)CR9]NX5Q@_3-WN>37BZEV:.)O7W-6 M$%-)UL'E/HSRG^@X49WW4!*YW!%NV%I0A2UX4,@M)1X M9M705UE.D37_9L)6^NNJV5Y>?A^3>YIP)U1EV0\?!9YB_-I, TB*TQ+V36 MHT:G9TMYPJR>9.9)G>_#/!;X' MSWGE^A5O0?)GV%/%"*#_;S52KQ,?^2E(AM.*M-CPPE-C7+2+&2G!K9*&Q@@2#,_MY';96!F%-7F3@;2I2:13?99+B? @&#;@YEW2IZ)'OY9CF^V+%7075G3&%A?M2$ BOX>U+;8'$'!@GCHTAU<'+VYUD:H)A\E_-C6I.P?LQ!O@+D[@6AL7$+1 M$R284:GG$M60DQ0K8L#5X=,$5K2L%+<>DEMJ22-$4OQ;9L3(3 MMO1G $^/C\>LAZU9.Z%+7;'Z_J??KO7M;.(-K8"!CDY7V+UGQK*@ MJ'@C/'>,U)WMWSZJEB+}2|5>)J3 D34C!!O^?,@.TIX]=. .;|)1Q+5<FQ M6'O.O{KKZ%/K_%/LEWZP+;.^/^TKKWX]_N(D ;YB[_2A-HV548+EZ(.5%F9AE"+FC+[TT2VL-R4Q755<)*I=+E! K^BRZ$9V!+OO3LIR:Z_WOHRZJG<.M^J+M96_K.=!Y2F7IKB8@3}>7'>@C#!R.E!%.^IXDH @H\+|&<DK>.D.<\14 MD02-O|UV&UA<!+C=#.\V5.DGFFO4.[22-L6MGE_T\IDUE6G"!>.K\/MC>E6,\!#V/=XZ=@!PQ<0 MOB++[.6^K0Y>'-%.^!#H/2K@MUF7#V^'2[#.2K$N MIO^6#T0+3]2L>=B[+K$YB5D|HSVONF|#0%.< 4E2^X6VAP846I-2X;<@1'#U MB0[P!M5ZJ$%,I+15KQ=.A<+[,XBVPTU?EY(E8K$;O.?EH8;=MX.KK10 M:7A>*&&DH#!78PT^PC.?+\Q%%,[7@; T.V1.A; CHO /S]OO.OEZ?2\=M?:!0|> ;(L'Y-HOO^3O]15]05YE#&ZFK.XT(O'&P.!>W=']JC.,3,/"?7L MDCM +C9>8&SC070E8s00)CV4&E] SX_7SR]2^!7/F'%=FIC4,&BBBCKW!@ MU_GNNH>].#H%/4Z5F#5!-O496(B.V3:D&B_^9&0H2A2OM:.1+E8XUMK8W$ ML.#.YU5+TO(HOKG=WFO&G>68F(.2D/0HO .1K]?.XCA%U^M6KU<'<*WYDZ+H%+4^R4B|5&>4O905LTKWU4CV*M564_U=Y7G%CALBGD>/3PO)-

1C5<&@ER3YT(AC6)N+WBG|HW_QACS;@#E@GDC-M38:O5$*&|%)S2SC (!I\Y==,>&F9TP2(%7[ATP02C\0.^UBZ,)7""GX^3,Z. MRC_Y4WW.8%AL@/(]B)U?Y) <+9,9Q7%_"55#]YA@5X], .+\T0:OGM/3.+C0-M.$Z>{N:1M/O_?

!#NAZG!+PW0.$WQ>0AIM^)6CA0N.("R1K.Z_M.F. M60!S&<-6PNP2LF6-HQ_B.*51<-A43NYOO.C(E 0U"IP3H"E^N'#!=(F(,.6- M!QBV"RF.9T(K@.0.3O6A0T$.6(ZO-&)76R4>!1? KR"!K%"BZ$.&O?P45Y!+$] M.)8SMOZK!QN^S5OLM\^"-66-%/%'G4S'0Z86 ,'VLC.+ -@.M3;)D%N2_1.^ MG2G/H$?6O.G>'1A0$+48SNY< 4N-1.6.1R)?#O1+.^#B5.1OS=.1.6.1R)?#O1+.^#B5.1OS=.1.6.1R)?#O1+.^#B5.1OS=.

Company is exploring the potential for combination therapies using FXR314 and currently approved mechanisms in preclinical animal studies and the Company's IBD disease models.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's second focus is building high fidelity, 3D tissues that recapitulate key aspects of human disease. The Company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. The Company believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As with the clinical development program, the Company is initially focusing on the intestine and has ongoing 3D tissue development efforts in human tissue models of UC and CD. The Company uses these models to identify new molecular targets responsible for driving these diseases and to explore the mechanism of action of known drugs including FXR314 and related molecules. The Company intends to initiate drug discovery programs around these new validated targets to identify drug candidates for partnering and/or internal clinical development. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's current understanding of intestinal tissue models and IBD disease models leads it to believe that it can create models that provide greater insight into the biology of these diseases than are generally currently available. The Company is creating high fidelity disease models, leveraging its prior work including the work found in its peer-reviewed publication on bioprinted intestinal tissues (Madden et al. Bioprinted 3D Primary Human Intestinal Tissues Model Aspects of Native Physiology and ADME/Tox Functions. iScience. 2018 Apr 27;2:156-167. doi: 10.1016/j.isci.2018.03.015.) Organovo's advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Using these disease models, the Company intends to identify and validate novel therapeutic targets. After finding therapeutic drug targets, the Company intends to focus on developing novel small molecule, antibody, or other therapeutic drug candidates to treat the disease, and advance these novel drug candidates towards an Investigational New Drug ("IND") filing and potential future clinical trials. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company expects to broaden its work into additional therapeutic areas over time and is currently exploring specific tissues for development. In the Company's work to identify the areas of interest, it evaluates areas that might be better served with 3D disease models than currently available models as well as the potential commercial opportunity. In line with these plans, the Company is building upon both its external and in house scientific expertise, which will be essential to its drug development effort.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">In February 2024, the Company formed its Mosaic Cell Sciences division ("Mosaic") to serve as a key source of certain primary human cells that the Company utilizes in its research and development efforts. The Company believes Mosaic can help optimize its supply chain, reduce operating expenses related to cell sourcing and procurement and ensure that the cellular raw materials the Company uses are of the highest quality and are derived from tissues that are ethically sourced in full compliance with state and federal guidelines. Mosaic provides the Company with qualified human cells for use in its clinical research and development programs. In addition to supplying the Company with primary human cells, Mosaic offers human cells for sale to life science customers, both directly and through distribution partners, which the Company expects to offset costs and over time become a profit center that offsets overall research and development ("R&D") spending by the Company.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Except where specifically noted or the context otherwise requires, references to "Organovo Holdings", "the Company", and "Organovo" in these notes to the unaudited condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiary, Organovo, Inc.</p> 2 2000 <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note 2. Summary of Significant Accounting Policies</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Basis of Presentation and Principles of Consolidation</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2024 is derived from the Company's audited consolidated balance sheet as filed with the SEC on May 31, 2024.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The unaudited condensed consolidated financial statements include the accounts of Organovo and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company's financial position, results of operations, stockholders' equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, as filed with the Securities and Exchange Commission ("SEC"). Operating results for any interim period are not necessarily indicative of the operating results for any other interim period or the Company's full fiscal year ending March 31, 2025 (see "Note 1. Description of Business").</p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liquidity and Going Concern</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The accompanying consolidated financial statements have been prepared on the basis that we are a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of September 30, 2024, the Company had cash and cash equivalents of approximately $3.2 million, restricted cash of approximately $0.1 million and an accumulated deficit of approximately $345.6 million. The restricted cash was pledged as collateral for a letter of credit that the Company is required to maintain as a security deposit under the terms of the lease agreement for its facilities. The Company also had negative cash flows from operations of approximately $5.6 million during the six months ended September 30, 2024. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Through September 30, 2024, the Company has financed its operations primarily through the sale of common stock through public and at-the-market ("ATM") offerings, the private placement of equity securities, from revenue derived from the licensing of intellectual property, products and research service-based services, grants, and collaborative research agreements, and from the sale of convertible notes. During the six months ended September 30, 2024, the Company issued- 1,352,600- shares of its common stock through its ATM facility, for net proceeds of approximately $1.7- million.- </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Additionally, on May 8, 2024, the Company priced a best efforts public offering (the "Offering") of: (i) 1,562,500 shares of its common stock and accompanying common warrants ("Common Warrants") to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) pre-funded warrants ("Pre-Funded Warrants") to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. The closing of the Offering occurred on May 13, 2024. The Company received net proceeds of approximately $4.5 million from the Offering, after deducting the estimated offering expenses payable by the Company, including the Placement Agent fees.- </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On July 18, 2024, the Company received a written notice (the "Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) ("Rule 5550(a)(2)"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until January 14, 2025, to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of the Company's common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. The Notice provides that the Nasdaq staff will provide written confirmation to the Company if the Company regains compliance with Rule 5550(a)(2). If the Company does not regain compliance with Rule 5550(a)(2) by January 14, 2025, the Company may be eligible for an additional compliance period of 180 calendar days. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice to Nasdaq of its intention to cure the bid price deficiency during the second compliance period. However, if it appears to the </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities will be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq staff's determination to delist its securities, but there can be no assurance the Nasdaq staff would grant any request for continued listing.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Based on the Company's current operating plan and available cash resources, it will need substantial additional funding to support future operating activities. The Company has concluded that the prevailing conditions and ongoing liquidity risks faced by it raise substantial doubt about its ability to continue as a going concern for at least one year following the date these financial statements are issued. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. As the Company continues its operations and is focusing its efforts on drug discovery and development, the Company will need to raise additional capital to implement this business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. The Company will seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Company's business, operating results, and financial condition.- </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Use of Estimates </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. On an ongoing basis, management reviews these estimates and assumptions. </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Investments </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Investments in debt securities consist of investments in U.S. Treasury bills. All investments that have original maturities of three months or less are classified as cash equivalents on the condensed consolidated balance sheets. As of September 30, 2024 and March 31, 2024, all investments are classified as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies. Available-for-sale debt securities are recorded at fair value. Any unrealized gains and losses are included in accumulated other comprehensive income as a component of stockholders' equity until realized. As U.S. Treasury bills have minimal risk, any declines in fair value are considered temporary. </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair value measurement </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: </p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">Level 1 — Quoted prices in active markets for identical assets or liabilities. </div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory</p></div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventories are stated at the lower of cost or net realizable value. Inventory as of September 30, 2024 and March 31, 2024 consisted of approximately $0.6 million, net of reserve, and $0.3 millionin finished goods, respectively, which is related to Mosaic. An inventory reserve of approximately $0.2 million was established during the three months ended September 30, 2024 to write-down inventory to its new cost basis. Please refer to "Note 11.- Business Segment Information" for further information regarding Mosaic's inventory.</p>- </p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Insurance Premium Financing Liability</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In September 2024, the Company entered into an insurance premium financing agreement for $0.4 million, with a term of nine months and an annual interest rate of 8.37%. The Company made a down payment of 10% and is required to make monthly principal and interest payments of $44,281 over the term of the agreement, which matures in June 2025.Related prepaid insurance at September 30, </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-

width:fit-content;">2024 of $0.4 million is included in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets. Net Loss Per Share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options, shares reserved for purchase under the Company's 2023 Employee Stock Purchase Plan ("2023 ESPP"), the assumed vesting of restricted stock units ("RSUs"), the exercise of warrants, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the six months ended September 30, 2024 and 2023 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 11.3 million at September 30, 2024 and 1.0 million at September 30, 2023 Revenue recognition Royalty revenue The Company has entered into an intellectual property license agreement with another company that includes royalties based on specified percentages of net product sales. If any, At the initiation of the agreement, the Company analyzed whether it results in a contract with a customer under Accounting Standards Codification ("ASC") Topic 606. The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the Company is a principal vs. agent, whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, sales-based royalty payments have been identified as variable consideration which must be evaluated to determine if it has been constrained and, therefore, excluded from the transaction price. Please refer to "Note 6. Collaborative Research, Development, and License Agreements" for further information. Product revenue, net The Company's product-based division, Mosaic, produces high-quality cell-based products for use in Organovo's R&D and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Company's product, typically upon delivery. Product revenues are recorded at the transaction price under Topic 606. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption. In December 2023, the FASB issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Company's Consolidated Financial Statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM") and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this guidance. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2024 is derived from the Company's audited consolidated balance sheet as filed with the SEC on May 31, 2024. The unaudited condensed consolidated financial statements include the accounts of Organovo and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company's financial position, results of operations, stockholders' equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, as filed with the Securities and Exchange Commission ("SEC"). Operating results for any interim period are not necessarily indicative of the operating results for any other interim period or the Company's full fiscal year ending March 31, 2025 (see "Note 1. Description of Business"). Liquidity and Going Concern The accompanying consolidated financial statements have been prepared on the basis that we are a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of September 30, 2024, the Company had cash and cash equivalents of approximately $3.2 million, restricted cash of approximately $0.1 million and an accumulated deficit of approximately <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$345.6 million. The restricted cash was pledged as collateral for a letter of credit that the Company is required to maintain as a security deposit under the terms of the lease agreement for its facilities. The Company also had negative cash flows from operations of approximately $5.6 million during the six months ended September 30, 2024. Through September 30, 2024, the Company has financed its operations primarily through the sale of common stock through public and at-the-market ("ATM") offerings, the private placement of equity securities, from revenue derived from the licensing of intellectual property, products and research service-based services, grants, and collaborative research agreements, and from the sale of convertible notes. During the six months ended September 30, 2024, the Company issued 1,352,600 shares of its common stock through its ATM facility, for net proceeds of approximately $1.7 million. Additionally, on May 8, 2024, the Company priced a best efforts public offering (the "Offering") of: (i) 1,562,500 shares of its common stock and accompanying common warrants ("Common Warrants") to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) pre-funded warrants ("Pre-Funded Warrants") to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. The closing of the Offering occurred on May 13, 2024. The Company received net proceeds of approximately $4.5 million from the Offering, after deducting the estimated offering expenses payable by the Company, including the Placement Agent fees. On July 18, 2024, the Company received a written notice (the "Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) ("Rule 5550(a)(2)"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until January 14, 2025, to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of the Company's common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. The Notice provides that the Nasdaq staff will provide written confirmation to the Company if the Company regains compliance with Rule 5550(a)(2). If the Company does not regain compliance with Rule 5550(a)(2) by January 14, 2025, the Company may be eligible for an additional compliance period of 180 calendar days. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice to Nasdaq of its intention to cure the bid price deficiency during the second compliance period. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities will be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq staff's determination to delist its securities, but there can be no assurance the Nasdaq staff would grant any request for continued listing. Based on the Company's current operating plan and available cash resources, it will need substantial additional funding to support future operating activities. The Company has concluded that the prevailing conditions and ongoing liquidity risks faced by it raise substantial doubt about its ability to continue as a going concern for at least one year following the date these financial statements are issued. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. As the Company continues its operations and is focusing its efforts on drug discovery and development, the Company will need to raise additional capital to implement this business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. The Company will seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Company's business, operating results, and financial condition. 3200000 100000 -345600000 -5600000 1352600 1700000 May 8, 2024 1562500 1562500 0.8 5000000 5000000 0.799 4500000 Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. On an ongoing basis, management reviews these estimates and assumptions. Investments Investments in debt securities consist of investments in U.S. Treasury bills. All investments that have original maturities of three months or less are classified as cash equivalents on the condensed consolidated balance sheets. As of September 30, 2024 and March 31, 2024, all investments are classified as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies. Available-for-sale debt securities are recorded at fair value. Any unrealized gains and losses are included in accumulated other comprehensive income as a component of stockholders' equity until realized. As U.S. Treasury bills have minimal risk, any declines in fair value are considered temporary. Fair value measurement Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Inventory Inventories are stated at the lower of cost or net realizable value. Inventory as of

September 30, 2024 and March 31, 2024 consisted of approximately $ 0.6 million, net of reserve, and $ 0.3 million, respectively, which is related to Mosaic. An inventory reserve of approximately $ 0.2 million was established during the three months ended September 30, 2024 to write-down inventory to its new cost basis. Please refer to " Business Segment Information" for further information regarding Mosaic's inventory. 600000 300000 200000

Insurance Premium Financing Liability

In September 2024, the Company entered into an insurance premium financing agreement for $ 0.4 million, with a term of nine months and an annual interest rate of 8.57%. The Company made a down payment of 10% and is required to make monthly principal and interest payments of $ 44,281 over the term of the agreement, which matures in June 2025. 400000 P9M 0.0857 0.10 44281 400000

Net Loss Per Share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options, shares reserved for purchase under the Company's 2023 Employee Stock Purchase Plan ("2023 ESPP"), the assumed vesting of restricted stock units ("RSUs"), the exercise of warrants, and shares subject to repurchase as the effect would be anti-dilutive.

No

dilutive effect was calculated for the six months ended September 30, 2024

and 2023 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive.

Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately

11.3

million at September 30, 2024 and

1.0

million at September 30, 2023

0 0 11300000 1000000

Revenue recognition

Royalty revenue

The Company has entered into an intellectual property license agreement with another company that includes royalties based on specified percentages of net product sales, if any. At the initiation of the agreement, the Company analyzed whether it results in a contract with a customer under Accounting Standards Codification ("ASC") Topic 606.

The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the Company is a principal vs. agent, whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, sales-based royalty payments have been identified as variable consideration which must be evaluated to determine if it has been constrained and, therefore, excluded from the transaction price. Please refer to "Note 6, Collaborative Research, Development, and License Agreements" for further information.

Product revenue, net

The Company's product-based division, Mosaic, produces high-quality cell-based products for use in Organovo's R&D and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Company's product, typically upon delivery. Product revenues are recorded at the transaction price under Topic 606. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.

In December 2023, the FASB issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least

5

% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Company's Consolidated Financial Statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures

. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM") and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods

within

fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this guidance.

0.05

Note 3. Investments and Fair Value Measurement

Investments in debt securities

As of September 30, 2024, the Company held

1.0

million of investments in debt securities (which are included in the $

and

3.2

million of cash and cash equivalents). For the six months ended September 30, 2024, there was less than

0.1

million of interest income related to the investments in debt securities. As the investments in debt securities consist of U.S. Treasury bills from active markets, the fair value is measured using level 1 inputs.

The following table summarizes the Company's investments in debt securities that are measured at fair value as of September 30, 2024 and March 31, 2024, respectively (in thousands):

colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Investment in debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">997</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">998</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table></div> 1000000 3200000 100000 <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the Company's investments in debt securities that are measured at fair value as of September 30, 2024 and March 31, 2024, respectively (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:33.507%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.122999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td></tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized costs basis</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross unrealized gains</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross unrealized losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Investment in debt securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Investment in debt securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 997 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 998 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr></table> 994000 1000 0 995000 997000 1000 0 998000 Note 4. Accrued Expenses
Accrued expenses consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.673%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.923%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.923%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td></tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 31,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">356</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 536 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued legal and professional fees </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 462 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 93 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other accrued expenses </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 61 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 98 </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Accrued legal and professional fees </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 462 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 93 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Other accrued expenses </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 61 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td></tr><tr><td colspan="2" style="vertical-align:bottom;text-align:center;"> September 30,
2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 31,
2024 </td></tr><tr><td style="vertical-align:top;"> Accrued compensation </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">356</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 536 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Accrued legal and professional fees </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 462 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 93 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Other accrued expenses </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 61 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 98 </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Accrued legal and professional fees </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 462 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 93 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Other accrued expenses </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 61 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff;"> </td></tr><tr><td colspan="2" style="vertical-align:bottom;text-align:center;"> September 30,
2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 31,
2024 </td></tr><tr><td style="vertical-align:top;"> Accrued compensation </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">356</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 536 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Accrued legal and professional fees </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 98 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr><td style="white-space:nowrap;vertical-align:bottom;"> Total </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">727</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued expenses consisted of the following (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.673%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.923%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.923%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,
2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">March 31,
2024</p></td></tr><tr><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued compensation</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 727 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr></table> On January 26, 2024, the Company filed a prospectus to the 2024 Shelf (the "2024 ATM Prospectus"), pursuant to which the Company may offer and sell, from time to time through the Agents, shares of its common stock in ATM sales transactions having an aggregate offering price of up to $2,605,728. Any shares offered and sold in these ATM transactions will be issued pursuant to the 2024 Shelf. During the three and six months ended September 30, 2024, the Company issued zero and 1,352,600 shares of common stock in ATM offerings, respectively, for net proceeds of approximately $1.7 million, all of which were sold pursuant to the 2024 Shelf. As of September 30, 2024, the Company has sold an aggregate of 1,389,002 shares of common stock in ATM offerings under the 2024 ATM Prospectus, with gross proceeds of approximately $1.8 million and net proceeds of approximately $1.8 million. As of September 30, 2024, there was approximately $100.0 million available for future offerings under the 2024 Shelf, and approximately $0.8 million available for future offerings through the Company's ATM program under the 2024 ATM Prospectus. May 2024 Best Efforts Public Offering On May 8, 2024, the Company priced a best efforts public offering (the "Offering") of: (i) 1,562,500<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;"> shares of its common stock and accompanying common warrants ("Common Warrants") to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) pre-funded warrants ("Pre-Funded Warrants") to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. In connection with the Offering, the Company entered into Securities Purchase Agreements with the purchasers of the securities in the Offering on May 8, 2024. The per share exercise price for the Pre-Funded Warrants is $0.001, subject to adjustment as provided therein. The Pre-Funded Warrants were immediately exercisable, subject to certain beneficial ownership limitations, and will expire when exercised in full. The holders may exercise the Pre-Funded Warrants by means of a "cashless exercise." The per share exercise price for the Common Warrants is $0.80, subject to adjustment as provided therein. The Common Warrants were immediately exercisable, subject to certain beneficial ownership limitations, and will expire on the date that is five years following the original issuance date. If a registration statement covering the issuance of the shares of common stock issuable upon exercise of the Common Warrants is not available for the issuance, then the holders may exercise the Common Warrants by means of a "cashless exercise." In connection with the Offering, the Company paid JonesTrading Institutional Services LLC, which acted as the placement agent in connection with the Offering, a cash fee of 5.0% of the aggregate gross proceeds raised in the Offering. The closing of the Offering occurred on May 13, 2024. The Company received net proceeds of approximately $4.3 million from the Offering, after deducting the offering expenses payable by the Company, including the Placement Agent fees. </p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted Stock Units</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the Company's RSUs activity for the six months ended September 30, 2024:</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:67.313%;box-sizing:content-box;"></td><td style="width:1.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.323%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.843%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of
Shares</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted
Average Price</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unvested at March 31, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">122,642</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">$ </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Vested </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2,500 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10.27</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cancelled / forfeited</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> Unvested at September 30, 2024 </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 237,784 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1.07 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> Stock Options During the six months ended September 30, 2024, under the 2022 Plan, 1,150,343 stock options were granted at various exercise prices. On August 5, 2024, the Company granted 1,006,116 stock options to its Executive Chairman under the 2022 Plan. Of the stock options granted, 574,923 will vest evenly on an annual basis over three years. 143,731 of the options granted have unique vesting criteria based on market conditions, more specifically the Company's stock price. As these market condition based stock options require significant estimates and assumptions to calculate their fair value, the Company engaged with valuation specialists to calculate the fair value and requisite service periods using Monte Carlo simulations. The stock options will be expensed over their determined requisite service periods. The remaining 207,462 options granted have unique vesting criteria based on specific Company performance conditions. The vesting criteria for 143,731 of these options includes the Company achieving cumulative revenue of $1.5 million. The vesting criteria for the remaining 143,731 options includes the Company entering into a definitive agreement that constitutes a major strategic partnership, at the discretion of the Board. </p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the Company's stock option activity from March 31, 2024 to September 30, 2024: </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.672%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.242%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.28%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.762%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.28%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.762%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Options
Outstanding</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted
Average Price</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Aggregate
Intrinsic
Value</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding at March 31, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">698,007</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.26 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">— </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Options granted </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,150,343 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.59</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Options cancelled / forfeited </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,912 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.30</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Options expired </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (6,072 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.14</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding at September 30, 2024 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,835,366 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.96</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Vested and Exercisable at September 30, 2024 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 470,301 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.00</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr></table> The weighted average remaining contractual term of stock options exercisable and outstanding at September 30, 2024 was approximately 8.93 years. Warrants In connection with the Offering described above, the Company issued Common Warrants to purchase up to 1,562,500 shares of common stock at a combined public offering price of $0.80 per share and accompanying Common Warrant to purchase one share of common stock and (ii) Pre-Funded Warrants to purchase 5,000,000 shares of common stock and accompanying Common Warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.799 per Pre-Funded Warrant and accompanying Common Warrant to purchase one share of common stock. The Company has determined that these warrants should be classified as equity instruments since they do not require the Company to repurchase the underlying common stock and do not require the Company to issue a variable amount of common stock. In addition, these warrants are indexed to common stock and do not have any antidilution rights.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the Company's Common Warrant activity from March 31, 2024 to September 30, 2024:</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.9%;box-sizing:content-box;"></td><td style="width:1.46%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:17.6%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.92%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:17.119999999999997%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of
Warrants</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Exercise
Price</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding at March 31, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Issued</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,562,500</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.80 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Exercised </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.80</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding at September 30, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,562,500</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.80 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> The following table summarizes the Company's Pre-Funded Warrants activity from March 31, 2024 to September 30, 2024: <p style="font-

size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.9%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.1199999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Warrants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercise
Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding at March 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Issued</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,000,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.001 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,370,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.001</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,630,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 0.001 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> Employee Stock Purchase Plan In July 2023, the Board adopted, and on October 31, 2023, the Company's stockholders subsequently approved, the 2023 Employee Stock Purchase Plan (the "2023 ESPP"). The 2023 ESPP became effective on October 31, 2023. The Company reserved 45,000 shares of common stock for issuance thereunder. The 2023 ESPP permits employees to purchase common stock through payroll deductions, limited to 15 percent of each employee's compensation up to $25,000 per employee per year or 500 shares per employee per six-month purchase period. Shares under the 2023 ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering under the 2023 ESPP commenced on March 1, 2024. During the six months ended September 30, 2024, 500 shares were issued under the 2023 ESPP. At September 30, 2024, there were 44,500 shares remaining available for purchase under the 2023 ESPP. Common Stock Reserved for Future Issuance Common stock reserved for future issuance consisted of the following at September 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:83.84%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to options outstanding and reserved under the 2012 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 423,488 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock reserved under the 2012 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to options outstanding and reserved under the 2022 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,361,870 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock reserved under the 2022 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:text-center;"> 452,038 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock reserved under the 2021 Inducement Equity Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to restricted stock units outstanding under the 2012 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:text-center;"> 2,500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to restricted stock units outstanding under the 2022 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 235,204 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to options outstanding and reserved under the Inducement Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to outstanding pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,630,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to outstanding common warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,562,500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;

Roman;margin-bottom:0;text-align:right;">11,763,188 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Stock-based Compensation Expense and Valuation Information Stock-based awards include stock options and RSUs under the 2022 Plan, 2012 Plan, Inducement Plan, and rights to purchase stock under the 2023 ESPP. The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense. Stock-based compensation expense for all stock-based awards consists of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"> <td style="width:27.64%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.86%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff03;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (60) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">51</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 130 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 735 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 260 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,103 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">155</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 675 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">311</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,150 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The total unrecognized compensation cost related to unvested stock option grants as of September 30, 2024 was approximately $0.8 million and the weighted average period over which these grants are expected to vest is 2.74 years. The total unrecognized compensation cost related to unvested RSUs as of September 30, 2024 was $0.1 million, which will be recognized over a weighted average period of 0.6 years. The Company uses either the Black-Scholes or Monte Carlo option-pricing models to calculate the fair value of stock options, depending on the complexity of the equity grants. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The assumed dividend yield is based on the Company's expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption is based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. The measurement and classification of share-based payments to non-employees is consistent with the measurement and classification of share-based payments to employees. The fair value of stock options was estimated at the grant date using the following weighted average assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:27.309%;box-sizing:content-box;"></td> <td style="width:1.479%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.693%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.479%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.693%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.479%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.693%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2"

style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td> </td> <tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Dividend yield </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 99.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 99.37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 98.51 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.64 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.75 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Expected life of options </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 6 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 0 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 6 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Weighted average grant
  date fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.43</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.47</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.45 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table> * There were no stock options granted during the three months ended September 30, 2023. The fair value of each RSU is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant. The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the 2023 ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:27.309%;box-sizing:content-box;"></td><td style="width:1.479%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.693%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.479%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.693%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.479%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.693%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.479%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.693%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023* </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023* </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Dividend yield </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Volatility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td></tr><tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Risk-free interest rate </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.27 </td><td style="white-space:nowrap;vertical-align:bottom;"> % </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td><td style="white-space:nowrap;vertical-align:bottom;"> % </td></tr><tr style="height:9pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Expected term </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 months </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Grant date fair value </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.39</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr></table> * There were no participants in the ESPP for the purchase periods that commenced on March 1, 2023 September 1, 2023. The assumed dividend yield is based on the Company's expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption is based on U.S. Treasury rates. The expected life is the 6-month purchase period. 25000000 0 750000 750000 51000 50000 2.75 1000 1000 1363000 126262 1236738 1500000000 2024-01-29 150000000 50000000 2605728 0 1352600 1700000 1389002 1800000 1800000 100000000 800000 1562500 1562500 0.8 5000000 5000000 0.799 May 8, 2024 0.001 0.8 P5Y 0.05 4500000 The following table summarizes the Company's RSUs activity for the six months ended September 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:67.313%;box-sizing:content-box;"></td><td style="width:1.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.323%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.843%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Shares </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average Price </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Unvested at March 31, 2024 </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,642 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.75</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Granted</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">117,642</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.55 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Vested </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,500 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10.27</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cancelled / forfeited</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unvested at September 30, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">237,784</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.07 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> 122642 1.75 117642 0.55 2500 10.27 0 0 237784 1.07 1150343 1006116 574923 P3Y 143731 287462 143731 1500000 143731 The following table summarizes the Company's stock option activity from March 31, 2024 to September 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td

style="width:57.672%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.242%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.762%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.762%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Options
Outstanding </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Exercise Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Intrinsic
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding at March 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 698,007 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.26</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Options granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,150,343 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.59</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Options cancelled / forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,912) </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.30</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Options expired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (6,072 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.14</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,835,366 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.96</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Vested and Exercisable at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 478,301 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> *698007 4.26 0 1150343 0.59 6912 5.14 0 1835366 1.96 0 478301 5.00 0 PBYIMAD 1562500 0.0 5000000 5000000 0.799* The following table summarizes the Company's Common Warrant activity from March 31, 2024 to September 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.9%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.1199999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Warrants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercise
Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding at March 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Issued</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,562,500</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.80 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 0.80 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-

bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,562,500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.80</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the Company's Pre-Funded Warrants activity from March 31, 2024 to September 30, 2024: </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.9%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.1199999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:0pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:0pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:0pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:0pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of
Warrants</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:0pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:0pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:0pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Exercise
Price</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:0pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding at March 31, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> —</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Issued </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.001</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercised</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(2,370,000)</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.001 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,630,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.001 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock reserved under the 2012 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to options outstanding and reserved under the 2022 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,361,878 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock reserved under the 2022 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 452,038 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock reserved under the 2023 ESPP </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock reserved under the 2021 Inducement Equity Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to restricted stock units outstanding under the 2012 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to restricted stock units outstanding under the 2022 Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 235,284 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to options outstanding and reserved under the Inducement Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to outstanding pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,630,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable pursuant to outstanding common warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,562,500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,763,188 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 423488 0 1361878 452038 44500 1000 2500 235284 50000 2630000 6562500 11763188 Stock-based compensation expense for all stock-based awards consists of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:27.64%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.86%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td

style="width:14.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (60 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">51</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 130 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 735 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 260 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,103 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">155</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 675 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">311</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,150 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> *25000 -60000 51000 47000 130000 735000 260000 1103000 155000 675000 311000 1150000 800000 P2Y8M26D 100000 P0Y7M6D* The fair value of stock options was estimated at the grant date using the following weighted average assumptions: <table style="margin-left:auto;border-collapse:collapse;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:27.309%;box-sizing:content-box;"></td> <td style="width:1.479%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.479%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.693%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.479%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.693%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.479%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.693%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Dividend yield </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Volatility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 99.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">% </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 99.37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 98.51 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.64 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.75 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Expected life of options </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 6 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 0 </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 6 years </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 6 years </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 6 years </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Weighted average grant
  date fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.43</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.47</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 6 years </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 6 years </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.27 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.27 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.27 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Expected term </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 months </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Grant date fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.39 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 months </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table> *There were no participants in the ESPP for the purchase periods that commenced on March 1, 2023 September 1, 2023. 0 0 0 0 0.952 0 0.952 0 0.0527 0 0.0527 0 P6M P6M 0.39 0 0.39 0 Note 6. Collaborative Research, Development, and License Agreements License Agreements BICO Group AB From June 2021 to February 2022, certain patents owned or sublicensed by the Company became the subject of inter partes review proceedings filed by Cellink AB and its subsidiaries (collectively, “BICO Group AB”). The Company and BICO Group AB were also engaged in litigation regarding patent infringement during the same time period. On February 22, 2022, the Company and BICO Group AB signed a settlement and patent license agreement (“License Agreement”) to close all matters noted above. In addition to closing all legal matters and patent disputes noted above, as part of the agreement, the Company agreed to grant a non-exclusive license to BICO Group AB to use the Company’s aforementioned patents for its business operations of manufacturing and selling bioprinters as well as bioinks. The Company concluded that the nature of the license granted represents functional intellectual property. As part of the License Agreement, BICO Group AB agreed to pay the Company ongoing sales-based royalties (based on percentages of BICO Group AB’s net sales) for the use of the granted license. The sales-based royalties became effective beginning on February 22, 2022, the effective date of the License Agreement, and continue until the expiration of the last surviving licensed patent. As the sales-based royalties are required to be paid 45 days after the end of every quarter, there is variable consideration that must be estimated to determine royalty revenue within a given reporting period. Once actual revenue earned is determined in the following fiscal quarter, an adjustment is made from the previously estimated amount. For the three and six months ended September 30, 2024, the Company recorded $29,000 and $60,000 of royalty revenue, respectively, based on sales-based royalties from the License Agreement. Royalty revenue presented on the statements of operations and other comprehensive loss is $20,000 and $53,000 for the three and six months ended September 30, 2024, respectively, due to adjustments related to prior quarters. Also as part of the License Agreement, certain patents involved in the agreement are sublicensed by the Company from the University of Missouri and Clemson University. See below for further information. University of Missouri In March 2009, the Company entered into a license agreement with the Curators of the University of Missouri (“University of Missouri”) to in-license certain technology and intellectual property relating to self-assembling cell aggregates and intermediate cellular units. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. The Company is required to pay the University of Missouri royalties ranging from 1% to 3% of net sales of covered tissue products, and of the fair market value of covered tissues transferred internally for use in the Company’s commercial service business, depending on the level of net sales achieved by the Company each year. On December 5, 2022, the Company amended the license agreement with the University of Missouri, whereby the Company agreed to pay a single, up-front payment of $50,000 to the University of Missouri in exchange for the aforementioned licensed intellectual property to be fully paid up by the Company. As a result, the Company will continue to have rights to the licensed intellectual property until its expiration, but will no longer owe minimum annual royalty payments, royalty payments based on net sales, or any other payments (other than patent annuities and any prosecution costs) in the future. Clemson University In May 2011, the Company entered into a license agreement with Clemson University Research Foundation (“CURF”) to in-license certain technology and intellectual property relating to ink-jet printing of viable cells. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. Under the agreement, the Company was required to pay CURF royalties ranging from 1.5% to 3% of net sales of covered tissue products and the fair market value of covered tissues transferred internally for use in the Company’s commercial service business, depending on the level of net sales reached each year. The license agreement was to terminate upon expiration of the patents licensed, which expired in May 2024, and was subject to certain conditions as defined in the license agreement. Minimum annual royalty payments of $20,000 were due for two years beginning in calendar 2014, and $40,000 per year beginning in calendar 2016. Royalty payments of $40,000 were made in each of the years ended March 31, 2024 and 2023. The annual minimum royalty was to be creditable against royalties owed during the same calendar year. As the licensed patents expired in May 2024, there will be no further royalty payments owed. In addition to the annual royalties noted above, CURF would have been owed 40% of all payments including but not limited to, upfront payments, license fees, issue fees, maintenance fees, and milestone payments received from third parties, including sublicensees, in consideration for sublicensing rights to licensed products. However, per the agreement, in the event that the Company defends the technology by litigation, it can offset any royalties due by legal expenses incurred. As of September 30, 2024, the Company’s legal expenses exceeded royalties owed from the upfront payment and sales-based royalties related to the license agreement. Therefore, no royalty expense to CURF was recorded for the three and six months ended September 30, 2024 and 2023, respectively. No royalty expense related to sales-based royalties has been recorded to date. 29000 60000 28000 53000 0.01 0.03 50000000 0.015 0.03 2024-05 20000 20000 40000 40000 0.40 0 0 0 0 Note 7. Commitments and Contingencies Legal Matters In addition to commitments and obligations in the ordinary course of business, the Company may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of its business. On August 27, 2024, H.C. Wainwright & Co., LLC (“H.C. Wainwright”) filed a complaint against the Company in the State of New York alleging that the Company breached a tail financing provision included in an engagement agreement the Company entered into with H.C. Wainwright in May 2023. In its complaint, H.C. Wainwright is seeking compensatory and consequential damages and attorneys’ fees. On October 10, 2024, the Company filed an answer to the complaint. The Company is defending these claims vigorously, but there is no guarantee that it will be successful in these efforts. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability. The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures and monitors each related legal issue and adjusts accruals as might be warranted based on new information and further developments. During the three months ended September 30, 2024, the Company recorded an accrual of $0.6 million (which was considered a financing fee related to the Offering discussed in Note 5, Stockholders’ Equity) for the loss contingencies associated with the above described H.C. Wainwright complaint as it determined that an unfavorable outcome is probable or reasonably possible and believed that the amount or range of any possible loss was reasonably estimable. However, amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments, and the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. If one or more legal matters were resolved against the Company in a reporting period, the Company’s consolidated financial statements for that reporting period could be materially adversely affected. 600000 Note 8. Leases After the initial adoption of ASC Topic 842 (“ASC 842”), on an on-going basis, the Company evaluates all contracts upon inception and determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If a lease is identified, the Company will apply the guidance from ASC 842 to properly account for the lease. Operating Leases On November 23, 2020, the Company entered into a lease agreement, pursuant to which the Company permanently leased approximately 8,051 square feet of lab and office space (the “Permanent Lease”) in San Diego once certain tenant improvements were completed by the landlord and the premises were ready for occupancy. Additionally, on November 17, 2021, the Permanent Lease was amended to add an additional 2,892 square feet of office space in the same building. The Permanent Lease commenced on December 17, 2021 and is intended to serve as the Company’s permanent premises for approximately sixty-two months. Monthly rental payments will be approximately $40,800 with 3% annual escalators. The Company determined that the Permanent Lease is considered an operating lease under ASC 842, and therefore upon the lease commencement date of December 17, 2021, recognized lease liabilities and corresponding right-of-use assets of $<span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-

width:fit-content;">2.3 million. The Company records operating lease expense on a straight-line basis over the life of the lease (referred to as "operating lease expense"). Variable lease expenses associated with the Company's leases, such as payments for additional monthly fees to cover the Company's share of certain facility expenses (common area maintenance) are expensed as incurred. The table below summarizes the Company's lease liabilities and corresponding right-of-use assets as of September 30, 2024 (in thousands except the year and percentage): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.46%;box-sizing:content-box;"></td><td style="width:1.8%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.74%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> ASSETS </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:middle;text-align:left;"> </td><td style="vertical-align:middle;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Operating lease right-of-use assets </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,086</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total lease right-of-use assets</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,086 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> LIABILITIES </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Current </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="vertical-align:bottom;"> Operating lease liability </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">513</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Noncurrent</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease liability, net of current portion</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 660 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Total lease liabilities </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,173 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr><tr style="background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Weighted average remaining lease term: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> 2.33 </td><td style="vertical-align:bottom;text-align:center;"> years </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Weighted average discount rate: </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td><td style="white-space:nowrap;vertical-align:bottom;"> % </td></tr></table> Variable lease expense was approximately $22,000 and $23,000for the three and six months ended September 30, 2024, respectively, and approximately $3,000 and $75,000for the three and six months ended September 30, 2023, respectively. Operating lease expense was approximately $126,000 and $252,000for the three and six months ended September 30, 2024, respectively, and approximately $126,000 and $252,000for the three and six months ended September 30, 2023, respectively. Cash flows associated with the Company's operating lease for the three and six months ended September 30, 2024, were approximately $130,000 and $260,000, respectively, and approximately $126,000 and $252,000for the three and six months ended September 30, 2023, respectively.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Future lease payments relating to the Company's operating lease liabilities as of September 30, 2024, are as follows (in thousands):</p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.444%;box-sizing:content-box;"></td><td style="width:1.8%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.757%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fiscal year ending March 31, 2025</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 263 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Fiscal year ending March 31, 2026 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 538 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Fiscal year ending March 31, 2027 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 460 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Total future lease payments </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,261 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Less: Imputed interest </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (80) </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Total lease obligations </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,173 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Less: Current obligations </td><td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (513 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Noncurrent lease obligations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">660</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr> </table></div> *8051 2892 P62M 40800 0.03 2300000 2300000* <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The table below summarizes the Company's lease liabilities and corresponding right-of-use assets as of September 30, 2024 (in thousands except the year and percentage):</p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.46%;box-sizing:content-box;"></td> <td style="width:1.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:0pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:0pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">ASSETS</p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease right-of-use assets</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,086 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total lease right-of-use assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,086</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">LIABILITIES</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Current</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 513 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="vertical-align:bottom;"> Noncurrent </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Operating lease liability, net of current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">660</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total lease liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,173 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Weighted average remaining lease term: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2.33 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Weighted average discount rate: </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> *1086000 1086000 513000 660000 1173000 P2Y3M29D 0.06 22000 23000 9000 75000 126000 252000 126000 252000 130000 260000 126000 252000* Future lease payments relating to the Company's operating lease liabilities as of September 30, 2024, are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.444%;box-sizing:content-box;"></td> <td style="width:1.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.757%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Fiscal year ending March 31, 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">263</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fiscal year ending March 31, 2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">538</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fiscal year ending March 31, 2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">460</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total future lease payments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,261</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: Imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(88</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total lease obligations</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,173</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: Current obligations</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(513</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Noncurrent lease obligations</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 660 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> *263000 538000 460000 1261000 88000 1173000 513000 660000* Note 9. Concentrations Credit risk and significant customers Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. However, the Company only receives royalty revenue from one licensee and has not historically experienced any accounts receivable write-downs. <span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-

*size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 10. Related Parties From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business. These agreements are ratified by the Board or a committee thereof pursuant to its related party transaction policy. Vincient Biosciences ("Vincient") is an entity for which Keith Murphy, the Company's Executive Chairman, serves as the Chief Executive Officer and President. On December 28, 2020, the Company entered into an intercompany agreement (the "Intercompany Agreement") with Vincient and Organovo, Inc., the Company's wholly-owned subsidiary, which included an asset purchase agreement for certain lab equipment. Pursuant to the Intercompany Agreement, the Company agreed to provide Vincient certain services related to 3D bioprinting technology, which include, but are not limited to, histology services, cell isolation, and proliferation of cells and Vincient agreed to provide the Company certain services related to 3D bioprinting technology, including bioprinter training, bioprinting services, and qPCR assays, in each case on payment terms specified in the Intercompany Agreement and as may be further determined by the parties. In addition, the Company and Vincient each agreed to share certain facilities and equipment and, subject to further agreement, to each make certain employees available for specified projects for the other party at prices to be determined in good faith by the parties. During the second quarter of fiscal 2025, the companies added a Statement of Work ("SOW") to the Intercompany Agreement, where Vincient agreed to provide the Company with certain testing services related to the Company's ongoing R&D. The Company evaluated the accounting for the Intercompany Agreement and concluded that any services provided by Vincient to the Company will be expensed as incurred, and any compensation for services provided by the Company to Vincient will be considered a reduction of personnel related expenses. Any services provided to Vincient do not fall under Topic 606 as the Intercompany Agreement is not a contract with a customer. For the three months and six months ended September 30, 2024, the Company incurred $70,000 of toxicity testing services from Vincient. The Company incurred -zero expenses from Vincient for the three and six months ended September 30, 2023. Additionally, for the three months and six months ended September 30, 2024, the Company provided approximately $4,000 of histology services to Vincient, and approximately less than $1,000 and $10,000 of histology services to Vincient for the three and six months ended September 30, 2023, respectively. 70000 70000 0 0 4000 4000 1000 10000 Note 11. Business Segment Information Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing performance. The Company's operating segments were identified in fiscal 2024 and did not impact prior periods. The Company's operating segments are as follows: Research & Development The research and development ("R&D") segment consists of the Company's drug development efforts. The Company's current clinical focus is in advancing FXR314 in IBD, including UC and CD. The Company plans to start a Phase 2a clinical trial in UC in the calendar year 2025. The Company released Phase 2 data for FXR314 for the treatment of MASH in April 2024 that are supportive of ongoing development, and believes FXR314 has a commercial opportunity in MASH, most likely in combination therapy. The Company is exploring the potential for combination therapies using FXR314 and currently approved mechanisms in preclinical animal studies and its IBD disease models. The Company's second focus is building high fidelity, 3D tissues that recapitulate key aspects of human disease. The Company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. The Company believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. As with the clinical development program, the Company is initially focusing on the intestine and has ongoing 3D tissue development efforts in human tissue models of UC and CD. The Company uses these models to identify new molecular targets responsible for driving the disease and to explore the mechanism of action of known drugs including FXR314 and related molecules. The Company intends to initiate drug discovery programs around these new validated targets to identify drug candidates for partnering and/or internal clinical development. Mosaic Cell Sciences The Mosaic Cell Sciences segment, which began operations in February 2024, consists of our Mosaic Cell Sciences division ("Mosaic"), which will serve as a key source of certain of the primary human cells that the Company utilizes in its research and development efforts. The Company believes Mosaic can help optimize its supply chain, reduce operating expenses related to cell sourcing and procurement, and ensure that the cellular raw materials it uses are of the highest quality and are derived from tissues that are ethically sourced in full compliance with state and federal guidelines. Mosaic provides the Company with qualified human cells for use in its clinical research and development programs. In addition to supplying the Company with primary human cells, Mosaic offers human cells for sale to life science customers, both directly and through distribution partners, which the Company expects to offset costs and over time become a profit center that offsets overall R&D spending by the Company. Business Segment Information The Company's R&D segment generates royalty revenue related to its IP. The Company's Mosaic segment generates product revenue as part of its core operations. Segment revenues consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:20.42%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.040000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.12%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.12%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.12%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.12%;box-sizing:content-box;"></td></tr><tr style="height:0pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> Three Months Ended </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> Three Months Ended </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> Six Months Ended </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> Six Months Ended </td></tr><tr style="height:0pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> R&D </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;">

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total segment revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">30</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">69</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 75 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total Company revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">30</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">69</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 75 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr></table> Operating segment costs and expenses consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:20.986%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.263%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.32%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Three Months Ended </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Three Months Ended </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Six Months Ended </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Six Months Ended </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff03;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:top;"> R&D </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td>

space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 276 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Selling, general, and administrative expenses </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 60 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> Total segment costs and expenses </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,053</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,335 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,524</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,001 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other selling, general, and administrative expenses </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,585 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,780 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,539</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,384</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total Company costs and expenses</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,638 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,115</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,063 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,385</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The R&D segment's identifiable assets are its fixed assets. The Mosaic segment's identifiable assets are its fixed assets and inventory. Other Company assets are comprised of all other assets that are not distinctly identifiable to a segment.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;">Operating segment assets consisted of the following (in thousands):</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.924999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.881%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:26.564999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">March 31, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">R&D</p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fixed assets, net</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 343 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">423</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Mosaic</p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fixed assets, net</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">161</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">183</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">640</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">297</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total segment assets</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,144 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 903 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other Company assets </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,610 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,446 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total Company assets </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,754</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,349 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> Segment revenues consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:20.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.040000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.12%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Three Months Ended </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Three Months Ended </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Six Months Ended </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Six Months Ended </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> R&D </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;">

~~style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">75</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> 28000 0 53000 75000 2000 0 16000 0 30000 0 69000 75000 30000 0 69000 75000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating segment costs and expenses consisted of the following (in thousands):</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:28.986%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.263%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.32%;box-sizing:content-box;"></td></tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended</p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended</p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six Months Ended</p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six Months Ended</p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">R&D</p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development expenses</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 934 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,335</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,001</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Mosaic</p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cost of revenues</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development expenses</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Mosaic</p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Selling, general, and administrative expenses</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">68</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">276</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Segment costs and expenses</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,053 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">

$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,335</p></td> <td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,524 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,001</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,700</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,539</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,384</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total Company costs and expenses</p></td> <td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,638 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,385 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td></tr></table> 934000 1335000 2110000 3001000 1000 0 3000 0 50000 0 276000 0 68000 0 135000 0 1053000 1335000 2524000 3001000 1585000 2780000 3539000 5384000 2638000 4115000 6063000 8385000 Operating segment assets consisted of the following (in thousands):
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.628%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.924999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.081%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:26.564999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td></tr> <tr style="height:0pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> March 31, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> R&D </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Fixed assets, net </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">343</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 423 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Mosaic </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Fixed assets, net </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">161</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">183</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">640</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">297</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total segment assets</p></td> <td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,144 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">903</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other Company assets</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,610</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,446</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total Company assets</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,754 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,349 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 343000 423000 161000 183000 640000 297000 1144000 903000 5610000 5446000 6754000 6349000 false false false false There were no stock options granted during the three months ended September 30, 2023. There were no participants in the ESPP for the purchase periods that commenced on March 1, 2023 September 1, 2023.

"

"